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i 
ABSTRACT 
 
Due to concerns about international differences in treatment effectiveness, many countries are 
reluctant to extrapolate overseas clinical data to form the basis of guideline recommendations 
and intervention approval processes. The evidence on which these concerns are based, 
however, comes from a limited dataset, with few studies directly assessing international 
differences in treatment effectiveness. This study aims to assess differences in the results of 
cardiovascular trials between Europe, North America, and Asia using the panoramic meta-
analysis approach. 
All meta-analyses containing randomised control trials for the treatment or prevention of 
cardiovascular diseases were searched for in The Cochrane Library (2000 to 2008) and 
Medline (2005-2008). Analysis was then conducted within and over the included meta-
analyses by performing pair-wise comparisons of the trial results between Europe and North 
America, Europe and Asia, and North America and Asia and a universal comparison of all 
three continents’ trial results together. All analyses were conducted over fatal and non-fatal 
endpoints. 
The findings suggested that for both endpoints, interventions performed best in Asian trials. 
For fatal endpoints, a high proportion of positive trial results were observed for Japan. 
Further investigation showed that between-continent differences in treatment effect could be 
explained by between-continent differences in trial quality. However, the types of 
intervention prone to inter-continental differences could not be identified for fatal or non-fatal 
endpoints.  
  
ii 
These findings suggest that those developing guidelines and approving interventions should 
be cautious when extrapolating overseas data. In particular, this study highlights the 
importance of taking trial quality into account when extrapolating and interpreting clinical 
trial data from different regions. 
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CHAPTER 1. 
INTRODUCTION 
 
1.1: The Research Context 
Over recent years, national and international communities of health policy-makers, policy-
analysts, and healthcare professionals have called for medical and healthcare interventions to be 
based on robust evidence about an intervention’s effectiveness. With national governments and 
international agencies expressing increased concern over healthcare provision and costs, an 
evidence-based approach to healthcare planning and delivery has become increasingly important. 
These concerns over effectiveness and costs have led to the development of ‘Evidence Based 
Medicine’ (EBM), an approach that involves systematically examining and appraising the 
findings of international clinical research to help achieve optimum levels of clinical care. Indeed, 
EBM is now considered one of the “gold standard tools” for assessing healthcare (Belsey, 2009). 
In a bid to optimise healthcare and provide efficacious interventions, EBM has been used for 
developing clinical guidelines on the most appropriate treatment for patients. Given that these 
guidelines should be built on the best available international evidence, it is reasonable to expect 
that clinical guidelines in different countries would be based on similar studies and, therefore, 
that a country’s clinical guidelines would have similar recommendations for practice to those in 
another country. However, this is not the case. Numerous studies have shown that countries tend 
to base their clinical guidelines on trials conducted within their own country (Burgers et al. 
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2002). Even when evidence from other countries is used in guideline development, the resulting 
recommendations still tend to differ between countries (Eisinger et al. 1999). Many reasons may 
account for these differences. For instance, guideline recommendations may differ due to cultural 
differences in the perception of risk, different interpretations of the same evidence, and honest 
differences in the opinion of experts (Magill & Shlim, 2011). 
The effectiveness of the intervention may also account for some of this variability. Effectiveness 
is the degree to which an intervention has achieved its desired effect for those to whom it is 
offered (Abramson & Abramson, 1999). While guidelines may differ because of ‘local’ issues 
such as socio-economic, cultural, and geographical considerations or regional/national 
differences in intervention costs, it is also possible that they differ because of concerns about 
differences in treatment effectiveness between countries. Believing that the effectiveness of 
interventions differs between countries, even when factors such as culture or socio-economic 
differences are excluded, may make those developing clinical guidelines more sceptical about 
recommending treatments based on non-native clinical data. Indeed, the European Medicines 
Agency (EMA) (2006) asserts that concerns about international differences in treatment 
effectiveness deter many countries from relying on overseas
1
 clinical data.  
Although there is some evidence to suggest that treatment effectiveness may differ between 
countries (Pan et al. 2005; Zhang, Freemantle, & Cheng, 2011), much of this evidence derives 
from multinational trials whose primary aim was not the examination of inter-country differences 
                                                 
1
 Data from another country or continent. 
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in treatment effectiveness. Therefore, the difference in results may simply be an artefact of 
variation in treatment management strategies or implementation of the research protocol in the 
different countries involved in the study. 
It is possible that international differences in treatment effectiveness may only exist for particular 
types of intervention. This could have important implications for guideline development because 
if intervention type A is not prone to such differences, then data regarding that intervention’s 
effectiveness can simply be extrapolated from one country to another. Conversely, if intervention 
type B is known to be prone to international differences, those approving these types of 
interventions will know that a duplicate trial may be needed before a recommendation can be 
made. Data showing effectiveness differences by type of intervention could contribute to 
international guidance about which interventions data could be directly extrapolated and which 
might need nation-specific investigation.  
With the above in mind, research is required that specifically explores international differences in 
effectiveness which is based on a robust method. This will provide countries with a strong 
foundation on which to base decisions about extrapolating overseas clinical data to national 
guidelines and for use in intervention approval processes. This study aims to provide this 
information for cardiovascular diseases. 
1.2: Research Aims 
The focus of this study is to investigate the existence of international differences in treatment 
effectiveness. There are two aims: 
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 To assess whether international differences in the effectiveness of cardiovascular 
interventions exist. 
 To identify whether there are certain types of intervention that are more likely to exhibit 
differences in effectiveness between countries. 
 
The following research questions have been posed to help achieve these aims: 
 Does treatment effectiveness for cardiovascular conditions differ between regions? 
 What types of cardiovascular intervention are more likely to show these differences in 
treatment effect? 
These research questions will be explored using panoramic meta-analysis. 
1.3: Panoramic Meta-Analysis 
Panoramic meta-analysis is based upon the procedures and principles of standard meta-analysis 
and follows a systematic process within which relevant studies are identified, evaluated, and 
combined to give an overall result (see Chapter 3 for methodological description). Developed by 
Bowater, Stirling and Lilford (2009), panoramic meta-analysis enables the testing of generic 
hypotheses
2
 and also allows for bias and heterogeneity within large datasets to be examined. 
Panoramic meta-analysis is the most appropriate method to answer the research questions for the 
following reasons: 
 it enables the exploration of international differences in treatment effectiveness by 
specifically scrutinising heterogeneity within datasets 
 it allows for trial quality to be investigated as a possible reason for such differences 
 it allows for different interventions to be explored in the same investigation  
                                                 
2‘Generic’ in the sense that they can apply to all members of a family of interventions or to a group of different but 
related medical conditions. 
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 it is a more efficient approach of assembling data compared to current systematic 
reviewing and meta-analysis methods. 
 
 
The benefits of using panoramic meta-analysis are that: 
 it allows for the collection of a vast amount of information about relevant trials faster than 
standard meta-analysis by identifying trials from meta-analyses 
 it can provide a broader overview than can standard meta-analytic techniques, by testing 
hypotheses (over meta-analyses) about different interventions for different but related 
health conditions 
 the required data for relevant studies can simply be extracted from meta-analyses rather 
than from individual studies 
 it uses the robust methods of standard meta-analysis for data analysis. 
 
1.4: Cardiovascular Diseases 
Cardiovascular diseases (CVD) (i.e. disorders affecting the heart and blood vessels) were chosen 
as the focus for this study because they are of worldwide interest and a variety of intervention 
types for treatment and/or prevention are available.  
Cardiovascular diseases are both a national and international concern, as although many CVDs 
are preventable or can be treated, it is estimated that 17.1 million people worldwide die of a CVD 
annually (World Health Organisation, 2010). In many countries, it is the leading cause of death 
(Gaziano et al. 2006). Therefore, it is important to establish appropriate interventions for the 
prevention and/or treatment of CVDs that can be used on the international stage. Indeed, many 
countries conduct extensive research on CVD treatment and prevention (Neal, Chapman, & Patel 
2002). Thus, evidence on CVD interventions is available from many countries, and it is therefore 
an ideal topic for this study. 
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This investigation is important as it has the potential to impact upon the speed at which new CVD 
interventions are implemented and approved by aiding decisions on the extrapolation of overseas 
clinical data. Furthermore, by investigating whether the effectiveness of CVD interventions 
differs between countries, this investigation may impact upon the types of intervention that are 
recommended for CVD treatment both at national and international levels.  
1.5: The Structure of the Thesis. 
The study is organised into eight chapters divided into three parts. Part One focuses on the 
methodology and data collection, Part Two on the statistical analyses and results of the 
investigation and Part Three on the overall conclusions that can be reached. 
Chapter 1 provides the introduction to the study. It presents an overview of the study area and 
explains why the research is important. The introduction provides a preliminary insight into the 
research context, problems, questions and the methodological approach to be deployed in the 
thesis.  
PART ONE: There are three chapters in Part One organised under the heading “Methodology 
and Data Collection” (Chapters 2 to 4).  
Chapter 2 provides the background to the thesis by providing the evidence for international 
differences in treatment effectiveness and evaluates this evidence. 
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Chapter 3 provides a description of panoramic meta-analysis and details of why and how 
panoramic meta-analysis was used. The chapter also discusses the issues of bias and 
heterogeneity. 
Chapter 4 describes how the study was conducted. It details identification of evidence as well as 
the results from the literature search. It also provides an explanation of the methods used to 
analyse and synthesise the data. 
PART TWO: There are three chapters in Part Two that are organised under the heading “The 
investigation of international differences in treatment effectiveness” (Chapters 5 – 7). 
Chapter 5 provides the results from the investigation into treatment effect differences between 
Europe and North America. It draws together the results from pair-wise comparisons as well as 
global estimates of continental difference over both fatal and non-fatal endpoints. 
Chapter 6 provides the results from the investigations concerning Europe, North America, and 
Asia. It provides the results from the pair-wise comparisons conducted between Europe and Asia 
and between North America and Asia and provides the results of the global estimates of 
continental difference. It also provides a universal comparison of international differences in 
treatment effect that analyses all regions together and reports the investigation into the types of 
intervention prone to international differences in treatment effect. 
Chapter 7 provides a description of the methods used to assess trial quality and reports the 
results of this assessment. 
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PART THREE: There is one chapter within Part Three organised under the heading “Evaluation 
and Conclusion”. This is Chapter 8. 
Chapter 8 integrates the results from all investigations to show whether international differences 
in treatment effectiveness for cardiovascular diseases exist and the extent of any differences. The 
chapter provides the limitations and strengths of the thesis before providing suggestions on future 
research. 
1.6: The Importance of the Study 
Through the use of panoramic meta-analysis, this thesis advances beyond the existing literature 
and directly investigates the existence of international differences in treatment effectiveness. 
Methodologically, this study applies a novel research method and has advanced beyond previous 
studies that have used panoramic meta-analysis in two main ways. First, it has been used to 
critically compare the clinical effectiveness of CVD interventions between regions. Second, 
panoramic meta-analysis was enhanced in this study by examining differences in trial quality. 
Empirically, this study investigates directly the existence of international differences in the 
clinical effectiveness of CVD interventions and also examines differences over a variety of 
intervention types. Combining these two approaches provides a novel investigation into 
international differences. This research could, therefore, have important implications for 
decisions and recommendations made by both national and international agencies about data 
extrapolation and guideline development. As such, this study has importance for policy makers, 
practitioners, and researchers and would be of interest to national and international agencies 
involved in producing guideline recommendations. It would also be useful for those who 
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extrapolate (or are sceptical about extrapolating) overseas clinical data from one country to 
another as well as to those conducting multinational trials by bringing to the forefront the 
importance of considering international differences in treatment effect when analysing clinical 
data. 
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PART ONE: METHODOLOGY AND DATA 
COLLECTION 
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CHAPTER 2. 
BACKGROUND 
 
Several studies looking at clinical guideline recommendations between countries have recently 
been conducted. They conclude that guideline recommendations differ between countries and that 
recommendations are commonly based upon evidence generated in the country producing the 
guideline (Burgers et al. 2002; Matthy et al. 2007). One would not expect this given the advent of 
EBM and technological advances allowing global accessibility to trial databases and clinical trial 
results. While many explanations have been proposed for these differences, it is possible that 
disparities in guideline recommendations result from the belief that the effectiveness of 
interventions differs between countries (European Medicines Agency, 2006); a possible 
explanation for why recommendations are usually based upon trials conducted in the country 
constructing the guideline. This thesis will address this issue by examining whether inter-country 
differences in treatment effectiveness exist. 
This chapter provides an overview of the available evidence about international differences in 
clinical effectiveness. It is organised into four main sections. It begins by exploring EBM and its 
impact upon clinical guideline recommendations. Section two discusses the reasons why 
recommendations differ between countries. Section three explores evidence of international 
differences in treatment effectiveness and the factors that might have contributed to these 
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findings. The chapter concludes by summing up the evidence and explaining why this study is 
important for national and international healthcare systems and the people who benefit from 
them. 
2.1: Evidence Based Medicine and Clinical Guidelines 
Although the practice of EBM is relatively new, the concept behind it is well established. 
Professor Archie Cochrane’s book “Effectiveness and Efficiency: Random Reflections on Health 
Services” (Ashcroft, 2004) is widely recognised as the catalyst for EBM. Since then, the concept 
and its development into a practical methodology have become accepted worldwide, with EBM 
now considered one of the “gold standard tools” in assessing health care (Belsey, 2009) and 
helping clinicians decide on the best treatment available for their patients. EBM is described by 
Sackett (2000) as "the integration of the best research evidence with clinical expertise and patient 
values" and involves systematically examining and appraising the findings of clinical research to 
ensure that patients receive optimum clinical care. It influences not only clinical practice but also 
health policy, medical education, and patient information (Straus & Jones, 2004) and is often 
seen as objective (Turkelson & Hughes, 2006) in that its recommendations and results are based 
on the highest quality research from around the world (Rosenberg & Donald, 1995). 
EBM has brought about an increase in the formulation of evidence based clinical guidelines. 
These are systematically developed recommendations for practitioners and patients on the 
appropriate treatment and care for specific medical conditions (Field & Lohr, 1990). They 
provide a guide to best practice and can be used as a standard against which clinical practice can 
be assessed. Moreover, they provide a framework within which clinical decisions can be made 
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(Turner et al. 2008). In the construction of such guidelines, comprehensive literature searches are 
conducted and the quality of the evidence is assessed. Patients’ preferences and values are also 
considered. These processes ensure that the recommendations made in such guidelines are based 
upon the best available evidence (Lim et al. 2008) and, by including patient views, are likely to 
be acceptable to people affected by the condition. 
With this in mind, and with increased access to clinical trial results, it might be expected that 
guideline recommendations, and the evidence on which they were based, would be similar 
worldwide. However, this is not the case. A number of studies have found that both guideline 
recommendations and the studies on which they are based differ between countries (Eisinger et 
al. 1999; Matthy, DeMeyere, van Driel, & DeSutter, 2007). One such study, conducted by 
Burgers et al (2002),examined diabetes guidelines in thirteen countries to explore whether they 
were based on similar research. They concluded that the evidence on which the guidelines were 
based differed between countries because many of the countries based their guidelines on 
evidence that had originated in their own country. Further evidence is provided by Matthys et al 
(2007) who found that guideline recommendations regarding the use of rapid antigen tests and 
throat cultures differed between North America and Europe; the use of the rapid antigen test was 
recommended in most US, French, and Finnish guidelines but not in Belgian, Dutch, or Scottish 
guidelines. Throat cultures were advised within US, Canadian, and Finnish guidelines but not in 
those of Belgium, France, Scotland, England, or the Netherlands.  
Why, then, do guideline recommendations and the evidence on which they are based differ 
between countries?  
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2.2: Reasons for Global Differences in Clinical Guideline 
Recommendations 
Many explanations have been provided to explain the differences in clinical guidelines between 
countries, including methodological and interpretation issues and issues linked to effectiveness.  
The differences in guideline recommendations found between countries may be explained by 
different interpretations of the evidence (Fahey & Peters 1996; Ravago, Mosniam, & Alem 2000; 
Vogel et al. 2000). However, others suggest that the between-country differences can be 
explained by the use of unsystematic guideline development methods (Matthy, DeMeyere, van 
Driel, & DeSutter, 2007). As there is no international standardised procedure for the construction 
of guidelines, the methods used to produce them are likely to differ between countries, which 
may result in different evidence being found and different recommendations being made. 
Thomson, McElroy, and Sudlow (1998) found that not all the guidelines they examined showed 
clear links between the quality of the supporting evidence and the recommendations. 
Furthermore, they found that in the majority of cases, literature reviews and the appraisal of 
evidence on which recommendations were based were unsystematic, as were methods for 
incorporating evidence and opinions. They conclude that this results in guidelines that are 
different not only in content, but also in impact.  
Others, however, propose that between-country disparities could be due to the relative influence 
of professional bodies over guideline development (Burgers et al. 2002; Matthy, DeMeyere, van 
Driel, & DeSutter, 2007). Littlejohns et al (1999) found that the views of the Royal College of 
General Practitioners and the Royal College of Physicians strongly influenced recommendations 
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made in nine UK guidelines on the treatment of depression in primary care. After comparing 
national diabetes guidelines in 13 countries, Burgers et al ( 2002) agree. They found that all, with 
the exception of Scotland and England, were strongly influenced by the American Diabetes 
Association. As such, it is likely that the guidelines in these two countries differ from those in the 
other 11 countries. 
Studies suggest other factors such as patient preference (van Driel et al. 2006), socio-economic 
issues, characteristics of healthcare systems (DeMaeseneer & Derese, 1999; Eccles 2003), and 
culture (Christiaens et al. 2004) may offer some explanation for international variation in 
guideline recommendations. Fervers et al (2006), for example, claim cultural differences between 
countries may create legitimate variations in clinical guidelines, even when  based on the same 
evidence. Eisinger et al.’s (1999) study exemplified this, proposing cultural differences in the 
symbolic and aesthetic values placed upon breasts and the emphasis placed on patient control and 
autonomy as possible explanations for guideline differences between the US and France on the 
clinical management of women with an inherited predisposition to ovarian and breast cancer.  
It may be the case that clinical guideline recommendations differ due to the belief of those 
developing guidelines that treatment effectiveness differs between countries. This would make 
countries more sceptical about recommending treatments based on overseas clinical data and 
using such data as the basis for their guidelines. Indeed, the European Medicines Agency (EMA) 
(2006) suggests that clinical effectiveness is an important factor to consider as it impacts on the 
extrapolation of clinical trial results between countries. According to the EMA, concerns about 
international differences in clinical effectiveness have limited the willingness of many countries 
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to rely on overseas clinical data. This has led to many countries requesting that duplicate studies 
be conducted before approving a new treatment, thus increasing the cost of such treatments and 
delaying their approval. But to what extent does evidence support the belief that differences in 
treatment effectiveness exist between countries? 
2.3: Evidence of International Differences in Treatment 
Effectiveness 
Vickers et al.’s (1998) research, one of the few studies directly assessing the existence of 
international differences in treatment effectiveness, found that studies conducted in Eastern Asia 
or Eastern Europe had a higher proportion of positive
3
 results than those conducted in other 
countries, which suggests that interventions were more effective in these regions. Pan et al. 
(2005) found that Chinese trials on human genome epidemiology showed significantly more 
positive results than non-Chinese studies. A more recent study by Zhang, Freemantle, and Cheng 
(2011) also found that Chinese trials produced more positive results than those conducted in India 
or Western countries, suggesting that interventions were more effective in Chinese trials than in 
the other regions. 
An early piece of direct evidence for differences in clinical effectiveness between countries 
examined isoniazid (INH) preventive therapy for Tuberculosis in seven Eastern European 
countries (Thompson, Snider and Farer, 1985). This trial showed that variation between countries 
was larger than variation within countries for all the variables being studied. For instance, one 
                                                 
3
 A finding that the intervention was more effective than its comparator 
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country had an incidence rate of drug-related adverse reactions that was almost 50% greater than 
the other six countries. However, they argue that these differences might result from differences 
in healthcare practice, behaviours, and methodological factors. 
Other studies, however, have found little evidence that treatment effect differs between countries. 
Chang et al (2005) investigated whether inter-country differences in the following outcomes –one 
year all-cause mortality, thirty-day death, or post-admission myocardial infarction (MI) –could be 
explained by patient, hospital and country-level factors by using data from the Global Utilisation 
of Strategies to Open Occluded Coronary Arteries IV Acute Coronary Syndromes (GUSTO IV 
ACS) trial, which involved 7800 patients from 458 hospitals in 24 countries. They found that 96-
99% of total variance in the results could be explained by patient-level factors rather than hospital 
or country-level factors. It is possible, therefore, that the inter-country differences found in 
previous studies are the consequence of patient-level differences rather than country-level 
differences. 
Because studies assessing international differences in therapeutic effectiveness are scarce, 
evidence of these differences must be looked for in the results of multinational trials. Although 
the investigation of country differences in treatment effect is not the primary aim of these trials, 
evidence of such disparities can be found by examining the differences in outcomes between the 
countries studied. It should be noted, however, that while disparities in outcomes may not 
necessarily represent differences in treatment effect, because they may also apply to the control 
group, disparities in effectiveness will certainly lead to such differences in outcome. Therefore, 
country differences in outcome can provide prima facie evidence of an interaction between 
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country and treatment effect. Table 2.1 provides the details of the seven multinational trials that 
provided evidence of international differences in treatment effect. 
Table 2.1: Multinational Trials That Provided Evidence of International Differences in 
Treatment Effectiveness. 
Author Name of Trial Acronym Aims of Study Regions 
Involved 
Findings Explanations 
for Findings 
Senn and 
Harrell 
(1997) 
O’Shea 
and 
DeMets 
(2001) 
Beta-Blocker 
Heart Attack 
Trial 
BHAT Evaluate beta-
blockers as the 
immediate 
treatment for MI 
patients 
US and 
Canada 
A difference 
in the 
direction and 
size of 
treatment 
effect between 
countries 
Random 
variation 
(Senn and 
Harrell, 1997) 
Small sample 
sizes in some 
trial centres’ 
(O’Shea and 
DeMets, 2001) 
O’Shea 
and Califf 
(2001) 
Flolan 
International 
Randomised 
Survival Trial 
FIRST Evaluate 
effectiveness of 
Epoprostenol 
US, Canada 
and Europe 
Difference in 
treatment 
effect between 
North 
America and 
Europe 
Due to 
patients in 
Europe 
receiving the 
placebo 
having 
improved 
performance 
O’Shea 
and Califf 
(2001) 
 
Platelet 
IIb/IIIa in 
Unstable 
Angina: 
Receptor 
Suppression 
Using 
Integrilin 
Therapy 
PURSUIT Evaluate 
effectiveness of 
Eptifibatide 
North 
America, 
Western 
Europe, 
Eastern 
Europe and 
Latin 
America 
Treatment 
benefit was 
greater in 
North 
America.  
Fewer 
composite 
events in 
Western 
Europe for 
Eptifibatide 
group than in 
Latin America 
and Eastern 
Europe 
Different 
baseline 
demographics 
Different 
adjunctive 
treatment 
strategies  
Different 
definitions of 
MI 
(Akkerhuis, 
Deckers, 
Boersma et al, 
2000) 
Van de 
Werf, 
Topol, Lee 
et al 
(1995) 
Global Use of 
strategies to 
open 
Occluded 
Coronary 
Arteries 
GUSTO Evaluate Effect of 
4 thrombolytic 
strategies on 
mortality rates 
US, 
Australia, 
Belgium, 
Canada, 
France, 
Germany, 
In non-US 
patients, the 
combination 
strategy 
worked as 
well as 
Country 
differences in 
the rate of 
Haemorrhagic 
stroke 
(O’Shea and 
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Ireland, 
Israel, 
Luxembourg
, The 
Netherlands, 
New 
Zealand, 
Poland, 
Spain, 
Switzerland 
and UK 
accelerated 
tPA regimen, 
while in US 
patients it had 
the worst 
outcomes.  
Accelerated 
tPA had 
greatest 
benefit in US 
patients 
Califf, 2001) 
Madan, 
Labinaz, 
Cohen, 
Buller et 
al (2004) 
Enhanced 
Suppression of 
the Platelet 
IIb/IIIa 
Receptor with 
Integrilin 
Therapy  
ESPRIT The 30-day and 
one-year rates of 
death, myocardial 
infarction (MI) 
and target vessel 
revascularisation 
(TVR) were 
compared 
between Canadian 
and US patients  
US and 
Canada 
While the 
beneficial 
effect of 
Eptifibatide 
was observed 
in both 
countries, 
Canadian 
patients had 
better 30 day 
and 1 year 
clinical 
outcomes then 
North 
American 
patients after 
PCI 
 
Cohen et 
al ( 2001) 
Evaluation of 
IIb/IIIa 
Platelet 
Inhibition for 
Stenting 
EPISTENT Compared clinical 
outcomes between 
Canada and US 
after PCI 
US and 
Canada 
Canadian 
patients had a 
lower 
incidence of 
death, MI, 
TVR 
 
Kang, 
Ohtsu, 
Van 
Cutsem et 
al ( 2010) 
 
Unknown AVAGAST Compared overall 
survival between 
Asia, Europe, and 
North and South 
America to 
evaluate effect of 
Bevacizumab plus 
chemotherapy in 
Gastric Cancer 
patients 
Asia, 
Europe, 
North and 
South 
America 
Overall 
Survival was 
heterogeneous 
across regions 
for the 
intervention 
under 
investigation 
Regional 
Differences in 
patient 
characteristics 
and treatment 
strategy 
(Saijo, 2010) 
 
Although finished prematurely, one study looking at  beta-blockers as an immediate treatment for 
those surviving MI, showed a difference in both the direction and the size of treatment effect 
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between the US and Canada (Senn and Harrell, 1997; O’Shea and DeMets, 2001). Senn and 
Harrell (1997), when analysing this data, concluded that the variation could be explained by 
random variation. However, O’Shea and DeMets (2001) suggest that these differences cannot be 
explained by differences in the quality of care, because all participating centres were chosen by 
virtue of their ability to recruit patients and their outstanding academic records. Despite sample 
sizes from some of the centres being small, which possibly explains some of these differences, 
their work indicates that an interaction between country-level factors and treatment existed, 
supporting the notion of international differences in treatment effectiveness. 
Another multinational trial with similar results is reported by O’Shea and Califf (2001), who 
examined the results from the FIRST trial. Findings showed that patients in North America who 
received Epoprostenol experienced fewer major events than those receiving a placebo and 
showed that there was no difference in unadjusted survival probability between patients who did 
and did not receive the intervention. This contrasted with the findings from Europe, where those 
treated with the intervention showed an increased risk of death, suggesting that there was some 
interaction between region and treatment. However, O’Shea and Califf argue that these 
differences may have been the consequence of a perceived clinical improvement by those treated 
with placebo in Europe compared with their North American counterparts. 
O’ Shea and Califf (2001) also analysed the data from the PURSUIT multinational trial, in which 
10,948 patients with acute coronary syndrome (ACS) from 28 countries in four geographic 
regions (North America, Western Europe, Eastern Europe and Latin America) were randomised 
to either Eptifibatide or placebo in addition to standard care. It was found that treatment benefit 
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with regard to death or MI at 30 days was greatest in North America. Furthermore, patients in 
Western Europe were found to have fewer composite events when treated with Eptifibatide 
compared to Latin America and Eastern Europe, where no apparent treatment effect was found. 
This implies that there was an interaction between country and effect. However, Akkerhuis et al 
(2000), analysing the same data,  suggested that  inter-country differences could be explained by 
different baseline demographics, adjunctive treatment strategies, and definitions of MI. 
The GUSTO trial reported by Van de Werf, Topol, Lee et al (1995) provides further evidence of 
these differences. This trial randomised 41,012 patients in 15 countries to four thrombolytic 
strategies to investigate their effect on mortality rates. The four thrombolytic therapies were 
Streptokinase with subcutaneous Heparin, Streptokinase with intravenous Heparin, Accelerated 
tPA with intravenous Heparin, and a combination of Streptokinase with tPA and intravenous 
Heparin. In non-US patients, the combination strategy worked as well as the accelerated tPA 
strategy, while in US patients this combination was associated with the worst clinical outcomes. 
Furthermore, accelerated tPA had the greatest benefit in US patients over the other regimens, but 
this benefit was not observed in the other countries involved in the study. However, O’Shea and 
Califf (2001) suggest that these differences result from a greater occurrence of haemorrhagic 
strokes in patients who received the combination regimen in the US compared with the other 
participating countries and those treated with the other three regimens. This, they suggest, may 
have impacted the perceived effectiveness of this regimen, making it seem less effective in the 
US patients.  
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Data from the ESPRIT multinational trial (Madan et al. 2004) shows differences between 
Canadian and US patients undergoing non-urgent Percutaneous Coronary Interventions (PCI). 
Results showed that Canadian patients had better thirty-day and one-year clinical outcomes than 
their US counterparts, differences that persisted even after adjustment for known baseline 
differences. This suggests the existence of an interaction between country and treatment and is 
consistent with the findings of the EPISTENT trial, which also compared outcomes between 
Canada and the US after PCI  (Cohen et al. 2001). Cohen et al. found that at one year, Canadian 
patients had a lower incidence of target vessel revascularisation, MI, and death after undergoing 
PCI than their US counterparts. Madan et al. (2004) suggest that consistency in the findings 
between these trials means that observed differences cannot be fully explained by chance, but are 
a consequence of differences in effectiveness between countries. 
Although trials involving patients with conditions other than cardiovascular diseases also show 
this interaction between country and treatment,
4
 these are not explored here because this thesis is 
exclusively concerned with cardiovascular disease. 
                                                 
4
For example, the AVAGAST trial explored the effect of Bevacizumab versus placebo as an addition to 
chemotherapy on overall survival in 774 patients with inoperable Gastric Cancer in three regions: Asia, Europe and 
the Americas (Kang et al. 2010). It showed that although Bevacizumab failed to significantly improve overall 
survival, its effect was heterogeneous between all regions investigated. In Asia, the overall survival rate was found to 
be 12.1 months with Bevacizumab compared to 13.9 months with placebo. This contrasted with Europe where 
overall survival was 8.6 months with Bevacizumab and 11.1 months with placebo and the Americas where overall 
survival was 6.8 months and 11.5 months respectively. However, the regional differences found in this trial could be 
due to regional differences in patient characteristics and treatment strategies (Saijo, 2010). 
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The evidence presented above suggests the existence of international differences in treatment 
effectiveness, but the majority of this originates from data that were not collected for this 
purpose. As such, much of the evidence is prima facie evidence of an interaction between country 
and treatment or country and outcomes, with little direct evidence of international differences in 
treatment effectiveness. Furthermore, authors commonly suggest that these inter-country 
differences can be explained by differences in patient characteristics or clinical management, 
factors which had not been accounted for when the trial was conducted. However, it is clear from 
the studies presented here that some of the variation cannot be explained by these two factors 
alone. The next section discusses the factors that may explain international differences in 
treatment effectiveness found in multinational trials. 
2.4: Explanations for Treatment Effectiveness Differences 
There are many factors that might explain the interaction found between country and treatment. 
As with guideline recommendations, differences could derive from culture or ethnicity. In the 
case of multinational trials, they may also be a consequence of participating countries 
implementing the trial protocol differently (see Box 2.1). 
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BOX 2.1: FACTORS THAT MAY EXPLAIN INTERNATIONAL DIFFERENCES IN 
TREATMENT EFFECT FOUND IN MULTINATIONAL TRIALS (DISPLAYED USING 
AN ADJUSTED PICO
5
 FRAMEWORK). 
Patients/ 
Population 
Differences in Patient Selection Factors: 
 
 Patient baseline demographics 
 Disease severity levels 
 Patient risk level 
 Compliance 
 Ethnicity 
 Healthcare System 
 Socio-economic status 
Intervention Differences in Timeliness of Treatment: 
 Time taken to receive treatment 
Comparator 
centre/site 
Differences in centre or site: 
 Teaching or non-teaching hospitals 
 Staffing 
 Length of Hospital Stay 
 Access to facilities 
 Thresholds for admission to centre 
Outcome Differences in Outcome Ascertainment and Accuracy: 
 Differences in how centres ascertain an endpoint  
 Differences in the accuracy of laboratory results used to ascertain an 
endpoint 
                                                 
5
 Participants, Intervention, Comparator and Outcomes 
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Adjunct 
Treatment 
Differences in Treatment Management: 
 Adjunctive surgical procedure use 
 Adjunctive medication use 
 Route of administration for adjunctive medications  
 Dosage of medications 
Trial 
Quality 
Differences in Trial Quality: 
Differences in the degree to which centres follow trial procedures, i.e. 
randomisation procedures 
 
2.4.1: Patient Differences 
Any international differences in treatment that multinational trials have reported may be a 
consequence of four main patient baseline differences between the countries in the trial. 
2.4.1.1: Baseline demographics 
Trials reporting an interaction between treatment and country have found differences between 
countries in patient baseline demographics (Domanski et al. 2004; Fox et al. 2000).White (2000) 
suggests that while patient selection factors can significantly affect treatment outcome in 
multinational trials, their effect is often ignored by researchers. O’Shea and Califf (2001) point 
out that clinical baseline demographics also differ between countries in such trials. They found 
that in trials examining fibrinolytic therapy, non-US patients are more likely than US patients to 
have suffered an anterior MI prior to randomisation. Other factors that may create differences in 
patient baseline demographics are social class, income, and education (Dragano et al. 2007; 
Galobardes, Lynch, & Smith, 2007). 
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It is possible, therefore, that patient baseline differences may explain the interaction found 
between country and treatment in multinational trials, differences that Roberts and Torgerson 
(1999) term “chance bias”. Nevertheless, they note that many RCTs already protect against this 
type of bias by implementing appropriate randomisation techniques or adjusting statistical 
analysis for baseline characteristics that are known to influence the outcome of a treatment. Each 
of these procedures goes some way to ensuring that the outcomes of the trial can be assumed to 
be a consequence of treatment.  
Patient baseline demographics also include a number of physiological and environmental factors 
that could explain the country-treatment interaction. One such factor is ethnicity, and studies 
looking at many different conditions have shown that care seeking behaviour, type and quality of 
care received, and the incidence of diseases vary between ethnic groups (Broderick et al. 2010; 
Jha et al. 2005: Shen et al. 2007) as do outcomes after treatment ( Saha et al. 2008). The Veterans 
Administration Cooperative Study Group on Antihypertensive Agents (1982), for example, found 
that those of white European descent had a better antihypertensive response to beta-blockers than 
those of black African descent. It is possible, therefore, that the interaction between country and 
treatment found in many multinational trials is due to differences in ethnicity. Different ethnic 
groups receive different types and levels of treatment, react differently to treatment, and are 
exposed to different disease associated risk factors, all of which are known to influence treatment 
outcomes.  
The interaction found in multinational trials between country and treatment might be explained 
by taking into account socio-economic status (SES). This not only affects individual patient 
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health and risk factors (Marmot, 2003; Marmot, Shipley, & Rose, 1984), but also influences 
treatment outcomes (Brechner et al. 1993). Evidence suggests that those in the lowest socio-
economic groups have greater risk factors for certain diseases (Almqvist, Pershagen, & 
Wickman, 2005; Millar & Wigle, 1986), are less likely to receive some treatments, wait longer 
for treatment, and have worse outcomes than their counterparts in higher socio-economic groups 
(Gornick et al. 2009; Potosky et al. 1998; Kapral et al. 2002). The interaction between country 
and treatment found in a number of multinational trials, therefore, may be a consequence of 
participating countries having different SES compositions, which then affects not only how, 
when, and where patients receive treatment, but also their outcomes. 
Another factor that should be considered is variation in healthcare systems. Healthcare may be 
provided in the private or public sector. For instance, in 2001, Canada spent only 57% as much 
per capita on healthcare expenditure as the US (Reinhardt, Hussey, & Anderson, 2004). This was 
because the US was able to utilise more expensive technology and had larger administrative 
expenses than Canada, which had imposed healthcare budgetary restraints (O’Shea et al. 2001). 
This led to Canada having less access to highly technological procedures such as magnetic 
resonance imaging. Such differences in healthcare systems may result in differing patient 
outcomes and should be accounted for when adjustments are made in the analysis of 
multinational trials. 
Countries also differ on how healthcare budgets are spent. Some countries may have the 
resources to procure treatments, equipment, and staff that have a beneficial effect on patients in 
some areas of their healthcare system, while in other parts of their system, interventions and 
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equipment may be less advanced. The areas that each country prioritises also differ. For example, 
Heijink et al. (2008) found that while Australia spent a lot of money on ambulatory care, France 
spent the majority of its health budget on medical goods. If a country in a multinational trial 
spends more of their healthcare budget in the clinical area studied, this may have implications for 
the outcome of the study intervention and needs to be considered when comparing the results of 
trials across the countries involved. 
The mechanisms through which healthcare systems are funded may influence treatment 
outcomes. Funding of healthcare systems differs internationally, and countries with differently 
funded systems are usually involved in multinational trials. In the UK, for example, healthcare 
costs are met through funds raised through general taxation; in others, healthcare systems are 
privately run but receive some funding from government (e.g. Canada) or are funded jointly by 
beneficiaries and employers, with contributory insurance rates to a person’s wage (e.g. Japan). Of 
course, the way in which healthcare systems are funded can have a direct impact on whether new 
technologies can be purchased and the quality of care a patient receives. All these factors can 
affect treatment and services and could lead to treatment outcomes differing between countries. 
2.4.1.2:  Disease severity 
International differences may be a consequence of one country in the trial enrolling patients with 
a high disease severity, while another enrols patients with a low disease severity, with patient 
outcomes differing according to the patients’ severity levels. White (2000) contends that in many 
multinational trials examining patients with coronary disease, disease severity will vary between 
populations, and this may influence treatment outcomes. Indeed, there is evidence to suggest that 
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responses to treatment differ in line with this factor (Anderson et al. 2000). Lindsay, Zaman and 
Cowan (1995) propose that from post-infarction trials, it can be argued that the beneficial effect 
of ACE inhibitors is heterogeneous, as they appear to be most beneficial in patients who have 
clinical evidence of heart failure, that is, those who have the greatest level of disease severity. 
Closely related to disease severity is the risk level of patients enrolled in multinational trials. As 
White (2000) points out, the risk of events among patients will differ as a consequence of 
differences in the degree of the disease. For example, as the level of disease severity increases, so 
does the likelihood of experiencing a significant event such as an MI. This may create between-
regional differences in treatment effect when treatment effect is measured in absolute terms such 
as the risk difference. This is because absolute treatment effect measures are sensitive to baseline 
risk, with absolute estimates of treatment effect being higher in centres with higher base rates 
(Borenstein et al. 2011). 
2.4.1.3:  Patient Behaviour 
Evidence suggests that exposure to disease related risk factors, such as smoking or diet 
behaviours, and beneficial behavioural factors, such as moderate amounts of exercise, differs 
between countries (Bergovec et al. 2008; Kromhout et al. 2002; Park D et al. 1998; Myers, 2003; 
Rimm et al. 1999). It is unsurprising, therefore, international differences in response to treatment 
have been found in multinational trials. However, many trials do not examine patients’ differing 
exposures to associated risk factors across countries and are, in effect, comparing heterogeneous 
groups of patients. National behavioural characteristics therefore need to be considered before 
international differences in treatment outcomes and effectiveness can be explained. 
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2.4.1.4: Treatment Compliance 
Compliance, defined by Hayes (cited in Bosworth, Oddone, & Weinberger, 2005) as the extent to 
which patients adhere to medical and health advice, has been found to influence the overall 
effectiveness of a treatment (Cramer, 2002; Psaty et al. 1990). Bleyer et al (1999) suggest that 
differences in compliance between countries could significantly alter the efficacy of some 
treatments and could, therefore, explain international differences. Indeed, when low levels of 
compliance are not considered in trials, it is thought that treatment effect is underestimated 
(Pullar, Kumar, & Feely, 1989).  As such, inter-country differences in treatment effectiveness 
may be a consequence of differing levels of compliance between countries. 
However, multinational trials may analyse data using the intention to treat (ITT) principle, which 
includes all randomised patients in the analysis according to the group to which they were 
allocated, regardless of the treatment they received, whether they completed treatment, or 
whether they complied with treatment (Newell, 1992: Fisher et al. 1990). In doing this, ITT 
analysis deliberately ignores differences in compliance, meaning that biases related to such 
differences cannot be introduced into the analysis. This is important, since patients who comply 
with treatment tend to have better outcomes regardless of group assignment (intervention or 
control) (Montori & Guyatt, 2001).Therefore, in trials that have used ITT analysis, inter-country 
differences in treatment effectiveness cannot be the consequence of differing levels of 
compliance between countries. 
  
31 
 
2.4.2: Differences in the Timeliness of the Investigative Intervention. 
International differences in outcomes that multinational trials have reported may be a 
consequence of differences in the time it took to administer the investigative treatment. 
2.4.2.1: Timeliness of Treatments 
Time to treatment has been found to differ internationally (Fu et al. 2000; Gupta et al. 2003) and 
can affect event rates for a variety of conditions (Besselink et al. 2007; De Luca et al. 2004) as 
well as determining the benefits of certain interventions. The Fibrinolytic Therapy Trialist 
Collaborative Group (1994) found that the benefit of intravenous thrombolysis was influenced by 
the time between symptom onset and start of treatment. It may be, therefore, that inter-country 
differences in multinational trials can be explained as a consequence of time to treatment 
differences between the countries participating. However, Welsh et al. (2005) found that in the 
ASSENT-3 PLUS trial, event rates differed, even though time from randomisation to treatment 
(including any adjunctive medications) was homogenous over all participating countries.  
2.4.3: Comparator Centres or Sites 
Between-country differences in the types of centre or site enrolled in multinational trials may also 
lead to differences in outcomes. 
2.4.3.1: Types of Institutions Included in Multinational Trials 
As many multinational trial protocols do not stipulate the type of site that should be included in 
the study, different types of institutions may be recruited in each country, leading to patients 
receiving different approaches to treatment management. Evidence suggests that the type of 
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institution affects treatment management and patient outcomes (Jensen, Webster, & Witt, 2009), 
and differences in types of site may therefore help explain the interaction between country and 
treatment. For example, patients admitted to academic hospitals have better outcomes than those 
admitted to community hospitals (Allison et al. 2000). Chaudhry, Goal and Sawaka (2001) state 
that the teaching status of a hospital may affect a patient’s outcome both directly and indirectly, 
as teaching status not only leads to better knowledge and skills, but also to improved processes of 
care. Other studies, however, suggest that hospital type has little impact upon patient outcome. 
Papanikolaou, Christidi and Ioannidis (2006), for instance, found that there was insufficient 
evidence that teaching hospital status improved patient outcome. This does not mean that 
international differences in patient outcome are in no way due to the types of sites enrolled, but 
rather that it may not be the most important factor, especially given that the lack of reporting on 
the difference in the types of institutions makes it difficult to assess its impact. 
2.4.3.2:  Staffing of Sites Recruited 
Evidence suggests that patient outcomes are influenced by the type of staff caring for the patients; 
mortality rates are lower for patients treated by specialists (Jollis et al. 2009; Nash, Nash, & 
Fuster, 1997). Brevetti et al. (2007) found that survival rates for patients with peripheral arterial 
disease were higher when patients were managed by a specialist. It is argued this is because 
specialists are more likely to use more effective medicines and are less likely to use treatments 
with limited benefits (Abubakar et al. 2004; Brevetti et al. 2007; White 2000). Welsh et al. (2005)  
used the assessment of the safety and efficacy of a new thrombolytic (ASSENT-3 PLUS) trial to 
assess global variations on the impact of pre-hospital care and found that pre-hospital treatment 
for patients in Sweden, Canada, and the Netherlands was provided by advanced cardiac life 
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support trained nurses and paramedics, while in France, Spain, and Germany it was provided by 
physicians. In the UK and Norway, pre-hospital treatment was provided by physicians in some 
sites and not in others. Overall, only 63.8% of patients received pre-hospital treatment from a 
physician. They found that the presence of a physician was related to fewer patients experiencing 
recurrent ischemia and repeated MI at thirty days. This suggests that how sites or hospitals are 
staffed influences patient outcomes and may be an important factor in explaining the interaction 
between country and treatment found in multinational trials. 
2.4.3.3: Length of Hospital Stay 
Evidence that length of hospital stay differs between countries in multinational trials comes from 
Kaul et al. (2004). They examined early discharge and length of hospital stay for patients with 
uncomplicated acute MI in The Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO-I), the Global Use of Strategies to Open 
Occluded Coronary Arteries (GUSTO-III), and the Assessment of the Safety and Efficacy of a 
New Thrombolytic (ASSENT-2) trials, which took place between 1990–1998. They found that in 
the ASSENT-2 trial, the median length of hospital stays was lower than that from the GUSTO-I 
trial conducted six years earlier (See Table 2.2). 
Table 2.2: Median Length of hospital stays (in days) across GUSTO –I and ASSENT -2. 
Country GUSTO-I ASSENT-2 
Germany 24 17 
Spain 12 10 
France 12 11 
Belgium 12 11 
US 8 5 
Australia 8 6 
New Zealand 7 5 
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They also found that the decrease in median length of hospital stay over all countries was 
significant (p<0.0001), with the median length of hospital stay of nine days in the GUSTO-I trial 
decreasing to seven days in the ASSENT–2 trial.6 
Differences in the length of hospital stay can affect overall outcomes for patients. Kondo, Zierler 
and Hagino (2010) found that patients who had undergone hip fracture surgery and who were 
discharged within two weeks had a significantly higher risk of mortality than patients who had 
undergone the same type of surgery but remained in hospital for more than 40 days. The 
interaction between country and treatment reported by some multinational trials may therefore be 
a consequence of these differences in hospital stay. White (2000) suggests that an ascertainment 
bias may have existed in the PURSUIT trial owing to longer hospital stays in Eastern Europe 
compared to North America. Longer hospital stays meant patients were more likely to have an 
electrocardiogram and to have cardiac enzymes monitored. Furthermore, longer hospital stays 
made extra monitoring possible. However, it should be pointed out that while the length of 
hospital stay may be an important factor in explaining between-country differences in patient 
outcome, it may be part of an interplay of factors. Indeed, Christensen et al. (2009) found that 
while there was a strong correlation between the length of hospital stay and patient mortality, the 
                                                 
6
Further evidence is provided by Christensen et al (2009), who, when investigating data from the FAST trial, found 
that the average length of hospital stay differed between the participating countries. The average length of hospital 
stay was 27 days in Sweden and Israel, 14 days in the Netherlands, 25 days in China, and just 16 days in Australia. 
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same was true for other factors such as the proportion of patients receiving magnesium and 
whether patients received treatment for oedema. 
2.4.3.4: Access to Facilities 
Sites that have better access to facilities such as catheterization laboratories are more likely to 
perform more procedures, have shorter waiting times for treatment, and therefore increase the 
benefits of treatment overall than sites with less access to these facilities (White, 2000; Yusuf et 
al. 1998). Every et al. (1993) found that patients admitted to hospitals with on-site catheterisation 
facilities were more likely to have coronary angiography than those admitted to hospitals without 
these facilities. This is important because coronary angiography can increase the benefits of 
treatments that reduce the incidence of periprocedural infarction (White, 2000). Furthermore, Fu 
et al. (2000), examining data from the US and Canadian sites of the GUSTO-IIb trial, found that 
US hospitals were more likely to have on-site facilities for revascularisation and angiography 
than Canadian hospitals. They argue that the availability of on-site facilities within the US 
resulted in shorter waiting times for these procedures. This may then affect patient outcomes.
7
 
2.4.3.5: Thresholds for Admission 
 Different countries may have differing thresholds for admission, which the multinational study 
protocol may fail to control for. Rouleau et al. (1993), using data from the Survival and 
                                                 
7
Evidence can also be found in multinational trials involving stroke patients. Gray et al. (2006) examined data from 
the Tinzaparin in acute ischaemic stroke (TAIST) multinational trial, which investigated the effectiveness and safety 
of Tinzaparin at different doses in patients with acute ischemic stroke. They found that admission to a stroke care 
unit differed between countries. In Norway 67.1% of patients were admitted to a stroke care unit compared with no 
patients in Finland and only 4.9% in Ireland.  
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Ventricular Enlargement (SAVE) trial, investigated differences in admission thresholds in the US 
and Canada for patients with chest pain and found that Canada had the higher admission 
threshold. In Canada, 51% of patients admitted to one of the coronary care units had clinical MIs 
as compared to 35% of US patients. This is important because different thresholds for admission 
mean that different patients with different risk factors could be admitted to a study, meaning that 
patient outcomes are likely to differ. By ignoring this factor, multinational trials may be 
unwittingly comparing heterogeneous patient groups, which  may contribute to the international 
variation in outcomes (White, 2000). 
However, it should be noted that most multinational trials will adjust any analysis by centre. This 
is to account for any between-centre variation caused by known and unknown factors such as 
inconsistent operating procedures, staffing differences, different lengths of hospital stay, and 
different patient baseline demographics (Chow & Liu, 2004). In doing this, an unbiased estimate 
of treatment effect can be calculated, which can be generalised over centres. This means that 
while between-country differences in centre type, staffing, and admission thresholds may impact 
upon patient outcomes, they are unlikely to influence estimates of treatment effect.  
2.4.4: Outcomes 
Other factors may play a role in producing the international differences found in multinational 
trials. Some of these may relate to outcome definition and measurement. 
2.4.4.1: Definition of Endpoint 
 The criteria used to define an endpoint of MI may differ between countries and may result in 
differences in the number of MIs recorded. However, this factor may be less important than 
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others in explaining the occurrence of country-treatment interactions, since in many multinational 
trials, clinical event committees are used to adjudicate suspected endpoints and exclude events 
that do not adhere to the strict trial definitions (Mahaffey et al. 2001; White, 2000). Furthermore, 
over 100 countries use the classification of diseases (ICD) system to define and report clinical 
events. This means that definitions of clinical events, such as an MI, should be similar between 
countries. Despite this, the use of these committees and the ICD is not a standard requirement in 
multinational trials, and the means of specifying endpoints may still differ between countries. 
Moreover, the country-treatment interaction found may be produced by the varying accuracy of 
laboratory results between countries. In multinational trials, laboratory reports and results may be 
used to diagnose a clinical event. For instance, laboratory reports of cardiac enzymes may be 
used to define the occurrence of an MI. Differences between countries would be apparent if the 
accuracy of these results differed between countries. Indeed, if reproducibility is weak, then the 
specificity and sensitivity of the endpoint diagnosis may vary (White, 2000).  
 
2.4.5: Adjunct Treatment 
Treatment management varies between countries, meaning that adjunctive treatments also vary, 
and this may explain the apparent interaction between country and treatment in multinational 
trials. Many multinational trials do not take into account the treatment management differences 
between the participating centres and countries that can occur after randomisation (Fox et al. 
2000), even though such differences may lead to differences in the use of adjunctive treatments, 
which may influence patient outcomes. Reed et al (2006) suggest that multinational trials may 
introduce a bias into their dataset by comparing patients who have been unequally treated, 
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especially in cases where treatment management differs between centres and where an interaction 
exists between the investigative treatment and a background treatment, which may give rise to the 
apparent differences in patient response to treatment. 
2.4.5.1: Surgical Interventions 
The rate of surgical procedures varies between countries included in multinational trials. For 
example, the PURSUIT trial showed regional variations both in the number of PCIs performed, 
with only 2% of Eastern European patients receiving this intervention as compared to 25% of 
North American patients (White, 2000), and in the rate of CABG during hospitalisation (11.3% 
of cases in Latin America as compared to 19.4% in North America) (Cohen et al, 2001).
8
 
The association found between country and treatment in many multinational trials may be due to 
the different rates at which surgical procedures are used alongside the trial interventions. If these 
surgical procedures are beneficial, then their use will influence patients’ responses. In such cases, 
patient outcomes may be better in some countries not because of the intervention per se, but 
because of the adjunctive use of a beneficial surgical procedure. 
Indeed, Gupta et al. (2003) found that the Assessment of the Safety and Efficacy of a New 
Thrombolytic (ASSENT-2) trial showed that increased revascularisation in some countries was 
related to better outcomes. They concluded that adjunctive surgical procedures better explain 
inter-country variation in mortality rates and outcomes than patient baseline characteristics. 
                                                 
8
Similar results were also reported from the ESSENCE trial (Fox et al. 2000), where participating countries had 
different revascularisation rates, with rates being high in Argentina but low in the UK. 
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However, results from the Intravenous nPA for Treatment of Infarcting Myocardium Early II 
(InTIME-II) trial challenges this, finding that Latin America had a higher mortality rate following 
Fibrinloysis than Western Europe, despite having similar revascularisation rates (Giugliano et al. 
2001). This suggests that international differences in patient response exist regardless of the use 
of adjunctive beneficial surgical procedures. 
2.4.5.2: Medicinal Treatments 
The types of medication used alongside the intervention under investigation also differ between 
countries involved in multinational trials, possibly because the protocols of such trials do not 
always stipulate which adjunctive medications should be used, and may, therefore, explain 
between-country differences in patient outcomes.  
2.4.5.2.1: Type of Medicinal Treatment 
Evidence that countries participating in multinational trials use different adjunctive medications 
comes from a number of trials. The Factor Seven for Acute Hemorrhagic Stroke (FAST) trial 
(Christensen et al. 2009) showed that 95% of Chinese patients received medication for oedema 
compared to 21% of US patients, 9% of Canadian patients, and 0% of patients in Finland. The 
ESSENCE trial (Fox et al. 2000) found that, of the countries involved, UK patients received the 
lowest percentage of nitrates and beta-blockers and a higher percentage of calcium channel 
blockers compared to those in Argentina.
9
 
                                                 
9
 In another trial, the use of low molecular weight heparin in patients with ACS has been found to be up to three 
times lower in the U.S when compared to other countries (Sinnaeve& Van de Werf, 2004). 
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As with adjunctive surgical procedures, adjunctive medications may influence patient outcomes. 
However, not all studies support this explanation for international differences. For instance, 
Rouleau et al. (1993) found that variation in the number of recurrent MIs and deaths between 
Canada and the U.S was not associated with a greater use of adjunctive medicinal therapies.  
2.4.5.2.2: Route of Medicinal Treatment 
The administration route of adjunctive medications may also account for the interaction between 
country and treatment in multinational trials. White (2000) found that the route of heparin 
administration differed between countries in the PURSUIT trial. If some routes of administration 
are more effective than others, this may influence the response of patients to conventional 
treatment and the investigative intervention (Butkiewicz et al. 1995; Fisher, Shahshahani, & 
Kitabchi, 1977; Schwartzman & Morgan, 2004). 
2.4.5.2.3: Dose 
 Dosages of adjunctive medications are rarely stipulated in multinational trial protocols and may 
differ across participating countries, thus contributing to international differences. In the 
Scandinavian Simvastatin Survival Study (4S), Faergeman et al. (1998) found that aspirin 
dosages given as an adjunctive medication differed across the participating countries. For 
example, Norwegian patients were given less aspirin than their Danish counterparts. This means 
that multinational trials may be comparing patients who are treated differently, which might 
produce differences in patient outcome, particularly if one dosage regime was more effective than 
another. Indeed, there is evidence to suggest that differences in the dosage of adjunctive 
medications affect the overall outcome of a treatment (Berger et al. 2008). 
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2.4.6: Trial Quality 
One of the most important factors to consider when investigating international differences in 
treatment effectiveness is trial quality. It may be that the differences found between countries in 
outcomes and treatment effect are a result of the trial centres enrolled in multinational trials 
differing in the degree to which they follow trial procedures. For instance, if the centres in one 
country do not strictly follow randomisation procedures, then treatment effect estimates may be 
higher than a country in which the centres strictly follow procedures since treatment assignment 
will no longer be masked. Therefore, countries showing the most positive results may be 
producing lower quality trials. Indeed, studies suggest that low quality trials tend to exaggerate 
the effect of treatment (Egger et al. 2003; Kjaergard, Villumsen, & Gluud, 2001; Noseworthy et 
al. 1994; Peduzzi et al. 1993).  Moher et al. (1998) examined 127 trials from 11 meta-analyses 
concerning circulatory and digestive diseases, mental health, pregnancy and childbirth. They 
found that when trial results from low quality trials were pooled, there was a statistically 
significant exaggeration of treatment effect by 30-50%. Furthermore, there was an association 
between inadequate allocation concealment and treatment benefit estimates, with trials that had 
inadequate allocation concealment tending to show increased treatment benefit. However, these 
large distorted treatment effects were not evident when trials were not double-blinded. According 
to Juni, Altman, and Egger (2001), this is because the impact that a lack of double blinding has 
on the distortion of the effect estimate will, to some extent, depend on the outcomes assessed. For 
instance, when investigating treatment effect with regards to overall mortality, the blinding of 
outcome assessment will be immaterial. 
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Further evidence of treatment effect estimates being affected by trial quality is provided by 
Schulz et al. (1995). They used a database of systematic reviews of randomised controlled trials 
concerned with pregnancy and childbirth to investigate whether biases were related to inadequate 
methodological approaches. Trial results were examined with respect to randomisation, blinding, 
and attrition. They found that inadequate methodological approaches exaggerated treatment 
effect. For randomisation, odds ratios were exaggerated by around 41% when trials inadequately 
concealed treatment allocation, while trials that did not report how they concealed treatment 
allocation exaggerated the treatment effect by around 30%. Trials that were not double-blind 
gave larger effect estimates, exaggerating the effect of a treatment by around 17%. However, 
when attrition was examined, trials that had excluded patients after randomisation did not result 
in exaggerated treatment effect estimates, but this lack of association may be a consequence of 
incomplete reporting (Schulz et al. 1995). To conclude, Schulz et al. argue that such results 
highlight both the importance of adequate methodological approaches and reliable and complete 
reporting, without which the assessment of trial quality is not feasible. 
The above evidence suggests that trial quality can have a significant impact upon the estimate of 
treatment effect. It may be the case, therefore, that differences in trial quality between countries 
create the international differences found in therapeutic effect. As such, trial quality is an 
important factor to investigate and is therefore examined in more detail in Chapter 7. 
2.5: Conclusion 
This chapter has provided an overview of the evidence for the argument that international 
differences in treatment effectiveness exist while also highlighting possible explanations for these 
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differences. It has shown that although there is little direct evidence of international differences in 
treatment effectiveness, prima facie evidence is available from multinational trials that show an 
interaction between country and treatment. In doing this, it has shown that trial data can be 
utilised in investigating international differences in treatment effectiveness. It has also presented 
influencing factors that may still be present, even under ideal conditions, when multinational 
trials are conducted and that, if not accounted for in the trial protocols and analysis, have an 
impact upon treatment outcomes. 
With this mind, this study will look at whether international differences in treatment effectiveness 
exist for cardiovascular diseases. To do this, panoramic meta-analysis will be used, an approach 
that is described in the next chapter. 
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CHAPTER 3. 
THE METHODOLOGY OF PANORAMIC 
META-ANALYSIS. 
 
The primary aim of this study was to investigate the existence of international differences in the 
clinical effectiveness of medical interventions. To do this, it used the novel approach of 
panoramic meta-analysis. This uses the same stringent procedures and techniques as standard 
meta-analysis when searching for and analysing data from relevant literature but is used for 
collating data from existing meta-analyses rather than from individual studies. It enables testing 
of generic hypotheses over a set of meta-analyses concerned with different types of intervention 
for related health conditions.  
This chapter sets out the methodological position and the novel methods that will be used to 
answer the research aims. Panoramic meta-analysis has been selected because it is an approach 
that allows for international differences in treatment effect to be directly investigated and, as 
such, allows a more comprehensive understanding of such differences to be crafted. It also 
enables generic hypotheses, such as the one in this study, to be investigated. In addition, 
panoramic meta-analysis is more efficient than “standard” meta-analysis as relevant studies can 
be identified more swiftly by searching for meta-analyses rather than the studies themselves.  
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3.1: Panoramic Meta-analysis 
Panoramic meta-analysis has its foundations in the principles and procedures of standard 
systematic reviewing and meta-analysis, and likewise it follows a systematic process in which 
relevant studies are identified, evaluated, and combined. However, it uses information from 
published systematic reviews containing meta-analyses to investigate the validity of “generic” 
hypotheses.
10
 So, for instance, panoramic meta-analysis is applicable to any situation in which a 
hypothesis involves different types of intervention used for similar medical conditions. It can also 
be used when similar interventions are employed to manage or cure different, but related, medical 
conditions or when the same intervention is used to treat or cure the same condition in different, 
but related, clinical scenarios.  
3.2: Why is Panoramic Meta-analysis Needed? 
It is estimated that studies of healthcare interventions are growing at a rate of tens of thousands 
per year (Ghersi & Pang, 2009; Hawker et al. 2002). While these studies are essential for 
evidence based medicine, the sheer number of studies can create problems for health policy-
makers, analysts, and professionals when making decisions about the most appropriate clinical 
treatment to use. This issue has long been recognised, with many researchers preparing reviews 
to collate, appraise and summarise the individual studies (Smith et al. 2011). As far back as 1753, 
James Lind carried out a review of the reports on the prevention and treatment of scurvy (The 
James Lind Library, 2007). Egger, Smith and O’Rourke (2001) state that one of the earliest noted 
                                                 
10
 generic in the sense that they can apply to all members of a family of interventions or to a group of medical 
conditions 
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meta-analyses was carried out in 1904 by Pearson, who integrated the results of five studies to 
examine the effectiveness of inoculation on typhoid. Today, there are many national and 
international organisations that are committed to conducting systematic reviews and meta-
analyses, including the National Institute of Health and Clinical Excellence (NICE),
11
 the NHS 
Centre for Reviews and Dissemination,
12
 the Institute for Work and Health,
13
 and The Cochrane 
Collaboration.
14
 
Due to the number of organisations and researchers conducting systematic reviews and meta-
analysis, the healthcare literature is now overrun with such types of research. For example, The 
Cochrane Library contains around 4,500 systematic reviews and around 2000 protocols for new 
or updated systematic reviews (The Cochrane Collaboration, 2011). The sheer quantity of 
literature could prove overwhelming to those involved in decision making, a problem exacerbated 
by there usually being more than one review on a topic, with reviews sometimes reaching 
different conclusions and being of varied quality (Cook et al. 1996; Katerndahl & Lawler, 1999; 
Smith, Devane, Begley, & Clarke, 2011). Furthermore, the steps required to produce and report 
systematic reviews and meta-analyses have increased in recent years, producing longer reports 
(Bastian, Glasziou, & Chalmers, 2010). For instance, Bastian, Glasziou and Chalmers (2010) 
note that early Cochrane reviews were usually only 10-20 pages long, whereas today they can be 
over several hundred. This makes reading and evaluating these publications time consuming for 
those involved in decision-making processes.  
                                                 
11
 Information on NICE can be found at: http://www.nice.org.uk/ 
12
 Information on the NHS Centre for Reviews and Dissemination can be found at: http://www.york.ac.uk/inst/crd/ 
13
 Information on the Institute for Work and Health can be found at: http://www.iwh.on.ca/ 
14
 Information on the Cochrane Collaboration can be found at: http://www.cochrane.org/ 
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Consequently, leaner, more efficient, and innovative methods are required to compare and 
contrast the findings of systematic reviews and meta-analyses and provide an overview of the 
best available evidence for health policy-makers, analysts, and healthcare professionals. 
Panoramic meta-analysis is one method for achieving this. 
However, panoramic meta-analysis is distinguished from other meta-epidemiological approaches 
in that unlike other approaches, the trial data from published meta-analyses can be used to 
investigate the validity of generic hypotheses. For example, it can be used to investigate and 
compare the effectiveness of different intervention types for different, but related, medical 
conditions within the same analysis and has been used to investigate the effectiveness of 
prophylactic antibiotics in surgery for a variety of medical conditions (Bowater, Stirling, and 
Lilford, 2009). In doing this, it can provide a broader overview of intervention effectiveness and 
provide a good foundation on which healthcare decisions can be made. 
3.3: A History of Panoramic Meta-analysis 
One of the fundamental aspects of panoramic meta-analysis is the systematic reviewing of 
published systematic reviews containing meta-analysis. This concept is not new and has been 
used in a number of past studies. For example, using this approach, Ernst (2002) investigated the 
effectiveness of homeopathy by conducting a critical analysis of seventeen systematic reviews 
involving meta-analyses of controlled trials on homeopathic treatments in human patients or 
volunteers  from four relevant databases. Of these, 11 were independent systematic reviews, 
while six were related to the re-analysis of a landmark meta-analysis in this area that had 
suggested that homeopathy was efficacious and was more than a mere placebo. Ernst found that 
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the six systematic reviews that had re-analysed the landmark meta-analysis did not support its 
positive findings. Furthermore, when all the included systematic reviews were analysed 
collectively, they failed to provide any evidence that homeopathic treatments were effective. 
More recently, Derry et al. (2006) conducted a systematic review of systematic reviews to 
establish the usefulness of systematic reviews in assessing the evidence for acupuncture, as while 
reviews of acupuncture supported its use, they were based on imprecise inclusion criteria which 
may have influenced their overall conclusions. They found that when excluding trials from the 
included reviews that were known to have sources of bias, none of the 35 systematic reviews 
provided strong support for the effectiveness of acupuncture. They concluded that by including 
studies that showed bias, systematic reviews of acupuncture had exaggerated the effectiveness of 
this intervention and that there was no robust evidence that acupuncture worked for any 
condition. 
Tennant et al. (2007) also performed a systematic review of systematic reviews to evaluate the 
effectiveness of interventions promoting mental health and preventing mental illness. From ten 
electronic databases, they found 27 relevant systematic reviews on mental illness prevention and 
mental health promotion interventions for infants, children, and young people up to the age of 19. 
They then categorised each systematic review according to the type of intervention assessed: 
parenting interventions, programmes for prevention of anxiety and depression, programmes to 
promote self-esteem, violence and aggression prevention programmes, school based programmes, 
and general reviews. The evidence from each category was then critically appraised using the 
Critical Appraisal Skills Programme Appraisal Tool for Systematic Reviews (Critical Appraisal 
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Skills Programme, 2002). Where possible, effect sizes and 95% confidence intervals (CI) were 
calculated for each review to assess the effect of the intervention. They found that while many of 
the systematic reviews lacked methodological rigour, they did provide evidence of the 
effectiveness of a range of interventions for preventing and promoting mental health, even though 
the effect sizes of many of the reviews were relatively modest. In concluding, Tennant et al. 
argue that systematically reviewing systematic reviews is beneficial since it enables the inclusion 
of a range of different interventions while comparing the relative effectiveness of different 
approaches to mental health. However, they point out that with this approach, it is inevitable that 
some form of double-counted data will exist, as the trials in each systematic review may be 
included in more than one of the included systematic reviews.  
Nonetheless, systematic reviews of systematic reviews are becoming increasingly popular. In 
2009, The Cochrane Collaboration introduced a new type of review: the overview of Cochrane 
reviews (Becker & Oxman, 2009). These summarise the findings of multiple Cochrane reviews 
and address the effectiveness of two or more different interventions for the same condition. They 
have a similar structure to standard systematic reviews, but instead of being based on primary 
studies, are based on systematic reviews. Although two of these new overviews should have been 
published by the end of October 2010, in fact only two protocols were in print by this time.  
However, panoramic meta-analysis goes beyond a simple systematic review of systematic 
reviews by using meta-analytic techniques to create pooled effect estimates. This is similar to 
meta-epidemiological studies, which investigate the relationship between the treatment effect 
estimates of a group of meta-analyses and a particular study characteristic. For instance, Schulz et 
  
50 
 
al. (1995) conducted a meta-epidemiological study to investigate the impact of trial quality on the 
effect estimates of meta-analyses from the Cochrane pregnancy and childbirth database. They 
classified the component trials of the included meta-analyses according to whether they had used 
appropriate randomisation and blinding methods and then examined whether those that had used 
inadequate methods had provided inflated effect estimates.  
Panoramic meta-analysis also uses a similar strategy to meta-epidemiological studies when 
assembling study data, in that it identifies relevant studies through identifying relevant meta-
analyses. However, panoramic meta-analysis differs from meta-epidemiological studies in that it 
facilitates the assessment of the validity of generic hypotheses that apply across different medical 
conditions and interventions. As such, it is able to investigate whether “country” is an important 
factor to consider when extrapolating data for multiple intervention types and medical conditions. 
It was first used by Bowater, Stirling and Lilford (2009), who wanted to use the information from 
meta-analyses in published systematic reviews to assess the validity of generic hypotheses about 
the effectiveness of antibiotic prophylaxis in preventing postoperative wound infection across 
various types of surgery. Bowater et al. searched Medline and the Cochrane Database of 
Systematic Reviews for systematic reviews that: 
 were published in English between 1990 and 2006  
 reported the effect of antibiotic prophylaxis in preventing wound infection in surgery that 
involved an incision to the skin  
 included studies reported in a meta-analysis 
 had studies that reported outcomes based on wound infection rates 
 had studies with control groups where patients received no antibiotics 
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The literature search identified 21 systematic reviews containing meta-analysis that reported the 
combined estimates of the treatment effects of 21 different types of surgery. To analyse the data, 
the pooled treatment effect estimate calculated for each of the systematic reviews was placed 
onto a forest type plot along with estimates of confidence bands. From observing these plots, 
Bowater et al. were able to conclude that antibiotic prophylaxis was effective in all types of 
surgery and suggested that it be used routinely across all surgical types. 
Hemming, Lilford and Bowater (2010) have augmented Bowater et al.’s panoramic meta-analysis 
by re-analysing the original data using a newly proposed meta-analytic model based upon the 
Bayesian approach. They proposed a hierarchical model using the random effects approach to 
combine pooled effect estimates that incorporates a “between disease” component of variance 
and a “between study” (within disease) component in its overall effect estimate (pooled over all 
diseases). In applying this model to the data, they found that the risk of post-surgery infection 
was lower in almost all surgical types, except one, in the treatment groups.  
Panoramic meta-analysis, therefore, is a very useful approach in drawing together the extensive 
systematic review literature on a topic. To do this, a systematic approach to data collection, 
management, and analysis has to be followed. This is discussed in the following sections. 
3.4: Methodology of Panoramic Meta-analysis 
As in standard meta-analysis, the panoramic meta-analytic approach aims to achieve objectivity, 
precision, and generalisability (Dickersin & Berlin, 1992) by including all available, relevant 
evidence and following these five main stages in order: 
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1. Formulating  the scope of the panoramic meta-analysis 
2. Data collection 
3. Data Evaluation 
4. Analysis and interpretation of data from included meta-analyses 
5. Presenting findings of the analysis. 
 
These will now be discussed in turn. 
3.4.1: Formulating the Scope of Panoramic Meta-analysis 
The first stage in any panoramic meta-analysis is to consider the scope of the research. The aims 
and research questions should be formulated with their parameters defined. The population to be 
investigated and the medical condition of concern also need to be defined. As with standard 
meta-analysis, these are all considered prior to conducting the literature search to ensure that 
selection and inclusion biases are minimised. This may also guarantee greater efficiency since 
establishing detailed, clear objectives prior to conducting the research eliminates retrieving 
irrelevant literature (Torgerson, 2003).  
It is also at this stage that eligibility criteria are established. These are concerned with the type of 
meta-analyses to be included or excluded in the panoramic meta-analysis. For instance, 
panoramic and standard meta-analyses may contain eligibility criteria pertaining to participants, 
the intervention under investigation, and its comparators (Higgins & Green, 2011). In addition, in 
some meta-analyses, eligibility can be restricted to certain outcomes. 
3.4.2: Data Collection 
In panoramic meta-analysis, the methods used to source potentially relevant literature are 
comparable to those used in systematic reviewing and standard meta-analysis. In short, data 
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collection entails conducting a systematic literature search over relevant databases using a search 
string of relevant terms and checking the reference lists of the publications found for further 
relevant studies. Authors may also be contacted directly during this phase in order to gain more 
information on an individual study, systematic review, or meta-analysis.  
As with standard meta-analysis, the panoramic approach requires an objective, comprehensive, 
and reproducible search of a range of sources so that as many relevant meta-analyses as possible 
can be identified. Doing this minimises bias and consequently assists in producing reliable effect 
estimates (Higgins & Green, 2011). However, data collection methods in panoramic meta-
analysis differ from standard meta-analytic practices in several ways. First, rather than having to 
identify many different individual studies, panoramic meta-analysis needs only to identify 
relevant meta-analyses. The data from the studies comprising these meta-analyses are extracted 
and used in the panoramic meta-analysis. This means that it is a more efficient approach and can 
provide evidence on a broad topic quickly. Second, when trying to identify relevant studies for a 
panoramic meta-analysis, searches can be limited to a few databases dedicated to systematic 
reviews and meta-analysis, such as the Cochrane Database of Systematic Reviews. This is 
because all relevant studies can be captured through identifying relevant, up-to-date meta-
analyses on the issue under consideration. This is not the case for standard meta-analysis, where 
it is recommended that many different electronic databases are searched to ensure that all relevant 
studies are included so as to minimise reporting bias (Critical Reviews Advisory Group, 1996). 
Third, the searches used in panoramic meta-analysis can be limited to certain time periods. As the 
widespread use of meta-analysis is relatively new, limiting the search to meta-analyses conducted 
within specific time periods (for example, searching only for meta-analyses from 1990 onwards) 
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will still identify almost all relevant up-to-date meta-analyses (Smith, Devane, Begley, &Clarke, 
2011). This cannot be said for standard meta-analysis, as narrowing the search by placing 
limitations on search periods could result in some relevant studies not being identified, which 
may then bias its findings.  
3.4.3: Data Evaluation 
In the data evaluation stage of panoramic meta-analysis, the potentially relevant meta-analyses 
that have been identified are assessed for inclusion. Processes similar to standard meta-analysis 
are used, but the panoramic meta-analysis approach differs slightly in that it assesses both the 
meta-analyses and the studies that they contain. The process is as follows: 
1) Initial screening of meta-analyses ‘titles and abstracts to assess relevance and duplication 
2) Obtain the full reports of potentially relevant meta-analyses  
3) Assess the full reports of meta-analyses for relevance 
4) Screening studies in meta-analyses for inclusion. 
 
As with standard systematic reviews and meta-analysis, data evaluation should be carried out by 
at least two researchers using predefined and agreed criteria in order to reduce review and 
selection bias (Smith, Devane, Begley, & Clarke, 2011). Disagreements about study inclusion 
should be resolved through discussion with a third party (Bhandari & Joensson, 2009). 
In standard meta-analysis, the quality of included studies is also assessed at this stage. This is 
important to this approach as study quality may influence the overall effect estimate it produces. 
Indeed, study quality has been found to affect the size of treatment effect estimates (Khan, Daya, 
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& Jadad, 1996; Moher et al. 1998). This is also the case in panoramic meta-analysis, where 
analysis is based not on the meta-analyses included, but on the trials they contain. 
3.4.4: Analysis and Interpretation of Data 
In the fourth stage, data is analysed and interpreted. Panoramic meta-analysis uses the same 
robust techniques as standard meta-analysis to combine data while also examining bias and 
heterogeneity that may affect the overall treatment effect estimate. Like standard meta-analysis, 
panoramic meta-analysis also investigates any trial characteristics that are considered important 
in relation to the overall treatment effect estimate. However, panoramic meta-analysis differs 
from standard meta-analysis in that in order to provide a broader view, it draws data together for 
analysis from studies that have investigated different interventions for different but related health 
conditions. 
Issues of heterogeneity and bias will be discussed first since these may impact upon the overall 
analysis and what conclusions can be drawn from a study using panoramic meta-analysis.  
3.4.4.1: Heterogeneity and Bias 
As with standard meta-analysis, heterogeneity and bias are concerns in panoramic meta-analysis. 
Heterogeneity and bias are quite distinct concepts that can exist simultaneously in any meta-
analytic approaches. While heterogeneity pertains to the variability of the true underlying effects 
between the studies, bias relates to a systematic difference between the study results and the true 
results arising from how the  primary studies or meta-analysis were conducted (British Medical 
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Journal, 2011). Although both are investigated independently, bias can create heterogeneity in 
any set of data, and this should be considered when conducting any type of meta-analysis.  
For this research, heterogeneity is important because this study investigates country as a 
component of heterogeneity. It is also necessary to consider both heterogeneity and bias because 
they may impact upon the extent to which studies can be combined and the effect estimate that is 
calculated. These concepts are now considered in turn. 
3.4.4.1.1: Heterogeneity 
In any form of meta-analysis, estimates of treatment effect will vary between the studies that 
have been included (Song et al. 2001). It is important to investigate between-study differences 
because such variations can influence the overall results of the analysis. Study results may vary 
by chance due to sampling error, but when there is a variation between study results greater than 
that expected by chance alone, this is termed statistical heterogeneity. Thompson (1994) argues 
that statistical heterogeneity can be a consequence of clinical heterogeneity and/or 
methodological heterogeneity. Clinical heterogeneity occurs when the studies included in any 
meta-analysis contain clinical differences. These may include differences in patient management, 
different types of patient, and different treatment regimes. Methodological heterogeneity refers to 
differences in the methods and analyses that studies have used, such as variation in how patients 
have been randomised, how attrition was handled, and how issues of patient blinding were 
tackled. However, it should also be pointed out that heterogeneity can also be caused by 
unmeasured study characteristics, which should be investigated when conducting a meta-analysis 
(Thompson, 1994) or a panoramic meta-analysis.  
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To investigate whether statistical heterogeneity is present in meta-analyses, statistical tests can be 
conducted. The Q  test, as defined by Cochran in 1954 (Huedo-Medina et al. 2006), assesses 
whether studies are heterogeneous. It tests if the deviation of the results of the individual studies 
from the overall effect estimate is beyond that expected by chance. Cochran’s Q  test is based 
upon the squared difference between each study’s estimated treatment effect ( i ) and the overall 
combined treatment effect ( ). This is weighted by the inverse of the estimated variance of the 
treatment effect in each study ( )( IV
iw ). This means that large, more accurate studies are given 
greater weight in the Q  statistic than small studies.  
A high Cochran’s Q  value indicates large differences between studies and shows, therefore, that 
the effects from the included studies are heterogeneous. Consequently, the null hypothesis of 
homogeneity should be rejected in this case. However, to validate this and ascertain its 
significance, a p-value from the 2 distribution is also often given with the Cochran’s Q  statistic. 
This is an indication of the extent of between-study variability, with a p-value of <0.10 being 
commonly used  as the cut-off point (The Cochrane Collaboration, 2002). The equations used to 
calculate Cochran’s Q  can be seen in Box 3.1. 
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Another statistical measure of heterogeneity is the  Index developed by Higgins and Thompson 
(2002).  This gives a measure of the degree of inconsistency between the study results and 
describes the percentage of total variability across studies that is a consequence of true 
heterogeneity rather than chance. The equations used in its calculation can be seen in Box 3.2.
BOX 3.1: THE EQUATION FOR COCHRAN’S Q . 
2
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where k  is the number of studies combined in the meta-analysis and where   is calculated 
using this formula: 
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Cochran’s Q also has a chi-squared ( 2 ) distribution with 1k degrees of freedom (df) 
under the null hypothesis of homogeneity. 
 
 
BOX 3.2: THE EQUATIONS USED FOR THE  INDEX. 
  QdfQI /1002   
where Q is the value of Cochran’s Q and where: 
1 kdf  
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Negative  values are recorded as equal to zero so that  values can range between 0 and 
100%, with zero indicating that no observed heterogeneity exists across the included studies.  
values of 25%, 50%, and 75% are regarded as showing low, moderate and high heterogeneity, 
respectively (Higgins et al. 2003). 
 
The  Index has many advantages. Unlike Cochran’s ,Q it is not heavily dependent upon the 
number of studies included in a meta-analysis (Higgins et al. 2003). It can also be accompanied 
by an uncertainty interval, which is usually expressed with 95% confidence intervals and can be 
interpreted in the same way irrespective of the type of effect measure and outcome data used. It is 
also easy to interpret and can be easily calculated for any meta-analysis (Higgins et al. 2003). 
However, when meta-analyses contain few studies, the above statistical tests have low power to 
detect heterogeneity. Conversely, where many studies are included, these tests can indicate 
differences when heterogeneity is in fact negligible (Alexander, Scozzaro, & Borodkin, 1989; 
Cornwell, 1993; Cornwell & Ladd, 1993; Hardy & Thompson, 1998; Harwell, 1997). 
Consequently, non-significant results from such tests cannot be assumed to show homogeneity of 
studies, and significant results cannot be assumed to show heterogeneity between studies. Indeed, 
Egger and Smith (2001) suggest that low power can frequently result in failing to reject the null 
hypothesis about the existence of homogenous results, even if inter-study differences are present 
in the dataset. As a result, Thompson (2001) argues that it is reasonable to dispute the usefulness 
of heterogeneity testing, suggesting that such tests are irrelevant. This is because all studies 
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within a meta-analysis will differ, both in clinical and methodological terms. This is particularly 
the case in panoramic meta-analysis, where, to provide a broad overview, studies that differ in 
clinical and methodological terms are intentionally analysed together. For this reason, a statistical 
test of heterogeneity was not conducted in this study.  
Thompson (2001) suggests that it may be better to examine the influences of specific differences 
between the trials (for example, patient management) rather than depending upon a statistical test 
that shows the existence of heterogeneity. He suggests that if specific differences between studies 
can be identified, the true dissimilarities between the studies will be detected. This is supported 
by Colditz, Burdick, and Mosteller (1995) and Berlin (1995), who suggest that the sources of 
heterogeneity in a meta-analysis should be examined so as to understand the reasons for 
differences. Indeed, Berlin suggests that investigating the reasons why results differ between 
studies could lead to new insights about the relationships between study results and study 
protocol. This is the foundation of this study, which aims to examine country as a component of 
between-study variability. 
3.4.4.1.2: Techniques to Investigate Heterogeneity 
For any meta-analytic approach, there are two main ways to investigate heterogeneity between 
studies: meta-regression and stratified analysis. Meta-regression is a statistical assessment that 
examines whether certain study characteristics influence the size of the treatment effect across 
studies  (Lau, Ioannidis, & Schmid, 1997), with the size of these effects being calculated using 
the same type of effect measures as in standard meta-analysis. Study characteristics that could be 
investigated may be the dose of a drug, aspects of the intervention, and/or the length of treatment. 
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Stratified analysis, on the other hand, is used when a particular characteristic is to be investigated 
(e.g. when comparing studies with old versus young patients) (The Cochrane Collaboration, 
2010). In this approach, studies are sub-grouped according to a particular characteristic. Separate 
meta-analyses are then conducted on each group to provide a summary of treatment effect per 
group, its variance, and an estimate of the heterogeneity observed in each group. The overall 
summaries of treatment effect can then be examined to see whether there are variations in the 
clinical effectiveness of the intervention across sub-groups.  
In this approach, all assumptions that treatment effectiveness differs between groups of studies 
are based upon a recognised test of statistical significance (Deeks, Altman, & Bradburn,  2001). 
If there are only two groups in the analysis, then the significance of the differences between 
groups can be assessed by comparing the z statistic (the difference between the two groups’ 
estimates) with critical values of the normal distribution. See Box 3.3 for the equation for 
calculating z. 
 
 
 
Alternatively, if there are more than two sub-groups in the stratified analysis, the significance of 
the difference between sub-groups can be investigated by separating the overall heterogeneity 
into that which can be accounted for by the differences between the sub-groups and that which 
remains unexplained within the sub-groups. The process for this is shown in Box 3.4. 
BOX 3.3: Z STATISTIC EQUATION. 
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Stratified analysis can also be conducted when individual patient data is obtainable from the 
studies included in a meta-analytic approach, that is, when event rates in each study are available 
for every patient who participated. When this type of data is available, characteristics such as 
patients’ age or ethnicity can be investigated for heterogeneity. However, since individual patient 
data is rarely available or readily accessible when conducting a meta-analysis, stratified analysis 
using this type of data cannot always be performed. 
There are limitations to each of these approaches. For instance, when meta-regression is based 
upon a small number of studies, it will have insufficient power to detect any important effects 
(Petrie & Sabin, 2009), meaning that it is difficult to draw robust conclusions (Thompson & 
Higgins, 2002). Furthermore, in meta-regression, any relationship found is observational since, 
by being conducted across studies, it does not have the benefits associated with randomisation. 
As such, it can suffer from the same disadvantages as other observational investigations, namely, 
BOX 3.4: CALCULATING THE SIGNIFICANCE OF THE DIFFERENCE 
BETWEEN MORE THAN TWO GROUPS IN A STRATIFIED ANALYSIS. 
According to Deeks, Altman and Bradburn (2001), if the heterogeneity of the overall 
unstratified analysis is , the heterogeneity explained by differences between sub-
groups, , is given by: 
 
where is the heterogeneity observed within each group and where  is the number of 
studies. After this has been calculated  can be compared with the critical values of the 
Chi-squared distribution with  degrees of freedom. 
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confounding
15
 and bias (Thompson & Higgins, 2002). For example, if studies were investigating 
the effectiveness of a new treatment and some happened to enrol patients with a higher severity 
of a disease, it would be difficult to tell which aspect (the treatment itself or the severity of the 
disease) was to cause of any difference in treatment effect between these studies and the others 
examined. This is also the case with stratified analysis, where the investigation into differences in 
treatment effectiveness between sub-groups is not a randomised comparison and so is susceptible 
to all the issues that arise in inferring causality when observational studies are considered. 
Heterogeneity may also not be fully accounted for by meta-regression, as there may be many 
study and patient characteristics that could explain heterogeneity that are not considered in meta-
regression (Thompson & Higgins, 2002). As with meta-regression, the findings from stratified 
analysis should be treated with care since any differences found can be due to factors 
unaccounted for or due to chance (Deeks, Altman, &Bradburn,  2001). Moreover, both meta-
regression and stratified analysis can only include available data. To conduct a meta-regression or 
a stratified analysis, information concerning the topic of interest, the estimated treatment effect, 
and its variance have to be extracted from each included study, but such information is not 
always available or readily accessible. 
In addition, stratified analysis has specific limitations. Lau, Ioannidis and Schmid (1997) state 
that as the analysis of sub-groups is a post-hoc exercise, it has the potential to turn into what they 
call a “fishing expedition”.  They suggest that stratified analysis can sometimes be pernicious, as 
                                                 
15
 Characteristics are confounded if their influence on treatment effect cannot be separated.  
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differential treatment effects between sub-groups may have been taken from small sub-divisions 
of the aggregated data and so are unlikely to represent the “truth”, resulting instead in a high 
probability of drawing false positive conclusions. Moreover, in meta-analytic approaches, 
estimating the effects in sub-groups is restricted by the lack of standardised reporting of data 
between studies. Consequently, any analysis involving sub-groups should be based upon a 
scientific rationale (Hahn et al. 2000) or should be considered an exploratory method useful in 
generating hypotheses (Lau, Ioannidis, &Schmid, 1997). 
Nevertheless, for this study, stratified analysis was chosen as the main method to investigate 
heterogeneity because it was considered the most appropriate approach to use when making 
indirect comparisons between sub-groups (Higgins, Deeks, and Altman, 2011). Moreover, its 
utility is further enhanced because stratified analysis is a relatively simple method for 
investigating heterogeneity (Madhukar, 2009). 
To tackle some of the issues that arise when heterogeneity is investigated, possible sources of 
heterogeneity should be pre-specified when conducting stratified analysis and meta-regression. 
This is because pre-specification increases the credibility of any statistically significant findings, 
as it can be seen that such findings are not data-derived (Colditz, Burdick, & Mosteller, 1995; 
Deeks, Altman, & Bradburn,  2001). Furthermore, Thompson and Higgins (2002) suggest that 
pre-specification can protect against drawing false positive conclusions from investigations into 
heterogeneity. On the basis of this advice, country and continent were pre-specified as a possible 
source of heterogeneity in this study. 
  
65 
 
3.4.4.1.3: Bias 
When using any meta-analytic approach it is important to consider the impact of any types of bias 
upon the results. This is because bias has the potential to seriously distort any efforts made to 
estimate the effect under investigation (Thornton & Lee, 2000), leading to erroneous conclusions 
about what the body of evidence shows.  
Differential dissemination of research findings is one cause of bias in meta-analytic approaches. 
According to Dickersin (1990), since only a small proportion of research ever reaches publication 
in an indexed journal (and is therefore easily identifiable by systematic reviewers), information 
that may be potentially important to the results of a review remains unseen by reviewers, which 
may consequently lead to that review being biased. Moreover, the dissemination of research 
findings is greatly influenced by the nature and significance of a study’s result (Egger, Dickersin, 
& Davey Smith, 2001). For example, research showing a statistically significant result for the 
beneficial effect of a treatment is more likely to be published than research showing non-
significant results (Egger, Dickersin, & Davey Smith, 2001). Such occurrences are referred to as 
reporting biases, and these have the strongest influence upon which studies are likely to be 
identified for both standard and panoramic meta-analyses. Types of reporting bias are discussed 
below. 
3.4.4.1.3.1: Publication Bias 
One type of reporting bias is publication bias. This is defined in the dictionary of epidemiology 
(Thornton & Lee, 2000) as “an editorial predilection for publishing particular findings e.g. 
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positive results, which leads to the failure of authors to submit negative findings for publication.” 
(p. 207). 
Publication bias has long been recognised within the sciences, with studies from many disciplines 
reporting that statistically significant results are more likely to be published than non-significant 
results (Easterbrook et al. 1991). Indeed, Sterling, Rosenbaum and Weinkam (1995) found that in 
psychology journals, 95.6% of the published studies reported statistically significant results. This 
suggests that studies presenting results showing treatments to be beneficial are more likely to be 
published than studies showing no treatment benefit (or that studies showing no benefit are rarely 
submitted for publication to journals). In such cases, a meta-analysis based on only published 
research could show a false benefit of a treatment or fail to spot important adverse events related 
to it. This is supported by Simes (1986) who investigated whether a meta-analysis containing 
only published trials would produce a different treatment effect estimate than a meta-analysis 
containing both published and unpublished trials from an international trial registry. Using trials 
of different cancer chemotherapies, Simes found that when meta-analysis was based solely on 
published trials, the survival of patients with advanced ovarian cancer was improved by using 
combination chemotherapy. However, when the meta-analysis included trials from the 
international registry, it was found that combination chemotherapy had only a slight beneficial 
effect that was not statistically significant. When conducting meta-analysis, therefore, it is 
essential that published and unpublished literature is sourced to ensure that bias is minimised.  
A factor contributing to publication bias is source funding. According to Thornton and Lee 
(2000) the source of funding for a trial may influence whether a trial is published or not. 
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Evidence suggests that trials funded by voluntary organisations or a national government are 
more likely to be published than those funded by the pharmaceutical industry (Easterbrook et al. 
1991). Easterbrook, et al. (1991) argue that this is due to scepticism surrounding data 
management of trials funded by pharmaceutical companies. For example, Davidson (1986) found 
that many pharmaceutical company trials produce results favouring the intervention over the 
control. Davidson conducted a review of clinical trials to examine the difference in results 
between trials funded by the pharmaceutical industry and those funded by other means. He found 
that 89% of trials funded by the pharmaceutical industry favoured the treatment under 
investigation compared to only 61% of trials funded by other means. In a similar study, 
Bourgeois, Murthy and Mandl (2010) discovered that 85.4% of trials funded by the 
pharmaceutical industry reported the trial drug as having greater effect than its comparator. Etter, 
Burri and Stapleton (2007) suggest that the greater effectiveness of interventions found in 
industry-sponsored trials may be due to the amount of funding that such sponsors provide. They 
argue that since more resources are available, this may lead to higher levels of compliance and 
thus greater treatment effect. However, Egger and Smith (1998) suggest that the greater levels of 
intervention effectiveness found in industry-sponsored trials are due to pharmaceutical companies 
actively discouraging the publication of trials that they have funded and that have shown their 
interventions to have no effect. Consequently, a meta-analysis or a panoramic meta-analysis 
based only upon published studies funded by the pharmaceutical industry would be misleading 
since it would produce an over-stated overall effect estimate that would not occur if both 
published and unpublished studies were included.  
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3.4.4.1.3.2: Time-Lag Bias 
Time-lag bias is the rapid or delayed publication of study results owing to the nature and 
significance of the results. It has been argued that such a bias exists, whereby studies showing 
positive results are more likely to be published faster (Stern & Simes, 1997). For instance, 
Ioannidis (1998) found that trials relating to HIV infection in the US took 4.2 years after the start 
of patient enrolment to be published if results were statistically significant but 6.4 years if results 
were non-significant. According to Egger, Dickersin and Smith (2001), time-lag bias can occur in 
meta-analyses even in circumstances when a large number or all studies will eventually be 
published. This is because trials showing treatment benefit will dominate the literature until trials 
showing no or poor treatment benefit are finally published. This may then lead to interventions 
being accepted as effective, with meta-analyses overestimating the effect of treatment, even 
though they are not. In these instances, panoramic meta-analysis would also over-estimate the 
effect of interventions as it would be pooling information from biased meta-analyses. 
3.4.4.1.3.3: Language Bias 
Language bias describes the situation whereby statistically significant results are more likely to 
be published in particular languages (Egger et al. 1997).Egger et al. (1997) found that studies that 
have statistically significant results are more likely to be published in English than studies that do 
not have such results. It has also been found that statistically significant results are more likely to 
be published in English language based international journals and non-significant results 
published in local journals (Egger & Davey Smith, 1998; Gregoire, Derderian, & Le Lorier, 
1995). Bias leading to an overestimation of treatment effect could thus be introduced into meta-
analyses that are solely based upon studies written in English. However, some research does 
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suggest that language bias does not influence the overall outcome of a meta-analysis. A 
retrospective analysis conducted by Juni et al. (2002) found that excluding studies that were not 
published in English had little impact upon the overall treatment effect estimates given by meta-
analyses.  
3.4.4.1.3.4: Database Bias 
Database bias refers to the biased indexing of published studies within databases (Felson, 1992). 
While databases such as Medline and EMBASE index the majority of non-English language 
European journals, they do not index journals that are published in less developed or developing 
countries (Singh & Singh, 1994). Indeed, Egger and Davey Smith (1998) point out that of the 
3861 journals published in Medline, only 30 are from India, even though this country has one of 
the largest research outputs. Due to this, published studies in journals not indexed by a major 
database are likely to be hidden from researchers undertaking systematic reviews and are 
therefore unlikely to be used in meta-analysis. This may then have a detrimental impact upon the 
overall accuracy of the meta-analysis, especially if indexed studies and non-indexed studies have 
different results and characteristics. For example, Song (2000) suggests that if a meta-analysis is 
based upon a database where the indexed studies’ results systematically differ to non-indexed 
studies, then its literature search is likely to be biased and its overall effect estimate inaccurate. 
However, database bias is minimised in panoramic meta-analysis because data is gathered 
through relevant meta-analyses. These would have utilised many different databases in their 
literature searches, making the sample of studies in a panoramic meta-analysis more likely to 
include both indexed and non-indexed studies. 
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3.4.4.1.3.5: Citation Bias 
Citation bias occurs when the citation or non-citation of study results is dependent upon their 
nature and significance (Egger, Dickersin, & Davey Smith, 2001). Citation bias is introduced into 
a meta-analysis when database searches are enhanced by checking the reference lists of other 
studies and by contacting authors in the data collection stage. This is because the citing of 
previous work is not necessarily objective, as studies that report a positive beneficial effect of a 
treatment are likely to be cited more often than those reporting null or non-beneficial effects 
(Egger, Dickersin, & Davey  Smith, 2001; Ravnskov, 1992).  Indeed, Kjaergard and Gluud 
(2002) found that studies that had positive results were more frequently cited in other research 
and reviews than those with non-significant or negative results. Since locating supportive studies 
is more likely when using the reference lists of other studies, citation bias may negatively affect 
the results of any meta-analysis by biasing the results of meta-analyses in favour of treatment 
(Egger, Dickersin, & Davey Smith, 2001). Furthermore, citation bias can also influence the 
conclusions of panoramic meta-analysis. If positive studies are more likely to be cited, then they 
may be more likely to be located, making them more likely to be included in meta-analyses and 
thus more likely to be included in panoramic meta-analysis, which in using the data from the 
meta-analyses as the basis of its analyses will have biased findings. 
3.4.4.1.3.6: Multiple Publication Bias 
Multiple publication bias occurs when a single study is published more than once and is thought 
to lead to problems within meta-analysis in a variety of ways (Huston & Moher, 1996). For 
instance, research has found that studies that give a positive result are more likely to be published 
more than once (Easterbrook et al., 1991), meaning that such studies are more likely to be 
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identified and included in a meta-analysis. In addition, it is not always clear whether the multiple 
publications are reporting results from the same study. This may lead to duplicate data being 
placed into a meta-analysis or panoramic meta-analysis, which, if the data favours the 
intervention, may lead to an overestimation of the intervention’s clinical effectiveness. This is 
particularly the case when multi-centre trials are considered (Egger & Davey Smith, 1998; 
Leizorovicz, Haugh, & Boissel, 1992) as a meta-analysis or panoramic meta-analysis may 
include the data from a multi-centre trial while also including a subset of the same data reported 
separately by one of the centres within the multi-centre trial. However, unless the author can be 
contacted, it is difficult to eradicate this type of bias because it is not always easy for reviewers to 
discover whether two papers are duplicate publications of one trial or are two distinct trials 
(Egger & Davey Smith, 1998); they may report the same trial but may not have an author in 
common (Felson, 1992; Tramer et al. 1997). 
3.4.4.1.3.7: Additional Factors 
Additional factors may also introduce bias into a standard or panoramic meta-analysis. One such 
factor may be the provision of data by investigators. When using meta-analytic approaches, 
additional data that is not available in the published report is sometimes required. This, however, 
can be difficult to obtain, and there may be many reasons why an investigator is unable to give 
the information needed. For instance, investigators may no longer have the information to hand 
or are prohibited from providing the data by funders. In this instance, studies for which additional 
data was not provided would be excluded from the meta-analysis or panoramic meta-analysis, 
which would put these meta-analyses at risk of producing a biased effect estimate.  
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Finally, study quality may introduce bias into meta-analytic approaches. Many studies have 
shown that the size of the treatment effect estimate is greatly affected by the quality of the 
included studies (Egger et al. 2003; Moher et al. 1998; Wood et al. 2008c) . For instance, Khan, 
Daya and Jadad (1996) found that high quality studies tended to show no overall treatment 
benefit, whereas low quality studies showed a positive treatment effect. Therefore, it is important 
to consider the study quality when conducting a systematic review, meta-analysis, or panoramic 
meta-analysis. Indeed, Juni, Altman and Egger (2001) suggest that if the studies included in a 
review or meta-analysis are flawed, then the conclusions that can be drawn from the review or 
meta-analysis will be weakened and may be considered invalid.   
To counter this problem, many researchers will restrict inclusion criteria so that only randomised 
controlled trials are included (Berlin & Rennie, 1999). This assumes that bias does not exist 
within RCTs, but Moher et al.(1998) and Schulz et al.(1995) show that this is not the case. Thus, 
additional steps may be required to eradicate the influence of study quality on effect estimates.  
As panoramic meta-analysis can base its analysis on both data from the meta-analytic level and 
trial data level, it may also be important to assess the quality of the meta-analyses it includes. 
This should ensure that any analysis is grounded in the best available evidence. However, while 
several researchers have proposed guidelines and instruments for assessing the quality of meta-
analyses (Cook et al. 1997; Shea et al. 2007), there is as yet no consensus across disciplines about 
how this should be done or which instrument to use (Moher et al. 1999). Moreover, none of the 
instruments developed for this purpose assess the quality of the statistical methods used in the 
meta-analysis (Jude-Eze. 2011). Therefore, until a consensus is reached on how meta-analysis 
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quality should be assessed and until instruments become more robust and effective, the quality of 
meta-analyses cannot be accurately assessed in panoramic meta-analysis. 
3.4.4.1.4: Techniques to Investigate Bias 
As bias may have a detrimental impact upon the estimate of treatment effect that a meta-analysis 
or panoramic meta-analysis produces, it is important to know how to investigate its existence. 
Investigating publication bias in a meta-analysis is usually conducted using funnel plots in 
conjunction with statistical analyses. Funnel plots are simple scatter plots that plot the treatment 
effect estimate of each included study (on the x axis) against a measure of precision (on the y 
axis) (Sterne & Harbord, 2008). In general, the precision of the estimated underlying treatment 
effect increases as the sample size of the included studies increases. This causes large studies to 
have a narrow spread and be placed at the top of the graph and small studies to scatter widely 
around the bottom, thus creating a funnel-type shape. If bias is not present, then the graph should 
look like an inverted symmetrical funnel, as in Figure 3.1. If bias is present, then the funnel plot 
might look like Figure 3. 2.  
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FIGURE 3.1: HYPOTHETICAL SYMMETRICAL FUNNEL PLOT IN THE ABSENCE 
OF BIAS* 
 
*Treatment effect versus a measure of study size from Sterne, Egger & Moher (2008) 
 
FIGURE 3.2: HYPOTHETICAL ASYMMETRICAL FUNNEL PLOT IN PRESENCE OF 
PUBLICATION BIAS* 
 
*plotting the estimates of treatment effect against a measure of study size from Sterne, Egger & 
Moher (2008) 
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A funnel plot may also be asymmetrical in the presence of publication bias where smaller studies 
that have no significant effect remain unpublished and, therefore, are not placed on to the funnel 
plot. Biases due to language, citation, and multiple publication can also cause this asymmetry 
(Egger et al. 1997), as can chance. In addition, funnel plots can detect bias due to low 
methodological quality, where small trials in a meta-analysis are exaggerating the treatment 
effect estimate. Figure 3.3, for instance, shows a hypothetical funnel plot in which the small low 
quality trials (shown as open circles) are contributing to asymmetry by exaggerating the treatment 
effect. For both types of asymmetric funnel plot, the more prominent the asymmetry, the more 
significant the bias and, therefore, the higher the probability that the combined effect estimate for 
the meta-analysis in question will be overestimated. 
FIGURE 3.3: HYPOTHETICAL ASYMMETRICAL FUNNEL PLOT IN THE 
PRESENCE OF BIAS DUE TO LOW QUALITY SMALL STUDIES* 
 
* The estimates of treatment effect versus a measure of study size from Sterne, Egger & Moher 
(2008). 
  
76 
 
However, asymmetry in a funnel plot may not be proof of bias. The shape of a funnel plot may 
also be affected by the choices made in relation to its construction. Tang and Liu (2000) suggest 
that the shape of a funnel plot depends, to a great extent, upon what effect measure is used and 
how precision is defined within its construction. From their study, they found that selection bias 
was suggested by asymmetry in 21.7% of all the meta-analyses they examined. However, 86% of 
these asymmetric funnel plots became symmetrical when different definitions for precision 
and/or effect measure were employed, showing that the shape of a funnel plot is associated with 
the approach used to construct it. Furthermore, as funnel plots must be examined visually they are 
open to subjectivity. Therefore, funnel plots were not utilised in this study. 
More formal statistical methods have been developed that examine the association between study 
size and its effect measure (Begg & Mazumdar, 1994; Egger et al. 1997). One such method is the 
Trim and Fill method proposed by Duval and Tweedie (2000). It works by omitting small studies 
one at a time until the funnel plot becomes symmetrical. This is called trimming. Once these 
studies have been removed, the trimmed plot is then used to estimate the adjusted overall effect 
estimate. Omitted studies are then reinstated into the plot, around the centre, along with their 
missing counterparts (i.e. “missing” studies). This is called filling. A new adjusted estimate of 
intervention effect is then calculated, along with its variance based upon this “filled” funnel plot. 
While this method may be useful as it provides an estimate of how many trials are missing and 
allows an adjusted treatment effect to be calculated, it cannot account for asymmetry other than 
by publication bias (Higgins and Green, 2011). Therefore, the adjusted estimate of intervention 
effect should be treated with caution. Furthermore, the Trim and Fill method performs poorly 
when considerable between-study heterogeneity is present in the dataset (Peters et al. 2007; 
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Terrin et al. 2003). Therefore, it would not be appropriate to use this in panoramic meta-analysis 
because the approach is based on studies that differ in clinical and methodological terms.  
3.4.4.2: Meta-analytic Techniques 
The panoramic meta-analytic approach uses similar techniques to standard meta-analysis to 
analyse and interpret data. Both approaches entail calculating individual treatment effect 
estimates for each of the included studies. The treatment effect estimate can be calculated for 
both binary (event-based) and continuous outcomes (i.e. weight). When data is event based, 
summary statistics are calculated in the form of odds ratios (OR), risk ratios (RR), or risk 
differences, while continuous data is usually given as the difference between the means (MD) or 
as a standardised mean difference (SMD). Hazard ratios are the summary statistic for survival 
time data. The effect estimates of each study can then be pooled to provide an overall treatment 
effect estimate. This can be done using a fixed or random effects approach. 
3.4.4.2.1: Calculating Individual Treatment Effect Estimates 
As panoramic meta-analysis involves calculating treatment effect estimates for studies from 
many meta-analyses that have assessed different types of outcome, all or some of these summary 
statistics will need to be calculated. The different summary statistics – odds ratios, risk ratios, risk 
difference, and mean difference – will be discussed in turn. Hazard ratios will not be discussed in 
this chapter because none of the meta-analyses included in this study reported outcomes in terms 
of Hazard ratios
16
 (see Chapter 4). 
                                                 
16
 For further information about hazard ratios see Deeks et al. (2001). 
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3.4.4.2.1.1: Binary Outcomes 
An outcome that takes 1 of 2 values is described as a binary outcome. For example, if the 
endpoint measured for a given intervention is mortality, the outcome for the patient is either 
death or no death and can be presented as shown in Table 3.1. In this example, if someone in the 
intervention group dies, they will be added to the intervention/event cell (cell a ). If someone in 
the control group does not die, they will be added to the control/no event cell (cell d ). The data 
from this table is then used to calculate the summary statistic for each trial. 
Table 3.1. Summary information for a Binary Outcome. 
 Event No Event Group Size 
Intervention a  b  
1n  
Control c  d  
2n  
Total   
iN  
 
 
The summary statistics can be expressed as either a relative or absolute measure. Odds ratios and 
risk ratios are relative measures, whereas the risk difference is an absolute measure. However, 
absolute measures of effect
17
 will not be discussed in this chapter because none of the meta-
analyses included in this study reported outcomes in terms of risk difference or numbers needed 
to treat. 
                                                 
17
 For further information about absolute measures of effect see Deeks et al. (2001). 
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BOX 3.5: THE EQUATIONS USED TO CALCULATE AN ODDS RATIO. 
ii
ii
i
cb
da
OR   
with the standard error of the log odds ratio, where ln denotes the logarithms to base e, 
being given by: 
  
iiii
i
dcba
ORSE
1111
ln   
 
The odds ratio is the ratio between the odds that an event will happen in one group and the odds 
of the event happening in another group. The equations used to calculate an odds ratio can be 
seen in Box 3.5. 
 
 
 
 
 
 
 
 
Risk Ratios represent the ratio of the probability of the event occurring in the intervention group 
to the probability of the event occurring in the control group. These are calculated using the 
formula in Box 3.6. 
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BOX 3.6: THE FORMULA USED TO CALCULATE RISK RATIOS. 
ii
ii
i
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na
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with the standard error of the log risk ratio being provided by; 
 
  
iiii
i
nnca
RRSE
21
1111
ln   
 
 
 
When conducting a meta-analysis, the standard errors of these summary statistics are required, 
along with the actual summary statistics, in order to combine studies. However, problems can 
arise when calculating the standard error if the event rate in both the intervention and control 
group is zero. When this occurs, 0.5 is added to each of the cells in the table (Table 3.1) so that 
calculations can be made (Deeks, Altman, &Bradburn,  2001). 
3.4.4.2.1.2: Continuous Outcomes 
When a study has taken data from a range of values, for instance body weight, this is a 
continuous outcome and can be presented as shown in Table 3.2. 
Table 3.2. Summary Information for Continuous Outcomes. 
 Mean Response Standard 
Deviation 
Group Size 
Intervention 
1m  1SD  1n  
Control 
2m  2SD  2n  
Total   N  
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As can be seen, continuous measures are calculated using different information than that needed 
for binary outcomes. In order to calculate a summary statistic from continuous outcomes, the 
number of participants, the mean response, and its standard deviation for both intervention and 
control groups are needed. Summary statistics are given as either a mean difference
18
 (Box 3.7) 
or as a standardised mean difference (Box 3.8). 
 
 
 
 
 
 
 
The mean difference measures the difference between the means of the two groups and estimates 
by how much, on average, the intervention has changed the outcome relative to the control. This 
is similar to the standardised mean difference, except that this expresses the treatment effect in 
terms of standard units rather than the original units of measurement. For the standardised mean 
difference, there are three main formulations of effect size, which differ according to the standard 
deviation used in their calculations (see Box 3.8). 
                                                 
18
 Analyses using this treatment effect measure have historically called it the weighted mean difference. This can be 
confusing as although a meta-analysis will calculate a weighted average of the mean difference, calculating the 
individual study summary statistic would not involve weighting.  
BOX 3.7: THE FORMULAS TO CALCULATE THE MEAN DIFFERENCE. 
iii mmMD 21   
with its standard error given by; 
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They also differ in whether they make corrections for small sample bias, which Deeks, Altman 
and Bradburn (2001)define as “the difference between the expected value of an estimate given a 
BOX 3.8: CALCULATIONS FOR THE STANDARDISED MEAN 
DIFFERENCE. 
Cohen’s d: 
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Hedges’ adjusted g: 
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
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with its standard error provided by: 
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Unlike the Cohen’s d effect estimate, this treatment effect estimate includes an adjustment 
in order to correct for the small sample bias. 
 
Glass’s  . 
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21  with the standard error as: 
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This method differs from the others as it uses the standard deviation of the control group as 
its scaling factor. 
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small sample and the expected value if the sample is infinite” (p. 290). Because the standardised 
mean difference is not dependent upon the measurement scale, it can be extensively utilised as a 
treatment effect measure (Tian, 2007) and is particularly useful when conducting panoramic 
meta-analysis, where the effectiveness of different interventions needs to be compared. 
3.4.4.2.2: Calculating a Pooled Effect Estimate 
In meta-analysis, it may be appropriate to calculate a pooled effect estimate by combining the 
data from each study. This pooled effect estimate will represent the weighted mean of the 
included studies’ treatment effects. To do this, consideration need to be given to the most 
appropriate summary statistic and the best approach to use to combine the studies. 
3.4.4.2.2.1.: Binary Data 
For binary data, studies can be combined using both relative and absolute measures of effect, 
namely, odds ratios, risk ratios, or risk difference. For relative measures, the individual trial’s 
treatment effect estimates are combined on the log scale. Since none of these summary statistics 
is necessarily better than the others for summarising treatment effect (Higgins & Green, 2011), 
three criteria should be considered when deciding on which to use: consistency, mathematical 
properties, and ease of interpretation (Deeks, 2002). 
3.4.4.2.2.1.1: Consistency 
Evidence suggests that absolute measures, such as risk difference, are less consistent that relative 
measures (Engels et al. 2000). As such, meta-analyses should not be conducted using absolute 
measures unless there is strong evidence to suggest that this measure will be consistent in a 
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particular context (Higgins & Green, 2011). Between OR and RR, however, there is considered 
to be little difference in consistency (Deeks, 2002). 
3.4.4.2.2.1.2: Mathematical Properties 
According to Higgins and Green (2011), the most vital mathematical property for any summary 
statistic is the availability of a reliable variance estimate (i.e. standard error). While most 
summary statistics have a variance estimator and so could be used, the OR is considered to have 
the most mathematical properties that facilitate data combination and testing statistical 
significance (Deeks & Altman, 2001). This is because it is unbounded and does not, unlike the 
RR, rely on which of the two outcome conditions is defined as the “event”. 
3.4.4.2.2.1.3: Ease of Interpretation 
Of all the summary statistics, the OR is regarded as the hardest to understand (Higgins & Green, 
2011),whereas RR are considered to be the most intuitively comprehensible (Deeks & Altman, 
2001). Absolute measures are thought to be more comprehensible to clinicians (Sinclair & 
Bracken, 1994) but are less generalisable than relative measures. 
3.4.4.2.2.2: Continuous Data 
If the outcomes of the included trials are continuous, data can be combined to provide a mean 
difference or a standardised mean difference. The mean difference can be used when all the 
studies have used the same scale for their outcome measurements. The standardised mean 
difference is used when all studies assess the same outcome but have measured it in different 
ways. In this method, each study’s effect estimate has to be standardised to a uniform scale 
before all studies can be pooled to give an overall treatment estimate. Therefore, the size of each 
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study’s treatment effect estimate is expressed relative to the variability observed in that study 
(Deeks, Altman, & Bradburn,  2001). 
It should be pointed out that both the mean difference and standardised mean difference assume 
that the outcome measurements of each study are normally distributed. If the data is skewed, then 
misleading results could occur. Furthermore, standardised mean differences tend to overestimate 
the treatment effect when limited samples are used. However, only when small sample sizes are 
used is this bias substantial. 
In this study, the RR was chosen as the summary statistic when event-based data was available. 
This was because it would be more comprehensible to most people. However, if event rates were 
not available or the outcome was a continuous measure, then the summary statistic from the 
original meta-analysis was used instead. For example, if the original meta-analysis used OR then 
the summary statistic used for that meta-analysis in this analysis was also an OR, and so on. 
3.4.4.2.3: Approaches to Calculating Pooled Effect Estimates 
In a meta-analysis, it may be considered appropriate to combine the individual study effect 
estimates to provide an overall treatment effect estimate (denoted by ). If all studies collected 
were equally precise, then combining them would only involve computing a mean of the effect 
size (perhaps on a log scale). However, this is generally not the case because some studies 
provide more information than others. In meta-analysis, therefore, it is usual to compute a 
weighted mean so that those studies that provide the greatest amount of information are assigned 
greater weights. In these cases, each study is given a weight ( iw ) related to the standard error of 
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the overall effect estimate (  SE ).19However, how the weights are assigned to each study 
depends upon the way the researchers define “combined effect” (Borenstein, Hedges, & 
Rothstein, 2007). This is because meta-analysis has two main models for combining studies, each 
with different methods: the fixed effect approach and the random effects approach. The different 
assumptions that the models make about the nature of the individual studies lead to different 
definitions for the combined estimate and, therefore, different ways of assigning weights to the 
studies (Borenstein, Hedges, & Rothstein, 2007). 
3.4.4.2.3.1: Fixed Effect Approach 
The fixed effect model is based upon the mathematical assumption that there is one true effect 
size that all the included studies of a meta-analysis share, with no between-study heterogeneity. 
Any differences found in effect size between studies are considered purely due to chance. 
Therefore, the overall combined effect estimate produced by a fixed effect model is the estimate 
of this one true effect size. Weights are assigned to each study according to the amount of 
information that they provide: a large study would be given a large weight, and a small study 
would be assigned a small weight.  
There are two main methods of combining studies using this model. The first is the inverse 
variance method, which can be utilised when the data that is needed to be combined is continuous 
or binary (Deeks, Altman, & Bradburn, 2001). As with all meta-analytic techniques, the 
individual studies’ effect estimates are combined to produce a pooled effect estimate with 
                                                 
19
It should also be pointed out that individual studies can also be weighted to reflect not only the quality of the trial, 
but also its sample size or other factors such as attrition.  
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weighted averages calculated for each of the individual study’s treatment estimates. However, for 
the inverse variance, the weight assigned to each study is the reciprocal of the study’s squared 
standard error (Deeks, Altman, & Bradburn, 2001). This means that small studies, which have 
large standard errors, are assigned less weight than large trials. The pooled effect estimate (
IV ) 
within the inverse variance method can be seen in Box 3.9.  
 
 
 
 
 
 
 
 
 
 
 
BOX 3.9: CALCULATIONS FOR THE POOLED EFFECT ESTIMATE IN THE 
INVERSE VARIANCE METHOD. 
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where i is the individual study effect estimate and where weights (
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This method of combining individual studies has advantages in that it can be used to pool any 
treatment effect estimates that have standard errors available (Deeks, Altman, & Bradburn, 
2001). Furthermore, by using weights that are equal to the precision of the individual studies, the 
variance of the pooled effect estimate is reduced (Van Den Noortgate & Onghena, 2003). 
However, it should be pointed out that when event rates are low and studies are small, the 
standard error estimates of the individual treatment effects that this method uses to weight studies 
may be weak, making the associated weights unstable (Deeks, Altman, & Bradburn, 2001) and, 
therefore, creating misleading results. 
Another fixed effect model used within meta-analysis is the Mantel-Haenszel method. This uses a 
different weighting scheme that is considered to be more robust when data is sparse (Deeks, 
Higgins, & Altman, 2008).
20
The Mantel-Haenszel method assumes that the true effect is the same 
across all the studies included in the meta-analysis and can only be used when data is binary. It 
employs the same table used to calculate the individual study’s treatment effect estimates (Table 
3.1) to calculate each study’s weight and the overall effect estimate. Boxes 3.10, 3.11, and 3.12 
show the formulas used to calculate a pooled treatment effect estimate in this approach. 
 
 
                                                 
20
 In situations when data is not sparse, both the inverse variance method and the Mantel-Haenszel method provide 
similar estimates. 
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BOX 3.10: FORMULAS USED BY THE MANTEL-HAENSZEL APPROACH 
TO CALCULATE A POOLED TREATMENT EFFECT ESTIMATE FOR 
ODDS RATIOS. 
 
The pooled treatment effect estimate (
MH ) is given by: 
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To combine all trails using odds ratios, each trial’s odds ratio is given weight by 
using the following formula: 
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The logarithm of MHOR then has the standard error given by: 
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BOX 3.11: FORMULAS USED BY THE MANTEL-HAENSZEL APPROACH 
TO CALCULATE A POOLED TREATMENT EFFECT ESTIMATE FOR RISK 
RATIOS. 
Risk Ratios, on the other hand are weighted using the following formula: 
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with the logarithm of MHRR having its standard error calculated by: 
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BOX 3.12: FORMULAS USED BY THE MANTEL-HAENSZEL APPROACH TO 
CALCULATE A POOLED TREATMENT EFFECT ESTIMATE FOR RISK 
DIFFERENCES. 
Risk Differences are also weighted differently from Odds Ratios and Relative risks. Each 
trial’s Risk Difference estimate is weighted by using the following calculation: 
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with the standard error of MHRD  provided by; 
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3.4.4.2.3.2: Random Effects Approach 
The random effects model is based upon the assumption that the actual individual effects vary 
around an overall average. It assumes that the true treatment effect estimate can differ between 
individual studies. As with the previous model, the weight assigned to each study is the inverse of 
that study’s variance, but unlike the previous model, it takes into account both the within- and 
between-study components of variance. This ensures that study weights are more balanced, 
prevents large studies from dominating the results, and small studies from effectively being 
ignored.  
The method used to combine studies under the random effects approach is the DerSimonian and 
Laird method. To assign weights in this method, the heterogeneity statistic (Cochran’s Q ) needs 
to be broken down into the amount that can be accounted for by within-study differences and the 
amount due to between-study differences. This is done by firstly calculating Cochran’s Q  and 
then isolating the within-studies variance. The difference between Cochran’s Q  and the within- 
study variance will then provide the between-study variance (
2 ) (Borenstein, Hedges, & 
Rothstein, 2007).  The formula to calculate the estimate of inter-study variance is provided in 
Box 3.13. 
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BOX 3.14: FORMULA FOR CALCULATING THE STUDY WEIGHT IN 
THE RANDOM EFFECTS APPROACH. 
  22
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BOX 3.13: THE FORMULA FOR INTER-STUDY VARIANCE. 
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As with the previous method of combining studies, this method then assigns weights to each 
study but includes the estimate of between-study variance (see Box 3.14 for the weighting 
formula). 
 
 
 
 
If  the between-study variance (
2 )is larger than zero, then the weights that this model assigns to 
each study will be smaller and more similar to each other than the weights that would be assigned 
  
94 
 
under a fixed effect model (Deeks, Altman, & Bradburn, 2001). Therefore, this method assigns 
more weight to smaller studies than the fixed effect approach.  
A pooled treatment effect estimate can then be calculated. The formula for this can be seen in 
Box 3.15. 
 
 
 
 
 
 
As with the inverse-variance method, this model is widely applicable and can be used to combine 
any kind of estimates as long as standard errors are available. This model is also considered to be 
more conservative than the fixed effect approaches by tending to have higher estimated variances 
and, therefore, wider confidence intervals. However, Poole and Greenland (1999) suggest that, in 
some situations, the opposite can be the case because the pooled estimate can lie further away 
from the null value or because it provides a lower null p-value. This causes the pooled effect 
estimate produced by a random effects model to appear more strongly supportive of an 
intervention than that produced by a fixed effect model. Such a situation can arise when small or 
BOX 3.15: THE FORMULA TO CALCULATE THE POOLED TREATMENT 
EFFECT ESTIMATE IN THE RANDOM EFFECTS APPROACH. 
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imprecise studies are combined, as the random effects model gives greater relative weight to 
these studies.  
In this study, both random and fixed effect approaches have been used. The reasons for this are 
discussed in Chapter 4 (section 4.7.1.1). The fixed effect approach selected for this study was the 
Mantel- Haenszel approach. This was chosen because it is more robust than the inverse variance 
approach when data is sparse or small trials are included in a meta-analysis, which was the case 
for this study. The random effects model chosen was the DerSimonian and Laird approach, which 
was selected because it is the most commonly used random effects approach in meta-analysis. 
For the universal comparison, the Mantel-Haenszel approach was selected to calculate the overall 
treatment effect estimate for each meta-analysis. While there is no agreement on which method is 
better (The Cochrane Collaboration, 2002), this fixed effect approach was chosen because it is 
thought to be more reliable when analysis includes small or few studies (The Cochrane 
Collaboration, 2002), as was the case here. 
3.4.5: Presenting Findings 
The final stage in a meta-analysis or panoramic meta-analysis is presenting the findings. All 
findings should be reported in a clear and systematic way with tables and figures used to illustrate 
points where appropriate. A number of factors should be considered and reported: 
 The limitations of the study 
 The strengths of the evidence gained 
 The implications of the research  
 Recommendations and future research 
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3.5: Why is Panoramic Meta-analysis a Good Approach to Use? 
To summarise, this chapter has presented the four key reasons for using panoramic meta-analysis 
for this study. Because panoramic meta-analysis collects and collates a vast amount of data, it 
enables the testing of generic hypotheses over a set of meta-analyses concerned with different 
types of intervention for related health conditions. It therefore provides a broad overview of 
intervention types and effectiveness that can be used to inform those involved in making 
healthcare decisions. In addition, panoramic meta-analysis employs a more efficient approach to 
data collection than standard meta-analytic practices because it searches for and collects data 
from meta-analyses in published systematic reviews. This means that a vast number of relevant 
studies can be identified more quickly, and individual study data can simply be extracted from 
the meta-analyses. By drawing together multiple meta-analyses, there will always be sufficient 
information from which to reach meaningful conclusions. Moreover, panoramic meta-analysis 
ensures that both published and grey literature will be included in any analysis since published 
meta-analyses should contain both published and unpublished literature. However, if this is not 
the case, then panoramic meta-analysis will be limited by the quality of the included meta-
analyses. 
Finally, as panoramic meta-analysis has its foundations in the meta-analytic approach, robust 
standard meta-analysis methods can be used to explore issues of heterogeneity and bias. This is 
essential for this study since it facilitates an investigation into “country” as a component of 
between-study heterogeneity.  
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3.6: Conclusion 
This chapter has set out the methodological position and novel approach that this study uses to 
achieve its research aims. Panoramic meta-analysis has been explained in its historical context, 
and the key differences between standard meta-analysis and panoramic meta-analysis have been 
presented. Panoramic meta-analysis has been selected for this study because it allows treatment 
effectiveness differences between countries or continents to be assessed directly and can provide 
a comprehensive understanding of these differences. In addition, it is more efficient than standard 
meta-analysis, as relevant studies are identified more quickly by searching for published 
systematic reviews containing meta-analyses. Furthermore, in using the statistical methods 
associated with meta-analysis, it can explore the issues of heterogeneity and bias.  
The next chapter describes the implementation of this methodological approach by explaining 
how data was collected and analysed for this study. 
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CHAPTER 4. 
INVESTIGATION METHODS: 
DESCRIPTIONS AND EXPLANATIONS. 
 
As described in the previous chapter, meta-analysis requires choices to be made about search 
strategies, data collection, data selection, and analysis. This chapter explains how data relevant 
for this study was identified and provides a thorough description of how data was extracted. It 
also presents the reasoning for the choices that were made about data synthesis and analysis and 
describes how these processes were conducted. 
This chapter is structured around the guidelines proposed by QUORUM
21
(Moher et al. 1999), 
which require that authors provide information about literature searches, selection of relevant 
data, validity assessment, data abstraction, study characteristics, quantitative data synthesis, and 
trial flow, and is divided into three main sections. Section One provides details of how relevant 
data was identified and summarises the inclusion and exclusion criteria. Section Two presents the 
results of the literature search, detailing the number of meta-analyses found and data extraction 
processes. Section Three explains the methods of data synthesis and analysis utilised in this study 
and discusses the decisions made regarding these processes. 
                                                 
21
 Quality of Reporting of Meta-Analysis 
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4.1: The Study Topic 
To meet the aims of this study, namely, to explore international differences in treatment 
effectiveness and ascertain whether differences existed in the effect of certain types of 
intervention, the research focused on cardiovascular diseases (CVDs).
22
 CVDs are of increasing 
national and international concern and are, therefore, an appropriate clinical area through which 
to pursue the aims of this study.  
CVDs are the leading cause of mortality in developed and developing countries (Bonneux et al. 
1994; Rayner et al. 2001). The World Health Organisation (2011) estimates that CVDs cause 
17.1 million deaths globally each year. An estimated 198,000 of these deaths are in the UK 
(British Heart Foundation, 2011). It is projected that by 2020 the two leading causes of death 
worldwide will continue to be ischemic heart disease and cerebrovascular disease (Murray & 
Lopez, 1997). Being the most common of all chronic conditions, CVDs are also a leading cause 
of morbidity across the world (Gaziano, Opie, & Weinstein, 2006; Poole-Wilson, 2005).  Neal, 
Chapman and Patel (2002) suggest that the number of disability-adjusted life-years
23
 (DALY’s) 
worldwide attributed to CVDs will have increased from 134 million in 1994 to around 204 
million by 2020.  
Some evidence does suggest, however, that mortality and morbidity associated with CVDs are 
decreasing, especially in developed countries such as the UK (British Heart Foundation, 2011; 
                                                 
22
 For the purpose of this research, CVD included any condition that primarily affected the heart and/or blood vessels 
in the Ventral body cavity. 
23
A measure of the total burden of disease where the total burden is caused by the combination of non-fatal events 
and premature death. 
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Kuulasmaa et al. 2000). This is because the major risk factors associated with CVDs have been 
identified, and effective control strategies are used in health promotion and clinical practice 
(Reddy & Yusuf, 1998). Nonetheless, uncertainty remains about whether this decrease will 
continue in the future; while major risk factors such as smoking are now better prevented, 
detected, and treated, other risk factors such as obesity are increasing and are likely to decelerate 
this decrease in CVD morbidity and mortality (Lyratzopoulos, 2006).  
CVDs also impose a significant burden on healthcare costs (Bonneux et al. 1994). It is estimated 
that CVDs cost the EU economy around €192 billion per annum (British Heart Foundation, 
2008). Of this total, productivity losses due to mortality and morbidity account for 21%, 22% is 
attributed to the cost of informal care,
24
 and 55% is direct healthcare costs. In the UK, around 
£29.1 billion is spent on CVDs, 60% of which is spent on direct healthcare. The remaining 40% 
is split between productivity losses (23%) and informal care costs (17%). The costs associated 
with CVDs are already very high and are likely to increase in the future (Lyratzopoulos, 2006) 
due to an ageing population
25
 combined with increases in medical spending on new (and hence 
more costly, even if only in the short term) and more effective procedures for dealing with CVDs 
(Heidenreich et al., 2011).  
Given the continued international concern about the increasing prevalence of CVDs and their 
associated costs, it is unsurprising that there has been an abundance of research into CVD on the 
worldwide stage looking at the different types of intervention used to prevent and treat CVD. 
                                                 
24
 Care provided by those who do not have a formal paid job in healthcare and in social care. 
25
 Elderly people are more prone to cardiovascular diseases (National Academy on an Ageing Society, 2000) 
  
101 
 
This wealth of research makes CVD a particularly appropriate topic on which to base a 
panoramic meta-analysis.  
4.2: The Continents under Investigation 
This study had originally intended to examine differences in treatment effectiveness between 
countries. However, several difficulties arose that prevented country based analysis. In most 
cases, specific country details were not available in study reports or in meta-analyses, with many 
only reporting continent-level information. In such cases, it would have been necessary to contact 
the authors of the study reports and meta-analyses directly to collect country-level data. This 
would have led to additional problems: it would have been time-consuming, and where authors 
did not respond or where they were not able to provide this level of data, it may have led to 
otherwise relevant studies being excluded. Furthermore, the statistical power of any analysis 
based on country-level information would have been low due to the small number of studies 
reporting country information. Due to these limitations, but also to allow a broader picture to 
develop, it was decided to investigate between-continent differences in treatment effectiveness 
instead. 
The continents included were Europe, North America, and Asia. North America included the US 
and Canada, and European countries were those included in the United Nations (UN) definition 
(United Nations Statistics Division, 2008).
26
 For Asia, the UN definition was also used,
27
 but 
                                                 
26
 Belarus, Bulgaria, Czech republic, Hungary Poland, Republic of Moldova, Romania, Russia, Slovakia, Ukraine, 
Aland Islands, Channel Islands, Denmark, Estonia, Faeroe Islands, Finland, Iceland, Ireland, Latvia, Lithuania, 
Norway, Sweden, UK, Albania, Andorra, Bosnia and Herzegovina, Croatia, Greece, Gibraltar, Italy, Malta, 
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Middle Eastern countries were excluded because few trials are conducted in the region and little 
information would be have been available about intervention effectiveness there. 
These continents were chosen because they allowed for the exploration of international 
differences in treatment effectiveness over continents that have different healthcare systems and 
that are culturally diverse. This investigation is essential, as a country may be less willing to 
extrapolate data from one that has a dissimilar healthcare system and culture due to fears that 
differences in these factors has an impact on treatment effectiveness.  
4.3: The Selection of Systematic Reviews Containing Meta-analyses. 
As with standard meta-analysis, panoramic meta-analysis is based on data collected from relevant 
randomised controlled trials (RCTs). However, as stated in Chapter 3 (Section 3.4.2), the 
processes for identifying relevant RCTs are different. In the panoramic meta-analytic approach, 
systematic reviews containing meta-analyses related to the topic of interest are identified and 
used to identity relevant and appropriate RCTs. This enables relevant RCTs to be identified more 
quickly. Furthermore, it enables RCT data to be collected and collated more efficiently because 
relevant RCT data can simply be extracted directly from the meta-analyses in the identified 
systematic reviews. Before searches can be conducted for relevant systematic reviews containing 
meta-analysis, inclusion and exclusion criteria need to be defined. 
                                                                                                                                                              
Montenegro, Portugal, Serbia, Slovenia, Spain, The former Yugoslav Republic of Macedonia, Austria, Belgium, 
France, Germany, Luxembourg, Monaco, Netherlands, Switzerland. 
27
China, China Hong Kong Special Administrative Region, China Macao Special Administrative Region, 
Democratic People’s Republic of Korea, Japan, Mongolia, Republic of Korea, Brunei Darussalam, Cambodia, 
Indonesia, Lao People’s Democratic Republic, Malaysia, Myanmar, Philippines, Singapore, Thailand, Timor-Leste, 
Viet Nam. 
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4.3.1: Inclusion Criteria for Systematic Reviews 
For the purpose of this study, published systematic reviews involving meta-analysis were eligible 
for inclusion if they satisfied the following criteria: 
 they involved randomised controlled trials 
 they were published in English - those searching and assessing reviews for inclusion were 
not competent in other languages and no translator was available to assist 
 they involved a comparator group - comparators could vary according to the type of 
intervention that the systematic review investigated. For instance, if the review examined 
a new surgical intervention, the comparator could be usual care, while for a systematic 
review examining a drug intervention, the comparator could be a placebo 
 they involved adult patients who had a cardiovascular disease or who were in a high risk 
group for this condition 
 they involved therapeutic or preventative interventions that were aimed at treating a 
problem with the heart or blood vessels within the ventral body cavity
28
 
 they reported a meta-analysis conducted over at least one fatal and/or one non-fatal 
endpoint.  
 
It should be noted that fatal (and non-fatal) endpoints could differ between the included meta-
analyses. For example, one meta-analysis might examine mortality at 30 days, while another 
might examine mortality at 6 months. This was not a concern, because these differences were 
taken into account when conducting this study’s analysis. For the pair-wise comparisons, each 
continent’s trial results were compared only within meta-analyses. This meant that trials from the 
same meta-analysis were compared only over the same fatal and/or non-fatal endpoint. For the 
                                                 
28
 The ventral body cavity is located at the front of the human body and is divided into three main cavities. The 
thoracic cavity (which is located in the chest and contains the heart, lungs, and large blood vessels), the abdominal 
cavity (containing the intestines and stomach), and the pelvic cavity (containing the bladder and reproductive 
organs). 
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universal comparison, each continent’s trial results were standardised, allowing the comparison 
of results from trials that had used different outcomes and that had investigated different 
interventions (see Section 4.7.2 for further information on this process). 
4.3.2: Excluded Systematic Reviews 
Systematic reviews were excluded from this study if they: 
 were only narrative reviews 
  were editorials 
  were opinions and reports that did not contain any outcome data 
 involved problems with blood vessels outside of the ventral chest cavity 
 
4.4: The Selection of Randomised Controlled Trials in Meta-
analyses. 
Data from RCTs found within the included meta-analyses were used as the basis for analysis. 
RCTs are considered the “gold standard” for the evaluation of clinical effectiveness because the 
processes involved make them less prone to bias (Haghdoost et al. 2007).  
4.4.1: Inclusion Criteria for RCTs 
Data from RCTs contained in meta-analyses were only used when the RCT fulfilled the 
following eligibility criteria: 
 they were published in or after 1990 - this was because it would be difficult to obtain the 
full trial reports of RCTs published before this date, which may have been needed to 
obtain country or continent-specific information. Furthermore, restricting the inclusion of 
RCTs to only those published from 1990 meant that this study could concentrate on the 
measurement of current international differences in treatment effectiveness, rather than 
on past differences. 
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 they were conducted in countries in Europe, North America, or Asia 
 they were published in any language – by placing no language restriction on RCTs, 
reassurance could be provided, to some extent, that no language bias was introduced into 
the findings of this study. 
 
Multi-centre trials were included in this study only where all the centres involved were based in 
one continent. For example, a multi-centre trial with all participating centres based in Europe 
would be included, whereas a multi-centre trial with participating centres in Europe and Asia 
would not. Since data from multi-centre trials are not usually provided on a centre-by-centre 
basis, it would be difficult, therefore, to distinguish which data related to which continent’s 
centres. Given the aims of this research, it was essential that data could be disaggregated at the 
continent level. 
4.4.2: Excluded Randomised Controlled Trials 
RCTs were excluded if: 
 they were multinational trials 
 country or continent information could not be obtained 
 if they had no outcome data for both the intervention and control group. 
 
4.5: Literature Search 
A literature search was developed and conducted. This section describes the search strategy 
implemented in this study, the screening strategies used, and the results of the literature search. 
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4.5.1: Search strategy 
A comprehensive search strategy was developed to ensure that all relevant systematic reviews 
containing meta-analyses were located. This involved systematically searching two electronic 
databases and limiting searches by language, dates of publication, study design, and human-only 
studies so that the resulting literature complied with the eligibility criteria described above. Since 
data from existing meta-analyses is collated for panoramic meta-analysis, searches need only be 
conducted on those databases that are most likely to hold systematic reviews containing meta-
analysis. Panoramic meta-analysis is not the only approach in which this limited approach to 
literature searching has been recommended. For example, Smith et al. (2011) contend that this is 
also appropriate when conducting an overview of systematic reviews, and this approach has been 
confirmed by several studies in which literature searching has been limited to a few databases 
(Bowater, Stirling, & Lilford, 2009; Derry et al. 2006; van der Wouden, Bueving, & Poole, 2005; 
Zed, Loewen, & Robinson, 1999). 
For this study, Medline and The Cochrane Library were searched for relevant published 
literature. The Cochrane Library was chosen because it reportedly contains the best systematic 
reviews produced by the world’s leading systematic reviewing organisation, The Cochrane 
Collaboration (Fedorowicz & Al-Muharraqi, 2009). The reviews contained within The Cochrane 
Library are regarded as the “gold standard” (Fedorowicz & Al-Muharraqi, 2009) and have been 
found to have greater methodological rigour and to be updated more often  than reviews found in 
paper-based journals (Jadad et al. 1998). Medline was chosen because it allowed identification of 
systematic reviews not written by The Cochrane Collaboration and because it is seen as the single 
most important database for those in medical and healthcare academia and practice (Pena, 1994). 
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It is designed to have worldwide coverage of journals and articles and is considered by some to 
be “the world’s most comprehensive source of life sciences and biomedical bibliographic 
information” (Rai, 2006 p. 2).  
The original searches of the databases were undertaken between September 2008 and February 
2009. The Medline search covered the period January 2005 – December 2008, and The Cochrane 
Library search covered the period January 2000 –December 2008. The search periods for each 
database differed because the initial Medline search, which had used the same time period as the 
Cochrane search, produced over 4000 systematic reviews. Due to the extensive work involved in 
extracting data when using panoramic meta-analysis, and the high quality standards for data 
management and analysis associated with this method, there would not have been time to review 
all these systematic reviews and extract the required data from each. Nevertheless, given that the 
Medline search revealed that some systematic reviews were updates of reviews published prior to 
2005 and that some overlaps existed between systematic reviews identified through Medline and 
The Cochrane Library, (see figure 4.1), it is reasonable to assume that few systematic reviews 
were overlooked as a result of using different search periods between the two databases. 
Furthermore, as this study used trial data from the meta-analyses of these systematic reviews, 
which could be expected to have included all relevant up-to-date trials, the different search date 
used for each database was less of a concern than would be the case for standard meta-analysis. 
Inclusion of older systematic reviews from Medline (i.e. published before 2005) may not 
necessarily have enhanced the data for this research since the older trials included in newer 
reviews may well have been included in earlier systematic reviews. 
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A different search strategy was used for each database. The Cochrane Library gave direct access 
to all systematic reviews indexed under the Medical Subject Heading (MeSH) of Cardiovascular 
Diseases simply by conducting a MeSH search. Thus using  “Cardiovascular Diseases” in the 
MeSH search box produced not only the MeSH tree for that term, but also an option for viewing 
the results of all systematic reviews that were indexed under this MeSH descriptor. The required 
limitations could then be placed on these viewed results to find all relevant systematic reviews 
involving meta-analysis.  
To identify relevant systematic reviews from Medline, search strings were created. Search strings 
were developed by consulting the MeSH tree for the MeSH term Cardiovascular Diseases within 
Medline. To do this, the term “Cardiovascular Diseases” was placed into the MeSH Database 
search box and the results scanned to find the terms that would provide systematic reviews on all 
conditions indexed under Cardiovascular Diseases. This process indicated that four sub-headings 
of the Cardiovascular Diseases MeSH tree would be sufficient to provide all relevant reviews 
pertaining to cardiovascular conditions (see Table 4.1).  
As some cardiovascular diseases may have been indexed under the MeSH term Vascular 
Diseases, another search string was created to ensure that no systematic reviews concerned with 
cardiovascular illnesses had been missed (see Table 4.1). A third search string was created to 
ensure that no systematic reviews containing meta-analysis had been missed in the Medline 
searches. This time, filters such as [ti], for title, and [pt], for publication type, were used to search 
for publications that had words relating to meta-analysis in the title but were not indexed by the 
publication type of meta-analysis (see Table 4.1). This search string was  “Cardiovascular 
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diseases” AND (“Meta – analysis” OR “Metaanalysis” OR “Metanalysis” OR “Systematic 
review” OR “Pooled analysis”) [ti] NOT meta – analysis [pt].   
Table 4.1: Individual Search Strings used in Medline. 
 
 
 
4.5.2: Screening Strategies 
A three-stage screening process was adopted to determine which systematic reviews were 
included in this study. This involved two reviewers, LH and RB. LH reviewed the titles and 
abstracts of each systematic review identified in the literature search, while both LH and RB 
independently reviewed the full text of any systematic review thought relevant by LH. LH then 
screened the trials in each meta-analysis. Any systematic reviews that appeared to be duplicates 
were independently screened by both LH and RB, and the most recent publication of the review 
was retained. Any disagreements between the two reviewers were resolved by discussion. This 
was the case in two instances where it was unclear whether the systematic reviews were 
duplicates. After further investigation, it was determined that both these reviews were duplicates 
and were therefore removed from the dataset. 
Stage one of the screening process involved initial screening of the titles and abstracts of the 
systematic reviews identified via the database searches in order to exclude publications that were 
not pertinent to this study. At this stage, publications were excluded if they were not systematic 
Search Strings used in Medline 
“Cardiovascular abnormalities” OR “Cardiovascular infections” OR “Heart diseases” OR 
“Pregnancy complications, Cardiovascular” 
“Vascular diseases” NOT (“Cardiovascular abnormalities” OR “Cardiovascular infections” 
OR “Heart diseases” OR “Pregnancy complications, cardiovascular”). 
“Cardiovascular diseases” AND (“Meta – analysis” OR “Metaanalysis” OR “Metanalysis” 
OR “Systematic review” OR “Pooled analysis”) [ti] NOT meta – analysis [pt].  
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reviews, did not include the previously specified types of patients, or did not investigate an 
intervention aimed at treating or preventing CVDs. In stage two, a more detailed examination of 
the potentially relevant publications found in stage one was conducted. This involved examining 
the full text of the systematic reviews and excluding any that did not involve meta-analysis or 
RCTs. Stage three involved the screening of all the trials included in the systematic reviews to 
ensure that all trials in each review satisfied the inclusion criteria for RCTs outlined above. At 
this third stage, systematic reviews were excluded if: 
 all the trials they contained were published before 1990 
 all the trials they contained were conducted in one continent29 
 all trials they contained were not from the continents of interest 
 all trials were multinational30 
 the continents for all trials were unknown 
 they did not provide outcome data for both intervention and control groups for all trials 
contained in the meta-analysis.  
 
4.5.3: Literature Search Results 
A total of 2269 relevant systematic reviews involving meta-analysis were identified in the 
literature search: 2156 via Medline and 113 through The Cochrane Library. Thirty-seven 
systematic reviews appeared in both Medline and The Cochrane Library (see Table 4.2) 
 
. 
                                                 
29
To conduct between-continental comparisons within meta-analyses, as well as over meta-analyses, the trials in 
each meta-analysis could not all be from one continent. Furthermore, conducting analysis within meta-analyses 
meant that trials that had investigated the same intervention but were from different continents could be compared. 
30
 Multinational trials were not included in this study as they did not provide country by country or continent by 
continent breakdowns of results which were essential for this analysis. 
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Table 4.2: The Individual Yields for Each Search String 
 
 
 
 
 
Of these 2269 publications, 1745 were excluded in the first round through the first-stage 
screening process outlined above (see Figure 4.1). These reviews did not include relevant patient 
populations, relevant conditions, or were not systematic reviews. The full texts of the remaining 
524 publications were then screened by both reviewers.  
As shown in Figure 4.1, the second stage of screening resulted in the exclusion of 303 systematic 
reviews. The remaining 221 systematic reviews were then entered into the database for this study 
and screened further for inclusion (see Section 4.3). This confirmed whether all the RCTs 
included in the meta-analyses of the included systematic reviews were relevant and satisfied the 
inclusion criteria described above. 
Database Search String Yield 
Medline “Cardiovascular abnormalities” OR “Cardiovascular 
infections” OR “Heart diseases” OR “Pregnancy 
complications, Cardiovascular” 
1360 
Medline “Vascular diseases” NOT (“Cardiovascular abnormalities” 
OR “Cardiovascular infections” OR “Heart diseases” OR 
“Pregnancy complications, cardiovascular”). 
754 
Medline “Cardiovascular diseases” AND (“Meta – analysis” OR 
“Metaanalysis” OR “Metanalysis” OR “Systematic review” 
OR “Pooled analysis”) [ti] NOT meta – analysis [pt].  
42 
The Cochrane Library Cardiovascular Diseases 113 
 Overlap between Medline and The Cochrane Library 37 
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FIGURE 4.1: FLOW CHART OF STUDY SELECTION. 
 
 
    EXCLUDED 
 
    EXCLUDED 
 
 
 
 
    EXCLUDED 
 
 
 
 
Systematic Reviews identified from the Literature 
Search Screened in stage 1. 
 
Medline   n=2156    
The Cochrane Library     n=113 
Total   n=2269 
 
Not Relevant 
Medline  n=1686 
The Cochrane Library  n=59 
 
Systematic Reviews Overlapping 
between Medline and The Cochrane 
Library   n=37 
 
Total    n=1745 
Full Reports Screened in Stage 2  n=524 
Articles not Meeting Stage 2 Inclusion 
Criteria 
Medline   n=305 
The Cochrane Library             n=0 
 
Total               n=305 
 
Reasons for Exclusion: 
 
Outcomes              n=3 
Not Include RCTs             n=142 
Unavailable              n=5 
Not Involve Meta-analysis         n=153 
Duplicated Systematic Reviews n=2 
Systematic Reviews where Trials were Placed into 
Database and Screened for Stage 3   n=219 
Excluded systematic reviews  
   
Reasons for Exclusion: 
All trials came from one continent:       n= 55 
All trials were multinational or from a continent not 
of interest    n= 9 
All trials were multinational or from only 1 continent  
    n=22 
All trials were all multinational n=9 
No trial references  n=4 
All trials from one continent or from a continent not 
of interest                                                n=8 
No trial event data for continents of interest n=7 
Continent unknown for some trials with other trials 
only from one continent  n=2 
All trials from one continent and published before 
1990 n=5 
All trials published before 1990 n=4 
Continent unknown for all trials n=2 
 
Total  n = 127                                                                            
 
Included in Study     n=92 
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A further 127 systematic reviews were excluded at this point because the trials included in the 
meta-analysis did not fulfil the eligibility criteria listed earlier. Systematic reviews were excluded 
if trials in their meta-analysis met one of the following criteria: 
 they contained trials from only one continent 
 they contained trials from only one continent of interest, with other trials from continents 
not of interest 
 some trials in the meta-analysis were multinational, with all other trials from continents 
not of interest 
 they contained multinational trials, with other trials from only one continent of interest 
 all trials were multinational 
 included trials were only from one continent of interest, with other trials published before 
1990 
 all trials were published before 1990 
 no references were given for included trials 
 no outcome data was provided for relevant trials 
 the continents of the included trials were unknown 
 the continents of the included trials were unknown and other trials were only from one 
continent. 
 
Additional details are provided in Figure 4.1. Following the third round of exclusions, 92 
systematic reviews containing meta-analysis were eligible for this study.  
4.6: Data extraction and Management 
Data extraction was carried out by LH and was independently checked by RB. Data from the 
relevant systematic reviews was extracted into a database developed by LH. Data relating to the 
systematic reviews, their meta-analyses, and the trials contained within them were extracted.  
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For each systematic review, reference data was extracted (i.e. author, title, publication year, and 
journal). Information was also recorded about the intervention investigated and was categorised 
into one of the five following intervention types: drug, device, surgery, lifestyle, and 
management. The comparator treatment and the cardiovascular disease explored were recorded, 
as was the fatal and/or non-fatal outcome assessed in each systematic review. Recording fatal and 
non-fatal details was relatively easy in some cases as the systematic review contained only one 
fatal and/or non-fatal meta-analysis. In other systematic reviews, however, more than one fatal 
and/or non-fatal meta-analysis was reported. In these cases, the most commonly reported fatal 
and/or non-fatal meta-analysis in each systematic review was chosen, that is, the fatal (or non-
fatal) endpoint whose meta-analysis had combined the highest number of trials. For instance, in a 
systematic review where there were two meta-analyses for fatal endpoints and one combined 
seven trials and the other five, then the former was identified as the most commonly reported 
fatal endpoint. Where the same number of trials were combined in fatal and/or non-fatal meta-
analyses, the endpoint chosen was the one whose meta-analysis combined the greatest number of 
patients. 
Trial information for each trial contained in included systematic reviews’ meta-analyses was 
recorded in the database. For each trial, the following data was recorded: 
 author 
 publication year 
 event rate for fatal and/or non-fatal endpoints 
 trial effect estimate and its variance estimate 
 the type of effect measure used in each fatal and/or non-fatal meta-analysis 
 the country or continent in which each trial was conducted. 
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Information about the country or continent in which each trial was conducted was initially sought 
from the systematic reviews. Where this was not specified, the trial’s abstract was examined, and 
if still not found, the full text of the original trial report was examined. However, the countries or 
continents in which the trials were conducted were not always reported. In such cases, trial 
authors were contacted directly, but the majority of authors did not respond or did not provide the 
country or continent information required. To overcome this problem, when all authors were 
based in the same country or continent, trial country or continent was determined by the 
addresses of the authors themselves. If no country or continent information could be found for a 
trial, then that trial was excluded from the database and, therefore, from analysis. 
4.7: Data Synthesis and Analysis 
In panoramic meta-analysis, as in standard meta-analysis, data needs to be synthesised and 
analysed. In the panoramic meta-analytic approach, this can be done using pair-wise comparisons 
and a universal comparison. This section first explains the decisions that had to be made prior to 
data synthesis and analysis. Section 4.7.2 then describes the methods used for the comparisons. 
4.7.1: Decisions Surrounding Data Synthesis and Analysis 
In this study, three main decisions had to be made: 
1. Which meta-analyses should be included in each pair-wise comparison? 
2. Which type of effect measure should be used? 
3. What should be done with overlapping meta-analyses? 
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4.7.1.1: Meta-analyses Included in Each Pair-wise Comparison 
The continents studied in this research (Europe, North America, and Asia) were compared in 
pairs – Europe and North America, Europe and Asia, and North America and Asia – before a 
universal comparison that considered all three continents together was conducted. For these 
comparisons, it was important to decide which meta-analyses from the relevant systematic 
reviews would be included.  
For the comparison of treatment effectiveness between Europe and North America, meta-
analyses had to contain results from at least two recent (since 1990) trials conducted in Europe 
and at least two recent trials conducted in North America. Trials had to be recent so that this 
study could investigate differences that exist currently. Including meta-analyses that had two 
trials from each continent enabled heterogeneity within continents to be taken into account by 
using a random effects model. The analysis was also carried out using a fixed effects approach 
because this is considered to have increased statistical power and yields a more precise estimate 
of the pooled treatment effect than a random effects model (Cohn & Becker, 2003). In doing this, 
however, the overall treatment effect estimate calculated for each continent was found to differ 
between the random and fixed effect models, and so it was decided to report the results of the 
comparisons from the random effects model. 
For the pair-wise comparisons between Europe and Asia and between North America and Asia, 
meta-analyses only needed to contain at least one recent trial from each continent. This was due 
to the lack of Asian trials in some meta-analyses, with most of the included systematic reviews 
containing only one trial from Asia. If the selection criteria for meta-analyses had been the same 
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as in the previous comparison, (i.e. two trials from each continent), there would have been too 
few meta-analyses containing Asian trial data to make meaningful comparisons. 
For these pair-wise comparisons, trials from each continent were combined using a fixed effect 
model: the Mantel-Haenszel method. In doing this, however, the between-study heterogeneity for 
meta-analyses that included continents with more than two trials could not be included in the 
analysis and the impact of its inclusion studied. Therefore, all results for pair-wise comparisons 
obtained using the fixed effect model were checked and verified by re-running the analysis using 
a random effects model. As expected, the standard error and confidence intervals calculated using 
this model were larger than those using the fixed effect model. However, the overall treatment 
effect estimates for each continent calculated by both analytic models were similar, meaning that, 
for these comparisons, the fixed effect model was appropriate to report.  
4.7.1.2: Type of Effect Measure 
Decisions had to be made about the type of effect measure to use. To allow for a “cleaner”31 
comparison of treatment effectiveness between continents, trials were combined over RR, where 
possible, for the pair-wise comparisons and for calculating the best treatment effect estimates for 
each meta-analysis in the universal comparison. RR were used for each meta-analysis even if the 
original meta-analysis had combined trials using OR or MD. However, this was only possible 
where the endpoint reported in the meta-analysis was event-based and event rates were available. 
                                                 
31
 Fewer meta-analyses measuring treatment effect in different ways would make the comparisons more 
comprehensible. 
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If no event rates were reported and the results were given as OR, then trial results were combined 
using OR. When neither RR nor OR were available, MD were used.  
Before being used in analysis, ratio summary statistics, that is, RR and OR, underwent natural log 
transformations. The common feature of ratio summary statistics is that they take on values 
between zero and infinity, with a value of one corresponding to a neutral value.
32
 This means that 
they are easy to interpret. For example, a RR of 0.5 shows the intervention to be effective, 
whereas a RR of 1.5 shows the control group to be better. However, the number scale for these 
statistics is not symmetrical. For instance, a RR of 0.5 is opposite to a risk ratio of 2, such that 
when averaged they should produce 1. However, this is not the case, as when averaged they 
produce a RR of 1.25. Therefore, to make the scale symmetrical, natural log transformations are 
performed on ratio summary statistics. This enables ratio summary statistics of the same size but 
in opposite directions to be equidistant from one while also making  the confidence intervals of 
the combined treatment effect estimates symmetrical around the point estimate (Egger & Davey 
Smith, 2001).  In doing so, they ensure the results of this study are more easily comprehended. 
4.7.1.3: Overlapping Meta-analysis 
A decision had to be made about how to deal with overlapping meta-analyses. It was decided that 
overlapping meta-analyses were those that shared at least two trials with at least one other meta-
analysis in the database. This occurred where different systematic reviews had addressed similar 
clinical questions and was a concern for this research because it meant that some trial results 
                                                 
32
 A neutral value means no difference between groups. For a meta-analysis examining an intervention, 1 
corresponds to no intervention effect.  
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would be duplicated in the panoramic meta-analysis. This may be problematic if duplicated trial 
results favour the intervention in one continent over another. When meta-analyses are pooled, 
therefore, evidence for international differences in treatment effectiveness may appear stronger 
than the evidence really suggests, with interventions appearing to perform better in the continent 
with the most duplicated trials.  
Despite these concerns, overlapping meta-analyses were included in the dataset because it might 
otherwise have been too small to detect international differences in treatment effectiveness. 
Nevertheless, the impact of including overlapping meta-analyses upon the results of this study 
was considered. For each type of endpoint in each pair-wise comparison, the number of 
overlapping and non-overlapping meta-analyses was noted. The percentage of overlapping and 
non-overlapping meta-analyses that favoured the stronger
33
 continent was then calculated. The 
percentages were then compared to see if the inclusion of overlapping meta-analyses had 
exaggerated the percentage of meta-analyses favouring the stronger continent. For the universal 
comparison, the impact of including overlapping meta-analyses was taken into account by 
running the analysis both with and without the duplicated trial results from overlapping meta-
analyses. 
4.7.2: Methods of Synthesis and Analysis 
All comparisons were conducted on data from the meta-analyses in the 92 included systematic 
reviews using the Comprehensive Meta-analysis Version 2 Package, SPSS, STATA, and Excel. 
                                                 
33
The continent that was favoured by most of the included meta-analyses. 
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4.7.2.1: Conducting Pair-wise Comparisons 
The pair-wise comparisons conducted between Europe and North America, Europe and Asia, and 
North America and Asia were carried out for both fatal and non-fatal endpoints, with analysis 
conducted both within and over meta-analyses. 
The first task in conducting these pair-wise comparisons was to calculate individual estimates of 
treatment effectiveness for each continent in the comparison in each of the identified meta-
analyses. Random and fixed effect approaches were used for combining the trial results for each 
continent in each meta-analysis. For both approaches and in each meta-analysis, each continent’s 
treatment effect estimate was calculated using the event rates of each continent’s trials to produce 
an overall RR measure of treatment effect for that continent. This was done using the log scale, as 
described in the previous section. When data was binary and no event data was available for 
either the intervention or control group in a trial, 0.5 was added to all cells so that the treatment 
effect estimate could be calculated in line with the technique recommended by Deeks et al. 
(2001). This is done because computational problems in calculating the treatment effect estimate 
can occur when one or both groups contain zero events. Where event rates were unavailable, 
trials were combined using their original effect measure.
34
 
Next, for each meta-analysis, the difference between the two continent’s effect estimates was 
calculated. This was calculated using the formula in Box 4.1. 
                                                 
34
 As stated in Section 4.4.1. 
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A positive (+) or negative (-) symbol was used to indicate the continent in which the intervention 
performed best because if continent two had a larger treatment effect estimate than continent one 
(when continent two’s estimate was subtracted from continent one’s estimate), the sign of the 
calculated difference would be negative. 
The standard error for the between-continent difference in effect estimates was also calculated 
using the formula in Box 4.2. 
BOX 4.1: THE FORMULA TO CALCULATE THE BETWEEN-CONTINENT 
DIFFERENCE IN TREATMENT EFFECT. 
21 ccDE     
where
1c  is the treatment effect estimate of continent one and 2c  is the treatment effect 
estimate of continent two. 
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The z-score, confidence intervals, and 2-sided p-values were also calculated for the between-
continent difference in treatment effect for each of the relevant meta-analyses.
35
 The number of 
meta-analyses favouring
36
 each continent was then summed. Binomial sign tests were then 
conducted to discover whether the difference in the number of meta-analyses favouring one 
continent over the other was statistically significant at the 5% level. 
For each pair-wise comparison, the types of intervention prone to inter-continental differences in 
treatment effect were also investigated. For each pair-wise comparison, the included meta-
analyses were grouped according to the type of intervention investigated (Drug, Device, Surgery, 
Lifestyle or Management). Then, within each intervention group, the Z-statistic and 2-sided p-
value calculated for the between-continent difference in treatment effect for each meta-analysis 
                                                 
35
 These were calculated in Excel using the formula for a z-test 
36
 Where the intervention performed better in one continent over the other – significance not required 
BOX 4.2: THE FORMULA TO CALCULATE THE STANDARD ERROR FOR 
THE BETWEEN-CONTINENT DIFFERENCE IN TREATMENT EFFECT. 
 
 
where the  1cSE   is the standard error for the effect estimate of continent one and 
 2cSE   is the standard error for the effect estimate of continent two. 
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were observed to find any differences that were statistically significant at the 5% level. This was 
done in order to see if there was any clear pattern of statistically significant differences for any 
intervention type. This would show the types of intervention that were more or less prone to 
international differences in treatment effect over all of the included meta-analyses.  
Global estimates of continental difference were also produced for each pair-wise comparison. 
These showed the average between-continent difference in treatment effect over all of the 
included meta-analyses. They were calculated by combining the estimates of between-continent 
difference of all the included meta-analyses, on the log scale, using the fixed effects model. This 
was done for each type of effect measure, for example, a global estimate was calculated for all 
meta-analyses where risk ratios had been used, while a separate global estimate was calculated 
for those meta-analyses that had provided odds ratios. 
4.7.2.2: Conducting the Universal Comparison 
In addition, a universal comparison was conducted to examine the spread of each continent’s 
individual trial results. To do this, the result of each European, North American and Asian trial in 
each included meta-analysis was standardised.
37
  The standardised trial results were then 
extracted from their meta-analysis and pooled together. They were then plotted onto graphs 
according to the continent in which they were conducted. This was done for fatal and non-fatal 
endpoints. 
                                                 
37
This was done within meta-analyses and meant that each trial’s intervention effect estimate was only being 
compared to trials that had investigated the same intervention using the best available effect estimate for the 
intervention investigated. 
  
124 
 
Standardising the effect measure allowed for different interventions that had measured treatment 
effect in different ways to be compared. Furthermore, standardised measures always follow a 
standard normal distribution, which has a mean of zero and a standard deviation equal to one. 
Consequently, the two standard deviations rule (Anderson & Finn, 1996) was used to look for 
outliers, that is, to identify trials that fell over two standard deviations either side of the mean. 
The standardisation formula used in this study is shown in Box 4.3. 
 
 
 
 
 
 
 
 
 
The standardisation of each trial’s treatment effect estimate and plotting these onto graphs 
according to the continent in which they originated facilitated an investigation into whether trials 
BOX 4.3: STANDARDISATION FORMULA. 
 
i
i
i
SE
Y
 
  
 
where i is the i th trial’s effect estimate, μ is the combined estimate of all of the trials from all 
three continents in each meta-analysis (combined using the Mantel Haenszel approach) and 
the iSE  is the standard error of the deviation between the two estimates. The standard error is 
given by: 
 
22 ssSE ii   
 
where
is  is the standard error of the effect estimate of the i th trial and s  is the standard error 
of .  
 
NOTE: this formula is only exact when the Inverse Variance method is used to estimate  . 
Therefore, it is only approximately correct for use with the Mantel Haenszel method that was 
utilised for this part of the investigation.  
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from some continents were more likely to provide positive results favouring the intervention over 
the control. Binomial sign tests were then conducted for each continent to see whether the 
difference in the number of trials favouring the intervention relative to the control was 
statistically significant.  
For each continent, the mean effect size was also calculated along with a z-score and a p-value. 
From these, the difference in effect size between each continent could be observed. While 
binomial sign tests make few assumptions about the nature of the distributions being tested, 
meaning they have general applicability, they throw away useful data and as such, may lack 
statistical power. Therefore, t-tests
38
 were conducted between Europe and Asia and between 
North America and Asia to observe the direction and significance of results, as they are 
considered to have more statistical power and, therefore, to be more robust (Searle, 1999).  
The standardised effect measures were used to further investigate and identify the types of 
intervention prone to inter-continental differences. This was done by grouping each trial’s 
standardised effect estimates by continent and then sub-grouping these into intervention type. T-
tests were then performed between continents for each type of intervention. This meant that 
comparisons of the effect estimate of each intervention type could be made between Europe and 
Asia and between North America and Asia.  
                                                 
38
 T-tests could not be conducted in the pair-wise comparison (that had also used the binomial sign test) since this 
investigation was conducted at the meta-analysis level and not the trial data level.  
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4.8: Conclusion 
This chapter has established the importance of this study and explained and justified the 
approaches taken.  
This investigation is important as it may have international implications since it will provide 
evidence about when it is appropriate to directly extrapolate overseas clinical data. As such, it has 
the potential to impact upon the speed at which new cardiovascular interventions are approved 
across countries and save money when using such information as the basis for decisions on the 
implementation of a new intervention. In addition, this may influence the types of CVD 
intervention that are recommended at both national and international levels. For instance, if it is 
known that a certain type of intervention is less effective in one country than another, then the 
country in which it is less effective may be less likely to recommend this type of intervention in 
its guidelines and treatment management strategies. If, on the other hand, international 
differences in effectiveness are known not to exist in a certain type of intervention then an 
international guideline can be developed and used. 
This chapter has provided a thorough description of the methods used for identifying relevant 
systematic reviews containing meta-analysis and the processes and tests used to conduct 
panoramic meta-analysis. In addition, the reasons that particular methodological decisions were 
made have been explained, and the processes used to counter any limitations of these decisions 
and methods have been described and justified.  
  
127 
 
Part one of this thesis, then, has identified and explained the importance of this research and the 
novel methodological approach that will be used. It has also described the processes around data 
collection for this study and explained how data was analysed.  
Part Two turns to the actual results of the study. The next chapter presents the results of the first 
pair-wise comparison conducted between trials from Europe and North America. 
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PART TWO: THE INVESTIGATION OF 
INTERNATIONAL DIFFERENCES IN 
TREATMENT EFFECTIVENESS 
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CHAPTER 5. 
AN INTER–CONTINENTAL 
COMPARISON OF TREATMENT 
EFFECTIVENESS BETWEEN EUROPE 
AND NORTH AMERICA. 
 
To investigate the existence of inter-continental differences in treatment effectiveness three pair-
wise comparisons were conducted using secondary data from meta-analyses of cardiovascular 
interventions as described in the previous chapter. This chapter presents the findings from the 
first of these pair-wise comparisons: treatment effectiveness differences between Europe and 
North America for both fatal and non-fatal endpoints. The results are separated into two parts. In 
the first part, findings are presented for fatal endpoints, and in the second part, the findings for 
non-fatal endpoints are presented. The chapter then concludes by summarising the overall 
findings for this pair-wise comparison. 
5.1: The Pair-wise Comparison. 
The pair-wise comparisons allowed for between-continent differences in treatment effectiveness 
to be investigated at the meta-analysis data level. That is, data from each of the continents was 
compared both within and over meta-analyses. 
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As stated in Chapter 4 (Section 4.4.1), each meta-analysis, for the pair-wise comparison between 
Europe and North America, had to contain at least two trials in each continent. Of the 92 
systematic reviews that contained meta-analyses relevant for this study, only 59 had a meta-
analysis that satisfied this criterion. The findings in this chapter are based on these 59 meta-
analyses. 
5.1.1: Fatal Endpoints. 
Only 47 of these 59 meta-analyses contained two trials from each continent with fatal endpoint 
data that allow for separate estimates of treatment effect to be calculated for each continent. 
Details of these meta-analyses, including details of the intervention and control groups per meta-
analysis, endpoint reported and number of trials each meta-analysis contained from Europe and 
from North America are shown in Table 5.1 to 5.4. The effect estimate for each continent in each 
meta-analysis is also provided, as is the identity of the continent in which the intervention 
performed best. 
5.1.1.1: Meta-analyses Grouped by Treatment Effect Measure for Fatal Endpoints 
The 47 meta-analyses that contained fatal endpoint data have been grouped on how treatment 
effect was measured. For example, Table 5.1 details the 37 meta-analyses that measured 
treatment effect using RR and Table 5.3 details the six meta-analyses that used the OR. 
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5.1.1.1.1: Fatal Endpoints Measured as Risk Ratios 
37 of the 47 meta-analyses that reported a fatal endpoint did so using a RR. The details of these 
studies are summarised in Table 5.1.
39
 
Table 5.1: Meta-analyses with Fatal Endpoint Data. Treatment Effect Measured by the RR. 
                                                 
39
Best Region is defined as the continent in which the intervention performed best.  
Article 
Ref. 
no 
Intervention Control End point No. of 
trials 
(Europe/ 
N. 
Amer.) 
RR 
estimate 
for 
Europe 
(95% CI) 
RR estimate 
for N. 
Amer.(95% 
CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
178 
[C22] 
Digitalis for CHF Placebo All-Cause 
Mortality 
2/3 0.55 
(0.12, 
2.53) 
0.99 
(0.93,1.06) 
Europe 
(0.447) 
179 
[C23] 
Omega 3 fatty 
acids for CVD 
Placebo, no 
supplement or 
usual diet 
Cardiovascular 
mortality 
8/2 1.00 
(0.73,1.38) 
0.25 
(0.03, 2.24) 
N. Amer. 
(0.219) 
304 
[C25] 
Psychological 
interventions for 
CHD 
Usual care or 
no intervention 
Cardiovascular 
mortality 
2/6 0.70 
(0.32, 
1.52) 
0.93 
(0.67, 1.28) 
Europe 
(0.505) 
18 
[C12] 
Phosphodiesterase 
III inhibitors for 
HF 
Placebo Cardiovascular 
mortality 
2/5 1.55 
(1.01, 
2.37) 
1.03 
(0.72, 1.49) 
N. Amer. 
(0.160) 
223 
[P96] 
Beta-blockers 
without ACE 
inhibitors 
Placebo All-cause 
mortality 
2/3 0.93 
(0.35, 
2.47) 
0.72 
(0.45,1.17) 
N. Amer. 
(0.641) 
313[P7
5] 
Warfarin plus 
aspirin after MI 
or ACS 
Aspirin only All-cause 
mortality 
3/2 0.93 
(0.71, 
1.22) 
1.63 
(0.33,8.02) 
Europe 
(0.498) 
216 
[P62] 
Facilitated PCI 
for ST-elevation 
MI 
Primary PCI Short-term 
death (all cause) 
8/2 1.07 
(0.57, 
1.99) 
0.64 
(0.08, 5.10) 
N. Amer. 
(0.644) 
103 
[P133] 
Combined 
aspirin-oral 
anticoagulation 
therapy 
Oral 
anticoagulation 
therapy alone 
All-cause 
mortality 
4/2 1.13 
(0.88, 
1.45) 
0.61 
(0.15, 2.41) 
N. Amer. 
(0.382) 
131 
[P114] 
Implantable 
cardioverter 
defibrillators for 
LVSD 
Usual care All-cause 
mortality 
2/3 0.82 
(0.62, 
1.08) 
0.75 
(0.63, 0.89) 
N. Amer. 
(0.584) 
227 Anti-arrhythmics Placebo, drugs All-cause 6/4 1.00 1.43 Europe 
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[C4] after 
cardioversion of 
AF 
for rate control 
or no treatment 
mortality (0.78, 
1.29) 
(0.76, 2.70) (0.301) 
389 
[P41] 
Rescue PCI after 
failed fibrinolytic 
therapy for MI 
Conservative 
therapy 
All-cause 
mortality 
2/2 0.68 
(0.38, 
1.22) 
0.80 
(0.04, 14.5) 
Europe 
(0.918) 
93 
[P105] 
Early IIb/IIIa 
inhibitors for 
primary PCI 
Late IIb/IIIa 
inhibitors 
All-cause 
mortality 
6/2 0.64 
(0.33, 
1.23) 
1.19 
(0.38, 3.67) 
Europe 
(0.357) 
320 
[P99] 
PCI-based 
invasive strategy 
for stable CAD 
Usual medical 
treatment 
Cardiovascular 
mortality 
5/2 0.51 
(0.26, 
1.00) 
0.92 
(0.53, 1.59) 
Europe 
(0.187) 
388 
[P101] 
Prophylactic 
steroids for 
cardiopulmonary 
bypass 
Placebo or 
standard care 
In-hospital 
mortality (all 
cause) 
4/6 0.67 
(0.22, 
2.09) 
 
0.65 
(0.23, 1.86) 
N. Amer. 
(0.967) 
390 
[P1] 
Early invasive 
strategy after 
fibrinolytic 
therapy for MI 
Ischemia-
guided 
management 
All-cause 
mortality 
3/2 0.58 
(0.37, 
0.94) 
0.60 
(0.16, 2.22) 
Europe 
(0.976) 
51 
[C11] 
Glycoprotein 
IIb/IIa inhibitors 
for PCI 
Placebo Death within 30 
days (all cause) 
7/8 0.60 
(0.32, 
1.11) 
0.72 
(0.50, 1.06) 
Europe 
(0.598) 
21 
[P60] 
Antichlamydial 
antibiotic therapy 
for CAD 
Placebo All-cause 
mortality 
4/2 1.11 
(0.70, 
1.76) 
1.08 
(0.86, 1.35) 
N. Amer. 
(0.898) 
71 
[P64] 
Secondary 
prevention 
programmes for 
CAD 
Usual care All-cause 
mortality 
17/10 0.81 
(0.70, 
0.94) 
1.08 
(0.83, 1.40) 
Europe 
(0.066) 
148 
[C48] 
Hormone 
replacement 
therapy for 
preventing CVD 
Placebo Cardiovascular 
mortality 
2/4 0.70 
(0.41, 
1.20) 
1.11 
(0.88, 1.39) 
Europe 
(0.130) 
177 
[P78] 
Multidisciplinary 
interventions for 
HF 
Usual care All-cause 
mortality 
13/10 0.80 
(0.61, 
1.06) 
0.82 
(0.66, 1.01) 
Europe 
(0.922) 
309 
[P138] 
Disease 
management 
programmes for 
HF 
Usual care All-cause 
mortality 
12/13 0.85 
(0.65, 
1.11) 
0.84 
(0.67, 1.05) 
N. Amer. 
(0.967) 
354 
[C13] 
Case 
management 
intervention for 
HF 
Usual care All-cause 
mortality 
4/5 1.12 
(0.85, 
1.47) 
0.75 
(0.53, 1.05) 
N. Amer. 
(0.074) 
5 
[P148] 
 CRT for LSVD No CRT All-cause 
mortality 
5/3 0.69 
(0.54, 
0.87) 
0.82 
(0.66, 1.03) 
Europe 
(0.287) 
82 
[P162] 
Systematic early 
PCI after 
fibrinolytic 
therapy 
Ischemia-
guided PCI 
All-cause 
mortality 
2/2 0.52 
(0.27, 
1.00) 
0.92 
(0.24, 3.61) 
Europe 
(0.460) 
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Table 5.1 shows, in addition to study details and the favoured continent, the significance of any 
difference in how the intervention performed between the two continents. For example, in P160 
(385) the intervention group received statins for Chronic heart disease (CHD), while the control 
109 
[C43] 
Thrombolytic 
therapy for PE 
Heparin or 
placebo plus 
heparin 
All-cause 
mortality 
2/3 1.57 
(0.45, 
5.45) 
0.91 
(0.16, 5.32) 
N. Amer. 
(0.620) 
155 
[P55] 
Disease 
management 
programmes for 
CHF 
Standard care All-cause 
mortality 
12/15 0.79 
(0.59, 
1.06) 
0.86 
(0.71, 1.04) 
Europe 
(0.653) 
310 
[P67] 
Drug eluting 
stents 
Bare metal 
stents 
All-cause 
mortality 
3/5 0.47 
(0.06, 
3.64) 
0.98 
(0.52, 1.84) 
Europe 
(0.506) 
328 
[P108] 
Off pump CABG 
surgery 
On pump 
CABG surgery 
All-cause 
mortality 
9/3 0.92 
(0.44, 
1.93) 
1.21 
(0.41, 3.58) 
Europe 
(0.677) 
75 
[P139] 
Secondary 
prevention 
programmes for 
CHD 
Usual care All-cause 
mortality 
9/7 0.81 
(0.70, 
0.94) 
0.99 
(0.71, 1.38) 
Europe 
(0.278) 
76 
[P34] 
Remote 
monitoring 
programmes for 
chronic HF 
Usual care All-cause 
mortality 
3/9 0.63 
(0.43, 
0.92) 
0.78 
(0.60, 1.00) 
Europe 
(0.363) 
211 
[P31] 
Sirolimus- 
eluting stents 
Bare metal 
stents 
All-Cause 
mortality 
5/2 1.00 
(0.69, 
1.44) 
0.95 
(0.65, 1.39) 
N. Amer.  
(0.837) 
226 
[P125] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo or 
standard care 
Death within 30 
days (all cause) 
4/7 0.44 
(0.21, 
0.89) 
0.72 
(0.50, 1.04) 
Europe 
(0.221) 
250 
[P115] 
CRT for LVSD No CRT All-cause 
mortality 
5/4 0.72 
(0.57, 
0.90) 
0.83 
(0.67, 1.03) 
Europe 
(0.349) 
298 
[P168] 
Thrombolytic 
therapy for 
submassive PE 
Placebo Short-term 
death (all cause) 
2/2 1.57 
(0.45, 
5.45) 
0.70 
(0.08, 6.44) 
N. Amer. 
(0.534) 
308 
[P126] 
Statin 
monotherapy for 
CVD in older 
adults 
Placebo All-cause 
mortality 
5/6 0.89 
(0.84, 
0.94) 
0.97 
(0.43, 2.18) 
Europe 
(0.828) 
385 
[P160] 
Statins for CHD Placebo CHD Mortality 12/5 0.81 
(0.74, 
0.89) 
0.82 
(0.64, 1.05) 
Europe 
(0.900) 
259 
[P102] 
Off pump CABG 
surgery 
On pump 
CABG surgery 
All-cause 
mortality 
14/4 0.96 
(0.60, 
1.53) 
1.55 
(0.72, 3.36) 
Europe 
(0.290) 
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group received a placebo. The endpoint reported was CHD mortality and 12 European and 5 
North America trials contributed to this endpoint. The estimate for treatment effect for Europe 
was a RR of 0.81 while for North America the RR was 0.82. The intervention did perform better 
in Europe but a 2-sided p-value of 0.900
40
 showed that the difference between continents in effect 
was not significant at the 5% level. 
Some meta-analyses that reported fatal endpoints as RR did not report which group was the 
intervention under investigation and which was the control group. Therefore, it was not possible 
in these cases to calculate which region the intervention favoured, as it was not clear what the 
intervention was. This was only the case for three meta-analyses as shown in Table 5.2. 
 
 
 
 
 
 
                                                 
40
 The p-values reported are those given by the Z-tests calculated for each meta-analysis for the between-continent 
difference. 
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Table 5.2: Meta-analyses with Fatal Endpoints for Europe vs. North America that do not 
Identify which Group is the Intervention under Investigation. Effectiveness measured by 
RR. 
Article 
Ref. no 
Intervention 
1 
Intervention 
2 
End 
point 
No. of 
trials 
(Europe/ 
N. 
Amer.) 
RR 
estimate 
for 
Europe 
(95% CI) 
RR 
estimate 
for N. 
Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
56 
[P24] 
PCI CABG 
surgery  
All-cause 
mortality 
7/3 0.61 
(0.33,1.13) 
0.74 
(0.41, 
1.34) 
Not Applic. 
(0.652) 
252 
[P54] 
Routine 
invasive 
strategies for 
ACS 
Selective 
invasive 
strategies 
All-cause 
mortality 
2/3 0.55 
(0.17, 1.83) 
1.18 
(0.93, 
1.51) 
Not Applic. 
(0.221) 
296 
[P16] 
Routine 
invasive 
strategy for 
ACS 
Selective 
invasive 
strategy 
All-cause 
mortality 
4/3 0.74 
(0.47, 1.16) 
1.18 
(0.93, 
1.51) 
Not Applic. 
(0.0728) 
 
5.1.1.1.2: Fatal Endpoints Measured as Odds Ratios 
Six of the 47 meta-analyses that reported fatal endpoints did so using OR. The details of these 
meta-analyses are summarised in Table 5.3. 
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Table 5.3: Meta-analyses with Fatal Endpoint Data. Treatment Effect measured by OR. 
 
One meta-analysis using OR did not report which was the intervention group and which was the 
control group. This is shown in Table 5.4. As with fatal endpoints reported as RR, no calculation 
was able to be made about which region the intervention favoured for this meta-analysis. 
 
Article 
Ref. no 
Intervention Control End point No. of 
trials 
(Europe/ 
N. Amer.) 
OR 
estimate 
for 
Europe 
(95% CI) 
OR 
estimate 
for N. 
Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
7 
[P152] 
ACE 
inhibitors for 
LSVD 
Placebo All-cause 
mortality 
3/4 0.50 
(0.19, 
1.33) 
0.87 
(0.73, 
1.02) 
Europe 
(0.280) 
286 
[P153] 
Amiodarone 
for Preventing 
Post-operative 
AF 
Placebo or 
routine 
treatment 
Death within 
30 days (all 
cause) 
3/6 1.79 
(0.34, 
9.43) 
0.82 
(0.43, 
1.59) 
N. Amer. 
(0.397) 
65 
[P93] 
Immediate 
PCI after 
thrombolytic 
therapy 
Delayed PCI Death within 
12 months (all 
cause) 
3/2 0.55 
(0.32, 
0.92) 
1.42 
(0.73, 
2.76) 
Europe 
(0.027) 
68 
[P159] 
Hormone 
replacement 
therapy for 
preventing 
CVD 
Placebo Cardiovascular 
mortality 
2/3 1.41 
(0.26, 
7.62) 
1.10 
(0.88, 
1.38) 
N. Amer. 
(0.776) 
274 
[P49] 
Drug-eluting 
stents for 
CAD 
Bare metal 
stents 
Cardiovascular 
death within 1 
year 
4/4 0.85 
(0.37, 
1.97) 
0.94 
(0.50, 
1.77) 
Europe 
(0.849) 
28 
[P154] 
Azithromycin 
for secondary 
prevention of 
CAD 
Placebo All-cause 
mortality 
2/2 0.90 
(0.22, 
3.71) 
0.94 
(0.62, 
1.42) 
Europe 
(0.952) 
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Table 5.4: The Meta-analysis with Fatal Endpoints for Europe vs. North America that does 
not Identify which group is the Intervention and which the Control. Effectiveness measured 
by OR. 
Article 
Ref. no 
Intervention 
1 
Intervention 
2 
End point No. of 
trials 
(Europe/ 
N. Amer.) 
OR 
estimate 
for Europe 
(95% CI) 
OR 
estimate 
for N. 
Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
69 
[P81] 
Invasive 
management 
strategy for 
angina and 
MI 
Non-
invasive 
management 
strategy 
All-cause 
mortality 
3/3 0.74 
(0.40, 1.36) 
1.22 
(0.92, 1.61) 
Not Applic. 
(0.147) 
 
5.1.1.2: Examination over all Meta-analyses for Fatal Endpoints 
Table 5.5 shows the number of meta-analyses identifying their intervention and control groups 
that favoured each continent. 
Table 5.5: The Number of Meta-analyses Favouring Each Continent for Fatal Data 
Total Number of Meta-
analyses (%) 
Number of Meta-analyses 
Favouring Europe (%) 
Number of Meta-analyses 
Favouring North America 
(%) 
43 (100%) 28 (65%) 15 (35%) 
 
As can be seen, 28 of the 43 meta-analyses showed the intervention to perform best in Europe 
and in 15 the intervention to perform best in North America. To find the significance of this, a 
binomial sign test was conducted under the null hypothesis that the effect of interventions, 
relative to controls, would be the same in both continents. This showed that the effect of 
interventions, relative to controls, was not significantly different between Europe and North 
America, (2-sided p-value = 0.066).  
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5.1.1.3: Global Estimates of Continental Differences for Fatal Endpoints 
Global estimates of continental difference were also produced. These were the calculated 
weighted average difference between the treatment effect estimates of Europe and North America 
over all of the meta-analyses. These estimates were produced for RR and OR. From these global 
estimates, it was found that for RR (37 meta-analyses), the mean log difference over all of the 
meta-analyses was -0.0839 with 95% confidence intervals of -0.172 and 0.0046 (2-sided p-value 
= 0.06), while for OR (6 meta-analyses), the mean log difference over all of the meta-analyses 
was -0.378 with 95% confidence intervals of -0.852 and 0.0966 (2-sided p-value = 0.119).These 
results showed that there was insufficient evidence for a difference in overall treatment effect 
between Europe and North America over all of the meta-analyses that had identified their 
intervention and control groups, as neither of these global estimates was statistically significant at 
the 5% level. 
5.1.1.4: Inter-Continental Differences by Intervention Type – Fatal Endpoints 
Even though statistically significant differences were not found in treatment effect between 
Europe and North America, it was considered important to establish whether specific intervention 
types were prone to inter-continental differences in treatment effect. This was investigated by 
grouping the meta-analyses according to intervention type and then, within each group, observing 
the Z-statistic and 2-sided p-value of each meta-analysis. This was to see whether, over all meta-
analyses in that intervention type, there was any clear pattern of statistically significant 
differences in treatment effect. This was done by using Tables 5.6 to 5.10. 
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Table 5.6 provides details of the meta-analyses that examined drug therapies. For each meta-
analysis, information is provided on the intervention examined, the number of trials included 
from Europe and North America, the pooled treatment effect estimate for each continent, the 
between-continental difference, and the result of the Z-test. 
Table 5.6: Meta-analyses Investigating Drugs with the Z-statistic for the Difference in 
Treatment Effect between Europe and North America for Fatal Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment   
Effect 
Measure 
No. of 
Trials 
(Europe
/ N. 
Amer.) 
Pooled 
Estimate 
Europe 
(95% CI) 
Pooled 
Estimate 
North 
America 
(95% CI) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-Statistic 
for 
difference 
2-sided p-
value of 
difference 
298 
[P168] 
Thrombolytic 
Therapy 
RR 2/2 0.89 
(0.84,0.9
4) 
0.97 
(0.43, 2.18) 
0.8062 
(-1.74, 
3.35) 
0.622 0.534 
103 
[P133] 
Aspirin plus 
Oral Anti-
coagulation 
Therapy 
RR 4/2 1.13 
(0.88, 
1.45) 
0.61 
(0.15, 2.41) 
0.6236 
(-0.77, 
2.02) 
0.874 0.382 
93 
[P105] 
Glycoprotein 
IIb/IIIa 
RR 6/2 0.64 
(0.33, 
1.23) 
1.19 
(0.38, 3.67) 
-0.6128 
(-1.91, 
0.69) 
-0.921 0.357 
178 
[C22] 
Digitalis RR 2/3 0.55 
(0.12/2.5
3) 
0.99 
(0.93/1.06) 
-0.5950 
(-2.13, 
0.94) 
-0.761 0.447 
313 
[P75] 
Warfarin plus 
Aspirin 
RR 3/2 0.93 
(0.71, 
1.22) 
1.63 
(0.33, 8.02) 
-0.5587 
(-2.17, 
1.06) 
-0.678 0.498 
109 
[C43] 
Thrombolytic 
Therapy 
RR 2/3 1.57 
(0.45, 
5.45) 
0.91 
(0.16, 5.32) 
0.5465 
(-1.61, 
2.71) 
0.496 0.620 
226 
[P125] 
Glycoprotein 
IIb/IIIa 
RR 4/7 0.44 
(0.21, 
0.89) 
0.72 
(0.50, 1.04) 
-0.5017 
(-1.30, 
0.30) 
-1.225 0.221 
18 Phosphodieste
rase III 
Inhibitors 
RR 2/5 1.55 1.03 0.4014 1.407 0.160 
  
140 
 
 
As can be seen, none of the meta-analyses investigating drugs showed a statistically significant 
difference in treatment effect between Europe and North America. Therefore, no clear pattern of 
statistically significant differences could be identified to suggest that this type of intervention is 
prone to inter-continental differences in treatment effect.  
Table 5.7 provides the above details for the meta-analyses that investigated medical devices. 
[C12] (1.01,2.3
7) 
(0.72,1.49) (-0.16, 
0.96) 
227 
[C4] 
Anti-
arrhythmics 
RR 6/4 1.00 
(0.78,1.2
9) 
1.43 
(0.76, 2.70) 
0.3591 
(-1.04, 
0.32) 
-1.035 0.301 
223 
[P96] 
Beta-blockers RR 2/3 0.93 
(0.35,2.4
7) 
0.72 
(0.45,1.17) 
0.2578 
(-0.83. 
1.34) 
0.466 0.641 
51 
[C11] 
Glycoprotein 
IIb/IIIa 
RR 7/8 0.60 
(0.32,1.1
1) 
0.72 
(0.50,1.06) 
-0.1969 
(-0.93, 
0.53) 
-0.528 0.598 
308 
[P126] 
Statins RR 5/6 0.89 
(0.84,0.9
4) 
0.97 
(0.43,2.18) 
-0.0899 
(-0.90, 
0.72) 
-0.218 0.828 
21 
[P60] 
Antibiotic 
Therapy 
RR 4/6 1.11 
(0.70, 
1.76) 
1.08 
(0.86,1.35) 
0.0333 
(-0.48, 
0.54) 
0.128 0.898 
388 
[P101] 
Prophylactic 
Steroids 
RR 4/6 0.67 
(0.22, 
2.09) 
0.65 
(0.23,1.86) 
0.0324 
(-1.51, 
1.57) 
0.041 0.967 
385 
[P160] 
Statins RR 12/5 0.81 
(0.74, 
0.89) 
0.82 
(0.64, 1.05) 
-0.0169 
(-0.28, 
0.25) 
-0.126 0.900 
286 
[P153] 
Amiodarone OR 3/6 1.79(0.3
4, 9.43) 
0.82(0.43, 
1.59) 
0.7727(-
1.02, 2.56) 
0.847 0.397 
7[P152] ACE 
Inhibitors 
OR ¾ 0.50(0.1
9, 1.33) 
0.87(0.73, 
1.02) 
-0.5424(-
1.53, 0.44) 
-1.079 0.280 
28[P154] Azithromycin OR 2/2 0.90(0.2
2, 3.71) 
0.94(0.62, 
1.42) 
-0.0451(-
1.53, 1.44) 
-0.060 0.952 
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Table 5.7: Meta-analyses Investigating Medical Devices with the Z-statistic for the 
Difference in Treatment Effect between Europe and North America for Fatal Endpoints. 
Meta-
analysis 
Ref. 
No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. 
Amer.) 
Pooled 
Estimate 
Europe 
(95% CIs) 
Pooled 
Estimate 
North 
America 
(95% CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
Statistic 
for 
difference 
2-sided p-
value of 
difference 
310 
[P67] 
Stent RR 3/5 0.47 
(0.06, 
3.64) 
0.98 
(0.52, 
1.84) 
-0.7255 
(-2.87, 
1.41) 
 
-0.665 0.506 
5 
[P148] 
Cardiac 
Resynchronisation 
Therapy 
RR 5/3 0.69 
(0.54,0.87) 
0.82 
(0.66, 
1.03) 
-0.1754 
(-0.50, 
0.15) 
-1.065 0.287 
250 
[P115] 
Cardiac 
Resynchronisation 
Therapy 
RR 5/4 0.72 
(0.57,0.90) 
0.83 
(0.67,1.03) 
-0.1477 
(-0.48, 
0.17) 
-0.936 0.349 
131 
[P114] 
Implantable 
Cardioverter 
Defibrillators 
RR 2/3 0.82 
(0.62, 
1.08) 
0.75 
(0.63,0.89) 
0.0896 
(-0.23, 
0.41) 
0.548 0.584 
211 
[P31] 
Stents RR 5/2 1.00 
(0.69,1.44) 
0.95 
(0.65,1.39) 
0.0557 
(-0.48, 
0.59) 
0.206 0.837 
274 
[P49] 
Stents OR 4/4 0.85(0.37, 
1.97) 
0.94(0.50, 
1.77) 
-0.1023(-
1.15, 
0.95) 
-0.191 0.849 
 
As Table 5.7 shows, none of the medical devices investigated showed a statistically significant 
difference in treatment effect between Europe and North America. Therefore, for medical 
devices, no clear pattern could be identified to show that this intervention type was prone to inter-
continental differences.  
Table 5.8 shows the details of the meta-analyses that investigated surgical interventions. As 
before, it states the intervention investigated, the number of European and North American trials 
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included, the treatment effect estimate for each continent, and the Z- statistic for the between-
continental difference with its 2-sided p-value. 
Table 5.8: Meta-analyses Investigating Surgery with the Z-statistic for the Difference in 
Treatment Effect between Europe and North America for Fatal Endpoints. 
 
 
As can be seen, the difference in treatment effect between Europe and North America was 
statistically significant in none of the meta-analyses at the 5% level. Consequently, no clear 
pattern was found to suggest that surgical interventions were prone to between-continental 
differences in treatment effect.  
Table 5.9 shows the details of the meta-analyses that investigated lifestyle interventions. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. Amer.) 
Pooled 
Estimate 
Europe 
(95% CI) 
Pooled 
Estimate 
North 
America 
(95% CI) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-Statistic 
for 
difference 
2-sided p-
value of 
difference 
216 
[P62] 
Primary PCI RR 8/2 1.07 
(0.57, 
1.99) 
0.64 
(0.08, 5.10) 
0.5102 
(-1.65, 
2.67) 
0.462 0.644 
259 
[P102] 
Off-pump 
CABG 
RR 14/4 0.96 
(0.60, 
1.53) 
1.55 
(0.72, 3.36) 
-0.4869 
(-1.39, 
0.42) 
-1.058 0.290 
328 
[P108] 
Off-pump 
CABG 
RR 9/3 0.92 
(0.44, 
1.93) 
1.21 
(0.41, 3.58) 
0.2789 
(-1.59, 
1.03) 
-0.416 0.677 
389 
[P41] 
Rescue PCI RR 2/2 0.68 
(0.38,1.22
) 
0.80 
(0.04,14.5) 
-0.1555 
(-3.11, 
2.80) 
-0.103 0.918 
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Table 5.9: Meta-analyses Investigating Lifestyle Interventions with the Z-statistic for the 
Difference in Treatment Effect between Europe and North America for Fatal Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. Amer.) 
Pooled 
Estimate 
Europe 
(95% CI) 
Pooled 
Estimate 
North 
America 
(95% CI) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-Statistic 
for 
difference 
2-sided p-
value of 
difference 
179 
[C23] 
Omega 3 
Fatty Acids 
RR 8/2 1.00 
(0.73,1.38
) 
0.25 
(0.03, 2.24) 
1.3885 
(-0.83, 
3.60) 
1.229 0.219 
148 
[C48] 
Hormone 
Replacement 
Therapy 
RR 2/4 0.70 
(0.41, 
1.20) 
1.11 
(0.88, 1.39) 
-0.4514 
(-1.04, 
0.13) 
-1.516 0.130 
304 
[C25] 
Psychologic
al 
Intervention
s 
RR 2/6 0.70 
(0.32,1.52
) 
0.93 
(0.67,1.28) 
0.2854 
(-1.12, 
0.55) 
-0.666 0.505 
75 
[P64] 
Secondary 
Prevention 
Programmes 
RR 17/10 0.81 
(0.70,0.94
) 
1.08 
(0.83, 1.40) 
0.2829 
(-0.58, 
0.02) 
-1.839 0.066 
74 
[P139] 
Secondary 
Prevention 
Programmes 
RR 9/7 0.81 
(0.70,0.94
) 
0.99 
(0.71, 1.38) 
-0.2007 
(-0.56, 
0.16) 
-1.086 0.278 
68 
[P159] 
Hormone 
Replacement 
Therapy 
OR 2/3 1.41(0.26, 
7.62) 
1.10(0.88, 
1.38) 
0.2468(-
1.46, 1.95) 
0.284 0.776 
 
Again, all meta-analyses found the difference in treatment effect between Europe and North 
America to be statistically non-significant. As such, no clear pattern of statistically significant 
differences was found to suggest that lifestyle interventions were prone to between-continental 
differences. 
The next table provides the details of the meta-analyses that investigated management of 
cardiovascular disease. 
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Table 5.10: Meta-analyses Investigating Management with the Z-statistic for the Difference 
in Treatment Effect between Europe and North America for Fatal Endpoints. 
 
As can be seen, one meta-analysis investigating management found the difference in treatment 
effect between Europe and North America to be statistically significant. This was P93 (65), a 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. Amer.) 
Pooled 
Estimate 
Europe 
(95% CI) 
Pooled 
Estimate 
North 
America 
(95% CI) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-Statistic 
for 
difference 
2-sided p-
value of 
difference 
354 
[C13] 
Case 
Management 
RR 4/5 1.12 
(0.85,1.47
) 
0.75 
(0.53,1.05) 
0.4012 
(0.04, 
0.84) 
1.789 0.074 
76 
[P34] 
Telemonitoring RR 3/9 0.63 
(0.43,0.92
) 
0.78 
(0.60,1.00) 
-0.2139 
(-0.67, 
0.25) 
-0.910 0.363 
155 
[P55] 
Disease 
Management 
Programmes 
RR 12/15 0.79 
(0.59, 
1.06) 
0.86 
(0.71,1.04) 
-0.0804 
(-0.43, 
0.27) 
-0.450 0.653 
390 
[P1] 
Early Invasive 
Strategy 
RR 3/2 0.58 
(0.37, 
0.94) 
0.60 
(0.16, 2.22) 
-0.0211 
(-1.41, 
1.37) 
-0.030 0.976 
177 
[P78] 
Multi-
disciplinary 
Interventions 
RR 13/10 0.80 
(0.61, 
1.06) 
0.82 
(0.66, 1.01) 
-0.0175 
(-0.37, 
0.33) 
-0.098 0.922 
309 
[P138] 
Disease 
Management 
Programmes 
RR 12/13 0.85 
(0.65, 
1.11) 
0.84 
(0.67, 1.05) 
0.0073 
(-0.34, 
0.36) 
0.041 0.967 
82 
[P162] 
Early Invasive 
PCI 
RR 2/2 0.52 
(0.27, 
1.00) 
0.92 
(0.24, 3.61) 
-0.5698 
(-2.08, 
0.94) 
-0.739 0.460 
320 
[P99] 
PCI-based 
Invasive 
Strategy 
RR 5/2 0.51 
(0.26, 
1.00) 
0.92 
(0.53, 1.59) 
-0.5830 
(-1.45, 
0.28) 
-1.318 0.187 
65[P93] Immediate PCI OR 3/2 0.55(0.32, 
0.92) 
1.42(0.73, 
2.76) 
-0.9561(-
1.80,-0.11) 
-2.213 0.027 
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meta-analysis comparing immediate PCI after thrombolytic therapy (Intervention) with delayed 
PCI (Control). The immediate PCI performed better, with respect to all-cause death within 12 
months, in Europe compared with North America. The 2-sided p-value was 0.027. However, as 
no other meta-analyses in this group found a statistically significant difference between Europe 
and North America, no clear pattern could be identified to suggest that management interventions 
were prone to inter-continental differences in treatment effect. 
Since no group of interventions showed a clear pattern of statistically significant differences in 
treatment effect between Europe and North America, the types of intervention prone to such 
differences for fatal endpoints could not be identified. Furthermore, given that there were 47 
meta-analyses overall that provided fatal endpoint data, finding a between-continent difference 
statistically significant at the 5% level in only one of these is not more than would be expected by 
random chance. As such, there was insufficient evidence to conclude which types of intervention 
were prone to differences in treatment effect between Europe and North America for fatal 
endpoints.  
5.1.1.5: The Impact of Including Overlapping Meta-analyses on Fatal Endpoint Results 
Differences in treatment effect may have been diminished or enhanced by the inclusion of 
duplicated trial results from overlapping meta-analyses. As mentioned in Chapter 4 (Section 
4.4.1) some of the systematic reviews on which this comparison was based were investigating the 
same clinical question and, as such, their meta-analyses may have contained some of the same 
trials. This may create a problem if an excessively large number of such trials favoured Europe 
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over North America, as when meta-analyses comprising these trials were pooled there would be 
unreasonably strong support for interventions favouring Europe compared to North America.  
Of the 43 included meta-analyses,  26 overlapping meta-analyses were identified (C11,C13,C43, 
C48,P125, P34, P55, P78, P138, P168, P159, P31, P49, P67, P60, P154, P64, P139, P93, P162, 
P102, P108, P115, P148, P126, P160) and 17 non-overlapping meta-analyses (C4, C12, C22, 
C23, C25, P1, P41, P62, P75, P96, P99, P101, P105, P114, P133, P152, P153). Of the 26 
overlapping meta-analyses, there were nine pairs of meta-analyses that had one or more trials in 
common with each other (C11 and P125, C43 and P168, C48 and P159, P60 and P154, P64 and 
P139, P93 and P162, P102 and P108, P115 and P148 and P126 and P160). Furthermore, there 
was one group of five meta-analyses which had one or more trials in common (C13, P34, P55, 
P78, P138) and one group of three meta-analyses where this was the case (P31, P49 and P67).  
More importantly, it was found that of the meta-analyses considered to be overlapping, 73% (19 
out of 26 meta-analyses) favoured Europe over North America, while for non-overlapping meta-
analyses only 53% (9 out of 17 meta-analyses) favoured Europe. This suggests that, with regard 
to fatal endpoints, the large number of meta-analyses that had favoured Europe over North 
America (65% or 28 out of 43 meta-analyses) may have been inflated as a consequence of 
including overlapping meta-analyses. 
5.1.2: Non-Fatal Endpoints. 
Of the 59 meta-analyses relevant for the Europe versus North America comparison, only 44 had 
at least two trials from each continent with non-fatal data that would allow for separate estimates 
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of treatment effect to be calculated for each continent. Tables 5.11 to 5.15 provide the details of 
these meta-analyses. 
5.1.2.1: Meta-analyses Grouped by Treatment Effect Measure for Non-Fatal Endpoints 
Table 5.8 shows the details for the included meta-analyses that measured treatment effect by the 
RR for non-fatal endpoints. It includes the details about the intervention group, control group, 
and endpoint reported for each meta-analysis as well as the number of trials based in each 
continent. The treatment effect estimates are also given for each continent along with the details 
of the continent where the intervention performed best (Best region and 2-sided p-value). 
5.1.2.1.1: Non-Fatal Endpoints Measured as Risk Ratios. 
Thirty-five meta-analyses reported treatment effect in terms of RR. The details of these are 
summarised in Table 5.11. 
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Table 5.11: Meta-analyses with Non-Fatal Endpoint Data. Treatment Effect Measured by 
RR. 
Article Ref. 
no 
Intervention Control End point No. of 
trials 
(Europe
/ N. 
Amer.) 
RR 
estimate for 
Europe 
(95% CI) 
RR 
estimate for 
N. Amer. 
(95% CI) 
Best Region 
(p-value of  
between-
continental 
difference) 
178 
[C22] 
Digitalis for CHF Placebo Clinical 
deterioration 
2/2 0.19 
(0.02, 
1.62) 
0.34 
(0.11, 
1.07) 
Europe 
(0.644) 
304 
[C25] 
Psychological 
interventions for 
CHD 
Usual care 
or no 
interventio
n 
MI 4/7 0.74 
(0.54, 
1.02) 
0.76 
(0.57, 
1.02) 
Europe 
(0.872) 
18 
[C12] 
Phosphodiesterase 
III inhibitors for 
HF 
Placebo Worsening 
heart failure 
3/6 1.52 
(0.77, 
3.01) 
0.85 
(0.63, 
1.15) 
N. Amer. 
(0.130) 
21 
[P60] 
Antichlamydial 
antibiotic therapy 
for CAD 
Placebo MI 2/2 0.61 
(0.26, 
1.47) 
1.03 
(0.82, 
1.29) 
Europe 
(0.267) 
75 
[P64] 
Secondary 
prevention 
programmes for 
CAD 
Usual care Recurrent MI 13/5 0.727 
(0.60, 
0.89) 
0.733 
(0.49, 
1.10) 
Europe 
(0.971) 
48 
[P166] 
Vitamin-mineral 
supplements for 
CAD 
Placebo Restenosis 2/2 0.84 
(0.34, 
2.07) 
0.97 
(0.65, 
1.44) 
Europe 
(0.785) 
109 
[C43] 
Thrombolytic 
therapy for PE 
Heparin or 
placebo 
plus 
heparin 
Major 
Haemorrhagic 
events 
2/2 0.61 
(0.13, 
2.96) 
2.64 
(0.44, 
15.8) 
Europe 
(0.230) 
203 
[P120] 
Self-management 
strategy for HF 
Usual 
manageme
nt strategy 
Hospital re-
admission 
within 1 year 
2/3 0.73 
(0.56, 
0.95) 
0.74 
(0.58, 
0.93) 
Europe 
(0.954) 
216 
[P62] 
Facilitated PCI 
for ST-elevation 
MI 
Primary 
PCI 
Short-term 
major 
bleeding 
8/3 1.30 
(0.83, 
2.05) 
2.60 
(0.58, 
11.7) 
Europe 
(0.388) 
103 
[P133] 
Combined aspirin 
–oral 
anticoagulation 
therapy 
Oral 
anticoagul
ation 
therapy 
alone 
Major 
bleeding 
4/2 1.69 
(0.94, 
3.04) 
1.28 
(0.74, 
2.23) 
N. Amer. 
(0.502) 
175 
[P29] 
Intravenous 
magnesium for 
acute onset AF 
Placebo or 
other anti-
arrhythmic 
agent 
Conversion of 
AF to sinus 
rhythm 
2/3 3.55 
(1.21, 
10.4) 
1.07 
(0.59, 
1.95) 
Europe 
(0.056) 
227 
[C4] 
Anti-arrhythmics 
after 
cardioversion of 
AF 
Placebo, 
drugs for 
rate control 
or no 
AF recurrence 11/6 0.70 
(0.61, 
0.81) 
0.80 
(0.67, 
0.97) 
Europe 
(0.259) 
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treatment  
 
385 
[P160] 
Statins for CHD Placebo MI 13/4 0.67 
(0.58, 
0.77) 
0.78 
(0.66, 
0.93) 
Europe 
(0.176) 
93 
[P105] 
Early IIb/IIIa 
inhibitors for 
primary PCI 
Late 
IIb/IIIa 
inhibitors 
Post-
procedural 
TIMI 3 flow 
6/2 1.05 
(0.99, 
1.11) 
1.01 
(0.91, 
1.13) 
Europe 
(0.594) 
30 
[C54] 
Psychosocial 
smoking cessation 
help for CHD 
Usual care Abstinence 
from smoking 
6/7 1.22 
(0.95, 
1.57) 
1.32 
(1.13, 
1.53) 
N. Amer. 
(0.604) 
320 
[P99] 
PCI based 
invasive strategy 
for stable CAD 
Usual 
medical 
treatment 
MI 7/5 0.78 
(0.46, 
1.31) 
1.11 
(0.91, 
1.37) 
Europe 
(0.209) 
388 
[P101] 
Prophylactic 
steroids for 
cardiopulmonary 
bypass 
Placebo or 
standard 
care 
New onset AF 3/7 0.84 
(0.57, 
1.25) 
0.60 
(0.46, 
0.80) 
N. Amer.  
(0.172) 
390 
[P1] 
Early invasive 
strategy after 
fibrinolytic 
therapy for MI 
Ischemia-
guided 
manageme
nt 
Major 
bleeding 
3/2 1.56 
(0.57, 
4.26) 
1.24 
(0.48, 
3.24) 
N. Amer. 
(0.744) 
51 
[C11] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo 30 day urgent 
revascularisati
on 
7/7 0.60 
(0.38, 
0.96) 
0.48 
(0.32, 
0.71) 
N. Amer. 
(0.453) 
1 
[P123] 
Amiodarone 
prophylaxis for 
cardiac surgery 
Placebo Atrial 
fibrillation or 
flutter 
2/6 0.74 
(0.39, 
1.41) 
0.66 
(0.56, 
0.78) 
N. Amer. 
(0.721) 
34 
[P65] 
Sirolimus-eluting 
stents for PCI 
Bare metal 
stents 
Stent-
associated 
thrombosis 
2/2 0.25 
(0.07, 
0.90) 
0.60 
(0.14, 
2.53) 
Europe 
(0.376) 
148 
[C48] 
Hormone 
replacement 
therapy for 
preventing CVD 
Placebo Stroke 4/2 1.71 
(0.66, 
4.44) 
1.09 
(0.88, 
1.34) 
N. Amer. 
(0.363) 
153 
[P149] 
Amiodarone 
prophylaxis for 
cardiothoracic 
surgery 
Placebo Post-operative 
AF 
6/5 0.72 
(0.56, 
0.93) 
0.65 
(0.54, 
0.78) 
N. Amer. 
(0.506) 
177 
[P78] 
Multidisciplinary 
interventions for 
HF 
Usual care Hospital 
admission (all 
cause) 
7/10 0.81 
(0.63, 
1.04) 
0.88 
(0.77, 
1.00) 
Europe 
(0.579) 
309 
[P138] 
Disease 
management 
programmes for 
HF 
Usual care All cause 
rehospitalisati
on 
10/12 0.79 
(0.56, 
1.11) 
0.91 
(0.72, 
1.16) 
Europe 
(0.487) 
313 
[P75] 
Warfarin plus 
aspirin after MI or 
ACS 
Aspirin 
only 
MI 3/3 0.55 
(0.42, 
0.72) 
0.65 
(0.35, 
1.19) 
Europe 
(0.646) 
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354 
[C13] 
Case management 
intervention for 
HF 
Usual care Hospital 
readmission 
due to HF 
3/4 0.50 
(0.26, 
0.97) 
0.68 
(0.50, 
0.91) 
Europe 
(0.415) 
22 
[P73] 
Aspirin plus 
Warfarin after 
ACS 
Aspirin 
alone 
Major bleeds 4/6 2.36 
(1.53, 
3.65) 
1.53 
(1.21, 
1.92) 
N. Amer. 
(0.081) 
145 
[P135] 
CRT for LSVD No CRT Hospital 
admission due 
to HF 
3/2 0.52 
(0.41, 
0.67) 
0.67 
(0.44, 
1.05) 
Europe 
(0.316) 
155 
[P55] 
Disease 
management 
programmes for 
CHF 
Standard 
care 
Hospital 
readmission 
(all cause) 
12/16 0.75 
(0.64, 
0.90) 
0.86 
(0.77, 
0.97) 
Europe 
(0.196) 
310 
[P67] 
Drug eluting 
stents 
Bare metal 
stents 
Angiographic 
binary 
restenosis 
3/5 0.12 
(0.05, 
0.28) 
0.37 
(0.23, 
0.61) 
Europe 
(0.026) 
328 
[P108] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
Stroke 9/3 0.43 
(0.18, 
1.03) 
1.22 
(0.29, 
5.22) 
Europe 
(0.229) 
226 
[P125] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo or 
standard 
care 
MI within 30 
days 
4/7 0.87 
(0.59, 
1.30) 
0.62 
(0.50, 
0.77) 
N. Amer. 
(0.132) 
250 
[P115] 
CRT for LSVD No CRT Hospital 
admission due 
to HF 
2/3 0.53 
(0.41, 
0.68) 
0.82 
(0.55, 
1.20) 
Europe 
(0.069) 
259 
[P102] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
MI 14/4 0.75 
(0.45, 
1.27) 
1.23 
(0.40, 
3.77) 
Europe 
(0.437) 
 
As for fatal endpoints, the best region could not be identified for some of the meta-analyses using 
RR as these meta-analyses had not specifically identified which was the intervention group and 
which was the control group. As such, it was not possible to calculate the continent in which the 
intervention performed best. This was only the case in three meta-analyses and details of these 
can be found in Table 5.12. 
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Table 5.12: Meta-analyses with Non-Fatal Endpoints for Europe vs. North America that do 
not Identify which Group Was the Intervention and Which the Control Effectiveness 
measured by RR. 
Article 
Ref. no 
Intervention 
1 
Intervention 
2 
End 
point 
No. of 
trials 
(Europe/ 
N. Amer.) 
RR 
estimate 
for Europe 
(95% CI) 
RR estimate 
for N. Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
56 
[P24] 
PCI CABG 
surgery 
Stroke 4/3 0.36 
(0.09, 1.44) 
0.40 
(0.14, 1.13) 
Not Applic. 
(0.913) 
253 
[P54] 
Routine 
invasive 
strategies for 
ACS 
Selective 
invasive 
strategies 
Severe 
angina 
2/3 0.77 
(0.66, 0.89) 
0.93 
(0.69, 1.24) 
Not Applic. 
(0.254) 
296 
[P16] 
Routine 
invasive 
strategy for 
ACS 
Selective 
invasive 
strategy 
MI 4/3 0.90 
(0.49, 1.66) 
0.87 
(0.70, 1.08) 
Not Applic. 
(0.918) 
 
5.1.2.1.2: Non-Fatal Endpoints Measured as Odds Ratios 
Only three meta-analyses reported treatment effect in terms of OR. Table 5.13 provides the 
details (the same as the above Table) for the included meta-analyses that reported treatment effect 
in terms of OR. 
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Table 5.13: Meta-analyses with Non-Fatal End-Point Data. Treatment Effect Measured by 
OR. 
 
One meta-analysis reporting treatment effect in terms of OR did not report which was the 
intervention group and which was the control group. This is shown in Table 5.14. As with non-
fatal endpoints reported using RR, no calculation was able to be made about which continent the 
intervention favoured for this meta-analysis. 
 
 
 
 
Article Ref. 
no 
Intervention Control End point No. of 
trials 
(Europe/ 
N. Amer.) 
OR 
estimate 
for 
Europe 
(95% CI) 
OR 
estimate 
for N. 
Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
68 
[P159] 
Hormone 
replacement 
therapy for 
preventing 
CVD 
Placebo MI 2/3 0.70 
(0.22, 
2.19) 
1.07 
(0.84, 
1.36) 
 
Europe 
(0.472) 
27 
[P156] 
Amiodarone 
prophylaxis 
for cardiac 
surgery 
Placebo or 
routine 
treatment 
Post-
operative AF 
5/7 0.47 
(0.32, 
0.69) 
0.51 
(0.41, 
0.64) 
Europe 
(0.697) 
286 
[P153] 
Amiodarone 
for preventing 
post-operative 
AF 
Placebo Bradycardia 4/2 1.24 
(0.26, 
5.85) 
1.91 
(1.05, 
3.48) 
Europe 
(0.611) 
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Table 5.14: The Meta-analysis with Non-Fatal End-Points for Europe vs. North America 
That Does Not Identify the Intervention under Investigation. Treatment Effect Measured 
by the OR. 
Article 
Ref. no 
Intervention 
1 
Intervention 
2 
End point No. of 
trials 
(Europe/ 
N. Amer.) 
OR 
estimate 
for Europe 
(95% CI) 
OR 
estimate 
for N. 
Amer. 
(95% CI) 
Best 
Region 
(p-value of 
between-
continent 
difference) 
69 
[P81] 
Invasive 
management 
strategy for 
angina and 
MI 
Non-
invasive 
management 
strategy 
Hospital 
readmission 
2/2 0.45 
(0.39, 0.53) 
0.75 
(0.60, 0.93) 
Not Applic. 
(0.0003) 
 
5.1.2.1.3: Non-Fatal Endpoints Measured as Mean Difference 
The next table provides the details of the meta-analyses that contained non-fatal data but reported 
this using MD. Two of the meta-analyses reported non-fatal endpoints as MD and Table 5.15 
provides the summary information for these. 
Table 5.15: Meta-analyses with Non-Fatal End-Points Data. Treatment Effect Measured by 
MD. 
 
Article Ref. 
no 
Intervention Control End point No. of 
trials 
(Europe/ 
N. Amer.) 
MD 
estimate 
for 
Europe 
(95% CI) 
MD 
estimate 
for N. 
Amer. 
(95% CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
217 
[C35] 
Low glycaemic 
index diets for 
CHD 
Other diets Total 
cholesterol 
7/3 -0.11 
(-0.34, 
0.12) 
-0.06 
(-0.35, 
0.23) 
 
Europe 
(0.790) 
272 
[P165] 
Drug, 
biobehavioural  
and exercise 
therapies for 
CAD 
Placebo or 
no 
intervention 
Heart rate 
variability 
13/5 0.43 
(0.25, 
0.62) 
0.46 
(0.13, 
0.79) 
N. Amer. 
(0.893) 
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5.1.2.2: Examination over All Meta-analyses for Non-Fatal Endpoints 
Table 5.16 shows the number of meta-analyses specifically identifying their intervention and 
control groups that favoured each continent. 
Table 5.16: The Number of Meta-analyses Favouring each Continent for Non-Fatal Data. 
Total Number of Meta-
analyses (%) 
Number of Meta-analyses 
Favouring Europe (%) 
Number of Meta-analyses 
Favouring North America 
(%) 
40 (100%) 28 (70%) 12 (30%) 
 
As can be seen, of the 40 meta-analyses, 28 showed the intervention performed better in Europe 
compared to North America, while in 12 the intervention performed better in North America. As 
for fatal endpoints, a binomial sign test was conducted under the null hypothesis that the effect of 
interventions, compared to controls, would be the same in both continents. This indicated that 
there was a significant difference in the effect of interventions, relative to controls, between 
Europe and North America (2-sided p-value = 0.017).  
5.1.2.3: Global Estimates of Inter-Continental Difference for Non-Fatal Endpoints 
As for the fatal-endpoint comparison, global estimates of continental difference were produced 
that showed the average weighted difference in treatment effect between Europe and North 
America. These estimates showed that the mean log difference for RR (35 meta-analyses) was -
0.036 with 95% confidence intervals of -0.101 to 0.029 (2-sided p-value = 0.281) and for OR (3 
meta-analyses) the mean log difference over all of the meta-analyses was -0.152 with 95% 
confidence intervals of -0.562 and 0.257 (2-sided p-value = 0.466).These results showed that 
there was insufficient evidence for any difference in the effect of cardiovascular interventions 
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between Europe and North America over all of the meta-analyses that had identified their 
intervention and control groups, as neither of the global estimates of continental difference were 
statistically significant at the 5% level. 
5.1.2.4: Inter-Continental Differences by Intervention Type – Non-Fatal Endpoints 
As there was some evidence for inter-continental differences in treatment effect for non-fatal 
endpoints, it was important to know if there were particular types of intervention that were likely 
to exhibit such differences. The same process was repeated for these non-fatal endpoints as 
described in the previous section on fatal endpoints.  
Table 5.17 shows the meta-analysis that investigated drug therapies and included trials that had 
non-fatal endpoint data for Europe and North America. 
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Table 5.17: Meta-analyses Investigating Drugs with their Z-statistic for the Difference in 
Treatment Effect between Europe and North America for Non-Fatal Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe
/ N. 
Amer.) 
Pooled 
Estimate for 
Europe (95% 
CIs) 
Pooled 
Estimate for 
North 
America 
(95% CIs) 
Difference in 
Treatment 
Effect  
(95% CIs) 
Z-
statistic 
2-sided p-
value of 
difference 
109 
[C43] 
Thrombolytic 
therapy 
RR 2/2 0.61 
(0.13, 2.96) 
2.64 
(0.44, 15.8) 
-1.4628 
(-3.85,0.93) 
-1.201 0.230 
175 
[P29] 
Magnesium RR 2/3 3.55 
(1.21, 10.4) 
1.07 
(0.59, 1.95) 
1.2024 
(-0.03,2.43) 
1.912 0.056 
18 
[C12] 
Phosphodiesterase 
III Inhibitors 
RR 3/6 1.52 
(0.77, 3.01) 
0.85 
(0.63, 1.15) 
0.5761 
(-0.17, 1.32) 
1.514 0.130 
178 
[C22] 
Digitalis RR 2/2 0.19 
(0.02, 1.62) 
0.34 
(0.11, 1.07) 
-0.5678 
(-2.98, 1.84) 
-0.462 0.644 
21 
[P60] 
Antibiotic 
Therapy 
RR 2/2 0.61 
(0.26, 1.47) 
1.03 
(0.82, 1.29) 
-0.5119 
(-1.42, 0.39) 
-1.110 0.267 
22 
[P73] 
Aspirin plus 
Warfarin 
RR 4/6 2.36 
(1.53, 3.65) 
1.53 
(1.21, 1.92) 
0.4371 
(-0.05, 0.93) 
1.745 0.081 
226 
[P125] 
Glycoprotein 
IIb/IIIa 
RR 4/7 0.87 
(0.59, 1.30) 
0.62 
(0.50, 0.77) 
0.3476 
(-0.11, 0.80) 
1.505 0.132 
388 
[P101] 
Prophylactic 
Steroids 
RR 3/7 0.84 
(0.57, 1.25) 
0.60 
(0.46, 0.80) 
0.3363 
(-0.15, 0.82) 
1.364 0.172 
103 
[P133] 
Aspirin plus 
Oral 
Anticoagulation 
Therapy 
RR 4/2 1.69 
(0.94, 3.04) 
1.28 
(0.74, 2.23) 
0.2755 
(-0.53, 1.08) 
0.671 0.502 
51 
[C11] 
Glycoprotein 
IIb/IIIa 
RR 7/7 0.60 
(0.38, 0.96) 
0.48 
(0.32, 0.71) 
0.2348 
(-0.38, ,0.85) 
0.750 0.453 
313 
[P75] 
Warfarin plus 
Aspirin 
RR 3/3 0.55 
(0.42, 0.72) 
0.65 
(0.35, 1.19) 
-0.1560 
(-0.82,0.51) 
-0.459 0.646 
385 
[P160] 
Statin RR 13/4 0.67 
(0.58, 0.77) 
0.78 
(0.66, 0.93) 
-0.1555 
(-0.38, 0.07) 
-1.355 0.176 
227 
[C4] 
Anti-
arrhythmics 
RR 11/6 0.70 
(0.61, 0.81) 
0.80 
(0.67, 0.97) 
-0.1321 
(-0.36, 0.10) 
-1.129 0.259 
1 
[P123] 
Amiodarone RR 2/6 0.74 
(0.39,1.41) 
0.66 
(0.56,0.78) 
0.1198 
(-0.54, 0.78) 
-0.778 0.721 
153 
[P149] 
Amiodarone RR 6/5 0.72 
(0.56,0.93) 
0.65 
(0.54,0.78) 
0.1052 
(-0.20, 0.42) 
0.665 0.506 
93 
[P105] 
Glycoprotein 
IIb/IIIa 
RR 6/2 1.05 
(0.99,1.11) 
1.01 
(0.91, 1.13) 
0.0329 
(-0.09, 0.15) 
0.533 0.594 
286 
[P153] 
Amiodarone OR 4/2 1.24 
(0.26, 5.85) 
1.91 
(1.05, 3.48) 
-0.4312 
(-2.09, 1.23) 
-0.508 0.697 
27 
[P156] 
Amiodarone OR 5/7 0.47 
(0.32,0.69) 
0.51 
(0.41, 0.64) 
-0.0900 
(-0.54, 0.36) 
-0.389 0.611 
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As can be seen, all meta-analyses found the difference in treatment effect between Europe and 
North America to be statistically non-significant. As such, no clear pattern of statistically 
significant differences was identified to suggest that drug therapies were prone to inter-
continental differences in treatment effect. 
Table 5.18 shows the meta-analyses that investigated medical devices. 
Table 5.18: Meta-analyses Investigating Medical Devices with their Z-statistic for the 
Difference in Treatment Effect between Europe and North America for Non-Fatal 
Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. Amer.) 
Pooled 
Estimate 
for Europe 
(95% CIs) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Difference in 
Treatment 
Effect (95% 
CIs) 
Z-
statistic 
2-sided p-
value of 
difference 
310 
[P67] 
Stents RR 3/5 0.12 
(0.05, 
0.28) 
0.37 
(0.23, 
0.61) 
-1.1017 
(-2.07, -
0.13) 
-2.228 0.026 
34 
[P65] 
Stents RR 2/2 0.25 
(0.07, 
0.90) 
0.60 
(0.14, 
2.53) 
-0.8678 
(-2.79, 1.05) 
-0.885 0.376 
250 
[P115] 
Cardiac 
Resynchronisation  
Therapy 
RR 2/3 0.53 
(0.41, 
0.68) 
0.82 
(0.55, 
1.20) 
-0.4280 
(-0.89, 0.03) 
-1.815 0.069 
145 
[P135] 
Cardiac 
Resynchronisation 
Therapy 
RR 3/2 0.52 
(0.41, 
0.67) 
0.67 
(0.44, 
1.05) 
-0.2568 
(-0.76, 0.25) 
-1.002 0.316 
 
 Only one meta-analysis investigating medical devices found the difference in treatment effect 
between Europe and North America to be statistically significant at the 5% level. This was P67 
(310), a meta-analysis comparing drug eluting stents (the intervention) to bare metal stents (the 
control). In this meta-analysis, the intervention performed better (with respect to binary 
angiographic restenosis) in Europe than in North America, and the 2-sided p-value for the 
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difference in treatment effect was 0.026. However, as no other meta-analyses found statistically 
significant differences in treatment effect, no clear pattern could be identified to suggest that 
medical devices were prone to treatment effect differences between Europe and North America.  
Table 5.19 shows the meta-analyses that investigated surgical interventions and included trials 
that had non-fatal endpoint data for Europe and North America. 
Table 5.19: Meta-analyses Investigating Surgical Interventions with their Z-statistic for the 
Difference in Treatment Effect between Europe and North America for Non-Fatal 
Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. 
Amer.) 
Pooled 
Estimate for 
Europe (95% 
CIs) 
Pooled 
Estimate for 
North 
America 
(95% CIs) 
Difference in 
Treatment 
Effect (95% 
CIs) 
Z-
statistic 
2-sided p-
value of 
difference 
328 
[P108] 
Off-Pump 
CABG 
RR 9/3 0.43 
(0.18, 1.03) 
1.22 
(0.29, 5.22) 
-1.0366 
(-2.72, 0.65) 
-1.204 0.229 
216 
[P62] 
Primary PCI RR 8/3 1.30 
(0.83, 2.05) 
2.60 
(0.58, 11.7) 
-0.6926 
(-2.26, 0.88) 
-0.864 0.388 
259 
[P102] 
Off-Pump 
CABG 
RR 14/4 0.75 
(0.45, 1.27) 
1.23 
(0.40, 3.77) 
-0.4898 
(-1.72, 0.74) 
-0.778 0.437 
 
As can be seen, none of the meta-analyses investigating surgical interventions found the 
difference in treatment effect between Europe and North America to be statistically significant at 
the 5% level. Therefore, no clear pattern of statistically significant differences was identified to 
suggest that surgical interventions were prone to international differences.  
Table 5.20 shows the details of the meta-analyses that investigated lifestyle interventions. As 
before, it shows the intervention investigated, the number of European and North American trials 
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included, the treatment effect estimate for each continent, and the Z- statistic for the between-
continental difference with its 2-sided p-value. 
Table 5.20: Meta-analyses Investigating Lifestyle Interventions with their Z-statistic for the 
Difference in Treatment Effect between Europe and North America for Non-Fatal 
Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. 
Amer.) 
Pooled 
Estimate 
for Europe 
(95% CIs) 
Pooled 
Estimate for 
North 
America 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-statistic 2-sided p-
value of 
difference 
148 
[C48] 
Hormone 
Replacement 
Therapy 
RR 4/2 1.71 
(0.66, 
4.44) 
1.09 
(0.88, 1.34) 
0.4530 
(-0.52, 
1.43) 
0.910 0.363 
48 
[P166] 
Vitamin-
Mineral 
Supplementatio
n 
RR 2/2 0.84 
(0.34, 
2.07) 
0.97 
(0.65, 1.44) 
-0.1367 
(-1.12, 
0.85) 
-0.273 0.785 
30 
[C54] 
Psychological 
Interventions 
RR 6/7 1.22 
(0.95,1.57
) 
1.32 
(1.13,1.53) 
-0.0777 
(-0.37, 
0.22) 
-0.519 0.604 
304 
[C25] 
Psychological 
Interventions 
RR 4/7 0.74 
(0.54,1.02
) 
0.76 
(0.57, 1.02) 
-0.0354 
(-0.47, 
0.40) 
-0.161 0.872 
75 
[P64] 
Secondary 
Prevention 
Programmes 
RR 13/5 0.73 
(0.60,0.89
) 
0.73 
(0.49,1.10) 
-0.0085 
(-0.46, 
0.44) 
-0.037 0.971 
68 
[P159] 
Hormone 
Replacement 
Therapy 
OR 2/3 0.70 
(0.22, 
2.19) 
1.07 
(0.84, 1.36) 
-0.4313 
(-1.61, 
0.74) 
-0.720 0.472 
217 
[C35] 
Low Glycaemic 
Index Diets 
MD 7/3 -0.11 
(-
0.34,0.12) 
-0.06 
(-0.35,0.23) 
-0.0500 
(-0.42, 
0.32) 
-0.266 0.790 
272 
[P165] 
Drug, 
Behavioural and 
Exercise 
Therapies  
MD 13/5 0.43 
(0.25,0.62
) 
0.46 
(0.13,0.79) 
-0.0255 
(-0.40, 
0.35) 
-0.314 0.893 
 
As can be seen from Table 5.20, none of the meta-analyses showed a statistically significant 
difference in treatment effect between Europe and North America. As such, no clear pattern of 
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statistically significant differences could be identified for lifestyle interventions to suggest that 
these types of interventions were prone to inter-continental differences in treatment effect. 
Table 5.21 shows the details of the meta-analyses that investigated management strategies.  
Table 5.21: Meta-analyses Investigating Management Strategies with their Z-statistic for 
the Difference in Treatment Effect between Europe and North America for Non-Fatal 
Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/ 
N. Amer.) 
Pooled 
Estimate 
for 
Europe 
(95% CIs) 
Pooled 
Estimate for 
North 
America 
(95% CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
statistic 
2-sided p-
value of 
difference 
320 
[P99] 
PCI-based 
Invasive Strategy 
RR 7/5 0.78 
(0.46, 
1.31) 
1.11 
(0.91, 1.37) 
-0.3578 
(-0.92, 
0.20) 
-1.257 0.209 
354 
[C13] 
Case Management 
– Clinical Service 
Organisation 
RR 3/4 0.50 
(0.26, 
0.97) 
0.68 
(0.50, 0.91) 
-0.2985 
(-1.02, 
0.42) 
-0.815 0.415 
390 
[P1] 
Early Invasive 
Strategy 
RR 3/2 1.56 
(0.57, 
4.26) 
1.24 
(0.48, 3.24) 
0.2314 
(-
1.16,1.62) 
0.327 0.744 
309 
[P138] 
Disease 
Management 
Programmes 
RR 10/12 0.79 
(0.56, 
1.11) 
0.91 
(0.72,1.16) 
-0.1483 
(-0.57, 
0.27) 
-0.695 0.487 
155 
[P55] 
Disease 
Management 
Programmes 
RR 12/16 0.75 
(0.64, 
0.90) 
0.86 
(0.77, 0.97) 
-0.1357 
(-0.35, 
0.07) 
-1.292 0.196 
177 
[P78] 
Multi-disciplinary 
Interventions 
RR 7/10 0.81 
(0.63,1.0
4) 
0.88 
(0.77,1.00) 
-0.0801 
(-0.36, 
0.20) 
-0.555 0.579 
203 
[P120] 
Self-Management 
Interventions 
RR 2/3 0.73 
(0.56, 
0.95) 
0.74 
(0.58,0.93) 
-0.0104 
(-0.36, 
0.34) 
-0.058 0.954 
 
As can be seen, it was again found that the differences in treatment effect between Europe and 
North America were statistically non-significant in all of the included meta-analyses. As a result, 
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no clear pattern of statistically significant differences was identified to suggest that management 
interventions were prone to inter-continental differences in treatment effect.  
However, when further observing the 2-sided p-values of the between-continent difference in 
each meta-analysis for management interventions, it was discovered that one meta-analysis that 
did not identify which group was the intervention and which the control showed a significant 
difference between Europe and North America (2-sided p-value = 0.0003) (see Table 5.11). This 
was P81 (69), which simply compared an invasive management strategy for unstable angina and 
MI to a non-invasive management strategy.  
As no group of interventions showing a clear pattern of statistically significant findings could be 
identified, the types of intervention prone to differences between Europe and North America 
could not be identified for non-fatal endpoints. Furthermore, as there were 44 meta-analyses 
overall that provided non-fatal data, finding a between-continent difference that was statistically 
significant at the 5% level in only two of the meta-analyses is not more than would be expected 
by random chance. Therefore, there was insufficient evidence to conclude which types of 
intervention were prone to differences in treatment effect between Europe and North America for 
non-fatal endpoints. 
5.1.2.5: The Impact of Including Overlapping Meta-analyses on Non-Fatal 
Endpoint Results 
Any differences in treatment effect found may have been the consequence of including duplicated 
trial results from overlapping meta-analyses. Therefore, as with the comparison using fatal 
endpoints, these results were investigated to see if they had been influenced by the inclusion of 
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overlapping meta-analyses. Of the 40 included meta-analyses, 20 overlapping meta-analyses 
were identified. These were C11 and P125, C48 and P159, P65 and P67, P73 and P75, P102 and 
P108, P115 and P135, C13, P55, P78, P138 and P123, P149, P153, P156. There were also 20 
non-overlapping meta-analyses (C4, C12, C22, C25, C35, C43, C54, P1, P29, P60, P62, P64, 
P99, P101, P105, P120, P133, P160, P165, and P166). 
Furthermore, it was found that the percentage of meta-analyses where the intervention was 
favoured more in Europe than North America was 70% for both overlapping and non-overlapping 
meta-analyses. This was because both had 14 out of 20 meta-analyses where the intervention 
favoured Europe over North America. This suggested that the overall percentage of meta-
analyses in which the intervention favoured Europe over North America (70% or 28 out of 40 
meta-analyses) had not been inappropriately exaggerated by the duplication of trial results from 
overlapping meta-analyses.  
5.2: Conclusion 
With regards to fatal endpoints, this chapter has shown that there is no evidence that inter-
continental differences between Europe and North America for cardiovascular interventions exist. 
This is because no analysis was statistically significant at the 5 % level. This was not the case for 
non-fatal endpoints, where a statistically significant difference in the effect of interventions was 
found between Europe and North America. In particular, it was found that interventions perform 
better, relative to controls, in Europe than in North America. However, this was not supported by 
the global estimates of continental difference calculated for non-fatal endpoints, since no estimate 
was found to be statistically significant. It should also be noted that the types of intervention 
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prone to inter-continental differences in treatment effect could not be identified for either type of 
endpoint. 
Whilst there is little evidence for treatment effectiveness differing between Europe and North 
America it is vital to investigate further and examine whether such differences exist between 
other continents. An investigation, such as this, would provide us with further knowledge of 
inter-continental differences in treatment effectiveness as well as helping with the extrapolation 
of clinical trial results between continents. This is the basis for the following chapter, which 
investigates inter-continental differences in treatment effectiveness by comparing Europe, North 
America, and Asia. 
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CHAPTER 6. 
AN INTER-CONTINENTAL 
COMPARISON OF EUROPE, NORTH 
AMERICA AND ASIA. 
 
To investigate the existence of international differences in treatment effectiveness further, two 
more pair-wise comparisons were conducted for Europe and Asia and North America and Asia, 
respectively, with regards to both fatal and non-fatal endpoints. A universal comparison of 
continents was also conducted by comparing each continent’s individual trial results from the 
included meta-analyses. 
This chapter presents the findings of these comparisons and is organised into two main sections 
The first section concerns the investigation of fatal endpoints and is split into four parts: the pair-
wise comparison between Europe and Asia, the pair-wise comparison between North America 
and Asia, the universal comparison for this endpoint, and the investigation into the types of 
intervention prone to international differences in their effectiveness. The second section discusses 
the same comparisons as they pertain to non-fatal endpoints. The chapter concludes by 
summarising the evidence and briefly discussing its implications. 
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6.1: Fatal Endpoints 
This section presents the comparative findings for fatal endpoints between Europe and Asia and 
North America and Asia and the findings of the universal comparison of all three continents. 
6.1.1: The Pair-wise Comparisons 
In this investigation, pair-wise comparisons of Europe and Asia and North America and Asia, 
respectively, were conducted for fatal endpoints. Chapter 4 (Section 4.4) describes the detailed 
methods used to conduct these comparisons. In brief, for each meta-analysis, each continent’s 
trials were combined to provide a treatment effect estimate for each continent and then the 
difference between each continent’s effect estimate was calculated to ascertain in which continent 
the intervention performed best. The number of meta-analyses favouring each continent was then 
summed to investigate whether there was a difference, over all meta-analyses, in the effect of 
intervention (relative to control) between the continents in the pair-wise comparison. The results 
of each pair-wise comparison are now presented. 
6.1.1.1: Europe vs. Asia 
For the pair-wise comparison between Europe and Asia, the meta-analyses on which it was based 
had to comprise at least one trial from Europe and one from Asia (see Chapter 4). Of the 95 
systematic reviews containing meta-analyses, only 59 satisfied this criterion and could therefore 
be included in this comparison. 
Only 20 of the 59 meta-analyses contained at least one European and one Asian trial with fatal 
endpoint data that allowed separate estimates of treatment effect to be calculated for each 
  
166 
 
continent. Details of each of these meta-analyses can be found in Tables 6.1, 6.2, and 6.3, which 
show the intervention and control group, the endpoint reported, the number of European and 
Asian trials in each meta-analysis, the effect estimate for both continents, and the continent in 
which the intervention, in each meta-analysis, performed best.  
6.1.1.1.1.: Meta-analysis Grouped according to Treatment Effect Measure for Fatal 
Endpoints – Europe versus Asia. 
The 20 meta-analyses that contained fatal endpoint data were grouped on how treatment effect 
was measured. For example, Table 6.1 details the meta-analyses that measured treatment effect 
using RR, and Table 6.3 details those using OR. 
6.1.1.1.1.1: Fatal Endpoints for Europe versus Asia Measured as Risk Ratios 
Thirteen of the 20 meta-analyses that reported fatal endpoints did so using RR. The details of 
these meta-analyses are summarised in Table 6.1. 
Table 6.1 shows the meta-analysis details, the favoured continent, and the significance of any 
difference in how well the intervention performed between the two continents. For example, 
meta-analysis C12 (18) investigated two European and one Asian trial comparing 
Phosphodiesterase III inhibitors against a placebo for cardiovascular mortality. The treatment 
effect estimate was a RR of 1.562 for Europe and 0.51 for Asia. Intervention performed best in 
Asia, but the difference in treatment effect was not significant at the 5% level (2-sided p-value = 
0.369). 
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Table 6.1: Meta-analyses with Fatal Endpoints for Europe versus Asia. Treatment Effect 
Measured by RR 
Article 
ref. no. 
Intervention Control Endpoint No. of 
trials 
(Europe/
Asia) 
RR estimate 
Europe 
(95% CI) 
RR estimate 
Asia (95% 
CI) 
Best Region  
(p-value of 
between-
continent 
difference) 
18 
[C12] 
 
Phosphodiesterase 
III inhibitors for HF 
Placebo Cardiovascular 
mortality 
2/1 1.562 
(1.02, 2.40) 
0.51 
(0.05, 5.60) 
Asia 
(0.369) 
25 
[P94] 
Vasopressin for 
Cardiac arrest 
Epinephr
ine 
Death within 
24hours 
2/1 0.991 
(0.95, 1.03) 
0.83 
(0.68, 1.01) 
Asia 
(0.086) 
227 
[C4] 
Anti-arrhythmics 
after cardioversion 
of AF 
Placebo, 
drugs for 
rate 
control or 
no 
treatment 
All-cause 
mortality 
5/1 1.019 
(0.79, 1.31) 
0.62 
(0.03, 14.3) 
Asia 
(0.759) 
232 
[C10] 
Intravenous 
magnesium for 
Acute MI 
Placebo Mortality by 
time of 
admission 
5/1 0.776 
(0.61, 0.99) 
0.34 
(0.04, 3.21) 
Asia 
(0.475) 
4 
[P2] 
G-CSF therapy for 
Acute MI 
Placebo Death 3/1 1.377 
(0.28, 6.89) 
3.63 
(0.16, 
84.11) 
Europe 
(0.590) 
383 
[C41] 
NPPV for 
Cardiogeneic 
pulmonary edema 
Standard 
medical 
care 
Hospital 
Mortality 
6/4 0.587 
(0.37,0.92) 
0.40 
(0.18, 0.87) 
Asia 
(0.402) 
96 
[P90] 
Adjunctive 
mechanical devices 
for Acute MI 
Standard 
care or 
stenting 
30 day 
mortality 
5/2 1.00 
(0.47, 2.15) 
0.73 
(0.26, 2.07) 
Asia 
(0.628) 
191 
[P15] 
PCI for late 
reperfusion after MI 
Standard 
therapy 
Death 2/1 0.96 
(0.41, 2.23) 
0.22 
(0.03, 1.82) 
Asia 
(0.204) 
197 
[P33] 
MIDCAB for 
proximal stenosis of 
the left anterior 
descending artery 
PCI Mortality 3/1 0.93 
(0.45, 1.91) 
0.12 
(0.01, 2.43) 
Asia 
(0.194) 
237 
[P19] 
Intracoronary cell 
therapy for Acute 
MI 
Standard 
care 
Death 3/1 0.51 
(0.15, 1.66) 
1.07 
(0.07, 
16.33) 
Europe 
(0.619) 
2 
[P7] 
Late PCI for Acute 
MI 
Usual 
managem
ent 
Death 5/1 0.41 
(0.26, 0.66) 
0.18 
(0.02, 1.45) 
Asia 
(0.446) 
33 
[P97] 
Thrombectomy or 
Embolic protection 
devices with PCI for 
Acute MI 
PCI 
alone 
Mortality 9/2 0.70 
(0.16, 2.98) 
0.26 
(0.00, 
281.07) 
Asia 
(0.786) 
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Six meta-analyses that used RR did not report which was the intervention group and which was 
the control group. In these cases, it was not possible to calculate which continent favoured 
intervention, as shown in Table 6.2. 
Table 6.2: Meta-analyses with Fatal Endpoints for Europe vs. Asia that Do Not Identify 
Which is the Intervention Group and Which is the Control. Effectiveness measured by RR. 
247 
[C40] 
Stem cell treatment 
for Acute MI 
No 
treatment 
or 
Placebo 
Mortality 4/1 0.59 
(0.21, 1.68) 
0.33 
(0.01, 7.81) 
Asia 
(0.739) 
Article 
ref. no 
Intervention 
1 
Intervention 2 Endpoint No. of trials 
(Europe/Asia) 
RR 
estimate  
Europe 
(95% 
CI) 
RR 
estimate  
Asia 
(95% 
CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
11 
[P87] 
Stenting for 
Small Vessel 
CAD 
PTCA Death 6/1 0.859 
(0.46, 
1.61) 
0.12 
(0.01, 
2.13) 
Not applic. 
(0.187) 
273 
[C17] 
Stenting for 
Acute MI 
Balloon 
Angioplasty 
30 day 
mortality 
3/2 1.259 
(0.37, 
4.31) 
0.40 
(0.10, 
1.68) 
Not Applic. 
(0.234) 
56 
[P24] 
PCI* CABG 
surgery* 
All-cause 
mortality 
7/1 0.574 
(0.32, 
1.03) 
1.18 
(0.11, 
12.74) 
Not Applic. 
(0.567) 
94 
[P18] 
LMWH for 
STEMI 
UFH 30 day 
mortality 
1/1 0.570 
(0.26, 
1.25) 
0.80 
(0.39, 
1.64) 
Not Applic. 
(0.526) 
319 
[P21] 
SES for 
Coronary 
artery disease 
PES Patients 
experiencing 
death 
7/3 1.010 
(0.75, 
1.36) 
1.04 
(0.48, 
2.26) 
Not Applic.  
(0.944) 
26 
[P38] 
Minimally 
invasive left 
internal 
thoracic artery 
bypass for 
isolated 
lesions of left 
anterior 
descending 
artery 
Percutaneous 
coronary 
artery stenting 
Mortality at 
maximum 
follow up 
3/1 2.32 
(0.51, 
10.48) 
1 
(0.15, 
6.82) 
Not Applic.  
(0.500) 
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6.1.1.1.1.2: Fatal Endpoints for Europe versus Asia Measured as Odds Ratios 
Only one of the 20 meta-analyses that reported fatal endpoints did so using OR. The details for 
this meta-analysis are presented in Table 6.3. 
Table 6.3: The Meta-analysis with Fatal Endpoints for Europe vs. Asia. Effectiveness 
measured by the OR. 
 
6.1.1.1.2: Examination over all Meta-analyses for Fatal Endpoints – Europe versus Asia. 
Table 6.4 shows the number of meta-analyses on which Europe-Asia comparison calculations 
could be conducted. 
Table 6.4: The Number of Meta-analyses favouring Each Continent – Europe versus Asia 
Fatal Data 
Total Number of Meta-
analyses (%) 
Number of Meta-analyses 
favouring Europe (%) 
Number of Meta-analyses 
favouring Asia (%) 
14 (100%) 2 (14%) 12 (86%) 
Of the 14 meta-analyses, 12 showed interventions to perform best in Asia. To find the 
significance of this, a binomial sign test was conducted under the null hypothesis that the effect 
Articl
e ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(Europe/
Asia) 
OR 
estimate 
Europe 
(95% CI) 
OR 
estimate 
Asia (95% 
CI) 
Best 
Region  (p-
value of 
between-
continent 
difference) 
286 
[P153] 
Amiodarone for 
prevention of AF 
Placebo or 
routine 
treatment 
Death 3/1 1.79 
(0.00, 
1169.4) 
0.81 
(0.00, 
153.8) 
Asia 
(0.853) 
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of interventions, relative to controls, was the same in both Europe and Asia. This showed that the 
effect of interventions, compared to controls, was statistically significantly different between 
Europe and Asia (2-sided p-value = 0.013). 
6.1.1.1.3: Global Estimates of Continental Difference between Europe and Asia. 
Global estimates of continental difference were calculated. These reflected the average weighted 
difference in effect between Europe and Asia over all of the meta-analyses that had specified 
their intervention and control group. From these estimates, it was found that for RR (13 meta-
analyses) the mean log difference over all of the meta-analyses was 0.222 with 95% CIs of 
0.0279 and 0.416 (2-sided p-value = 0.025). For OR (1 meta-analysis) the mean log difference 
was 0.791 with 95% CIs of -7.55 and 9.13 (2 sided p-value = 0.853). As can be seen, the global 
estimate of continental difference for RR was found to be statistically significant at the 5% level 
(p-value = 0.025). This showed that when treatment effect was measured using this summary 
statistic, there was a statistically significant difference in the effect of interventions between 
Europe and Asia, with, on average, intervention performing better, relative to control, in Asia 
than in Europe. The result for OR, on the other hand, was inconclusive since this did not reach 
the 5% level of statistical significance. 
6.1.1.1.4: The Impact of Overlapping Meta-analyses 
Given that overlapping meta-analyses were included (see Chapter 4), it is possible that the results 
summarised above are an artefact of their inclusion. The impact of overlapping meta-analyses on 
the pair-wise comparison between Europe and Asia was investigated, and six meta-analyses were 
identified as overlapping: P7 and P15, P90 and P97, and P19 and C40. Eight meta-analyses were 
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non-overlapping (P33, C12, P94, C4, C10, P2, C41, P153). The percentage of meta-analyses 
where intervention was favoured in Asia rather than Europe was 83% for overlapping meta-
analyses but 88% for non-overlapping meta-analyses. This suggests that the proportion of meta-
analyses favouring Asia over Europe was not exaggerated as a consequence of including 
overlapping meta-analyses.  
6.1.1.1.5: Summary of the Europe versus Asia Pair-wise Comparison 
In summary, when investigating within and over meta-analyses, there was some evidence to 
suggest that differences existed between Europe and Asia in treatment effect. For instance, there 
was a statistically significant difference in the number of meta-analyses whose interventions, 
relative to controls, performed better in Asia than in Europe. This was confirmed by the global 
estimate of continental difference for RR, which showed a statistically significant difference in 
treatment effect between Europe and Asia, with interventions performing better in Asia. 
Moreover, by investigating the impact of overlapping meta-analyses, such differences in 
treatment effect between Europe and Asia do not appear to have been created or exaggerated by 
the inclusion of overlapping meta-analyses. Therefore, there is some evidence that inter-
continental differences exist between Europe and Asia when fatal endpoints are considered. 
6.1.1.2: North America vs. Asia 
The meta-analyses for this pair-wise comparison had to contain at least one North American trial 
and at least one Asian trial. Of the 95 relevant meta-analyses in the database, only 59 fulfilled this 
criterion and so could be used. 
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Of the 59 meta-analyses, only 12 contained trials with fatal endpoint data that would allow for 
separate estimates of treatment effect to be calculated for both continents. Details of these meta-
analyses can be found in Tables 6.5 to 6.7.  
6.1.1.2.1: Meta-analyses Grouped according to Treatment Effect Measure for Fatal 
Endpoints – North America versus Asia. 
The 12 meta-analyses that reported fatal endpoints were grouped by the treatment effect measure 
used. Nine meta-analyses reported treatment effect using RR, one used OR, and two did not 
identify the intervention and control groups. 
6.1.1.2.1.1: Fatal Endpoints for North America versus Asia as Risk Ratios. 
Table 6.5 shows the details for the nine meta-analyses that used RR for fatal endpoints: the 
intervention and control group for each meta-analysis, the endpoint reported, the number of trials 
for each continent, the treatment effect estimates for both continents, and the details of where the 
intervention performed best. 
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Table 6.5: Meta-analyses with Fatal Endpoints for North America vs. Asia. Treatment 
Effect Measured by RR. 
 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(North 
America/
Asia) 
RR 
estimate 
North 
America 
(95% CI) 
RR 
estimate 
Asia (95% 
CI) 
Best 
Region  (p-
value of 
between-
continent 
difference) 
18 
C12 
Phosphodiesterase 
III inhibitors for HF 
Placebo Cardiovasc
ular 
mortality 
5/1 1.13 
(1.02, 
1.26) 
0.51 
(0.05, 
5.60) 
Asia 
(0.517) 
25 
P94 
Vasopressin for 
Cardiac arrest 
Epinephrine Death 
within 
24hours 
1/1 1.02 
(0.92,1.14) 
0.83 
(0.68, 
1.01) 
Asia 
(0.068) 
96 
P90 
Adjunctive 
mechanical devices 
for Acute MI 
Standard 
care or 
stenting 
30 day 
mortality 
1 /2 5.50 
(1.23, 
24.55) 
0.73 
(0.26, 
2.07) 
Asia 
(0.030) 
227 
C4 
Anti-arrhythmics 
after cardioversion 
of AF 
Placebo, 
drugs for 
rate control 
or no 
treatment 
All-cause 
mortality 
4/1 1.49 
(0.80, 
2.77) 
0.62 
(0.03, 
14.30) 
Asia 
(0.593) 
2 
P7 
Late PCI for Acute 
MI 
Usual 
management 
Death 1/1 0.76 
(0.05, 
11.39) 
0.18 
(0.02, 
1.45) 
Asia 
(0.405) 
4 
P2 
G-CSF therapy for 
Acute MI 
Placebo Death 1/1 0.18 
(0.01, 
3.85) 
3.63 
(0.16, 
84.19) 
North 
America 
(0.179) 
33 
P97 
Thrombectomy or 
Embolic protection 
devices with PCI 
for Acute MI 
PCI alone Mortality 1 /2 2.80 
(0.05, 
151.13) 
0.26 
(0.00, 
281.07) 
Asia 
(0.562) 
383 
C41 
NPPV Standard 
medical Care 
Hospital 
Mortality 
1 /4 1 
(0.23, 
4.40) 
0.40 
(0.18, 
0.87) 
Asia 
(0.283) 
55 
P131 
Clopidogrel plus 
Aspirin for the 
Prevention of 
Vascular Events 
Antiplatelet 
Monotherap
y 
All-Cause 
Mortality 
1/1 0.76 
(0.41, 
1.39) 
0.93 
(0.88, 
1.00) 
North 
America 
(0.500) 
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The best region was not calculated for two of the meta-analyses using RR, as these meta-analyses 
did not specifically identify which group was the intervention and which the control. It was not 
possible, therefore, to calculate the continent favouring intervention. Details are provided in 
Table 6.6. 
Table 6.6: Meta-analyses with Fatal Endpoints for North America vs. Asia that Did Not 
Identify the Intervention or Control Groups. Effectiveness Measured by RR. 
 
6.1.1.2.1.2: Fatal Endpoints for North America versus Asia as Odds Ratios. 
Only one of the 12 meta-analyses reported fatal endpoints in terms of OR, the details of which 
are provided in Table 6.7. 
 
 
 
Articl
e ref. 
no. 
Intervention 1 Intervention 
2 
Endpoint No. of 
trials 
(North 
America/
Asia) 
RR 
estimate 
North 
America 
(95% CI) 
RR 
estimate 
Asia (95% 
CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
56 
P24 
PCI CABG 
surgery 
All-cause 
mortality 
3/1 0.74 
(0.41, 
1.33) 
1.18 
(0.11, 
12.74) 
Not Applic 
(0.713) 
168 
P140 
Clopidogrel 
plus Aspirin 
for 
Cardiovascular 
Disease 
Placebo plus 
Aspirin 
Cardiovascul
ar Mortality 
1/1 0.63 
(0.29, 
1.38) 
0.94 
(0.88, 
1.00) 
Not Applic. 
(0.328) 
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Table 6.7: The Meta-analysis with Fatal Endpoints for North America vs. Asia. 
Effectiveness measured by Odds Ratios (OR). 
 
6.1.1.2.2: Examination over All Meta-analyses for Fatal Endpoints – North America versus 
Asia. 
Table 6.8 shows the number of meta-analyses on which comparison calculations could be 
conducted favouring each continent.  
Table 6.8: The Number of Meta-analyses Favouring Each Continent –North American 
versus Asian Fatal Data. 
Total Number of Meta-
analyses 
Number of Meta-analyses 
Favouring North America  
Number of Meta-analyses 
Favouring Asia  
10 2  8 
 
Two of the meta-analyses showed interventions performed better in North America, while eight 
showed interventions performed better in Asia. To assess the significance of this difference, a 
binomial sign test was conducted under the null hypothesis that the effectiveness of interventions, 
relative to controls, was the same in North America and Asia. This revealed that the effect of 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(North 
America/
Asia) 
OR 
estimate 
North 
America 
(95% CI) 
OR 
estimate 
Asia  
(95% CI) 
Best Region  
(p-value of 
between-
continent 
difference) 
286 
[P153] 
Amiodarone for 
prevention of AF 
Placebo or 
routine 
treatment 
Death 6/1 0.82 
(0.06, 
10.48) 
0.81 
(0.00, 
153.8) 
Asia 
(0.997) 
  
176 
 
interventions (relative to controls) was not significantly different between North America and 
Asia (2-sided p- value = 0.1094). 
6.1.1.2.3: Global Estimates of the Difference between North America and Asia 
Global estimates of continental difference were produced for each type of effect measure. These 
reflected the weighted average difference between the treatment effect estimates of North 
America and Asia over all of the meta-analyses that had specified their intervention and control 
groups. For RR (9 meta-analyses), the mean log difference was 0.241 with 95% CIs of -0.161 and 
0.643 (2-sided p-value = 0.240). For OR (1 meta-analysis), the mean log difference was 0.0119, 
with 95% CIs of -5.82 and 5.84 (2- sided p-value = 0.9968). These findings suggested that over 
all of the meta-analyses and for both types of effect measure there was insufficient evidence to 
suggest a difference in overall treatment effect between North America and Asia, as neither 
estimate was statistically significant at the 5% level 
6.1.1.2.4: The Impact of Overlapping Meta-analyses 
Since there were no overlapping meta-analyses, they could have not have influenced the 
proportion of meta-analyses that favoured Asia over North America. 
6.1.1.2.5: Summary of the North America versus Asia Pair-wise Comparison 
In summary, when investigating both within and over meta-analyses, insufficient evidence was 
found to suggest that treatment effect differed between North America and Asia for fatal 
endpoints. This was because both the examination over all meta-analyses and the global estimates 
of continental difference were not statistically significant at the 5% level.   
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6.1.2: A Universal Comparison of Treatment Effectiveness Differences for 
Fatal Endpoints. 
To explore the existence of inter-continental differences in treatment effectiveness further, the 
individual trials that made up the meta-analyses used in the previous section were analysed. For 
this, the effect estimate of each trial from Europe, North America, and Asia in each relevant 
meta-analysis was standardised using the formula described in Chapter 4 (Section 4.7.2.2). This 
was done within meta-analyses so that the trial effect estimate was compared only to the overall 
effect estimate of the meta-analysis in which it was situated. For each meta-analysis, the overall 
effect estimate was calculated by extracting all trials from Europe, North America, and Asia and 
combining them using the fixed effect approach. This provided the best available estimate of 
effect for the intervention in the meta-analysis since it was based on the trial data from all the 
continents, weighted according to the amount of information provided.  
The standardised trial results from all meta-analyses were grouped by continent. Mean treatment 
effect estimates and standard deviations were calculated for each continent and then compared. 
Each continent’s trial results were plotted onto graphs to facilitate the detection of outliers and to 
observe the spread of each continent’s trial results. 
Separate graphs were produced for Europe, North America, and Asia. The standardised treatment 
effect estimate of each trial was plotted on the horizontal axis and sample size
41
 on the vertical 
                                                 
41
 Using the square root of the sample size rather than sample size enabled the vertical axis to be more condensed. 
Some trials had much larger sample sizes than the majority of trials. This meant that plotting data onto a graph using 
sample size would result in a large gap on the vertical axis between trials with the large samples and other trials. 
Using the square root of sample size reduced this gap.  
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axis.
42
The graphs were designed principally as visual aids for identifying outliers and the spread 
of trial results along the treatment effect axis. The zero on the x-axis of each graph represented a 
universal treatment effect estimate reflecting the best available effect estimate for the intervention 
in each trial.  
However, as mentioned in Chapter 4, some of the systematic reviews addressed the same or 
similar clinical question and, as such, their meta-analyses may have contained a proportion of the 
same trials. Consequently, when meta-analyses were pooled, some trial results may have been 
duplicated and thus included in the analysis more than once. This is an important consideration 
because the continent reporting most support for intervention may result from that continent 
having the most duplicate trials with positive results for intervention. 
In this study, duplications were classed as trials with the same authors, publication year, and 
sample size as another trial already in the meta-analysis dataset. Such evident duplications were 
removed from the dataset so that each trial only appeared once.
43
 However, it is acknowledged 
that this method may not have removed all possible trial duplications. Some meta-analyses may 
have reported a sub-group analysis of a trial, the sample size and authors of which may have been 
different from the trial from which the data was taken, making it difficult to identify as trial 
duplication. Consequently, some trials in this analysis may have been correlated because data 
may have been taken from the same set of participants. Table 6.9 shows the number of trials in 
                                                 
42
 Using a measure of sample size on the vertical axis (Y axis) made the graphs easier to interpret. Furthermore, 
using sample size allowed assessment of whether the smaller trials in each continent were overestimating or 
underestimating treatment effectiveness (small-study effect). 
43
 The universal comparison was also conducted with trial duplications included. However, its results became 
redundant once analysis had been conducted with duplications removed since the findings were qualitatively similar.   
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the original dataset,
44
 the number of trial duplications per continent, the number of trials 
duplicated once and more than once, and the total number of trials per continent after 
duplications were removed.  
Table 6.9: Duplicate and Non-duplicated Trials in each Continent that provided Fatal Data. 
Continent Number of 
Trials in 
Original 
Dataset 
Number of 
Duplicates 
Number of 
Trials 
Duplicated 
Once 
Number of 
Trials 
Duplicated 
More than 
Once 
Remaining 
Trials When 
Duplications 
Removed 
Europe 311 71  53 9 240 
North America 216 61  3 10 155 
Asia 30 3  3 0 27 
Total 557 135 89 19 422 
 
 
As can be seen, there were originally 557 trials: 311 from Europe, 216 from North America, and 
30 from Asia. Of these, 135 were duplicates and had to be removed from the dataset. This left 
240 European trials, 155 North American trials, and 27 Asian trials to analyse.  
 
6.1.2.1: Findings for the Universal Comparison – Fatal Endpoints 
Figures 6.1-6.3 show the spread of each continent’s trial results as regards fatal endpoints.  
 
 
                                                 
44
 Before duplications were removed. 
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FIGURE 6.1: THE SPREAD OF EUROPEAN TRIAL TREATMENT EFFECT 
ESTIMATES. 
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FIGURE 6.2: THE SPREAD OF NORTH AMERICAN TRIAL TREATMENT EFFECT 
ESTIMATES. 
 
FIGURE 6.3: THE SPREAD OF ASIAN TRIAL TREATMENT EFFECT ESTIMATES. 
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As described earlier, Figures 6.1-6.3 were used to detect outliers for each continent. Outliers were 
defined as trial results deviating markedly from the others and above 2 standard errors or below -
2 standard errors from the mean. However, few outliers were present in the datasets. For Europe 
and Asia, no outliers were detected for fatal endpoints. However, two outliers were found for 
North America. These were two extreme points below -4 standard errors (see Figure 6.2). Upon 
investigation, it was found that sponsors had discontinued both of these trials prematurely 
because of high mortality rates in the intervention group. As the early termination of trials has 
been found to distort treatment effect (Bassler et al. 2010; Schwartz, 1995; Souhami, Spiro, & 
Cullen, 1991),which could influence data analysis, it was decided to remove them from the 
dataset. 
Once outliers had been detected and removed, Figures 6.1-6.3 were used to observe the spread of 
the individual trial results from each continent. These observations produced an interesting 
finding. When all three Figures were compared, it appeared that Asia produced more positive 
trial results, that is, more trials in Asia found interventions to be more effective (relative to 
controls) than trials from Europe and North America.  
Table 6.10 shows the statistics calculated for each continent. It shows the mean effect estimate 
and its standard error, each continent’s z-score,45 its 2-sided p-value,46 the number of positive 
                                                 
45
  The z-score provides an estimate of how effective the interventions, relative to controls, were in each continent. 
Indeed, the z-score of a standard normal distribution is seen as equivalent to an effect estimate (Coe, 2002).  
46
This, and the calculated z-score, help to determine how probable it is for the sample proportions to have happened 
if the null hypothesis was true. 
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trials found in each continent, and the 2-sided p-value for the binomial sign tests conducted by 
continent. 
Table 6.10: Summary Statistics for Each Continent – Fatal Data 
 Europe North America Asia 
Mean Effect Estimate -0.097 0.173 -0.340 
Standard Error 0.062 0.084 0.160 
Z-Score -1.565 2.077 -2.121 
p-value (2-sided) 0.118 0.038 0.034 
Number of Trials (% of 
positive trials) 
240 (53%) 153 (47%) 27 (74%) 
Sign Test p-value (2-
sided) 
0.401 0.518 0.019 
 
The mean effect sizes differed greatly between continents. In North America, the treatment effect 
estimate (Mean = 0.173, SE = 0.084) seemed to favour controls, whereas in Europe (Mean= -
0.097, SE = 0.062) and Asia (Mean = -0.340, SE = 0.160) interventions were favoured. Indeed, 
the 2-sided p-value for the z-score of North America was statistically significant at the 5% level 
(2-sided p-value = 0.038), suggesting that in this instance, controls performed better relative to 
interventions. Asia appeared to provide the largest treatment effect estimate, suggesting that 
interventions performed better, relative to controls, in Asian trials than in their European and 
North American counterparts. The binomial sign test conducted for Asia confirmed that Asia did 
provide significantly more positive trial results, with a 20:27 ratio of trials showing interventions 
performing better relative to controls (2-sided p-value = 0.0192), a finding corroborated by the 
statistically significant at the 5% level 2-sided p-value calculated for the z-score in Asia (p-value 
= 0.034). 
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Figure 6.4 also shows that the effect of interventions differed greatly between continents.
47
It can 
be seen, for instance, that while intervention was more effective than control in Asia and Europe, 
control was more effective in North America. Moreover, the confidence intervals for each 
continent suggest the presence of a high level of heterogeneity, since there is no overlap between 
the confidence intervals of North America and Asia. This is supported by the  statistic, which 
shows that the percentage of total variation between continents due to heterogeneity, rather than 
chance, is 81%.  
FIGURE 6.4: A FOREST PLOT OF THE EFFECTIVENESS OF INTERVENTIONS IN 
EUROPE, NORTH AMERICA, AND ASIA FOR FATAL ENDPOINTS. 
Study or Subgroup
Asia
Europe
North America
Total (95% CI)
Heterogeneity: Chi² = 10.76, df = 2 (P = 0.005); I² = 81%
Test for overall effect: Z = 0.67 (P = 0.51)
Mean Difference
-0.34
-0.097
0.173
SE
0.16
0.062
0.084
Weight
8.9%
59.0%
32.1%
100.0%
IV, Fixed, 95% CI
-0.34 [-0.65, -0.03]
-0.10 [-0.22, 0.02]
0.17 [0.01, 0.34]
-0.03 [-0.13, 0.06]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours experimental Favours control
 
To investigate further, two independent sample t-tests were performed to compare the 
effectiveness of interventions between Europe and Asia and North America and Asia. The t-test 
for Europe versus Asia showed that the effectiveness of interventions, relative to controls, was 
                                                 
47
  It should be acknowledged that analysis was conducted on data within meta-analyses so that between-continent 
differences could not be created by the inclusion of different intervention types.  
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not significantly different between Europe (Mean = -0.097, SE = 0.062) and Asia (Mean = -
0.340, SE = 0.160), (t (34) = -1.4161, 2-sided p-value = 0.1658). The results for North America 
versus Asia, however, indicated that interventions, relative to controls, were more effective in 
Asia (Mean = -0.340, SE=0.160) than in North America (Mean = 0.017, SE = 0.084), with this 
difference being statistically significant (t (41) = -2.839, 2-sided p-value = 0.0070). 
These results suggested that there was some evidence for interventions, relative to controls, 
performing better in Asian trials than in their European and North American counterparts. As this 
finding was unexpected, it was decided to investigate further by conducting a post-hoc analysis 
on the Asian sample of trials. This was done by breaking down the Asian trials by country to 
establish if there was a particular country with a high proportion of positive trial results. The 
Asian trials were from China, Japan, Taiwan, and South Korea. As with the previous graphs, the 
spread of trial results from each country was examined by standardising each trial’s effect 
estimate, sub-grouping trial results according to country, and plotting these onto graphs.
48
  
In observing the spread of each Asian country’s trial results, it was found that Japanese trials 
produced more positive results, with the majority favouring intervention over control. Figure 6.5 
shows that the majority of the standardised effect estimates of Japanese trials were below zero. 
 
 
                                                 
48
Since this was a post-hoc analysis and the sample sizes for each Asian country were small, statistical tests were 
considered inappropriate and so were not used. 
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FIGURE 6.5: THE TREATMENT EFFECT ESTIMATES OF JAPANESE TRIALS 
 
This can be seen by examining Table 6.11, which shows the total number of trials in each country 
and the number of trials favouring intervention or control. 
Table 6.11: The Number of Asian Trials favouring the Intervention or Control in Japan, 
China, Taiwan, and South Korea 
Country of 
Trials 
Number of 
trials 
favouring the 
intervention 
(%) 
Number of 
Trials 
favouring the 
Control (%) 
Total 
Number of 
Trials (%) 
Japan 12 (92%) 1 (8%) 13 (100%) 
China 3 (60%) 2 (40%) 5 (100%) 
South Korea 2 (33%) 4 (67%) 6 (100%) 
Taiwan 2 (67%) 1 (33%) 3 (100%) 
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As can be seen, Japan provided a high proportion of positive trial results, with 12 of 13 trials 
reporting that intervention was more effective than control. A high proportion of positive trial 
results were not observed for any other Asian country included in this sample. This suggested 
that interventions, relative to controls, may be more effective in Japanese trials compared with 
the other Asian countries included here. 
6.1.3:  Types of Intervention Prone to Inter-Continental Differences in 
Effectiveness - Fatal Endpoints 
Since there was some evidence to suggest that differences in treatment effectiveness existed 
between Europe and Asia and North America and Asia, it was important to investigate which 
types of intervention were prone to these differences. First, this was investigated over and within 
meta-analyses. For each pair-wise comparison, the meta-analyses were grouped according to 
intervention type. Within these groups, the Z-statistic and 2-sided p-value of each meta-analysis 
were observed to see if, over all meta-analyses in that intervention type, there was a clear pattern 
of statistically significant differences in treatment effect. This was done using Tables 6.12 to 6.14 
and Tables 6.16 to 6.18. 
Second, the individual trials from the continents of interest contained in the included meta-
analyses were examined. The standardised results of each trial in each meta-analysis were pooled 
and grouped according to continent and intervention type. T-tests were then conducted between 
Europe and Asia and between North America and Asia for each type of intervention: Drug, 
Device, and Surgery. Lifestyle and Management interventions were not included because no 
Asian trials involved these types of intervention for fatal endpoints. Conducting t-tests meant that 
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the 2-sided p-value for the between-continent difference in treatment effect could be calculated 
for each intervention type. This enabled the types of intervention prone to inter-continental 
differences to be identified. 
6.1.3.1: Europe vs. Asia 
First, the investigation into the types of intervention prone to inter-continental differences for 
fatal endpoints was conducted over and within meta-analyses. To do this, the meta-analyses were 
grouped according to intervention type. The Z-statistic and 2-sided p-value for each meta-
analysis (now grouped by intervention type) were then “eyeballed” to see whether any difference 
was statistically significant at the 5% level. The number of statistically significant differences in 
each intervention group was then observed to see whether, over all of the meta-analyses in that 
intervention group, there was a clear pattern of statistically significant differences that would 
suggest that that intervention type was likely to show differences in treatment effect between 
Europe and Asia.  
Table 6.12 shows the meta-analyses investigating drug therapies for the Europe versus Asia pair-
wise comparison. 
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Table 6.12: Meta-analyses Investigating Drugs with their Z-statistic for the Difference in 
Treatment Effect between Europe and Asia for Fatal Endpoints. 
 
 
As can be seen, it was found that the difference in treatment effect between Europe and Asia was 
statistically significant in none of the included meta-analyses that had investigated drugs. As 
such, no clear pattern was identified to show that this type of intervention was prone to inter-
continental differences in treatment effect. 
Table 6.13 shows the details of the meta-analyses that investigated medical devices. 
 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe
/Asia) 
Pooled 
Estimate for 
Europe 
(95% CIs) 
Pooled 
Estimate for 
Asia (95% 
CIs) 
Difference in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
18 
[C12] 
Phosphodiesterase 
III inhibitors 
RR 2/1 1.56 
(1.02,2.40) 
0.51 
(0.05, 5.60) 
1.112 
(-1.32, 3.54) 
0.898 0.369 
4 
[P2] 
GCSF Therapy RR 3/1 1.38 
(0.28,6.89) 
3.63 
(0.16, 84.11) 
-0.970 
(-4.50, 2.56) 
-0.538 0.590 
232 
[C10] 
Magnesium RR 5/1 0.78 
(0.61, 0.99) 
0.34 
(0.04, 3.21) 
0.823 
(-1.43, 3.08) 
0.714 0.475 
237 
[P19] 
Intracoronary Cell 
Therapy 
RR 3/1 0.51 
(0.15, 1.66) 
1.07 
(0.07, 16.33) 
-0.752 
(-3.72, 2.22) 
-0.497 0.619 
 
247 
[C40] 
Bone Marrow Cell 
Therapy 
RR 4/1 0.59 
(0.21, 1.68) 
0.33 
(0.01, 7.81) 
0.565 
(-2.76, 3.89) 
0.333 0.739 
227 
[C4] 
Anti-arrhythmics RR 5/1 1.02 
(0.79, 1.31) 
0.62 
(0.03, 14.3) 
0.492 
(-2.65, 3.64) 
0.307 0.759 
25 
[P94] 
Vasopressin RR 2/1 0.99 
(0.95, 1.03) 
0.83 
(0.68, 1.01) 
0.181 
(-0.03, 0.39) 
1.716 
 
0.086 
286 
[P153] 
 
Amiodarone OR 3/1 1.79 
(0.00, 
1169.4) 
0.81 
(0.00, 153.8) 
0.791 
(-7.55, 9.13) 
0.186 0.853 
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Table 6.13: Meta-analyses Investigating Medical Devices with their Z-statistic for the 
Difference in Treatment Effect between Europe and Asia for Fatal Endpoints. 
 
 
Again, no meta-analysis found the difference in treatment effect between Europe and Asia to be 
statistically significant at the 5% level. As a result, no clear pattern of statistically significant 
differences was found to suggest that medical devices were prone to between-continental 
differences in treatment effect. 
Table 6.14 provides the details for the meta-analyses that investigated surgical interventions. 
 
 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe
/Asia) 
Pooled 
Estimate 
for 
Europe 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
33 
[P97] 
Thrombectomy 
or Embolic 
Protection 
Devices 
RR 9/2 0.70 
(0.16, 
2.98) 
0.26 
(0.00, 
281.07) 
0.991 
(-6.15, 
8.13) 
0.272 0.786 
96 
[P90] 
Adjunctive 
Mechanical 
Devices 
RR 5/2 1.00 
(0.47, 
2.15) 
0.73 
(0.26, 
2.07) 
0.320 
(-0.97, 
1.61) 
0.485 0.628 
383 
[C41] 
Non-Invasive 
Positive 
Pressure 
Ventilation 
RR 6/4 0.59 
(0.37, 
0.92) 
0.40 
(0.18, 
0.87) 
0.383 
(-0.51, 
1.28) 
0.838 0.402 
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Table 6.14: Meta-analyses Investigating Surgical Interventions with their Z-statistic for the 
Difference in Treatment Effect between Europe and Asia for Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/
Asia) 
Pooled 
Estimate for 
Europe (95% 
CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
197 
[P33] 
Direct 
Coronary 
Bypass 
Grafting 
RR 3/1 0.93 
(0.45,1.91) 
0.12 
(0.01,2.43) 
2.060 
(-1.05, 
5.17) 
1.300 0.194 
191 
[P15] 
PCI RR 2/1 0.96 
(0.41, 2.23) 
0.22 
(0.03, 
1.82) 
1.468 
(-0.80, 
3.73) 
1.270 0.204 
2 
[P7] 
Late PCI RR 5/1 0.41 
(0.26, 0.66) 
0.18 
(0.02, 
1.45) 
0.839 
(-1.32, 
3.00) 
0.763 0.446 
 
As with medical devices, no meta-analysis investigating surgical interventions found the 
difference in treatment effect between Europe and Asia to be statistically significant at the 5% 
level. Therefore, no clear pattern of statistically significant differences was found for surgical 
interventions to suggest that such interventions were prone inter-continental differences.  
Since no group of interventions was found to show a clear pattern of statistically significant 
differences in treatment effect, the types of intervention prone to differences between Europe and 
Asia could not be identified for fatal endpoints. 
To investigate further, analysis was conducted across the individual trials contained in the 
included meta-analyses. Table 6.15 shows the number of trials from each continent that 
investigated each intervention type, the mean effect estimate and its standard error per continent 
for each intervention type, and the 2-sided p-value for the t-tests that were conducted. 
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Table 6.15: Summary Statistics for Intervention Types – Europe versus Asia for Fatal Data. 
Intervention 
Type 
Number 
of  
European 
Trials 
European  
Mean 
Effect 
Estimate 
Standard 
Error 
Number 
of Asian 
Trials 
Asia 
Mean 
Effect 
Estimate 
Standard 
Error 
T-Test 
p-value 
Drug 91 -0.0779 0.103 8 -0.066 0.365 0.976 
Device 49 0.0054 0.106 14 -0.526 0.176 0.017 
Surgery 41 -0.0110 0.154 5 -0.257 0.435 0.617 
 
As can be seen, the number of trials investigating each intervention type differed between 
continents, as did each continent’s mean effect estimate. The 2-sided p-values for the t-tests show 
that the difference in treatment effect between Europe and Asia was only statistically significant 
at the 5% level for device interventions. The results of the t-tests, for each intervention type, are 
discussed further below. 
6.1.3.1.1: Drug Interventions  
The mean difference between continents for drug interventions was found to be -0.012, which is a 
small effect size (d = 0.022),
49
 with 95% confidence intervals of -0.887 to 0.863. An independent 
samples t-test revealed that the effectiveness of drug therapies did not significantly differ between 
Europe (Mean=-0.078, SE = 0.103) and Asia (Mean = -0.066, SE = 0.365): (t (8) = 0.0314, 2-
sided p-value = 0.976). Therefore, it was concluded that there was insufficient evidence for a 
difference in the effect of drug therapies, relative to controls, between Europe and Asia. 
                                                 
49
 Cohen’s d was used as the measure of effect size. When using this measure, Cohen (1988) considers that a d of 0.2 
represents a small effect size, a d of 0.5 a medium effect size, and a d of 0.8 a large effect size (Zhang, 2008).  
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6.1.3.1.2: Device Interventions 
The mean difference between continents for medical devices was 0.53, representing a large effect 
size (d = 1.08), with 95% confidence intervals of 0.106 to 0.956. An independent samples t-test 
showed that there was a statistically significant difference in the effect of device interventions, 
relative to controls, between Europe (Mean=0.005, SE=0.106), and Asia (Mean= -0.526, SE= 
0.176), (t (23) = 2.586, 2-sided p-value =0.017). Therefore, these results indicated that a 
difference in the effect of medical devices existed between Europe and Asia, with such devices 
performing better in Asia than in Europe. 
6.1.3.1.3: Surgical Interventions 
The mean difference between continents for surgical interventions was 0.246, reflecting a small-
medium effect size (d = 0.48), with confidence intervals of -0.940 to 1.42. An independent 
samples t-test indicated that there was no significant difference in the effect of surgical 
interventions, relative to controls, between Europe (Mean = -0.011, SE = 0.154) and Asia (Mean 
= -0.257, SE = 0.435): (t (5) = 0.5331, 2-sided p-value = 0.617). As a result, it was concluded that 
there was currently insufficient evidence that the effect of surgical interventions differed between 
Europe and Asia. 
6.1.3.2: North America vs. Asia 
As with the previous comparison, the types of intervention prone to differences in treatment 
effect was first examined over and within meta-analyses. As before, the meta-analyses were 
grouped according to the type of intervention investigated. Table 6.16 shows the meta-analyses 
investigating drug interventions for the pair-wise comparison between North America and Asia. 
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Table 6.16: Meta-analyses Investigating Drugs with their Z-statistic for the Difference in 
Treatment Effect between North America and Asia for Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(N. 
Amer./ 
Asia) 
Pooled 
Estimate for 
North 
America 
(95% CIs) 
Pooled 
Estimate for 
Asia (95% 
CIs) 
Difference in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided 
p-value of 
difference 
4 
[P2] 
GCSF Therapy RR 1/1 0.18 
(0.01, 3.85) 
3.63 
(0.16, 84.19) 
-3.007 
(-7.40, 1.38) 
-1.343 0.179 
227 
[C4] 
Anti-
arrhythmics 
RR 4/1 1.49 
(0.80, 2.77) 
0.62 
(0.03, 14.30) 
0.870 
(-2.32, 4.07) 
0.534 0.593 
18 
[C12] 
Phosphodiesterase 
III Inhibitors 
RR 5/1 1.13 
(1.02, 1.26) 
0.51 
(0.05, 5.60) 
0.792 
(-1.60, 3.18) 
0.649 0.517 
25 
[P94] 
Vasopressin RR 1/1 1.02 
(0.92, 1.14) 
0.83 
(0.68, 1.01) 
0.213 
(-0.016, 
0.44) 
1.826 0.068 
55 
[P131] 
Clopidogrel plus 
Aspirin 
RR 1/1 0.76 
(0.41, 1.39) 
0.93 
(0.88, 1.00) 
-0.210 
(-0.82, 0.40) 
-0.675 0.500 
286 
[P153] 
Amiodarone OR 6/1 0.82 
(0.06, 10.48) 
0.81 
(0.00, 153.8) 
0.012 
(-5.82,5.84) 
0.004 0.997 
 
As can be seen, none of the meta-analyses investigating drug interventions found the difference 
in treatment effect to be statistically significant at the 5% level. As a result, no clear pattern of 
statistically significant differences was found to show drug interventions as being prone to inter-
continental differences in treatment effect.  
Table 6.17 presents the details of the meta-analyses that investigated medical devices. 
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Table 6.17: Meta-analyses Investigating Medical Devices with their Z-statistic for the 
Difference in Treatment Effect between North America and Asia for Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(N. 
Amer./ 
Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
33 
[P97] 
Thrombectomy 
or Embolic 
Protection 
Devices 
RR 1/2 2.80 
(0.05, 
11.39) 
0.26 
(0.00, 
281.07) 
2.382 
(-5.67, 
10.43) 
0.580 0.562 
96 
[P90] 
Adjunctive 
Mechanical 
Devices 
RR 1/2 5.50 
(1.23, 
24.55) 
0.73 
(0.26, 
2.07) 
2.022 
(0.20, 
3.85) 
2.173 0.030 
383 
[C41] 
Non-Invasive 
Positive 
Pressure 
Ventilation 
RR 1/4 1 
(0.23, 
4.40) 
0.40 
(0.18, 
0.87) 
0.916 
(-0.76, 
2.59) 
1.074 0.283 
 
One meta-analysis investigating medical devices found a statistically significant difference in 
treatment effect between North America and Asia (P90 (96)). This meta-analysis compared 
adjunctive mechanical devices (intervention) to usual care (control) with respect to thirty-day 
mortality and found that adjunctive mechanical devices performed better in Asia than in North 
America. The 2-sided p-value for this Z-statistic was 0.030. However, as no other meta-analyses 
investigating medical devices found a statistically significant difference in treatment effect, no 
clear pattern of statistically significant differences could be identified to indicate that medical 
devices were prone to differences in treatment effect between North America and Asia. 
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Table 6.18 shows the meta-analysis containing North American and Asian trials that investigated 
a surgical intervention for fatal endpoints. 
Table 6.18: Meta-analyses Investigating Surgical Interventions with their Z-statistic for the 
Difference in Treatment Effect between North America and Asia for Fatal Endpoints. 
Meta-
analysis 
Ref. 
No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials (N. 
Amer. 
/Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% 
CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
2 
[P7] 
Late PCI RR 1/1 0.76 
(0.05, 11.39) 
0.18 
(0.02, 
1.45) 
1.456 
(-1.97, 
4.88) 
0.832 0.405 
 
As Table 6.18 shows, the difference in treatment effect did not reach statistical significance in 
this meta-analysis. Therefore, there was no evidence that this surgical intervention was prone to 
inter-continental differences in treatment effect.  
As no group of interventions showing a clear pattern of statistically significant differences could 
be identified, the types of intervention prone to treatment effect differences between North 
America and Asia could not be identified. Furthermore, finding only one meta-analysis that was 
statistically significant at the 5% level from the 10 available was no more than would be expected 
by random chance. Therefore, there was insufficient evidence to conclude which types of 
intervention were prone to differences in treatment effect between North America and Asia for 
fatal endpoints. 
To investigate further, the North American and Asian trials from each included meta-analysis 
were analysed, with independent samples t-tests conducted for each type of intervention: Drug, 
Device, and Surgery. Table 6.19 shows the summary statistics for North America and Asia. 
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Table 6.19: Summary Statistics for Intervention Types– North America versus Asia for 
Fatal Data. 
Intervention 
Type 
Number 
of  North 
American 
Trials 
North 
American 
Mean 
Effect 
Estimate 
Standard 
Error 
Number 
of Asian 
Trials 
Asia 
Mean 
Effect 
Estimate 
Standard 
Error 
T-Test 
p-value 
Drug 75 -0.186 0.128 8 -0.066 0.365 0.764 
Device 18 0.199 0.204 14 -0.526 0.176 0.012 
Surgery 12 0.291 0.209 5 -0.257 0.435 0.308 
 
As can be seen, for each intervention type the number of trials each continent provided differed, 
as did each continent’s mean effect estimate. The results of the t-tests indicated that the 
difference in treatment effect between North America and Asia was statistically significant at the 
5% level for medical devices. The results of each t-test are now discussed further. 
6.1.3.2.1: Drug Interventions 
The mean difference between continents for drug therapies was -0.120, representing a small 
effect size (d=-0.22), with 95% confidence intervals of -1.012 to 0.772. An independent sample t-
test revealed that there was not a statistically significant difference in the effect of drug 
interventions, relative to controls, between North America (Mean= -0.186, SE = 0.128) and Asia 
(Mean=-0.066, SE = 0.365) (t(8) = 0.3102, p=0.764). As such, there was insufficient evidence for 
the existence of a difference in treatment effect for drug interventions between North America 
and Asia. 
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6.1.3.2.2: Device Interventions 
The mean difference between continents for devices was found to be 0.7250, indicating a large 
effect size (d = 1.00), with 95% CIs of 0.174 to 1.276. An independent samples t-test showed that 
there was a statistically significant difference in the effect of medical devices, relative to controls, 
between North America (Mean = 0.199, SE = 0.204) and Asia (Mean = -0.526, SE = 0.176): t 
(29) = 2.6909, 2-sided p-value= 0.012. Therefore, these results demonstrated that there was a 
difference in the effect of medical devices between North America and Asia, with such devices 
performing better in Asia than in North America.  
6.1.3.2.3: Surgical Interventions 
The mean difference between continents for surgical interventions was 0.548, reflecting a large 
effect size (d = 0.98), with 95% CIs of -0.693 to 1.789. An independent samples t-test revealed 
that there was no statistically significant difference in the effect of surgical interventions, relative 
to controls, between North America (Mean = 0.281, SE = 0.209) and Asia (Mean= -0.257, SE= 
0.435) (t(5) = 1.1355, p = 0.308). As such, there was a lack of evidence that the effect of surgical 
interventions differed between North America and Asia. 
6.1.3.3: Summary of the Types of Intervention Prone to Inter-continental Differences. 
The types of intervention prone to inter-continental differences in treatment effect could not be 
identified from the investigation over and within meta-analyses for either pair-wise comparison. 
This was because no clear pattern of statistically significant differences was found for any 
intervention type. However, the investigation conducted across trials indicated that medical 
devices may be prone to showing inter-continental differences, since in both the Europe versus 
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Asia and the North America versus Asia comparisons the t-tests showed statistically significant 
differences between continents in treatment effect. 
6.2: Non-Fatal Endpoints 
This section presents the findings of the pair-wise comparison between Europe and Asia and 
North America and Asia for non-fatal endpoints and the findings from the universal comparison 
for this endpoint. 
6.2.1: Pair-Wise Comparison over Meta-analyses. 
As with the pair-wise comparison for fatal endpoints, two comparisons were conducted for non-
fatal endpoints between Europe and Asia and between North America and Asia. Each will be 
discussed in turn. 
6.2.1.1: Europe vs. Asia 
As explained previously (see Section 6.1.1.1.1), the meta-analyses on which this pair-wise 
comparison were based had to consist of at least one European and one Asian trial and only 59 of 
the 95 meta-analyses in the database fulfilled this criterion. 
Of these 59 meta-analyses, 39 contained at least one European and one Asian trial with data for a 
non-fatal endpoint that would allow for separate estimates of treatment effect to be calculated. 
The details of these meta-analyses can be found in Tables 6.20–6.24.  
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6.2.1.1.1: Meta-analyses Grouped according to Treatment Effect Measure for Non-Fatal 
Endpoints – Europe versus Asia. 
The 39 meta-analyses that contained non-fatal data were grouped according to the measure of 
treatment effect used. The following tables summarise the details of these meta-analyses, 
showing the intervention group, the control group, the endpoint reported in each meta-analysis, 
the number of trials provided by each continent, and each continent’s treatment effect estimate. 
6.2.1.1.1.1: Non-Fatal Endpoints for Europe versus Asia Measured as Risk Ratios. 
24 of the 39 meta-analyses that reported non-fatal endpoints did so using RR. The details of these 
are given in Table 6.20. 
 
 
 
 
 
 
 
 
 
  
201 
 
Table 6.20: Meta-analyses with Non- Fatal Endpoints for Europe vs. Asia. Effectiveness 
Measured by RR. 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(Europe
/Asia) 
RR 
estimate 
Europe 
(95% 
CI) 
RR 
estimate 
Asia 
(95% CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
18 
[C12] 
Phosphodiesterase 
III inhibitors for 
HF 
Placebo Worsening 
heart failure 
3/2 1.44 
(1.00, 
2.06) 
0.52 
(0.27, 
0.98) 
Asia 
(0.006) 
25 
[P94] 
Vasopressin for 
Cardiac arrest 
Epinephrine Failure of 
return of 
spontaneous 
circulation 
2/1 1.03 
(0.97, 
1.11) 
0.59  
(0.38, 
0.91) 
Asia 
(0.013) 
48 
[P166] 
Vitamin-mineral 
supplements for 
CAD 
Placebo Restenosis 2/1 1.05 
(0.43, 
2.61) 
0.56 
(0.06, 
5.31) 
Asia 
(0.609) 
176 
[C39] 
Calcium channel 
antagonists 
Adenosine Reversion 
Rate 
2/1 1.54 
(0.58, 
4.06) 
0.97 
(0.39, 
2.41) 
Asia 
(0.497) 
96 
[P90] 
Adjunctive 
mechanical devices 
for Acute MI 
Standard care 
or stenting 
Distal 
embolisation 
4/2 0.65 
(0.37, 
1.13) 
0.40 
(0.21, 
0.75) 
Asia 
(0.255) 
226 
[P125] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo or 
standard care 
MI within 30 
days 
4/1 0.86 
(0.58, 
1.28) 
0.13 
(0.01, 
2.38) 
Asia 
(0.206) 
227 
[C4] 
Anti-arrhythmics 
after cardioversion 
of AF 
Placebo, 
drugs for rate 
control or no 
treatment 
AF 
Recurrence 
11/2 0.75 
(0.71, 
0.79) 
0.85 
(0.70, 
1.03) 
Europe 
(0.220) 
232 
[C10] 
Intravenous 
magnesium for 
Acute MI 
Placebo Heart Failure 4/1 0.79 
(0.65, 
0.97) 
 
0.66 
(0.39, 
1.10) 
Asia 
(0.512) 
33 
[P97] 
Thrombectomy or 
Embolic protection 
devices with PCI 
for Acute MI 
PCI alone Target vessel 
revascularisati
on 
6/2 0.94 
(0.30, 
2.95) 
0.66 
(0.02, 
21.39) 
Asia 
(0.853) 
383 
[C41] 
NNPV for 
Cardiogenic 
Pulmonary Edema 
Standard 
Medical Care 
Endotracheal 
Intubation 
Rate 
4/1 0.86 
(0.58, 
1.28) 
0.13 
(0.01, 
2.38) 
Asia 
(0.206) 
388 
[P101] 
Prophylactic 
steroids for 
cardiopulmonary 
bypass 
Placebo or 
standard care 
New onset AF 3/1 0.78 
(0.62, 
0.98) 
1.25 
(0.49, 
3.16) 
Europe 
(0.338) 
51 
[C11] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo 30 day urgent 
revascularisati
on 
5/1 0.56 
(0.35, 
0.88) 
2.74 
(0.12,63.
63) 
Europe 
(0.327) 
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165 
[P130] 
ACEI or ARB Placebo or 
alternative 
therapy 
AF 6/1 0.93 
(0.86, 
1.00) 
0.60 
(0.37,0.9
7) 
 
Asia 
(0.080) 
328 
[P108] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
Stroke 9/1 0.41 
(0.18, 
0.95) 
0.35 
(0.01, 
8.56) 
Asia 
(0.928) 
2 
[P7] 
Late PCI for Acute 
MI 
Usual 
management 
Non-Fatal MI 5/1 0.49 
(0.31, 
0.77) 
0.38 
(0.11, 
1.37) 
Asia 
(0.715) 
4 
[P2] 
G-CSF Therapy Placebo Instent 
Restenosis 
4/1 0.91 
(0.58, 
1.41) 
1.22 
(0.08, 
18.20) 
Europe 
(0.830) 
188 
[P25] 
G-CSF 
Administration 
Placebo or 
No 
Treatment 
Binary        
Restenosis  
rate 
4/1 0.97 
(0.61, 
1.53) 
2.75 
(0.24, 
31.72) 
Europe 
(0.410) 
200 
[P155] 
ACEI or ARB for 
prevention of AF 
Placebo, 
other 
antihypertens
ive therapy 
or treatment 
drug plus 
Irbesartan 
Development 
of AF 
6/1 0.93 
(0.68, 
1.27) 
0.60 
(0.10, 
3.76) 
Asia 
(0.647) 
247 
[C40] 
Stem cell treatment 
for Acute MI 
No treatment 
or Placebo 
Incidence of 
Restenosis 
5/1 1.15 
(0.71, 
1.87) 
0.20 
(0.01, 
3.97) 
Asia 
(0.256) 
259 
[P102] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
MI 15/1 0.74 
(0.46, 
1.19) 
1.06 
(0.15, 
7.36) 
Europe 
(0.721) 
400 
[P5] 
G-CSF for Acute 
MI 
Placebo Angiographic 
Restenosis 
4/2 1.00 
(0.63, 
1.59) 
0.83 
(0.40, 
1.74) 
Europe 
(0.672) 
153 
[P149] 
Amiodarone 
prophylaxis for 
cardiothoracic 
surgery 
Placebo Post-operative 
AF 
6/1 0.70 
(0.55, 
0.90) 
0.36 
(0.18,0.7
1) 
Asia 
(0.066) 
191 
[P15] 
PCI for late 
reperfusion after 
MI 
Standard 
therapy 
MI 2/1 1.72 
(0.52, 
5.71) 
0.38 
(0.11, 
1.37) 
Asia 
 (0.092) 
237 
[P19] 
Intracoronary Cell 
Therapy 
Standard 
medical 
therapy 
Target vessel 
revascularisati
on 
6/1 0.997 
(0.70, 
1.43) 
0.36 
(0.02, 
8.41) 
 Asia 
(0.527) 
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As for fatal endpoints, the best region was not calculated for six of the meta-analyses using RR, 
as they had not specifically stated which group was the intervention and which group the control. 
Details are provided in Table 6.21. 
Table 6.21: Meta-analyses with Non-Fatal Endpoints for Europe vs. Asia that Do Not 
Identify Which Group is the Intervention and Which the Control. Effectiveness Measured 
by RR. 
 
6.2.1.1.1.2: Non-Fatal Endpoints for Europe versus Asia Measured as Odds Ratios. 
Only one meta-analysis reported non-fatal endpoints using OR. The details for this meta-analysis 
are presented in Table 6.22. 
Article 
ref. no 
Intervention 1 
 
Intervention 
2 
Endpoint No. of 
trials 
(Europe/
Asia) 
RR 
estimate  
Europe 
(95% CI) 
RR 
estimate  
Asia (95% 
CI) 
Best 
Region (p-
value of 
between-
continent 
difference) 
11 
[P87] 
Stenting for 
Small Vessel 
CAD 
PTCA Repeat 
revascularisa
tion 
6/2 0.77 
(0.64, 
0.92) 
0.72 
(0.41, 
1.26) 
Not applic. 
(0.821) 
273 
[C17] 
Stenting for 
Acute MI 
Balloon 
Angioplasty 
Revascularis
ation at 30 
days 
3/2 0.33 
(0.14,0.82) 
0.63 
(0.42, 
0.94) 
Not Applic. 
(0.204) 
26 
[P38] 
Minimally 
invasive left 
internal thoracic 
artery bypass 
 
Percutaneous 
coronary 
artery stenting 
Repeat 
Revascularis
ation 
4/2 0.26 
(0.15, 
0.47) 
0.25 
(0.06, 
1.04) 
Not Applic. 
(0.930) 
56 
[P24] 
PCI* CABG 
surgery* 
Stroke 6/1 0.36 
(0.11, 
1.23) 
0.20 
(0.01, 
4.78) 
Not Applic. 
(0.725) 
94 
[P18] 
LMWH for 
STEMI 
UFH 30 day 
Reinfarction 
1/1 0.74 
(0.45, 
1.23) 
1.29 
(2.45, 
0.68) 
Not Applic. 
(0.183) 
319 
[P21] 
SES PES myocardial 
infarction 
7/3 0.87 
(0.61, 
1.22) 
0.73 
(0.47, 
1.16) 
Not Applic. 
(0.572) 
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Table 6.22: The Meta-analysis with Non-Fatal Endpoints for Europe vs. Asia. Effectiveness 
Measured by OR. 
 
 
6.2.1.1.1.3: Non-Fatal Endpoints for Europe versus Asia Measured as Mean Difference. 
Table 6.23 provides the details of the seven meta-analyses that contained non-fatal data and 
reported treatment effect using MD. 
 
 
 
 
 
 
 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(Europe/
Asia) 
OR 
estimate 
Europe 
(95% CI) 
OR 
estimate 
Asia (95% 
CI) 
Best Region  
(p-value of 
between-
continent 
difference) 
27 
[P156] 
Amiodarone for 
prevention of AF 
Placebo, 
Metoprolol 
or routine 
treatment 
Prevention of 
Post cardiac 
surgery AF 
5/1 0.47 
(0.10, 
2.12) 
0.27 
(0.01, 
7.34) 
Asia 
(0.767) 
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Table 6.23: Meta-analyses with Non-Fatal Endpoints for Europe vs. Asia. Effectiveness 
Measured by MD. 
 
 
As with meta-analyses that had used RR, one of the meta-analyses using MD did not specifically 
identify which group was the intervention under investigation and which the control group. 
Therefore, the best region was not calculated for this meta-analysis. The details of this meta-
analysis can be found in Table 6.24. 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(Europe
/Asia) 
Mean 
difference 
estimate 
Europe 
(95% CI) 
Mean 
Difference 
estimate 
Asia (95% 
CI) 
Best 
Region (p-
value of 
between-
continental 
difference) 
107 
[P95] 
Beta-Blocker 
Therapy for Heart 
Failure 
Placebo Mean Change 
in QoL score 
1/1 -0.28 
(-1.69, 
1.13) 
-0.36 
(-4.19, 
3.47) 
Asia 
(0.853) 
6 
[P141] 
ACE inhibition  Placebo, 
convention
al 
treatment 
or no 
treatment 
Diastolic 
volume 
6/1 -2.37 
(-15.95, 
11.21) 
-18 
(-88.43, 
52.53) 
Asia 
(0.669) 
184 
[P51] 
Autologous bone 
marrow cells 
Standard 
medical 
therapy 
Change in EF 2/1 3.41 
(-
11.33,18.17
) 
13 
(4.96, 
21.04) 
Europe 
(0.264) 
4 
[P116] 
Bone Marrow 
Derived Cell 
Transplantation 
Placebo, 
Optimal 
therapy or 
no 
treatment 
Difference in 
mean 
improvement 
in left 
ventricular 
ejection 
fraction 
7/5 2.10 
(-2.26, 
6.45) 
8.15 
(-0.19, 
16.48) 
Asia 
(0.2070 
 
 
208 
[P17] 
G-CSF therapy Placebo or 
Blank 
control 
Change in 
LVEF 
4/3 0.47 
(-7.24, 
8.18) 
3.33 
(-9.17, 
15.83) 
Asia 
(0.703) 
 
23 
[P14] 
PCI Optimal 
treatment 
Change in EF 
from baseline 
to follow up 
1/1 4 
(-1.55, 
9.55) 
4 
(-7.41, 
15.41) 
None 
(1) 
207 
[P146] 
Bone marrow cells Placebo or 
no 
treatment 
LVEF change 
at follow up 
5/1 2.60 
(-2.25, 
7.45) 
6.7 
(-11.61, 
25.01) 
Asia 
(0.671) 
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Table 6.24: The Meta-analysis with Non - Fatal Endpoints for Europe vs. Asia that does not 
identify which Group is the Intervention and which the Control. Effectiveness Measured by 
MD. 
 
6.2.1.1.2: Examination over all Meta-analyses for Non-Fatal Endpoints – Europe versus 
Asia 
Table 6.25 shows the number of meta-analyses that identified their intervention and control 
groups favouring each continent. 
Table 6.25: A Summary of the number of Meta-analyses Favouring either Europe or Asia 
for Non-Fatal Endpoints. 
Total Number of 
Meta-analyses 
Number of Meta-
analyses with 
Intervention Performing 
Better in Europe (%) 
Number of Meta-
analyses with 
Intervention Performing 
Better in Asia (%) 
Number of Meta-
analyses with 
Intervention not 
Favouring either 
Continent (%) 
32 8 (25%) 23 (72%) 1 (3%) 
 
There were 23 meta-analyses where the intervention performed better in Asia than in Europe and 
eight where the opposite was the case. As with fatal endpoints, a binomial sign test was 
conducted under the null hypothesis that the effect of interventions, relative to controls, was the 
Article 
ref. no. 
Intervention 
1 
Intervention 
2 
Endpoint No. of trials 
(Europe/Asia) 
Mean 
difference 
estimate 
Europe 
(95% CI) 
Mean 
Difference 
estimate 
Asia (95% 
CI) 
Best Region  
(p-value of 
between-
continent 
difference) 
272 
[P165] 
Drugs, 
Behavioural 
therapy or 
Exercise for 
secondary 
prevention 
of Coronary 
artery 
disease 
Detraining, 
low intensity 
exercise, rest 
or no 
treatment 
Treatment 
outcome 
for time 
domain 
heart rate 
variability 
indices 
13/3 0.43 
(-0.16, 
1.01) 
0.33 
(-0.80, 
1.46) 
Not Applic. 
(0.878) 
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same in both Europe and Asia. This indicated that the difference in the effect of interventions 
between Europe and Asia was statistically significant (2-sided p-value = 0.0201).  
6.2.1.1.3: Global Estimates of Difference between Europe and Asia 
To investigate the existence of inter-continental differences in treatment effectiveness for non-
fatal endpoints further, global estimates of continental difference were produced. These reflected 
the weighted average difference between the treatment effect estimates of Europe and Asia over 
all of the meta-analyses that had identified their intervention and control groups. From these, it 
was found that for RR (24 meta-analyses) the mean log difference was 0.161 with 95% CIs of 
0.021 and 0.301 (2-sided p-value = 0.025), while for OR (1 meta-analysis) the mean log 
difference was 0.548 with 95% CIs of -3.08 and 4.18 (2-sided p-value = 0.767). For endpoints 
calculated in terms of MD (7 meta-analyses), the mean difference over all of the data was found 
to be -1.34, with 95% CIs of -4.7 and 2.01 (2-sided p-value = 0.433). As can be seen, the global 
estimate of continental difference for RR was statistically significant at the 5% level (2-sided p-
value = 0.025). This suggested that when treatment effect was measured using RR, there was a 
significant difference in the effect of interventions between Europe and Asia, with interventions 
on average performing better (relative to controls) in Asia than in Europe. The finding for both 
OR and MD, however, did not reach statistical significance, meaning that there was insufficient 
evidence to conclude that there was a difference in overall treatment effect between Europe and 
Asia over all of the included meta-analyses that used these treatment effect measures. 
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6.2.1.1.4: Impact of Overlapping Meta-analyses 
The results found above may have been the result of the inclusion of trial duplications in 
overlapping meta-analyses (see Chapter 4). When the impact of overlapping meta-analyses on the 
pair-wise comparison between Europe and Asia was investigated, 20 meta-analyses were 
identified as overlapping (P125, C11, P130, P108, P7, P2, P25, P155, C40, P102, P5, P51, P116, 
P17, P14, P146, P149, P156,P15,C40) and 12 meta-analyses considered as non-overlapping (P97, 
C12, P94, P166, C39, P90, C4, C10, C41, P101, P95, P141). Of the 20 overlapping meta-
analyses, there were four pairs of meta-analyses that shared a number of the same trials (P155 
and P130, P108 and P102, C11 and P125, P149 and P156). In addition, there was one group of 
three meta-analyses which shared a proportion of the same trials (P15, P7, and P14), one group of 
four meta-analyses where this was the case (P25, P2, P5, P17) and one group of five (P146, C40, 
P51, P116, P19). More importantly, the percentage of meta-analyses where the intervention 
performed better in Asia than Europe was 65% for overlapping meta-analyses but 83% for non-
overlapping meta-analyses. This suggests that the proportion of meta-analyses favouring Asia 
over Europe had not been exaggerated as a consequence of including overlapping meta-analyses.  
6.2.1.1.5: Summary of Pair-wise Comparison between Europe and Asia 
In summary, when investigating within and over meta-analyses, differences appear to exist 
between Europe and Asia in treatment effectiveness. Indeed, there was a statistically significant 
difference in the number of meta-analyses whose interventions, relative to controls, performed 
better in Asia than in Europe. This was confirmed by the global estimate of continental difference 
calculated for meta-analyses that reported treatment effect using RR. This also showed a 
statistically significant difference in treatment effect between Europe and Asia, with interventions 
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appearing to perform better in Asia. Moreover, by investigating the impact of overlapping meta-
analyses, we can be somewhat assured that such differences in treatment effect between Europe 
and Asia had not been created or exaggerated by the inclusion of overlapping meta-analyses.  
6.2.1.2: North America vs. Asia 
The meta-analyses on which this comparison was based were required to contain at least one 
North America trial and at least one Asia trial. Of the 95 relevant meta-analyses in the database, 
only 59 fulfilled this criterion and so could be used for this comparison.
50
 
Of the 59 meta-analyses, 25 had at least one trial in each continent with non-fatal data that would 
allow for separate estimates of treatment effect to be made for both North America and Asia. 
Tables 6.26–6.30 show the details of these meta-analyses.  
6.2.1.2.1: Meta-analyses Grouped according to Treatment Effect Measure for Non-Fatal 
Endpoints – North America versus Asia. 
As with the Europe versus Asia non-fatal comparison, the meta-analyses that contained non-fatal 
data have been grouped according to the treatment effect measure they used.  
6.2.1.2.1.1: Non-Fatal Endpoints for North America versus Asia Measured as Risk Ratios 
Eighteen of the 25 meta-analyses that reported non-fatal endpoints did so using RR. The details 
of these studies are summarised in Table 6.26. 
                                                 
50
 Some of these meta-analyses were used in the comparison between Europe and Asia while others were different 
meta-analyses. 
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Table 6.26: Meta-analyses with Non- Fatal Endpoints for North America vs. Asia. 
Effectiveness Measured by RR. 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(North 
Americ
a/Asia) 
RR 
estimate 
North 
America 
(95% CI) 
RR 
estimate 
Asia (95% 
CI) 
Best 
Region (p-
value of 
between-
continent 
difference) 
18 
[C12] 
Phosphodiesterase 
III inhibitors for 
HF 
Placebo Worsening 
heart failure 
6/2 0.92 
(0.83,1.02) 
0.52 
(0.27, 0.98) 
Asia 
(0.080) 
25 
[P94] 
Vasopressin for 
Cardiac arrest 
Epinephrine Failure of 
return of 
spontaneous 
circulation 
1/1 0.99 
(0.71, 1.39) 
0.59 
(0.38, 0.91) 
Asia 
(0.065) 
251 
[P167] 
Angiotensin 
Receptor Blockers 
for MI 
Placebo Risk of MI 1/1 1.49 
(0.06, 
35.96) 
1.03 
(0.04, 
24.70) 
Asia 
(0.774) 
48 
[P166] 
Vitamin-mineral 
supplements for 
CAD 
Placebo Restenosis 2/1 1.00 
(0.33,3.01) 
0.56 
(0.06, 5.31) 
Asia 
(0.424) 
96 
[P90] 
Adjunctive 
mechanical devices 
for Acute MI 
Standard care 
or stenting 
Distal 
embolisation 
1 /2 0.84 
(0.37, 1.90) 
0.40 
(0.21, 0.75) 
Asia 
(0.160) 
227 
[C4] 
Anti-arrhythmics 
after cardioversion 
of AF 
Placebo, 
drugs for rate 
control or no 
treatment 
AF 
Recurrence 
6/2 0.86 
(0.82, 0.89) 
0.85 
(0.70, 1.03) 
Asia 
(0.930) 
312 
[P124] 
Thiazolidinedione 
Therapy for 
Restenosis after 
Coronary Stent 
implantation 
Placebo or 
Standard 
Care 
Target Lesion 
Revascularisat
ion 
1/3 0.67 
(0.15, 2,98) 
 
0.28 
(0.14, 0.55) 
Asia 
(0.302) 
33 
[P97] 
Thrombectomy or 
Embolic protection 
devices with PCI 
for Acute MI 
PCI alone Target vessel 
revascularisati
on 
1 /2 5.00 
(0.00 
, 21379.8) 
0.66 
(0.02, 
21.39) 
Asia 
(0.662) 
 
200 
[P155] 
ACEI or ARB for 
prevention of AF 
Placebo, 
other 
antihypertens
ive therapy 
or treatment 
drug plus 
Irbesartan 
Development 
of AF 
1/1 0.22 
(0.02, 2.68) 
 
 
 
0.60 
(0.10, 3.76) 
North 
America 
(0.530) 
228 
[P6] 
Combination of 
ACEI plus 
Angiotensin 
Receptor Blocker 
ACEI alone Hypotension 1/1 3.05 
(0.39, 
24.15) 
8.14 
(1.04, 63.9) 
North 
America 
(0.510) 
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As for fatal endpoints, the best region was not calculated for some of the meta-analyses using RR 
as these meta-analyses had not specifically identified the intervention or control groups. As such, 
it was not possible to calculate the continent in which the intervention performed best since it was 
not clear what constituted the intervention. This was the case in two meta-analyses and details of 
these can be found in Table 6.27 
 
 
383 
[C41] 
NNPV for 
Cardiogenic 
Pulmonary Edema 
Standard 
Medical Care 
Endotracheal 
Intubation 
Rate 
1 /4 0.71 
(0.27, 1.89) 
0.37 
(0.23, 0.60) 
Asia 
(0.229) 
388 
[P101] 
Prophylactic 
steroids for 
cardiopulmonary 
bypass 
Placebo or 
standard care 
New onset AF 7/1 0.58 
(0.45, 0.75) 
1.25 
(0.49, 3.16) 
North 
America 
(0.121) 
51 
[C11] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo 30 day urgent 
revascularisati
on 
9/1 0.54 
(0.44, 0.67) 
2.74 
(0.12, 
63.63) 
North 
America 
(0.313) 
328 
[P108] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
Stroke 3/1 1.34 
(0.36, 5.05) 
0.35 
(0.01, 8.56) 
 
Asia 
(0.449) 
 
226 
[P125] 
Glycoprotein 
IIb/IIIa inhibitors 
for PCI 
Placebo or 
standard care 
MI within 30 
days 
7/1 0.63 
(0.56, 0.72) 
0.13 
(0.01, 2.38) 
Asia 
(0.287) 
 
55 
[P131] 
Clopidogrel Plus 
Aspirin for the 
Prevention of 
Vascular Events 
Antiplatelet 
Monotherapy 
Major 
Coronary 
Events 
1/1 0.74 
(0.57, 0.95) 
0.92 
(0.87, 0.97) 
North 
America 
(0.108) 
 
259 
[P102] 
Off pump CABG 
surgery 
On pump 
CABG 
surgery 
MI 4/1 1.34 
(0.47, 3.82) 
1.06 
(0.15, 7.36) 
Asia 
(0.836) 
153 
[P149] 
Amiodarone 
prophylaxis for 
cardiothoracic 
surgery 
Placebo Post-operative 
AF 
5/1 0.64 
(0.54, 0.77) 
0.36 
(0.18, 0.71) 
Asia 
(0.101) 
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Table 6.27: Meta-analyses with Non - Fatal Endpoints for North America vs. Asia that do 
not identify which Group is the Intervention and which the Control. Effectiveness 
Measured by RR. 
 
6.2.1.2.1.2: Non-Fatal Endpoints for North America versus Asia Measured as Odds Ratios 
Only one meta-analysis reporting a non-fatal endpoint used OR as its treatment effect measure. 
The details of this meta-analysis are provided in Table 6.28. 
Table 6.28: The Meta-analysis with Non-Fatal Endpoints for North America vs. Asia. 
Effectiveness measured by the OR. 
 
Article 
ref. no. 
Intervention 
1 
Intervention 
2  
Endpoint No. of trials 
(North 
America/Asia) 
RR 
estimate 
North 
America 
(95% CI) 
RR 
estimate 
Asia 
(95% CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
56 
[P24] 
PCI* CABG 
surgery* 
Stroke 3/1 0.39 
(0.14, 
1.08) 
0.20 
(0.01, 
4.78) 
Not Applic. 
(0.692) 
168 
[P140] 
Clopidogrel 
plus Aspirin 
for 
Cardiovascular 
Disease 
Placebo plus 
Aspirin 
MI 1/1 -0.26 
(-1.51, 
0.99) 
-0.15 
(-0.62, 
0.32) 
Not Applic. 
(0.871) 
 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(North 
America/
Asia) 
OR 
estimate 
North 
America 
(95% CI) 
OR 
estimate 
Asia 
(95% CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
27 
[P156] 
Amiodarone for 
prevention of 
AF 
Metoprolol, 
Placebo or 
Routine 
Treatment 
Prevention 
of Post 
Cardiac 
Surgery AF 
7/1 -0.67 
(-1.54, 
0.19) 
-1.31 
(-4.61, 
1.99) 
Asia 
(0.715) 
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6.2.1.2.1.3: Non-Fatal Endpoints for North America versus Asia Measured as Mean 
Differences. 
Only three meta-analyses used the MD as their treatment effect measure. Table 6.29 shows the 
details of these meta-analyses. 
Table 6.29: Meta-analyses with Non-Fatal Endpoints for North America vs. Asia. 
Effectiveness measured by the Mean Difference. 
 
 
One meta-analysis that reported non-fatal endpoints in terms of MD did not specifically identify 
its intervention group and control group. The details of this meta-analysis are provided in Table 
6.30. 
 
Article 
ref. 
no. 
Intervention Control Endpoint No. of 
trials 
(North 
America/
Asia) 
Mean 
difference 
estimate 
North 
America 
(95% CI) 
Mean 
Difference 
estimate 
Asia 
(95% CI) 
Best Region 
(p-value of 
between-
continent 
difference) 
6 
[P141] 
ACE inhibition  Placebo, 
convention
al 
treatment 
or no 
treatment 
Diastolic 
volume 
1/1 -13 
(-52.93, 
26.93) 
-1.8 
(-88.43, 
52.43) 
Asia 
(0.904) 
 
107 
[P95] 
Beta-Blocker 
Therapy for 
Heart Failure 
Placebo Mean 
Change in 
QoL score 
5/1 -0.05 
(-0.46, 0.36) 
-0.36 
(-4.19, 3.47) 
Asia 
(0.875) 
23 
[P14] 
PCI Optimal 
treatment 
Change in 
EF from 
baseline to 
follow up 
1/1 1.2 
(-11.85, 
14.25) 
4 
(-7.41, 
15.41) 
Asia 
(0.752) 
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Table 6.30: The Meta-analysis with Non - Fatal Endpoints for North America vs. Asia that 
does not identify which Group is the Intervention and which the Control. Effectiveness 
Measured by MD. 
 
6.2.1.2.2: Examination over all Meta-analyses for Non-Fatal Endpoints – North America 
versus Asia. 
Table 6.31 shows the number of meta-analyses, which had identified their intervention and 
control groups, which favoured each continent.  
Table 6.31: A Summary of the Number of Meta-analyses favouring either North America 
or Asia for Non-Fatal Endpoints. 
Total Number of Meta-
analyses 
Number of Meta-analyses 
with Interventions favouring 
North America (%) 
Number of Meta-analyses 
with Interventions favouring 
Asia (%) 
22 5 (23%) 17 (77%) 
 
This table shows that there were 17 meta-analyses where the intervention performed better in 
Asia than in North America and 5 where the intervention performed better in North America than 
Asia. As before, to examine the significance of this, a binomial sign test was conducted under the 
Article 
ref. no. 
Intervention 
1 
Intervention 
2  
Endpoint No. of trials 
(North 
America/Asia) 
MD 
estimate 
North 
America 
(95% CI) 
MD  
estimate 
Asia  
(95% CI) 
Best Region 
(p-value of 
difference) 
272 
[P165] 
Drugs, 
Behavioural 
therapy or 
Exercise for 
secondary 
prevention 
of Coronary 
artery 
disease 
Detraining, 
low intensity 
exercise, rest 
or no 
treatment 
Treatment 
outcome 
for time 
domain 
heart rate 
variability 
indices 
5/3 0.56 
(-0.31, 
1.42) 
0.33 
(-0.80, 
1.46) 
Not Applic. 
(0.750) 
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null hypothesis that the effectiveness of interventions, relative to the control, was the same in 
both North America and Asia. This indicated that there was a statistically significant difference in 
the effectiveness of interventions between North America and Asia (2-sided p value = 0.017). 
6.2.1.2.3: Global Estimates of Difference between North America and Asia. 
Global estimates of continental difference were calculated to see the average weighted difference 
in the effect of interventions between North America and Asia. For RR (18 meta-analyses), the 
mean log difference over all of the meta-analyses was 0.094 with 95% CIs of -0.094 and 0.182 
(2-sided p-value = 0.534) while for OR the mean difference was 0.231 with 95% CIS of -1.193 
and 1.655 (2-sided p-value = 0.715). For the meta-analyses using MD (3 meta-analyses) the mean 
difference overall was 0.174 with 95% CIs of -3.580 and 3.928 (2-sided p-value = 0.928). These 
results showed that there was insufficient evidence for a difference in overall treatment effect 
between North America and Asia over all of the included meta-analyses (which had identified 
their intervention and control groups), as none of these global estimates were statistically 
significant at the 5% level. 
6.2.1.2.4: Impact of Overlapping Meta-analyses 
For this comparison, it was found that there were six overlapping meta-analyses. These were C11 
and P125, P102 and P108, P149, and P156. There were also 16 non-overlapping meta-analyses 
(C12, P94, P167, P131 P166, P90, C4, P124, P97, P155, P6, C41, P101, P141, P95, and P14). 
The percentage of meta-analyses identified as overlapping, where the intervention performed 
better in Asia than North America, was 83% but was 75% for meta-analyses that were identified 
as non-overlapping. It was concluded, therefore, that the proportion of meta-analyses where the 
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interventions performed better in Asia over North America may have been inflated as a 
consequence of including duplicate trial results from overlapping meta-analyses. 
6.2.1.2.5: Summary of Pair-wise Comparison between North America and Asia 
In summary, this investigation within and over meta-analyses found some evidence to suggest 
that differences between North America and Asia in treatment effectiveness existed. This is 
because there was a statistically significant difference in the number of meta-analyses whose 
intervention, relative to controls, performed better in Asia than in North America. However, this 
result was not confirmed by the global estimates of continental difference, as none of these were 
statistically significant at the 5% level. Moreover, from the investigation concerning overlapping 
meta-analyses it was found that of the meta-analyses considered to be overlapping, 83% (5 out of 
6 meta-analyses) favoured Asia over North America, while for non-overlapping meta-analyses 
only 75% (12 out of 16 meta-analyses) favoured Asia. This suggests that, with regard to non-fatal 
endpoints, the large number of meta-analyses that had favoured Asia over North America (77% 
or 17 out of 22 meta-analyses) may have been inflated as a consequence of including overlapping 
meta-analyses. 
6.2.2: A Universal Comparison of Treatment Effectiveness Differences for 
Non-Fatal Endpoints. 
 By examining the individual trials per continent that were included in the meta-analyses, the 
existence of inter-continental differences in treatment effectiveness for non-fatal endpoints was 
explored further. The effect estimate from each relevant trial was standardised using the process 
reported in Chapter 4 and grouped according to continent. Each continent’s trial results were 
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plotted onto graphs to detect outliers and examine the spread of each continent’s trial results. The 
mean treatment effect estimate and its standard error were calculated for each continent and the 
results compared.  
As with the analysis with fatal endpoints, trial duplications were examined and removed.
51
 As 
can be seen from Table 6.32 there were originally 692 trials: 343 from Europe, 219 from North 
America and 67 from Asia. Of these, 118 were duplicated trials, which were removed from the 
analysis leaving 511 trials to be analysed. 
Table 6.32: Duplicate and Non-Duplicated Trials in each continent that had provided Non-
Fatal Data. 
 
6.2.2.1: Findings for the Universal Comparison – Non-Fatal Endpoints 
Figures 6.7-6.9 show the spread of each continent’s individual trial results for non-fatal 
endpoints. Initially, the graphs were used to detect outliers in each continent but for non-fatal 
endpoints, no outliers were found (see Figures 6.6-6.8). 
                                                 
51
 As with fatal endpoints, the analysis was also conducted with trial duplications included but the results became 
redundant when the analysis was conducted with duplications removed. Therefore, it is not reported. 
Continent Number of 
Trials in 
Original 
Analysis 
Number of 
Duplicated 
Trials (%) 
Number of 
Trials 
Duplicated 
once 
Number of 
Trials 
Duplicated 
more than 
Once 
Remaining 
Trials when 
Duplications 
Removed 
Europe 343 62 30 13 281 
North America 219 45 18 12 174 
Asia 67  11 10 1 56 
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FIGURE 6.6: THE SPREAD OF EUROPEAN TRIAL TREATMENT EFFECT ESTIMATES FOR 
NON-FATAL ENDPOINTS 
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FIGURE 6.7: THE SPREAD OF NORTH AMERICAN TRIAL TREATMENT EFFECT 
ESTIMATES FOR NON-FATAL ENDPOINTS 
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FIGURE 6.8: THE SPREAD OF ASIAN TRIAL TREATMENT EFFECT ESTIMATES 
FOR NON-FATAL ENDPOINTS 
 
Figures 6.6-6.8 were then used to observe the spread of each continent’s individual trial results in 
relation to non-fatal endpoints. This proved again to provide interesting findings regarding inter-
continental differences in treatment effectiveness since it was observed, when comparing these 
three figures, that Asian trials produced more positive trial results compared to Europe and North 
America. 
Table 6.33 shows the summary statistics calculated for each continent: the mean effect estimate 
and its standard error, each continent’s z-score and its 2-sided p-value. It also provides the 
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number of positive trials found in each continent and the 2-sided p-value for the binomial sign 
test that was conducted. 
Table 6.33: Summary Statistics for each Continent for Non-Fatal Endpoints. 
 Europe North America Asia 
Mean Effect 
Estimate 
-0.163 0.085 -0.297 
Standard Error 0.074 0.118 0.125 
Z-Score -2.22 0.72 -2.38 
P-value 0.026 0.472 0.017 
Number of Trials (% 
of Positive Trials) 
281 (55%) 174 (49%) 56 (59%) 
Sign Test P-Value 0.121 0.940 0.229 
 
The mean effect sizes between continents did differ. In North America, the mean treatment effect 
estimate (Mean = 0.085, SE = 0.118) favoured the control, whereas in Europe (Mean = -0.163, 
SE = 0.074) and Asia (Mean = -0.297, SE = 0.125) the intervention was more effective. This was 
confirmed by the 2-sided p-value calculated for the z-scores in Europe (2-sided p-value = 0.026) 
and Asia (p-value = 0.017). In addition, Asia provided the largest mean effect estimate, which 
suggested that interventions, relative to controls, performed better in Asia than in Europe and 
North America. However, this was not supported by any of the binomial signs tests that were 
conducted for each continent, as none was statistically significant at the 5% level. 
A visual examination of Figure 6.9 provided further evidence that the effectiveness of 
interventions differed between the three continents investigated since the controls appeared to be 
more effective in North America, while the interventions appeared more effective in Europe and 
Asia. This was further confirmed by the  statistic, which showed that the percentage of total 
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variation due to heterogeneity rather than chance was 62%. However, further examination of the 
forest plot suggested that the level of heterogeneity between the three continents was moderate as 
there was some degree of overlap in confidence intervals.  
FIGURE 6.9; A FOREST PLOT OF THE EFFECTIVENESS OF INTERVENTIONS IN 
EUROPE, NORTH AMERICA AND ASIA FOR NON-FATAL ENDPOINTS. 
Study or Subgroup
Asia
Europe
North America
Total (95% CI)
Heterogeneity: Chi² = 5.30, df = 2 (P = 0.07); I² = 62%
Test for overall effect: Z = 2.39 (P = 0.02)
Mean Difference
-0.297
-0.163
0.085
SE
0.125
0.074
0.118
Weight
20.1%
57.3%
22.6%
100.0%
IV, Fixed, 95% CI
-0.30 [-0.54, -0.05]
-0.16 [-0.31, -0.02]
0.09 [-0.15, 0.32]
-0.13 [-0.24, -0.02]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours experimental Favours control
 
Two independent samples t-tests were conducted between Europe and Asia and North America 
and Asia to confirm or refute these findings. These compared the effect of interventions, relative 
to controls, in Europe and Asia and North America and Asia. The t-test for Europe versus Asia 
revealed the effectiveness of interventions, relative to controls, did not differ significantly 
between Europe (Mean = -0.163, SE=0.074) and Asia (Mean = -0.297, SE = 0.125) (t (97) = 
0.9225, 2-sided p-value = 0.359). This contrasted with the independent samples t-test results for 
North America versus Asia where interventions, relative to controls, performed better in Asia 
(Mean = -0.297, SE = 0.125) than in North America (Mean = 0.085, SE = 0.118) with the 
difference being statistically significant (t(157) = 2.222, 2-sided p-value = 0.028). It was 
concluded, therefore, that there were statistically significant differences in the effect of 
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interventions between North America and Asia for non-fatal endpoints, with interventions 
performing better in Asia than in North America. 
6.2.3: Types of Intervention Prone to Inter-Continental Differences in 
Treatment Effectiveness - Non-Fatal Endpoints 
As there was some evidence that differences in the clinical effectiveness of interventions existed, 
it was important to investigate whether any of the intervention types were prone to showing inter-
continental differences in treatment effect. This was carried out using the same procedure as for 
fatal endpoint data (See section 6.1.3). The types of intervention were Drug, Device, Surgery, and 
Lifestyle. Management interventions were not included as there were no Asian trials involving 
these types of intervention with non-fatal data and so it was not possible to make comparisons. 
6.2.3.1: Europe vs. Asia 
First, the types of intervention prone to differences in treatment effect were examined over and 
within the meta-analyses that provided non-fatal data for the Europe versus Asia comparison. The 
meta-analyses were grouped according to the type of intervention investigated and placed into 
tables. Table 6.34 shows the meta-analyses included in the Europe versus Asia pair-wise 
comparison that investigated drug interventions. 
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Table 6.34: Meta-analyses Investigating Drugs with their Z-statistic for the Difference in 
Treatment Effect between Europe and Asia for Non-Fatal Endpoints. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/
Asia) 
Pooled 
Estimate 
for 
Europe 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect  
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
226 
[P125] 
Glycoprotein 
IIb/IIIa 
Antagonists 
RR 4/1 0.86 
(0.58, 
1.28) 
0.13 
(0.01, 
2.38) 
1.890 
(-1.04, 
4.82) 
1.264 0.206 
247 
[C40] 
Stem Cell 
Treatment 
RR 5/1 1.15 
(0.71, 
1.87) 
0.20 
(0.01, 
3.97) 
1.753 
(-1.27, 
4.78) 
1.136 0.256 
51 
[C11] 
Platelet 
Glycoprotein 
IIb/IIIa 
Blockers 
RR 5/1 0.56 
(0.35, 
0.88) 
2.74 
(0.12, 
63.63) 
-1.591 
(-4.77, 
1.59) 
-0.981 0.327 
188 
[P25] 
GCSF 
Therapy 
RR 4/1 0.97 
(0.61, 
1.53) 
2.75 
(0.24, 
31.72) 
-1.045 
(-3.53, 
1.44) 
-0.823 0.410 
237 
[P19] 
Intracoronary 
Cell Therapy 
RR 6/1 0.99 
(0.70, 
1.43) 
0.36 
(0.02, 
8.41) 
1.027 
(-2.15, 
4.21) 
0.633 0.527 
18 
[C12] 
Phosphodiest
erase III 
Inhibitors 
RR 3/2 1.44 
(1.00, 
2.06) 
0.52 
(0.27, 
0.98) 
1.022 
(0.29, 
1.75) 
2.746 0.006 
153 
[P149] 
Amiodarone 
prophylaxis 
RR 6/1 0.70 
(0.55, 
0.90) 
0.36 
(0.18, 
0.71) 
0.684 
(-0.04, 
1.41) 
1.836 0.066 
25 
[P94] 
Vasopressin RR 2/1 1.03 
(0.97, 
1.11) 
0.59 
(0.38, 
0.91) 
0.556 
(0.19, 
0.99) 
2.488 0.013 
388 
[P101] 
Steroid Use RR 3/1 0.78 
(0.62, 
0.98) 
1.25 
(0.49, 
3.16) 
-0.467 
(-1.42, 
0.49) 
-0.958 0.338 
176 
[C39] 
Calcium 
Channel 
Antagonists 
RR 2/1 1.54 
(0.58, 
4.06) 
0.97 
(0.39, 
2.41) 
0.462 
(-0.87, 
1.80) 
0.680 0.497 
200 
[P155] 
Angiotensin-
converting 
Enzymes or 
Receptor 
Blockers 
RR 6/1 0.93 
(0.68, 
1.27) 
0.60 
(0.10, 
3.76) 
0.434 
(-1.42, 
2.29) 
0.458 0.647 
165 
[P130] 
Angiotensin-
converting 
Enzymes or 
Receptor 
Blockers 
RR 6/1 0.93 
(0.86, 
1.00) 
0.60 
(0.37, 
0.97) 
0.432 
(-0.05, 
0.92) 
1.751 0.080 
4 
[P2] 
GCSF 
Therapy 
RR 4/1 0.91 
(0.58, 
1.41) 
1.22 
(0.08, 
18.20) 
-0.300 
(-3.04, 
2.44) 
-0.215 0.830 
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400 
[P5] 
Stem Cell 
Treatment 
RR 4/2 1.00 
(0.63, 
1.59) 
0/83 
(0.40, 
1.74) 
0.187 
(-0.68, 
1.05) 
0.423 0.672 
232 
[C10] 
Magnesium RR 4/1 0.79 
(0.65, 
0.97) 
0.66 
(0.39, 
1.10) 
0.185 
(-0.37, 
0.74) 
0.656 0.512 
227 
[C4] 
Anti-
arrhythmics 
RR 11/2 0.75 
(0.71, 
0.79) 
0.85 
(0.70, 
1.03) 
-0.124 
(-0.32, 
0.07) 
-1.225 0.220 
27 
[P156] 
Amiodarone OR 5/1 0.47 
(0.10, 
2.12) 
0.27 
(0.01, 
7.34) 
0.548 
(-3.09, 
4.18) 
0.296 0.767 
6 
[P141] 
ACE 
Inhibitors 
MD 6/1 -2.37 
(-15.95, 
11.21) 
-18 
(-88.43, 
52.53) 
 
15.632 
(-56.09, 
87.36) 
0.427 0.669 
184 
[P51] 
Bone 
Marrow Cell 
Therapy 
MD 2/1 3.41 
(-11.33, 
18.17) 
13 
(4.96, 
21.04) 
 
-9.583 
(-26.38, 
7.22) 
-1.118 0.264 
4 
[P116] 
Bone 
Marrow Cell 
Therapy 
MD 7/5 2.10 
(-2.26, 
6.45) 
8.15 
(-
0.19,16.4
8) 
-6.050 
(-15.45, 
3.35) 
-1.261 0.207 
207 
[P146] 
Bone 
Marrow Cell 
Therapy 
MD 5/1 2.60 
(-2.25, 
7.45) 
6.7 
(-11.61, 
25.01) 
-4.100 
(-23.04, 
14.84) 
-0.424 0.671 
208 
[P17] 
GCSF 
Therapy 
MD 4/3 0.47 
(-7.24, 
8.18) 
3.33 
(-9.17, 
15.83) 
-2.857 
(-17.55, 
11.83) 
-0.381 0.703 
107 
[P95] 
Beta-Blocker 
Therapy 
MD 1/1 -0.28 
(-1.69, 
1.13) 
-0.36 
(-4.19, 
3.47) 
0.080 
(-4.00, 
4.16) 
0.038 0.853 
 
As can be seen, two meta-analyses investigating drugs found a statistically significant difference 
in treatment effect between Europe and Asia. The first  meta-analysis (C12 (18)) compared 
Phosphodiesterase III Inhibitors (the intervention) to a placebo (the control), with 
Phosphodiesterase III Inhibitors performing better, with respect to a worsening in heart failure, in 
Asia than in Europe. The 2-sided p-value for this Z-statistic was 0.006. The second meta-analysis 
was P94 (25), in which Vasopressin (the intervention) was compared with Epinephrine (the 
control). In this meta-analysis, Vasopressin was found to perform better, with respect to the 
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failure of return of spontaneous circulation, in Asia than in Europe. The p-value for this 
intervention was 0.013.  
However, when looking over all of the meta-analyses investigating drug interventions, no clear 
pattern of statistically significant differences was found to suggest that this type of intervention 
was prone to inter-continental differences in treatment effect. 
Table 6.35 provides the details of the meta-analyses that investigated medical devices. 
Table 6.35: Meta-analyses Investigating Medical Devices with their Z-statistic for the 
Difference in Treatment Effect between Europe and Asia for Non-Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/
Asia) 
Pooled 
Estimate 
for 
Europe 
(95% 
CIs) 
Pooled 
Estimate 
for Asia 
(95% 
CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
96 
[P90] 
Adjunctive 
Mechanical 
Devices 
RR 4/2 0.65 
(0.37, 
1.13) 
0.40 
(0.21, 
0.75) 
0.485 
(-0.35, 
1.32) 
1.138 0.255 
383 
[C41] 
Non-Invasive 
Positive 
Pressure 
Ventilation 
RR 4/1 0.86 
(0.58, 
1.28) 
0.13 
(0.01, 
2.38) 
-0.600 
(-0.13, 
1.33) 
1.619 0.206 
33 
[P97] 
Thrombectomy 
or Embolic 
Protection 
Devices 
RR 6/2 0.94 
(0.30, 
2.95) 
0.66 
(0.02, 
21.39) 
0.345 
(-3.32, 
4.01) 
0.185 0.853 
 
As can be seen, none of the meta-analyses investigating medical devices found a statistically 
significant difference in treatment effect between Europe and Asia. Therefore, no clear pattern of 
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statistically significant differences was found to suggest that medical devices were prone to 
differences in treatment effect. 
Table 6.36 provides the details of the meta-analyses that investigated surgical interventions. 
Table 6.36: Meta-analyses Investigating Surgical Interventions with their Z-statistic for the 
Difference in Treatment Effect between Europe and Asia for Non-Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/
Asia) 
Pooled 
Estimate 
for 
Europe 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
191 
[P15] 
PCI RR 2/1 1.72 
(0.52, 
5.71) 
0.38 
(0.11, 
1.37) 
1.512 
(-0.24, 
3.27 
1.687 0.092 
259 
[P102] 
Off-Pump 
Coronary 
Artery Bypass 
Surgery 
RR 15/1 0.74 
(0.46, 
1.19) 
1.06 
(0.15, 
7.36) 
-0.364 
(-2.36, 
1.63) 
-0.357 0.721 
2 
[P7] 
PCI RR 5/1 0.49 
(0.31, 
0.77) 
0.38 
(0.11, 
1.37) 
0.253 
(-1.10, 
1.61) 
0.366 0.715 
328 
[P108] 
Off-Pump 
Coronary 
Artery Bypass 
Surgery 
RR 9/1 0.41 
(0.18, 
0.95) 
0.35 
(0.01, 
8.56) 
0.153 
(-3.14, 
3.45) 
0.091 0.928 
23 
[P14] 
Late PCI MD 1/1 4 
(-1.55, 
9.55) 
4 
(-7.41, 
15.41) 
0.000 
(-12.69, 
12.69) 
0.00 1 
 
Again, it can be seen that no meta-analyses found the difference in treatment effect between 
Europe and Asia to be statistically significant at the 5% level. As such, no clear pattern of 
statistically significant differences was found to suggest that this type of intervention was prone 
to inter-continental differences in treatment effect. 
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Table 6.37 provides the details of the meta-analysis that investigated a lifestyle intervention. 
Table 6.37: Meta-analyses Investigating Lifestyle Interventions with their Z-statistic for the 
Difference in Treatment Effect between Europe and Asia for Non-Fatal Endpoints. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(Europe/
Asia) 
Pooled 
Estimate 
for 
Europe 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect  
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
48 
[P166] 
Vitamin-mineral 
Supplementation 
RR 2/1 1.05 
(0.43, 
2.61) 
0.56 
(0.06, 
5.31) 
0.633 
(-1.79, 
3.06) 
0.512 0.609 
 
It shows that there was no statistically significant difference between Europe and Asia in 
treatment effect for vitamin mineral supplementation when non-fatal endpoints were considered. 
As such, there was no evidence that this intervention was prone to between-continental 
differences in treatment effect. 
As no group of interventions was found to show a clear pattern of statistically significant 
differences, the types of intervention prone to differences between Europe and Asia could not be 
identified. Furthermore, as there were 29 meta-analyses overall that provided non-fatal data, the 
finding that there were two meta-analyses among these that were statistically significant at the 
5% level is not more than would be expected by random chance. Therefore, there was insufficient 
evidence to conclude which types of intervention were likely to show differences in treatment 
effect between Europe and Asia for non-fatal endpoints. 
  
229 
 
To investigate further, the trials from each meta-analysis were analysed with independent 
samples t-tests conducted for each type of intervention: Drug, Device, Surgery and Lifestyle. 
Table 6.38 shows the number of trials from each continent that investigated each intervention 
type and provided non-fatal data. It also provides the mean effect estimate and its standard error 
per continent for each intervention type and the 2-sided p-value for the t-tests that were 
conducted. 
Table 6.38: Summary Statistics for Intervention Types for Non-Fatal Endpoints – Europe 
versus Asia. 
Intervention 
Type 
Number 
of 
European 
Trials 
European 
Mean 
Effect 
Estimate 
Standard 
Error 
Number 
of Asian 
Trials 
Asian 
Mean 
Effect 
Estimate 
Standard 
Error 
T-Test 
p-value 
Drug 122 -0.119 0.119 26 -0.287 0.231 0.523 
Device 38 -0.344 0.205 15 -0.433 0.162 0.735 
Surgery 48 -0.023 0.120 12 -0.199 0.225 0.499 
Lifestyle 38 -0.116 0.154 3 -0.093 0.332 0.956 
 
The table shows that the number of trials investigating each intervention type differed between 
continents, as did the mean effect estimate for each continent. The 2-sided p-values for the t-tests 
also show that the difference in treatment effect between Europe and Asia was not statistically 
significant at the 5% level for any of the intervention types. The results of the t-tests for each 
intervention type are discussed further below. 
6.2.3.1.1: Drug Interventions 
The mean difference between continents for drug therapies was 0.168, showing a small effect 
size (d = 0.21), with 95% CIs of -0.358 to 0694. An independent samples t-test revealed that 
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there was not a statistically significant difference in the effectiveness of drug therapies, relative to 
controls, between Europe (Mean = -0.119, SE= 0.119) and Asia (Mean = -0.287, SE = 0.231) (t 
(39) = 0.6465, 2-sided p-value = 0.523). Therefore, there was insufficient evidence for the 
existence of a difference in the effect of drug interventions between Europe and Asia. 
6.2.3.1.2: Device Interventions 
The mean difference for medical devices was found to be -0.089, representing a small effect size 
(d=0.10), with 95% CIs of -0.436 to 0.5614. An independent samples t-test revealed that there 
was not a statistically significant difference in the effect of medical devices between Europe 
(Mean = -0.344, SE=0.205) and Asia (Mean = -0.433, SE = 0.162), (t (48) = 0.3406, 2-sided p-
value =0.735). As such, it was again concluded that there was not sufficient evidence for the 
existence of a difference in the effect of medical devices between Europe and Asia. 
6.2.3.1.3: Surgical Interventions 
The mean difference between continents for surgical interventions was 0.176, which is a small-
medium effect size (d=0.33), with 95% CIs of -0.362 to 0.714. An independent samples t-test 
revealed that there was not a statistically significant difference in the effect of surgical 
interventions, relative to controls, between Europe (Mean= -0.023, SE = 0.120) and Asia (Mean 
= -0.199, SE = 0.225) (t(17)= 0.6902, 2-sided  p-value =0.499). Therefore, there was a lack of 
evidence for the existence of a difference in the effect of surgical interventions, relative to 
controls, between Europe and Asia. 
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6.2.3.1.4: Lifestyle Interventions 
The mean difference between continents for lifestyle interventions was found to be -0.023, a 
small effect size (d=0.13), with 95% CIs of -1.598 to 1.552. An independent samples t-test 
revealed that there was not a statistically significant difference in the effect of lifestyle 
interventions, relative to controls, between Europe (Mean = -0.116, SE = 0.154) and Asia (Mean 
= -0.093, SE = 0.332), (t(2) = 0.0628, 2-sided  p=0.956). Therefore, there was insufficient  
evidence for the existence of a difference in the effectiveness of lifestyle interventions between 
these two continents. 
6.2.3.2: North America vs. Asia 
As with the previous comparison, the types of intervention prone to between-continental 
differences in treatment effect were first examined over and within meta-analyses. Table 6.39 
shows the meta-analyses that investigated drug therapies and had non-fatal data for both North 
America and Asia. 
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Table 6.39: Meta-analyses Investigating Drugs with their Z-statistic for the Difference in 
Treatment Effectiveness between North America and Asia for Non-Fatal Data. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials (N. 
Amer./ 
Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
51 
[C11] 
Glycoprotein 
IIb/IIIa Antagonists 
RR 9/1 0.54 
(0.44, 0.67) 
2.74 
(0.12, 
63,63) 
-1.6224 
(-4.77,1.53) 
-1.009 0.313 
226 
[P125] 
Glycoprotein 
IIb/IIIa Antagonists 
RR 7/1 0.63 
(0.56, 0.72) 
0.13 
(0.01, 
2.38) 
1.5784 
(-1.33, 4.48) 
1.064 0.287 
200 
[P155] 
ACEI’s or ARB’s RR 1/1 0.22 
(0.02, 2.68) 
0.60 
(0.10, 
3.76) 
-0.9859 
(-4.07, 2.09) 
-0.627 0.530 
228 
[P6] 
ACEI’s plus ARB RR 1/1 3.05 
(0.39, 
24.15) 
8.14 
(1.04, 
63.9) 
-0.9805 
(-3.90, 1.94) 
-0.658 0.510 
312 
[P124] 
Thiazolidinedione 
Therapy 
RR 1/3 0.67 
(0.15, 2.98) 
0.28 
(0.14, 
0.55) 
0.8654 
(-0.78, 2.51) 
1.033 0.302 
388 
[P101] 
Steroid Use RR 7/1 0.58 
(0.45, 0.75) 
1.25 
(0.49, 
3.16) 
-0.7625 
(-1.73,0.20) 
-1.549 0.121 
153 
[P149] 
Amiodarone 
prophylaxis 
RR 5/1 0.64 
(0.54, 0.77) 
0.36 
(0.18, 
0.71) 
0.5936 
(-0.12, 1.30) 
1.638 0.101 
18 
[C12] 
Phosphodiesterase 
III Inhibitors 
RR 6/2 0.92 
(0.83, 1.02) 
0.52 
(0.27, 
0.98) 
0.5746 
(-0.07,1.22) 
1.752 0.080 
25 
[P94] 
Vasopressin RR 1/1 0.99 
(0.71, 1.39) 
0.59 
(0.38, 
0.91) 
0.5165 
(-0.03, 1.06) 
1.848 0.065 
251 
[P167] 
ARB RR 1/1 1.49 
(0.06, 
35.96) 
1.03 
(0.04, 
24.70) 
0.3662 
(-4.13, 4.86) 
0.160 0.774 
55 
[P131] 
Clopidogrel plus 
Aspirin 
RR 1/1 0.74 
(0.57, 0.95) 
0.92 
(0.87, 
0.97) 
-0.2175 
(-0.48, 0.05) 
-1.606 0.108 
227 
[C4] 
Anti-arrhythmics RR 6/2 0.86 
(0.82, 0.89) 
0.85 
(0.70, 
1.03) 
0.0087 
(-0.19, 0.20) 
0.087 0.930 
27 
[P156] 
Amiodarone OR 7/1 0.51 
(0.21, 1.21) 
0.27 
(0.01, 
7.34) 
 
0.63(-2.78, 
4.05) 
0.365 0.715 
6 
[P141] 
ACE Inhibitors MD 1/1 -13 
(-52.93, 
26.93) 
-1.8 
(-88.43, 
52.43) 
5 
(-75.96, 
85.96) 
0.121 0.904 
107 
[P95] 
Beta-blocker 
Therapy 
MD 5/1 -0.05 
(-0.46, 0.36) 
-0.36 
(-4.19, 
3.47) 
0.310 
(-3.54, 4.16) 
0.158 0.875 
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As can be seen, none of the meta-analyses investigating drugs found a statistically significant 
difference in treatment effect. Therefore, no clear pattern of statistically significant differences 
was found to suggest that drug therapies were prone to between-continental differences in 
treatment effect. 
Table 6.40 shows the meta-analyses that investigated medical devices. 
Table 6.40: Meta-analyses Investigating Medical Devices with their Z-statistic for the 
Difference in Treatment Effectiveness between North America and Asia for Non-Fatal 
Data. 
 
As Table 6.40 shows, none of the meta-analyses that investigated medical devices found the 
difference in treatment effect between North America and Asia to be statistically significant at 
the 5% level. As such, no clear pattern was identified to show these types of intervention as being 
prone to between-continental differences. 
Table 6.41 shows the meta-analyses that investigated surgical interventions. 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(N. 
Amer./ 
Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect  
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
33 
[P97] 
Thrombectomy 
or Embolic 
Protection 
Devices 
RR 1/2 5.00 
(0.00, 
21379.8) 
0.66 
(0.02, 
21.39) 
2.0211 
(-7.03, 
11.08) 
0.437 0.662 
96 
[P90] 
Adjunctive 
Mechanical 
Devices 
RR 1/2 0.84 
(0.37, 
1.90) 
0.40 
(0.21, 
0.75) 
0.7379 
(-0.29, 
1.77) 
1.406 0.160 
383 
[C41] 
Non-Invasive 
Positive 
Pressure 
Ventilation 
RR 1/4 0.71 
(0.27, 
1.89) 
0.37 
(0.23, 
0.60) 
0.6649 
(-0.42, 
1.75) 
1.202 0.229 
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Table 6.41: Meta-analysis Investigating Surgical Interventions with the Z-statistic for the 
Difference in Treatment Effectiveness between North America and Asia for Non-Fatal 
Data. 
Again, it was found that the difference in treatment effect was not statistically significant in any 
of the meta-analyses. As such, no clear pattern of statistically significant differences was found to 
suggest that surgical interventions were prone to differences in treatment effect between North 
America and Asia. 
Table 6.42 shows the meta-analysis that investigated a lifestyle intervention. 
Table 6.42: Meta-analysis Investigating a Lifestyle Intervention with its Z-statistic for the 
Difference in Treatment Effectiveness between North America and Asia for Non-Fatal 
Data. 
 
Meta-
analysis 
Ref. No. 
Intervention Treatment 
Effect 
Measure 
No. of 
Trials 
(N. 
Amer./ 
Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% 
CIs) 
Difference 
in 
Treatment 
Effect 
(95% CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
328 
[P108] 
Off-pump 
Surgery 
RR 3/1 1.34 
(0.36, 
5.05) 
0.35 
(0.01, 
8.56) 
1.3323 
(-2.12, 
4.78) 
0.757 0.449 
259 
[P102] 
Off-Pump 
Surgery 
RR 4/1 1.34 
(0.47, 
3.82) 
1.06 
(0.15, 
7.36) 
0.2323 
(-1.97, 
2.43) 
0.207 0.836 
23 
[P14] 
Late PCI MD 1/1 1.2 
(-11.85, 
14.25) 
4 
(-7.41, 
15.41) 
-2.800 
(-20.13, 
14.53) 
-0.317 0.752 
Meta-
analysis 
Ref. No. 
Intervention Treatmen
t Effect 
Measure 
No. of 
Trials (N. 
Amer./ 
Asia) 
Pooled 
Estimate 
for North 
America 
(95% CIs) 
Pooled 
Estimate 
for Asia 
(95% CIs) 
Difference 
in 
Treatment 
Effect (95% 
CIs) 
Z-
Statistic 
2-sided p-
value of 
difference 
48 
[P166] 
Vitamin-Mineral 
Supplementation 
RR 2/1 1.00 
(0.33, 3.01) 
0.56 
(0.06, 
5.31) 
0.5804 
(-1.92, 
3.08) 
0.454 0.424 
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As can be seen, the difference in treatment effect between North America and Asia for Vitamin-
mineral supplementation was not statistically significant at the 5% level. Therefore, there was no 
evidence that this lifestyle intervention was prone to between-continental differences in treatment 
effect.  
As no group of interventions could be identified as showing a clear pattern of statistically 
significant differences in treatment effect, the types of intervention prone to differences in 
treatment effect between North America and Asia could not be identified for non-fatal endpoints.  
To explore further, each continent’s trial results were examined with independent samples t-tests 
conducted for each type of intervention: Drug, Device, Surgery and Lifestyle. Table 6.43 shows 
the number of trials from each continent that investigated each intervention type and provided 
non-fatal data. It also provides the mean effect estimate and its standard error per continent for 
each intervention type and the 2-sided p-value for the t-tests that were conducted. 
Table 6.43: Summary Statistics for Intervention Types for Non-Fatal Endpoints –North 
America versus Asia 
Intervention 
Type 
Number 
of North 
American 
Trials 
North 
America 
Mean 
Effect 
Estimate 
Standard 
Error 
Number 
of Asian 
Trials 
Asian 
Mean 
Effect 
Estimate 
Standard 
Error 
T-Test 
p-value 
Drug 90 -0.015 0.171 26 -0.287 0.231 0.348 
Device 13 0.691 0.640 15 -0.433 0.162 0.113 
Surgery 9 0.229 0.259 12 -0.199 0.225 0.229 
Lifestyle 26 0.385 0.221 3 -0.093 0.332 0.297 
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The number of trials investigating each intervention type differed between continents, as did the 
mean effect estimate for each continent. The 2-sided p-values for the t-tests show that the 
difference in treatment effect between North America and Asia was not statistically significant at 
the 5% level for any of the intervention types. The results of the t-tests, for each intervention 
type, are discussed further below. 
6.2.3.2.1: Drug Interventions 
The mean difference between continents for drug therapies was 0.272, which is a large effect size 
(d = 3.21), with 95% CIs of -0.304 to 0.848. An independent samples t-test showed that there was 
no statistically significant difference in the effect of drug interventions, relative to controls, 
between North America (Mean = -0.015, SE=0.171) and Asia (Mean = -0.287, SE = 0.231): t(55) 
= 0.9464, 2-sided p-value=0.348. Therefore, there was insufficient evidence for the existence of a 
difference in treatment effect for drug interventions between North America and Asia. 
6.2.3.2.2: Device Interventions 
The mean difference for medical devices was found to be 1.124, showing a large effect size (d = 
10.16), with 95% CIs of -0.302 to 2.550. An independent samples t-test found this difference 
between North America (Mean = 0.691, SE = 0.640) and Asia (Mean = -0.433, SE=0.162) to be 
non-significant (t (13.) =1.703, 2-sided p-value =0.113). Thus, it was concluded that there was 
insufficient evidence for a difference in treatment effect for medical devices between North 
America and Asia. 
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6.2.3.2.3: Surgical Interventions. 
The mean difference between continents for surgical interventions was 0.428, which is a large 
effect size (d = 5.21), with 95% CIs of -0.296 to 1.152. An independent samples t-test revealed 
that there was no statistically significant difference in the effect of surgical interventions, relative 
to controls, between North America (Mean = 0.229, SE = 0.259) and Asia (Mean = -0.199, SE = 
0.225): t (17) =1.248, 2-sided p-value =0.229. This suggested that there was currently insufficient 
evidence that the effect of surgical interventions differed between North America and Asia. 
6.2.3.2.4: Lifestyle Interventions 
The mean difference for lifestyle interventions was 0.478, representing a large effect size (d = 
4.40), with 95% CIs of -0.629 to 1.586. An independent samples t-test showed that there was not 
a statistically significant difference in the effect of these types of intervention between North 
America (Mean = 0.385, SE = 0.221) and Asia (Mean = -0.093, SE = 0.332): t (4) = 1.1985, 2-
sided p-value =0.297. Again, it was concluded that there was insufficient evidence for any 
differences in the effect of lifestyle interventions between North America and Asia. 
6.2.3.3: Summary of the Types of Intervention Prone to Inter-Continental Differences 
From the investigation conducted over and within meta-analyses, the types of intervention prone 
to show between-continental differences in treatment effect could not be identified for either pair-
wise comparison. This was because, for both Europe versus Asia and North America versus Asia, 
no clear pattern of statistically significant differences was identified for any type of intervention. 
This was supported by the investigation conducted over trials. In this, none of the t-tests 
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(conducted for each intervention type) showed statistically significant results for Europe versus 
Asia or North America versus Asia. 
6.3: Conclusion. 
This chapter provides some evidence to suggest that inter-continental differences in treatment 
effect exist when both fatal and non-fatal endpoints are considered.  
 For fatal endpoints, the findings suggest that there is some evidence for the existence of a 
difference in treatment effect between continents, with interventions performing better in Asia 
than in Europe and North America. Furthermore, when looking at different Asian countries from 
which data was available, the observations suggested that Japanese trials produced more positive 
trial results compared to other Asian countries. From investigating the types of intervention likely 
to show such differences, the results for fatal endpoints revealed that medical devices may be 
prone to showing inter-continental differences in treatment effect. 
For non-fatal endpoints, the findings suggested that interventions performed better in Asia than in 
both Europe and North America, with both pair-wise comparisons finding statistically significant 
results. However, the results for the analyses conducted over meta-analyses between North 
America and Asia should be interpreted with caution, since these results may have been inflated 
as a consequence of including overlapping meta-analyses. Furthermore, for both the North 
America versus Asia and the Europe versus Asia comparisons, the types of intervention prone to 
differences in treatment effect could not be identified. 
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To conclude, this analysis has shown the existence of some inter-continental differences in 
treatment effectiveness; in particular, differences exist with regard to fatal endpoints. Since this 
result could not have been a consequence of the endpoint’s subjectivity, as is the case for non-
fatal endpoints, it needs to be investigated further. It is important to try to discover an explanation 
for this as it is possible that this result has the potential to impact on the extrapolation of clinical 
trial results between continents. 
As the results for fatal endpoints for Japan were unexpected, especially the finding that Japan 
produced a high proportion of positive trial results, it was important to investigate further in order 
to determine if there was a bias among Japanese trials that led to the true effect of the 
interventions being overestimated. Investigation of the influence of trial quality has become a 
standard procedure in meta-analytic approaches since the conclusions they draw from data cannot 
be trusted if the raw material is unsound (Juni, Altman & Egger, 2001). As was shown in Figure 
6.5, the Japanese trials were small. According to Egger et al (2003), small-scale trials are, in most 
cases, conducted and analysed with less methodological rigour than larger trials, resulting in an 
exaggeration of treatment effect. This points to trial quality as a potentially significant factor in 
producing the fatal endpoint findings. In other words, if all the Japanese trials suffered from low 
methodological rigour on account of their small size, they would be more likely to produce the 
positive trial results that were found. An exploratory study of the quality of the Japanese trials 
was therefore undertaken. 
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CHAPTER 7. 
TRIAL QUALITY INVESTIGATION. 
 
Trial quality was investigated as a potential explanation for the high proportion of positive 
Japanese trial results for fatal endpoints reported in the previous chapter (Section 6.3.1). 
Evidence suggests that trial quality is closely related to treatment effect estimates in that it can 
exaggerate the effect of treatment (Moher et al. 1998). To explore this, the Japanese trials were 
compared to a sample of trials from Europe and North America. This was done by two assessors 
using a modified Jadad Scale (Jadad et al. 1996). The Jadad scale is a validated scale for 
assessing the methodological quality of RCTs. However, to achieve a broader viewing of the 
quality of these trials, additional questions were included. 
This chapter is organised into four main sections. First, it provides the background to the 
investigation by presenting and discussing other research conducted on the impact of trial quality 
on treatment effect estimates. Section two provides a thorough description of the methods used in 
this study and explains how any discrepancies in ratings between investigators were resolved. 
The results of the investigation are provided in section three. The chapter concludes by 
summarising the findings of the trial quality investigation and describing their implications. 
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7.1: The Impact of Trial Quality on Treatment Effect Estimates 
Quality is a complicated concept and is not easy to define in relation to clinical trials (Jadad, 
1998). Quality evaluation should include not only the design, conduct, and analysis of a trial but 
also its clinical relevance and the standard of reporting (Berlin & Rennie, 1999; Ioannidis & Lau, 
1998). One of the most important dimensions of trial quality is the validity of the findings 
generated by the trial (Juni, Altman and Egger, 2001).Validity can be separated into two distinct 
types: internal and external. Internal validity is considered as the extent to which trial results are 
correct for the circumstances under investigation (Fletcher, Fletcher, & Wagner, 1982). It implies 
that any differences found between the groups being investigated can, apart from random error, 
be attributed to the intervention examined. External validity is the extent to which a trial’s result 
can provide an accurate foundation for generalisations to other populations and conditions (Chow 
& Liu, 2004). There are two types of external validity: population and ecological validity. 
Population validity is the extent to which the results of a study conducted in one sample can be 
applied to another set of patients (Houser, 2008) while ecological validity refers to the extent to 
which the findings of a study can be applied to other settings (Houser, 2008). Clearly, for clinical 
trials, the assessment of internal validity is essential and is a prerequisite for the assessment of 
external validity since if the trial results are flawed, and therefore unsound, the issue of whether 
or not the findings apply elsewhere is irrelevant and does not need to be contemplated (Jimenez-
Buedo & Miller, 2010). 
In any trial, internal validity can be threatened by bias. Potential biases to a trial’s internal 
validity fall into four main types: selection bias, performance bias, detection bias and attrition 
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bias. The first of these, selection bias, is the biased allocation of patients and relates to systematic 
differences in patient characteristics between the groups being compared. Randomisation aims to 
reduce, if not eliminate, selection bias by creating groups that are comparable with respect to 
identified or unidentified confounding factors (Altman & Bland, 1999). However, the success of 
randomisation relies upon two inter-connected procedures. The first of these is the generation of 
an allocation sequence that is unpredictable. This can be done, for example, by using computer 
generated random numbers, drawing lots or envelopes, using random number tables or tossing a 
coin. The second procedure involves ensuring that these sequences are concealed from those who 
are enrolling the patients and can be done with the use of central randomisation, sequentially 
numbered and sealed opaque envelopes or by using coded drug containers that have been 
prepared by an independent pharmacy. This procedure is of the utmost importance, to prevent 
selective enrolment of patients on prognostic factors.    
The second and third types of bias are performance and detection bias. Performance bias is the 
unequal provision of care between groups, apart from the intervention investigated, that occurs if 
extra treatments are given to one group in preference to another. Detection bias is a systematic 
difference between groups in how outcomes are ascertained, diagnosed or verified and occurs if 
knowledge of patient assignment has influenced the process of outcome assessment. Both of 
these types of bias can be prevented with the use of blinding. Performance bias can be prevented 
by blinding both patients and care-givers and detection bias can be prevented by blinding those 
who are assessing outcomes including patients, clinicians, investigators and endpoint review 
committees.  
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The fourth type of bias that can impact upon internal validity is attrition bias. This is the biased 
occurrence and handling of protocol deviations and loss of participants to follow-up (Juni, 
Altman, & Egger, 2001) that occurs when there are systematic differences in the loss of patients 
between comparison groups in the trial. Patients may be excluded after allocation to treatment 
because they deviated from the trial protocol (e.g. non-adherence to prescribed treatment) or 
because they were not able to be followed-up (e.g. the patient could no longer be contacted). 
Patients that are excluded are unlikely to be representative of all the patients enrolled in the trial 
and so, once they have been excluded, investigators can no longer be sure that important baseline 
characteristics, which may impact on therapeutic effect, are similar between the comparison 
groups. To reduce the effects of attrition bias, analysis of outcomes should use the “intention to 
treat” principle, whereby analysis involves all randomised patients kept in the groups to which 
they were originally assigned. 
In recent years, many studies have provided evidence of the biases occurring and distorting trial 
results. These studies suggest that low quality trials tend to exaggerate the effect of treatment 
(Egger et al. 2003; Kjaergard, Villumsen, & Gluud, 2001; Noseworthy et al. 1994; Peduzzi et al. 
1993). This is particularly the case in trials that have small sample sizes, as it has been found that 
such trials are usually conducted and analysed with low methodological rigour resulting in the 
inflation of treatment effect estimates (Egger et al. 2003). 
As there is evidence to suggest an association between treatment effect estimates and trial quality, 
it was appropriate to investigate whether the high proportion of positive trial results found in this 
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study from Japanese trials was a consequence of poor trial quality. This was especially important 
since the trials from Japan were small. 
Trial design and execution within the Japanese trials was compared to a sample of European and 
North America trials, using a modified Jadad scale. It was hypothesised that the high proportion 
of positive trial results reported in Japanese trials, when compared to trials from both Europe and 
North America, were a consequence of trials not using “adequate52” methodological approaches.  
7.2: Methods and Materials 
As the samples of European (240) and North American (155) trials were large, not all trials from 
these continents were quality assessed. Instead, a sample of trials from Europe and North 
America were selected. These were selected from the 10 meta-analyses that were identified as 
containing a Japanese trial that had fatal endpoint data. In each meta-analysis containing a 
Japanese trial, the Japanese trial data was extracted and the European and North American trials 
listed. A stratified random sample was then taken of one European and one North American trial 
from each of the 10 meta-analyses. In the cases where the meta-analysis only contained Japanese 
trials and European trials, the European trials were listed with a random sample of two
53
 
European trials being taken. This was also the case in meta-analyses that only contained Japanese 
and North American trials. This ensured that Japanese trials were only being compared to trials 
answering the same or similar scientific questions. Furthermore, it meant that trials could be 
                                                 
52
 RCTs that were well designed and properly executed 
53
 This allowed the quality of the Japanese trial to be compared to a larger sample of trials assessing the same 
intervention. One trial may not be representative of the quality of trials from the continents to which the Japanese 
trials are compared.   
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assessed for quality both within and over meta-analyses. A sample of 33 trials was created 
containing 13 Japanese trials, 14 European trials and 6 North American trials (see Table 7.1). It 
should be noted that prior to quality assessments being conducted all trial duplications were 
removed so that no trial had the opportunity to be assessed for quality more than once. 
 
Table 7.1: Details of the Trials included in the Trial Quality Investigation. 
Ref. No 
(Meta-
analysis 
code) 
Trial 
Author 
Region Methods Participants Intervention Outcomes Trial 
Effect 
Estimate 
(RR) and 
Confidence 
Intervals 
Jadad 
Score 
280 
[C4] 
Okishige, 
Nishizaki, 
Azegami et al 
(2000) 
Japan Randomised, 
Single-blind, 
Multi-
centred. 12 
month 
follow up 
62 Patients with 
AF lasting > 6 
months 
Pilsicainide vs. Placebo Mortality 
Pro-arrhythmia 
AF recurrence 
0.62    
(0.03, 
14.30) 
4 
347 
[C4] 
Stroobandt, 
Stiels, 
Hoebrechts 
(1997) 
Europe Randomised, 
double – 
blind, Multi-
centred. 
Follow up at  
6 months 
136 patients with 
persistent Atrial 
Fibrillation 
Propafenane 2mg/kg 
over 30 mins followed 
by oral Propafenone 
150mg 3 times daily vs. 
Matching Placebo 
Pharmacologic 
Conversion to 
Sinus Rhythm 
Free from 
Recurrent 
Symptomatic 
Arrhythmia 
Time to Atrial 
Fibrillation 
Relapse 
0.11    
(0.00, 2.64) 
3 
10 
[C4] 
AFIB 
Investigators 
(1997) 
North 
America 
Randomised, 
Multi-centre, 
Placebo-
controlled. 
12 month 
follow up 
1227 Patients with 
AF and 187 with 
Paroxysmal 
Supraventricular 
Tachycardia 
Bidisomide vs. Placebo Mortality 
Symptomatic 
recurrence of AF 
or Paroxysmal 
Supraventricular 
Tachycardia 
2.01  
(0.55, 7.41) 
3 
266 
[C10] 
Nakashima, 
Katayama, 
Honda et al 
(2004) 
Japan Randomised, 
Single-blind, 
Single-
centre 
180 Patients with 
successful PCI for 
AMI 
Magnesium Sulphate 
vs. Placebo 
Mortality 
Complications 
0.34    
(0.04, 3.22) 
1 
135 
[C10] 
Feldstedt, 
Boesgaard, 
Bouchelouche et 
al (1991) 
Europe Randomised, 
double-
blind, single-
centred. 
Median 
Follow up of 
245 days 
298 Patients with 
suspected AMI 
Intravenous Magnesium 
Chloride vs. Placebo 
In-hospital death 
Death at end of 
follow up 
Incidence of 
atrioventricular 
conduction 
disturbances 
1.23    
(0.50, 3.04) 
4 
393 
[C10] 
Woods, 
Fletcher, Roffe 
et al (1992) 
Europe Randomised, 
double-
blind, 
Single-
centre 
2316 Patients with 
suspected AMI 
Intravenous Magnesium 
Sulphate vs. Placebo 
Mortality 
Morbidity 
0.76    
(0.59, 0.99) 
5 
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3690 
[C12] 
The EPOCH 
Study Group 
(2002) 
Japan Randomised, 
Double –
blind and 
Multi-
centred 
306 Patients with 
CHF and a 
radionuclide or  
echocardiographic 
LVEF 
Pimobendon 1.25 or 2.5 
mg vs. Placebo 
Adverse cardiac 
events 
0.51    
(0.05, 5.60) 
5 
87 
[C12] 
Cowley and 
Skene (1994) 
Europe Randomised, 
Double-
blind, 
Placebo 
controlled 
Multi-
centred with 
1 year 
minimum 
follow up 
151 patients with 
severe 
symptomatic Heart 
Failure 
Enoximore vs. Placebo Survival 
Quality of Life 
Physical 
Mobility 
1.46    
(0.84, 2.53) 
3 
224 
[C12] 
Kubo, Gollub, 
Borge et al 
(1992) 
North 
America 
Randomised, 
double-
blind, multi-
centred.  
198 patients with 
symptoms of 
moderate to severe 
heart failure 
Pimobendanvs. Placebo Drug safety 
Exercise duration 
0.88    
(0.24, 3.18) 
3 
318 
[C17] 
Saito, 
Hosokawa, 
Tanaka et al 
(1999) 
Japan Randomised, 
Multi-centre. 
12 month 
follow up 
137 Patients with 
AMI 
Stent vs. Angioplasty Mortality 
MI 
Revascularisation 
0.42    
(0.08, 2.08) 
2 
215 
[C17] 
Kawashima, 
Ueda, Nishida et 
al (1999) 
Japan Randomised, 
Multi-centre. 
6 month 
follow up 
222 Patients with 
AMI 
Stent vs. Angioplasty Revascularisation 
Mortality 
0.34    
(0.01, 8.24) 
3 
244 
[C17] 
Maillard, 
Haman, Khalife 
et al (2000) 
Europe Randomised, 
Multi-centre. 
12 month 
follow up 
211 Patients with 
AMI 
Stent vs. Balloon 
Angioplasty 
Mortality 
MI 
Revascularisation 
3.26    
(0.13, 
79.24) 
4 
348 
[C17] 
Suryapranata 
,van’t Hof, 
Hoorntje et al 
(1998) 
Europe Randomised, 
Single-
Centre. 12 
month 
follow up 
227 Patients with 
AMI 
Stent vs. Angioplasty Mortality 
MI 
Revascularisation 
0.68    
(0.12, 4.02) 
5 
352 
[C41] 
Takeda, Takano, 
Ogawa et al 
(1997) 
Japan Randomised, 
unblended, 
single-centre 
30 Patients with 
severe cardiogenic 
PE 
CPAP vs. Standard 
Medical Care 
Mortality 
Tracheal 
intubation rate 
0.33    
(0.04, 2.85) 
1 
351 
[C41] 
Takeda, 
Neijima, 
Takano et al 
(1998) 
Japan Randomised, 
unblinded, 
Single-
centre. 
22 Patients with 
PE complicating 
AMI 
CPAP vs. Standard 
Medical Care and 
Oxygen mask 
Mortality 
Tracheal 
Intubation Rate 
0.14    
(0.02, 0.98) 
1 
89 
[C41] 
Crane, Elliott, 
Gilligan et al 
(2004) 
Europe Randomised, 
unblinded, 
Multi-centre 
60 Patients with 
acute Cardiogenic 
Pulmonary 
Oedema 
CPAP vs. BILEVEL vs. 
Standard Medical care 
plus Oxygen mask 
Mortality 
Tracheal 
intubation rate 
Incidence of 
AMI 
Side Effects 
0.42    
(0.14, 1.20) 
3 
231 
[C41] 
Levitt (2001) North 
America 
Randomised, 
unblinded, 
Single-
centre 
38 Patients with 
severe acute 
Congestive HF 
BILEVEL vs. Standard 
Medical Care and 
Oxygen Mask 
Mortality 
Tracheal 
Intubation Rate 
Incidence of 
AMI 
1.00    
(0.23, 4.40) 
3 
350 
[P2] 
Takano, 
Hasegawa, 
Kuwabara et al 
(2007) 
Japan Randomised, 
blinded, 
Multi-centre. 
6 month 
follow up 
40 Patients with 
AMI related with 
left anterior 
descending 
coronary artery 
who underwent 
successful PCI 
G-CSF vs. Placebo LVEF 
LVEDV 
LVESV 
Restenosis Rate 
Mortality 
3.63    
(0.16, 
84.11) 
5 
401 
[P2] 
Zohlnhofer, Ott, 
Mehilli et al 
(2006) 
Europe Randomised, 
double – 
blind and 
114 patients with 
ST-segment 
Elevation AMI 
Subcutaneous daily 
dose of 10 microg/kg of 
G-SF of Placebo for 5 
Reduction of left 
ventricular 
infarct size 
3.11    
(0.13, 
5 
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Multi-
centred 
days Improvement of 
left ventricular 
ejection fraction 
Incidence of 
angiographic 
restenosis 
74.66) 
124 
[P2] 
Ellis, Penn, 
Bolwell et al 
(2006) 
North 
America 
Randomised, 
double-
blind, 
Single-
centred. 30 
day follow 
up 
18 Patients with 
AMI 
G-CSF vs. Placebo Rupture free 
survival 
Recovery of LVF 
0.18    
(0.01, 3.85) 
5 
180 
[P7] 
Horie, 
Takahashi, 
Minai et al 
(1998) 
Japan Randomised, 
Single-
centre. 
83 Patients with 
initial Q-wave 
anterior MI > 
24hrs after onset 
PTCA vs. No PTCA Cardiac Death, 
Non-fatal 
recurrence of MI 
Development of 
Congestive HF 
0.18    
(0.02, 1.45) 
2 
126 
[P7] 
Erne, 
Schoenenberger, 
Burckhardt et al 
(2007) 
Europe Randomised, 
Unblinded, 
Multi-
centred trial 
with final 
follow up at 
10 years 
201 patients with 
recent MI, Silent 
Myocardial 
Ischemia and 1- or 
2- vessel Coronary 
Artery Disease 
PCI vs. Intensive Anti-
Ischemic Drug Therapy 
Survival free of 
major cardiac 
events 
Exercise induced 
ischemia 
Resting left 
ventricular 
ejection fraction 
0.15    
(0.05, 0.48) 
2 
113 
[P7] 
Dzavik, 
Beanlands, 
Davies et al 
(1994) 
North 
America 
Randomised, 
Multi-centre. 
4 month 
follow up 
44 Patients with 
occluded infarct-
related coronary 
artery 
FrCA vs. no PTCA Mortality 
LVEF 
0.76    
(0.05, 
11.39) 
2 
263 
[P87] 
Muramatsu, 
Iwasaki, Inou et 
al (2002) 
Japan Randomised, 
Multi-centre. 
6 month 
follow up 
302 Patients with 
CAD 
Stenting vs. PTCA Mortality 
Restenosis rate 
MACE 
0.12    
(0.01, 2.13) 
1 
254 
[P87] 
Moer, Myreng, 
Molstad et al 
(2001) 
Europe Randomised, 
Multi-centre. 
6 month 
follow up 
145 Patients with 
stable and unstable 
angina 
Elective stenting with 
Heparin coated beStent 
vs. PTCA 
MLD 
Restenosis Rate 
Event free 
Survival 
Angina status 
0.96    
(0.06, 
15.05) 
3 
212 
[P87] 
Kastrati, 
Schomig, 
Dirschinger et al 
(2000) 
Europe Randomised, 
Multi-centre. 
7 month 
follow up 
404 Patients with 
symptomatic CAD 
Stenting vs. PTCA Incidence of 
angiographic 
restenosis 
Adverse clinical 
events 
0.65    
(0.11, 3.87) 
3 
187 
[P90] 
Ikari, Kawano, 
Sakurada et al 
(2005) 
Japan Randomised, 
Multi-
Centre. 8 
month 
follow up 
368 Patients with 
STEMI 
Primary PCI with 
thrombus aspiration vs. 
PCI alone 
Success and 
complication rate 
of thrombus 
aspiration 
therapy 
Damage of 
Myocardial 
Microcirculation 
MACE 
0.97    
(0.06, 
15.42) 
1 
147 
[P90] 
Fujita, Suwa, 
Koyama et al 
(2004) 
Japan Randomised, 
Multi-
Centre. 
341 Patients with 
acute MI 
Adjunctive embolic 
protection vs. no 
adjunctive embolic 
protection 
30 day major 
cardiac adverse 
events 
0.69    
(0.22, 2.14) 
1 
40 
[P90] 
Beran, Lang, 
Schreiber et al 
(2002) 
Europe Randomised, 
Single – 
centre. 30 
day follow 
up 
66 Patients with 
ACS and 
suspected 
intracoronary 
thrombus 
Pretreatment with X-
sizer with PCI vs. 
Conventional PCI 
MACE 2.07    
(0.20, 
21.61) 
4 
14 
[P90] 
Ali, Cox, Dib et 
al (2006) 
North 
America 
Randomised, 
Multi-centre. 
30 day 
480 Patients 
presenting in 12hr 
of symptom onset 
Rheolyticthrombectomy 
adjunct to PCI vs. PCI 
alone 
Infarct size 
MACE 
5.50    
(1.23, 
3 
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follow up of STEMI 24.55) 
248 
[P97] 
Matsuo, Inoue, 
Sakurada et al 
(2007) 
Japan Randomised, 
Multi-centre. 
6 month 
follow up 
154 Patients with 
AMI in 24hr from 
onset 
PCI with Guardwire vs. 
PCI 
TIMI perfusion 
grade 
MACE 
0.31    
(0.03, 2.90) 
1 
97 
[P97] 
DeLuca, 
Sardella, 
Davidson et al 
(2006) 
Europe Randomised, 
single-
centred. 6 
month 
follow up 
76 Patients with 
anterior STEMI 
Intracoronary 
Thrombectomy and 
stent placement vs. 
Conventional stenting 
Major Adverse 
Cardiovascular 
Events (MACE) 
0.20    
(0.01, 4.03) 
2 
 
 
349 
[P97] 
Svilaas, Vlaar, 
van der Horst 
(2008) 
Europe Randomised, 
single-
centred, 
blinded. 
Follow up of 
30 days 
1071 patients with 
ST-segment 
elevation MI 
Thrombus aspiration vs. 
Conventional PCI 
Post procedural 
frequency of a 
Myocardial blush 
grade of 0 or 1 
Post procedural 
frequencies of 
TIMI flow grade 
of 3.  
Death, 
reinfarction or 
combination of 
adverse Cardiac 
events 
0.61    
(0.38, 0.99) 
5 
 
As only a sample of European and North American trials were chosen, it was important to see 
whether these samples had typical effect sizes. This would ensure that no bias was introduced 
into this assessment by comparing Japanese trials to an unrepresentative, biased sample of 
European and/or North American trials. To do this, the distribution of trials from both continents 
were examined by producing scatter plots in which each trial’s standardised effect estimate was 
plotted against the square root of trial sample size and in which the trials used in the trial quality 
assessment were highlighted (see Figures 7.1 and 7.2). This showed that the samples of both 
European and North American trials provided a range of typical effect sizes. As such, they would 
provide a good sample to compare with the Japanese trials. 
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FIGURE 7.1: THE SPREAD OF EUROPEAN TRIAL TREATMENT EFFECT 
ESTIMATES WITH THE TRIALS INCLUDED IN THE TRIAL QUALITY 
ASSESSMENT HIGHLIGHTED. 0 REPRESENTS A UNIVERSAL TREATMENT 
EFFECT ESTIMATE. 
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FIGURE 7.2: THE SPREAD OF NORTH AMERICAN TRIAL TREATMENT EFFECT 
ESTIMATES WITH THE TRIALS INCLUDED IN THE TRIAL QUALITY 
ASSESSMENT HIGHLIGHTED. 0 REPRESENTS A UNIVERSAL TREATMENT 
EFFECT ESTIMATE. 
 
 
 
7.2.1 The Assessment of Trial Quality 
To assess the quality of each of the 33 trials, a trial quality questionnaire was developed (see 
Appendix 1). The core of this questionnaire was the Jadad Scale. This was used because it is both 
quick and simple and is the most frequently used scale to assess trial quality in health care (Moja 
et al. 2005). In addition, this scale is reported to be the most reliable and valid scale in assessing 
the quality of randomised controlled trials (Olivo et al. 2008).The Jadad scale gives every trial a 
quality score which lies between one and five. Trials are scored according to the presence of the 
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three most important methodological aspects of a randomised controlled trial that can impact on 
the reliability of results: randomisation, blinding and attrition. A maximum of two points are 
available for appropriate and well reported randomisation and blinding and a maximum of one 
point for well-reported and explained attrition. If no information is provided for each of these 
elements of trial quality, the trial scores no points for each category. Trials are recorded as low 
quality if they score between zero and two, and high quality if they score between three and five.  
 
For this study, the Jadad score was calculated independently by both investigators using the Jadad 
scoring system mentioned above. Any discrepancies in Jadad score between reviewers were 
resolved by examining the papers and discussing disagreements with a third reviewer (RL). 
 
As well as using the Jadad scale, some additional trial quality questions about randomisation, 
blinding and attrition were included on the quality assessment questionnaire in this research. This 
allowed information not collected by the Jadad Scale to be collated. This enhanced Jadad scale 
included questions about the following: 
1. Was the trial multi-centred?  
2. If the trial does not specify blinding, does it specify that a placebo was used? 
3. Was the patient blinded? 
4. Was the investigator blinded? 
5. Was the main outcome considered objective rather than subjective? 
6. Did the trial follow a Consort type detailed breakdown of both withdrawals and drop-outs 
following randomisation? 
 
These additional questions were important as they meant that a more in-depth trial quality 
assessment could be conducted. The Jadad scale only asks whether there was a description of 
withdrawals and drop-outs and therefore, does not ask for a detailed breakdown, whereas in the 
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enhanced Jadad scale used here, question six allowed attrition to be investigated more 
thoroughly. This type of breakdown, however, is important since knowing the number of patients 
who were not eligible, who did not receive their allocated treatment or did not complete treatment 
means that the extent to which the treatment effect may be biased can be assessed. Furthermore, 
these additional questions allow observations to be made about whether those trials scored as low 
quality have a biased design as a consequence of the procedures it has used, for instance, its 
randomisation procedures. This is not possible when only using the Jadad scale, which although 
it asks whether appropriate randomisation techniques were used, does not take into account that 
some of these appropriate techniques are more prone to bias than others. 
 
Since sample size is thought to mediate the relationship between trial quality and treatment effect 
(Singh, Murphy, & Bhandari, 2010), single-centred trials are likely to exaggerate the effect of 
treatment due to their small sample sizes (Bellomo, Warrillow, & Reade, 2009) . Therefore, the 
first additional question asking whether the trial being assessed was single or multi centred 
enabled another factor that may be linked to trial quality and the exaggeration of treatment effect 
to be investigated. In addition, research suggests that subjective outcomes are specifically 
vulnerable to bias when a trial has a lack of blinding (Higgins & Altman, 2008) which may result 
in an exaggeration of treatment effect.
54
  As such, the addition of question five, allowed the 
assessment of whether an objective or subjective outcome had been measured for each trial. 
 
                                                 
54
 After trial quality assessment had been conducted all included trials were found to have assessed objective 
outcomes. Therefore, the results of this question are not reported in this thesis.  
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Once the questionnaire had been developed, it was pre-tested by two investigators (LH and UN). 
To do this, a selection of the included trials was chosen at random and the two investigators 
independently assessed them using the questionnaire. The investigators then compared their trial 
quality assessments and any discrepancies were discussed with a third party (RL). After this 
discussion, minor changes were made to the enhanced Jadad scale. It was agreed that two 
additional questions about randomisation processes should be included. The revised list of 
questions is given below: 
1. Was the trial multi-centred?  
2. Was randomisation done by a third party i.e. it was not within the control of a given 
clinic? 
3. Was randomisation done by envelopes in the local setting? 
4. If the trial does not specify blinding, does it specify that a placebo was used? 
5. Was the patient blinded? 
6. Was the investigator blinded? 
7. Was the main outcome considered objective rather than subjective? 
8. Did the trial follow a Consort type detailed breakdown of both withdrawals and drop-outs 
following randomisation? 
 
Inter-rater reliability and validity of the enhanced questionnaire was checked by comparing the 
Jadad scores provided by this questionnaire to those given in the quality assessment of Cochrane 
reviews. This was only done, however, if the trial being assessed had been extracted from a 
Cochrane review and that review had provided a Jadad score. 
 
The original reports of the all the trials being assessed were obtained and photocopied three 
times. On two copies, a black marker pen was used to make information regarding affiliations 
incomprehensible. This was done so that all trials could be assessed fairly. The other copy was 
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left with this information unmasked for reference after the assessment. Each investigator (LH and 
UN) was then handed a masked copy of each trial to assess trial quality.  
7.2.2 Data abstraction 
The two investigators
55
 (LH and UN) independently assessed trial quality using the enhanced 
Jadad questionnaire. Agreement on data abstraction was reached in 82% of cases. However, there 
were 7 disagreements between the reviewers. Three of these were with regards to blinding, three 
were concerned with randomisation and one was related to attrition. All of these disagreements 
were resolved through examining the papers with a third reviewer (RL) and discussing the issue 
concerned. The discussions resulted in a consensus between all three reviewers about trial 
quality. 
7.3 Results of Trial Quality Assessment 
The assessment of trial quality was conducted both over meta-analyses and trials. This section 
reports the findings of these assessments.  
7.3.1: Assessment at meta-analysis level 
To examine whether the quality of trials differed between Japan, Europe and North America, 
trials were first assessed within meta-analyses. This eliminated variation in quality between 
procedures since trials were only being compared to those using the same procedure. This 
investigation was important since quality assessment criteria may differ according to procedure 
                                                 
55
 Two investigators were chosen to assess trial quality so that mistakes and the risk of bias during assessment could 
be reduced.  
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type and, as such, may impact on the quality score given. For instance, when assessing the quality 
of trials for surgical interventions blinding is not feasible. Therefore, these trials would score 
lower than a trial investigating a procedure where blinding was possible and, as such, appear to 
be of lower quality. Table 7.2 shows the quality of each region’s trials within each of their meta-
analyses.  
 
As can be seen from Table 7.2, in two meta-analyses, concerning Anti-arrhythmic drugs and 
Phosphodiesterase III Inhibitors, (C4 (227) and C12 (18)) the Japanese trials appeared to be of 
better quality than both European and North American trials. In one meta-analysis (P2 (4)) that 
examined G-CSF therapy, the Japanese trial was of equal quality to its European and North 
American counterparts. In P7 (2), the Japanese trial was of the same quality as the North 
American trial but of lower quality compared to the European trial. However, in most cases (n=6) 
the Japanese trials were of lower quality than trials conducted in Europe and/or North America. 
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Table 7.2: A Table Showing the Jadad score for each Region's Trials in each Meta-analysis. 
Ref. No/ 
(Meta-
analysis) 
Intervention Trial Highest 
Quality 
Region 
  1 2 3 4  
  Region Jadad 
Score 
Effect 
Estimate 
(RR and 
CIs) 
Region Jadad 
Score 
Effect 
Estimate 
(RR and 
CIs) 
Region Jadad 
Score 
Effect 
Estimate 
(RR and 
CIs) 
Region Jadad 
Score 
Effect 
Estimate 
(RR and 
CIs) 
 
227 
[C4] 
Anti-arrhythmic Japan 4 0.62 (0.03, 
14.30)  
Europe 3 0.11 (0.00, 
2.64) 
North 
America 
3 2.01 (0.55, 
7.41) 
N/A N/A N/A Japan 
232 
[C10] 
Intravenous 
Magnesium 
Japan 1 0.34 (0.04, 
3.22) 
Europe 4 1.23 (0.50, 
3.04) 
Europe 5 0.76 (0.59, 
0.99) 
N/A N/A N/A Europe 
18 
[C12] 
Phosphodiestera
se III Inhibitors 
Japan 5 0.51 (0.05, 
5.60) 
Europe 3 1.46 (0.84, 
2.53) 
North 
America 
3 0.88 (0.24, 
3.18) 
N/A N/A N/A Japan 
273 
[C17] 
Stenting Japan 2 0.42 (0.08, 
2.08) 
Japan 3 0.34 (0.01, 
8.24) 
Europe 4 3.26 (0.13, 
79.24) 
Europe 5 0.68 (0.12, 
4.02) 
Europe 
383 
[C41] 
Non-invasive 
Positive 
Pressure 
Ventilation 
Japan 1 0.33 (0.04, 
2.85) 
Japan 1 0.14 (0.02, 
0.98) 
Europe 3 0.42 (0.14, 
1.20) 
North 
Americ
a 
3 1.00 (0.23, 
4.40) 
Europe/ 
North 
America 
4 
[P2] 
G-CSF Therapy Japan 5 3.63 (0.16, 
84.11) 
Europe 5 3.11 (0.13, 
74.66) 
North 
America 
5 0.18 (0.01, 
3.85) 
N/A N/A N/A All 
Continents 
Equal 
2 
[P7] 
Percutaneous 
Coronary 
Intervention 
Japan 2 0.18 (0.02, 
1.45) 
Europe 3 0.15 (0.05, 
0.48) 
North 
America 
2 0.76 (0.05, 
11.39) 
N/A N/A N/A Europe 
11 
[P87] 
Stenting Japan 1 0.12 (0.01, 
2.13) 
Europe 3 0.96 (0.06, 
15.05) 
Europe 3 0.65 (0.11, 
3.87) 
N/A N/A N/A Europe 
96 
[P90] 
Adjunctive 
Mechanical 
Devices 
Japan 1 0.97 (0.06, 
15.42) 
Japan 1 0.69 (0.22, 
2.14) 
Europe 4 2.07 (0.20, 
21.61) 
North 
Americ
a 
3 5.50 (1.23, 
24.55) 
Europe 
33 
[P97] 
Thrombectomy 
or Embolic 
Protection 
Device 
Japan 1 0.31 (0.03, 
2.90) 
Europe 2 0.20 (0.01, 
4.03) 
Europe 5 0.61 (0.38, 
0.99) 
N/A N/A N/A Europe 
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For instance, in C10 (232) it was found that the Japanese trial scored between 3-4 points 
lower on the Jadad scale than its European counterparts. This was also the case for both meta-
analyses (C17 (273), P87 (11)) concerned with stenting, where the Japanese trials scored 
lower than the trials conducted in Europe. Indeed, in 60% of the meta-analyses, the Japanese 
trials appeared to be of lower quality compared to European and North American trials. This 
can be seen in Figure 7.3 where six of the 10 meta-analyses show the Japanese trials scoring 
lower on the Jadad scale than their European and North American counterparts. However, a 
binomial sign test conducted under the null hypothesis that the quality of trials would be the 
same in Japanese trials compared to Europe and North America indicated that trial quality 
was not significantly different between the Japanese trials and their European and North 
American counterparts (2-sided p-value = 0.7539). 
 
FIGURE 7.3: THE TREATMENT EFFECT ESTIMATE AND JADAD SCORE OF 
EACH REGION’S TRIALS PER META-ANALYSES. 
 
 
 
X-axis Key 
Meta-analysis Number 
(Meta-analysis Reference 
Number) 
 
1 = C4 (227) 
2 = C10 (232) 
3 = C12 (18) 
4 = C17 (273) 
5 = C41 (383) 
6 = P2 (4) 
7 = P7 (2) 
8 = P87 (11) 
9 = P90 (96) 
10=P97 (33) 
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Table 7.2 was also used to see whether the Japanese trials in each meta-analysis provided 
higher treatment effect estimates than their European and North American counterparts. This 
was because the high proportion of positive Japanese trial results may have been due to such 
trials being of lower quality, compared to their European and North American counterparts, 
and, as such, exaggerating the effect of treatment. It was found that in the majority of meta-
analyses the treatment effect estimates provided by the Japanese trials were higher than those 
provided by their European and North American counterparts. Indeed, in 7 of the 10 meta-
analyses the treatment effect estimates provided by the Japanese trials were higher than their 
European and North American counterparts (see Table 7.2). To see if this was a significant 
finding, a binomial sign test was conducted under the null hypothesis that the effectiveness of 
interventions would be the same in the Japanese trials as in their European and North 
American counterparts. This indicated that treatment effectiveness was not significantly 
different between trials conducted in Japan and those conducted in Europe and North 
America (2-sided p-value = 0.344). 
7.3.2: Analysis over Trials 
An analysis was also conducted over trials. This involved assessing all of the trials included 
in the trial quality sample together. Trials from Japan, Europe and North America were 
compared in relation to whether they were single or multi-centred
56
 trials and with regards to 
randomisation, blinding and attrition.  
                                                 
56
 Trials conducted with all centres in one continent. 
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7.3.2.1: Single or Multi-centre Trials 
The percentage of single centre and multi-centre trials was first calculated for each continent. 
This was to ascertain if trials in Japan were more likely to be single-centred compared to 
trials conducted within Europe and North America. This was important to investigate, as the 
positive results in Japanese trials may have been created by chance as a consequence of small 
sample sizes in single-centred trials. This comparison showed that the proportion of single-
centre and multi-centre trials between continents were similar. Table 7.3 shows the 
percentage of trials in each region that were single or multi-centred. 
 
Table 7.3: The Percentage of Single Centre and Multi-Centre Trials in each Continent. 
 Japan Europe North America 
Single Centre Trials 4 (31%) 5 (36%) 2 (33%) 
Multi-Centre Trials 9 (69%) 9 (64%) 4 (67%) 
Total number of 
Trials 
13 14 6 
 
As can be seen from Table 7.3, the percentage of single-centre trials in Japan was 31% (4 out 
of 13 trials). This is similar to the percentages in both Europe (36% or 5 out of 14 trials) and 
North America (33% or 2 out of 6 trials). This suggested that the positive trial results found 
in Japanese trials could not solely be due to such trials being single-centred with small 
sample sizes. 
7.3.2.2: Trial Jadad Scores 
Examining the Jadad scores of each region’s trials showed that Japanese trials scored lower 
on the Jadad scale compared to trials from Europe and North America. As can be seen from 
Figure 7.4, 54% of Japanese trials only scored one on the Jadad scale. Furthermore, only 31% 
of Japanese trials scored between three and five. This was low compared to Europe and North 
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America, where no trial scored one and where 86% and 83% of trials respectively scored 
between three and five. 
FIGURE 7.4: A BAR CHART SHOWING THE PERCENTAGE OF TRIALS IN 
EACH CONTINENT SCORING AT EACH LEVEL OF THE JADAD SCALE. 
 
 
To investigate whether this difference in trial quality between Japan, Europe and North 
America was significant, a Kruskal-Wallis one-way ANOVA was performed on the regional 
groups. As expected, Japanese trials had the lowest quality scores (Median=1) compared to 
Europe (Median = 3.5) and North America (Median=3). The test was also statistically 
significant:  (2df, N=33) = 8.296, p= 0.016. Therefore, it was concluded that there was a 
statistically significant difference in the quality of trials between Japan, Europe and North 
America. 
 
To investigate where this significant difference may lie, follow-up Mann-Whitney U Tests 
were conducted that evaluated pair-wise differences among the three regions, controlling for 
Type I error across tests by using the Bonferroni Correction. The results of these tests 
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indicated that Japanese trials scored significantly lower on the Jadad score than European 
trials (U = 37.5, p = 0.008, N = 27, 2 tailed test).
57
 However, the tests also indicated that there 
was no significant difference in Jadad score between Japan and North America (U = 20.0, p = 
0.106, N = 19, 2 tailed test) or between Europe and North America (U = 28.5, p = 0.274, N = 
20, 2 tailed test).  
 
The quality of each region’s trials was then examined with regards to the three key 
methodological aspects described earlier in the chapter: randomisation, blinding and attrition. 
The findings from these comparisons will now be discussed in turn. 
7.2.3.3: Randomisation 
All trials from Japan, Europe and North America stated that they were randomised. However, 
the number of trials reporting an appropriate randomisation technique differed between 
continents, as can be seen from Table 7.4. It should be noted that in this instance an 
appropriate randomisation technique was considered to be where the allocation sequence was 
unpredictable and was concealed from those who enrolled the participants. 
Table 7.4: The Number of Trial in Each Region That Used an Appropriate 
Randomisation Technique. 
 
Region Randomisation Technique Appropriate Total Number 
of Trials 
 Yes No Not Stated  
Japan 3 (23%) 2 (15%) 8 (62%) 13 
Europe 9 (64%) 1 (7%) 4 (29%) 14 
North America 2 (33%) 1 (17%) 3 (50%) 6 
 
                                                 
57The probability is exact and was found using SPSS version 11. 
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As Table 7.4 shows, only 23% (3 of 13 trials) of Japanese trials reported the use of an 
appropriate randomisation technique. This was lower than the percentage of European trials 
(64% or 9 of 14 trials) and North American trials (33% or 2 of 6 trials). Moreover, 62% (8 of 
13 trials) of Japanese trials, 29% (4 of 14 trials) of European trials and 50% (3 of 6 trials) of 
North American trials did not state how they had randomised patients. Therefore, the low 
percentage of trials in both Japan and North America reporting an adequate randomisation 
technique could be the consequence of this non-reporting rather than the randomisation 
technique not actually being used in the study. Nonetheless, statistical analysis (2-sided 
Fisher’s Exact Test) did not show a statistically significant difference between regions in 
reporting adequate randomisation techniques (p = 0.261). As such, there was not sufficient 
evidence to claim that the reporting of adequate randomisation techniques was different 
between the regions investigated. 
Additional analysis of randomisation processes were conducted to see whether regions 
differed in the methods they employed to conceal allocation. This was done by observing the 
number of trials in each region that used third party randomisation or used envelopes in the 
local setting. This was important because deciphering allocation schedules is more likely to 
occur in trials that have used envelopes in the local setting since unsealed envelopes may be 
opened and translucent envelopes held up to a bright light (Schulz, 1995; Schulz & Grimes, 
2002) meaning that allocation may still be in the hands of the researcher. This could result in 
selection bias and consequently, an exaggeration of treatment effect. Third party 
randomisation, on the other hand, is considered to be the most desirable approach (Akkerhuis 
et al. 2000; Hotopf, 2007; Sim & Wright, 2000) because it minimizes selection bias and, 
therefore, is less likely to lead to over-stating treatment effect.  
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Table 7.5: Randomisation Techniques by Region 
 
As Table 7.5 shows, 23% (3 out of 13) of Japanese trials used third party randomisation 
compared to 29% (4 out of 14) of European trials and only 17% (1 out of 6) of North 
America trials. No Japanese or North American trials reported using envelopes in the local 
setting compared to 21% (3 of 14 trials) of European trials that did this. These results 
suggested, therefore, that the positive trial results found in Japanese trials may not be 
explained by the use of less robust “local envelope” randomisation techniques. Furthermore, 
a 2-sided Fisher’s Exact Test showed no evidence of a statistically significant difference 
between regions in reporting allocation concealment methods (p=0.386). However, it should 
be noted that 77% (10 of 13) of Japanese trials did not state whether third party 
randomisation or envelopes in the local setting were used. Therefore, it may be that Japanese 
trials did use envelopes in the local setting more often but did not report doing so.  
7.3.2.2: Blinding 
Only 31% (4 of 13) of Japanese trials were found to have reported the use of blinding (see 
Table 7.6). This was lower than both Europe (64% or 9 of 14) and North America (50% or 3 
of 6). 
 
 
Region Randomisation Method Total 
Number of 
Trials 
 Third Party  Envelopes in 
Local Setting  
Not Stated  
Japan 3 (23%) 0 (0%) 10 (77%) 13 
Europe 4 (29%) 3 (21%) 7 (50%) 14 
North America 1 (17%) 0 (0%) 5 (83%) 6 
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Table 7.6: The Number of Each Regions Trials That Used, Did Not Use or Did Not State 
if They Had Used Blinding. 
 
Region Was Blinding Used in the Trial? Total Number of 
Trials Yes No Not Stated 
Japan 4 (31%) 6 (46%) 3 (23%) 13 
Europe 9 (64%) 4 (29%) 1 (7%) 14 
North America 3 (50%) 1 (17%) 2 (33%) 6 
 
 
Furthermore, 23% (3 of 13 trials) of trials in Japan did not state whether blinding had been 
used. As can be seen from Table 7.6, this was higher than the percentage for Europe (7% or 1 
of 14 trials) but lower than the percentage for North America (33% or 2 of 6 trials). However, 
a 2-sided Fisher’s Exact Test showed no evidence of a statistically significant difference 
between regions in reporting the use of blinding (p = 0.304). This suggests that the 
differences in trial quality between regions may not be a consequence of differences in the 
use of blinding.  
 
The number of blinded trials stating the blinding method was also examined between regions. 
Table 7.7 shows that all Japanese trials that reported the use of blinding (n=4) stated the 
method used compared to 56% (5 of 9) of European trials and 67% (2 of 3) of North America 
trials (see also Figure 7.5). 
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Table 7.7: Method of Blinding per Region 
 
Region Blinding Method Described? Total Number of 
Trials 
Yes No 
Japan 4 (100%) 0 (0%) 4 
Europe 5 (56%) 4 (44%) 9 
North America 2 (67%) 1 (33%) 3 
 
 
FIGURE 7.5: A GRAPH SHOWING THE PERCENTAGE OF TRIALS IN EACH 
CONTINENT THAT USED BLINDING AND DESCRIBED THE BLINDING 
METHOD USED. 
 
 
However, a 2-sided Fisher’s Exact Test again found no evidence of a statistically significant 
difference between regions in reporting blinding methods (p = 0.291).Consequently, there 
was insufficient evidence to suggest that the reporting of blinding methods differed 
significantly between regions, suggesting that this factor may not solely explain the between-
regional differences in trial quality found. 
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7.3.2.3: Attrition 
Attrition rates refer to the number of patients that withdrew or dropped out of the trial. Table 
7.8 shows the number and percentages of each region’s trials that did or did not report 
attrition rates. 
Table 7.8: The Number of Trials in Each Region Reporting or Not Reporting Attrition 
Rates. 
 
Region Attrition Rates Reported Total Number of 
Trials Yes No 
Japan 4 (31%) 9 (69%) 13 
Europe 14 (100%) 0 (0%) 14 
North America 5 (83%) 1 (17%) 6 
 
It shows that 69% (9 of 13) of Japanese trials did not report attrition rates compared to no 
European trials and only 1% (1 of 6) of North American trials. To see if this was statistically 
significant, a 2-sided Fishers Exact Test was conducted. It indicated that there was evidence 
of a statistically significant difference in the reporting of attrition rates between regions (p = 
0.0001). 
 
Whether trials provided a CONSORT-type detailed breakdown of attrition rates was also 
explored. In the CONSORT Statement, trials are required to provide a flow diagram 
displaying the progress of all participants through the four stages of a trial: enrolment, 
intervention allocation, follow-up and analysis. In this sample, such a breakdown was only 
provided in 8% (1 of 13) of Japanese trials compared to 43% (6 of 14) of European trials and 
17% (1 of 6) of North American trials (see Table 7.9). 
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Table 7.9: The Number of Trials in Each Continent Reporting Attrition in a 
CONSORT-type Detailed Breakdown. 
Region Trials Reporting Attrition Rates in a 
Consort Type Detailed Breakdown 
Total Number of 
Trials 
Yes No 
Japan 1 (8%) 12 (92%) 13 
Europe 6 (43%) 8 (57%) 14 
North America 1 (17%) 5 (83%) 6 
 
It should be pointed out, however, that such a detailed breakdown of attrition rates was not 
presented in 25 of the 33 trials included in this sample. Moreover, a 2-sided Fisher’s Exact 
Test showed no evidence of a statistically significant difference between regions in reporting 
a CONSORT type breakdown of attrition rates (p = 0.107). The CONSORT  Statement was 
only established in 1996 (Begg et al. 1996), and as a result, trials published before this year 
could not have implemented its recommendations. What is more, since the CONSORT 
Statement only makes recommendations (not requirements) about reporting, trials published 
after this date may still not have put into practice these recommendations about attrition 
reporting.
58
 
7.4: Meta-regression 
Random effects meta-regression was conducted in STATA to further explore heterogeneity 
(for output see Appendix 2). First, a meta-regression was run to see whether treatment effect 
could be predicted by region. This showed that region could account for 32% of the between-
                                                 
58
In this study, trials that could not report attrition using the CONSORT Statement, i.e. those published before 
the CONSORT Statement existed, were not weighted less favourably in terms of quality. This was because the 
Jadad scale used to assess quality in this study does not ask a question about the CONSORT Statement, only a 
question about the reporting of attrition rates. As such, the quality score given to each trial by the Jadad scale 
does not take into account whether the trial followed the CONSORT Statement or not.  
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study heterogeneity and showed that there was a marginally significant difference between 
regions (F (2,30) = 3.29, p = 0.051) in the size of treatment effect. Furthermore, a statistically 
significant difference in the size of treatment effect was present between Japan and North 
America (F (1,30) = 6.55, p = 0.016).  
A second meta-regression was then conducted to examine the impact of Jadad score after 
adjusting for region. However, Jadad score was found to not significantly contribute to the 
differences in the size of treatment effect (p=0.411). The last meta-regression was carried out 
to observe the association between treatment effect and Jadad score without adjusting for 
region. This showed that Jadad score did not significantly contribute to the differences in 
treatment effect (p=0.1157). However, it should be noted that the results of these meta-
regressions are purely observational as by containing few trials, they have low power to 
detect any relationship between the covariates and treatment effect. 
7.5: Publication Bias 
To further explore the influence of bias on treatment effect estimation, publication bias was 
investigated in the Japanese, European, and North American sample of trials using the Egger 
test. The high proportion of positive Japanese trials found may result from publication bias in 
that trials showing positive results are more likely to be published. Indeed, the Egger test 
conducted on the Japanese trials showed that there was statistically significant publication 
bias (Egger statistic = 0.743, p = 0.047). Conversely, the Egger test result for Europe and 
North America did not show any evidence of publication bias (Europe Egger statistic =           
-0.714, p = 0.47, North America Egger statistic = -1.214, p = 0.67). 
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7.6: Conclusion 
The investigation into trial quality as an explanation for the high proportion of positive trial 
results found in Japan provided some interesting findings. Differences in reporting 
randomisation within trials explored in this chapter were not statistically significant, nor were 
the differences found in how blinding was reported. The lack of statistical significance for 
blinding could be explained by the fact that, unless the intervention is drug based, it can be 
difficult or indeed, impossible, to blind a study. This difference may, therefore, be a 
consequence of the intervention rather than poorly designed, managed, and reported trials. 
 
Nevertheless, examination over meta-analyses found that trial quality was different between 
trials conducted in Japan and those conducted in Europe and North America. Trials from 
Japan scored significantly lower on the Jadad scale of trial quality than trials from Europe 
and North America (p = 0.016). When explored further, it was found that they scored 
significantly lower than their European counterparts (p = 0.008) but not than their North 
American counterparts (p = 0.274). This may, however, be a consequence of the small sample 
size for North America. 
 
The difference in trial quality could be a result of Japanese trials reporting rates of attrition 
less often than their European and North America counterparts, a difference that was 
statistically significant at the 5% level. Furthermore, Japanese trials that did provide attrition 
information tended not to comply with the CONSORT recommendations for presenting this 
type of data, even though all Japanese trials involved in this study were published after 1996: 
only 8% (1 of 13) of Japanese trials, compared with 43% (6 of 14) of European trials and 
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17% (1 of 6) of North American trials presented attrition data using the CONSORT 
recommendations. However, this difference was not statistically significant at the 5% level. 
 
As studies about the impact of trial quality on effect estimates suggest, one might expect 
Japanese trials to provide larger treatment effects than the comparison trials, and this was the 
case in this study. Many of the included meta-analyses showed Japanese trials to have larger 
treatment effect estimates than their European and North American counterparts. However, 
these differences were not statistically significant at the 5% level. Analysis across trials found 
that the positive results from Japanese trials could not be attributed to these trials being 
single-centred because the percentage of single-centre trials was similar between Japan, 
Europe and North America, with the majority of trials from all three regions being multi-
centred. However, evidence suggested that the high proportion of positive trials in Japan was 
due to publication bias.  
 
To conclude the results of this investigation suggest that Japanese trials are of lower quality 
compared to their European and North American counterparts, especially with regards to the 
reporting of attrition rates. As might be expected, therefore, Japanese trials provided higher 
treatment effect estimates. While it is important to bear in mind that studies on trial quality 
indicate that poor reporting of trial methods and results is a reflection of poor trial methods 
and administration (Juni, Altman, & Egger, 2001; Liberati, Himel, & Chalmers, 1986; Schulz 
et al. 1995), as the trials across all three regions provided different types and levels of 
methodological information, it is possible that the results presented here about trial quality 
reflect not the trial quality itself but the quality of  decisions around reporting of trials. 
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PART THREE: EVALUATION AND 
CONCLUSION 
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CHAPTER 8. 
DISCUSSION & CONCLUSION 
 
The purpose of this study was to investigate the existence of international differences in 
treatment effectiveness in cardiovascular diseases. In addition, it aimed to identify the types 
of interventions that were likely to show such differences in treatment effect. Panoramic 
meta-analysis was used to detect and explore differences in treatment effect between Europe, 
North America and Asia for both fatal and non-fatal endpoints.  
This chapter summarises the main findings of this study and explains why the findings are 
important for research practice and the practice and policy of evidence based medicine. To do 
this, the findings are contextualised within the literature on inter-continental differences in 
treatment effectiveness. The limitations of the study are discussed and the areas that warrant 
further investigation outlined.  
8.1: Empirical Findings 
This study provides some evidence of the existence of international differences in the 
effectiveness of cardiovascular interventions between Europe, North America and Asia. 
These differences were evident for both fatal and non-fatal endpoints.  
8.1.1: Fatal Endpoints 
For the pair-wise comparison between Europe and North America no evidence of a 
statistically significant difference in the effectiveness of cardiovascular interventions between 
Europe and North America was found. This was also the case for the pair-wise comparison 
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between North America and Asia. For the comparison between Europe and Asia, however, 
statistically significant differences were found, with interventions performing better, relative 
to controls, in Asia compared to Europe. 
The universal comparison supported this finding, as it indicated that Asian trials provided 
more positive results favouring the intervention. This was also statistically significant. 
Furthermore, when Asian trials were grouped by country, it was observed that a high 
proportion of Japanese trials provided positive trial results, a finding that contrasted with 
previous research that suggested China would provide the highest proportion of positive 
study results (Pan et al. 2005; Zhang, Freemantle, & Cheng, 2011).  
To explore this unexpected finding, the quality of the included trials was evaluated because 
poor trial quality has been linked to exaggerated treatment effect estimates (Egger, Juni, 
Bartlett, Holenstein, & Sterne, 2003; Kjaergard, Villumsen, & Gluud, 2001; Noseworthy, 
Ebers, Vandervoort, Farquhar, Yetisir, & Roberts, 1994; Peduzzi, Wittes, Detre, & Holford, 
1993) . Indeed, Japanese trials were found to be of significantly lower quality compared to 
their European and North American counterparts and further, the effect estimates from the 
included Japanese trials were slightly higher, in most cases, compared to Europe and North 
America.  
However, it should be noted that as this evaluation was only able to assess trial quality based 
on information provided in trial reports, quality assessment may reflect continental 
differences in the quality of reporting randomised controlled trials rather than indicating the 
quality of the design and implementation of the trials themselves. Juni et al. (2001), however, 
suggest that trials that do not report randomisation or blinding methods, do not do so because 
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the methods for these are inadequate. In short, poorly reported trials indicate poor quality 
methods. This may, therefore, explain the results found in this study, where Japanese trials 
reported more positive results and appeared to be of poorer quality.  
Nonetheless, publication bias may also explain the high proportion of positive Japanese trial 
results found, with trials showing positive results being more likely to be published in this 
country. Indeed, statistical analysis showed that publication bias was present in the Japanese 
sample of trials but not present in the European or North American sample. 
However, it plausible that factors not investigated in this study also contributed towards 
international differences in treatment effectiveness. Selection bias, for instance, may explain 
some of the intercontinental differences in treatment effect because more negative trials from 
Japan may have been indexed in journal databases not used by the authors of the systematic 
reviews included in this study. Given that Medline and the systematic reviews included in 
The Cochrane Library were used to identify systematic reviews with meta-analyses for this 
study, and that they each draw from a broad spectrum of journals, it is unlikely that the 
results are due to selection bias of this kind. However, it may be the case that these findings 
are due to Japanese researchers being reluctant to publish negative findings. This would 
create an abundance of positive Japanese trial results in the public domain that would then be 
used in meta-analytic studies and therefore included in a study such as this. 
Issues around patient compliance with regimens could also offer an explanation. Indeed, 
Bleyer  et al. (1999) suggest that international differences in the rates of compliance could 
greatly change the effectiveness of treatment, with patients who are more compliant having a 
more positive outcome from the intervention.  
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With several factors possibly contributing to these findings, further exploration is required to 
ascertain how much of the difference in inter-continental treatment effect can be explained by 
trial quality alone, other possible factors or a combination of these.    
8.1.2: Types of Intervention and Fatal Endpoints 
From the investigation conducted over and within meta-analyses, the types of intervention 
prone to inter-continental differences in treatment effect could not be identified for either 
pair-wise comparison. However, the analysis conducted across the individual trials found that 
medical devices showed a statistically significant difference in treatment effect between both 
Europe and Asia and North America and Asia. This suggested that medical devices may be 
more likely to show international differences in treatment effect. 
There may be many reasons for this finding. The difference in treatment effect may be more 
prominent for medical devices because of regional differences in how the intervention was 
implemented which, in turn, impact upon effectiveness. Drummond et al. (2009) state that the 
effectiveness of a medical device depends on how the device works and also on how it is 
used. This is different to the effectiveness of a drug that solely depends, as long as it is given 
at the correct dose, route and so on, on the drug itself. Furthermore, continental differences in 
the training for medical devices may explain the prominent difference in effect found for this 
intervention type. For instance, in the continent that provides the most training the person 
implementing the device will have more experience and this may, therefore, impact on the 
effectiveness of the device and contribute to the large between-continent differences found in 
this study. 
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8.1.3: Non-Fatal Endpoints 
For non-fatal endpoints, there was some evidence that differences existed in treatment 
effectiveness between continents. The pair-wise comparison between Europe and North 
America showed that interventions performed better, relative to controls, in Europe. This 
being a statistically significant result. The results from the pair-wise comparisons between 
Europe and Asia and North America and Asia, meanwhile, showed that interventions 
performed better, relative to controls, in Asia compared to both Europe and North America, 
with both comparisons being statistically significant. These results were supported by the 
findings of the universal comparison in which the Independent sample t-test for North 
America versus Asia showed a statistically significant difference in treatment effect. 
However, no evidence was found for a difference in treatment effect between Europe and 
Asia since the Independent sample t-test for this comparison was not statistically significant 
at the 5% level.  
The reasons for the above findings may be complex and chance does not offer a reasonable 
explanation. However, it is possible that the differences for this type of endpoint are the 
consequence of measurement bias, whereby an investigator’s measurement is affected by 
their knowledge of treatment assignment. This is particularly important for subjective 
outcomes (i.e. non-fatal endpoints) as  research suggests that knowledge of treatment 
assignment exaggerates the effect of treatment by 30% when subjective outcomes, compared 
to objective outcomes, are assessed (Wood et al. 2008). It is possible, therefore, that trial 
management in the regions explored for this study are different and that investigators 
involved in Asian trials are more likely to be aware of treatment assignment than their 
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European and North American counterparts, and therefore, explain the positive treatment 
effect estimates for Asian trials. 
As with the fatal endpoint data, other factors could explain these differences, including 
publication bias, whereby trials where an intervention is found to be more effective than the 
control are more likely to be published. However, if this is the case for Asian studies, it is 
likely that it is also the case for non-Asian trials and as such, the effect on the findings of this 
study is likely to be minimal. 
8.1.4: Types of Intervention and Non-Fatal Endpoints 
For non-fatal endpoints the types of intervention prone to inter-continental differences could 
not be identified for any of the pair-wise comparisons. This was because, from the analysis 
across and within meta-analyses, no clear pattern of statistically significant differences was 
identified for any type of intervention. The investigation conducted across the individual 
trials provided similar results, with none of the t-tests conducted for each intervention type 
showing statistically significant results. Since the types of CVD intervention likely to show 
differences in treatment effectiveness could not be identified, this issue will need to be 
explored through further research. 
8.2 Relationship with Existing Literature 
Although no study was identified that directly assessed differences in treatment effectiveness 
between continents or countries, several studies have highlighted an interaction between 
country and treatment effect (Christensen, Broderick, Vincent, Morris, & Steiner. 2009; 
O'Shea & DeMets, 2001; Wolfe et al. 1999)  which the results of this study can support. 
Furthermore, the findings presented in this thesis suggested that trials from Asia tended to 
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produce more positive results (i.e. results that favoured the intervention) when compared to 
other continents; a finding consistent with recent research conducted by Zhang et al. (2011) 
and confirmed by the findings of Pan et al. (2005) and Vickers et al. (1998). 
However, this thesis has provided additional information, showing that this difference in the 
proportion of positive trial results can be explained, in part, by studies conducted in Japan 
reporting more positive results of interventions for cardiovascular disease. A finding that 
contrasts with that found by Zhang et al. (2011) and Pan et al. (2005), who suggested the 
differences were attributable to Chinese trials. As such, this country based analysis needs 
further investigation to ascertain which countries are more likely to produce these positive 
trial results. 
As discussed in Chapter 7, trial quality may explain some of these differences between 
continents. Studies focusing on trial quality have shown that Asian trials are of low quality 
and require improvement (Zhang et al, 2011); a finding echoed in this thesis. In addition, 
Moher et al. (1999) found that low trial quality tends to exaggerate treatment effect and the 
findings from this thesis could be seen to support this suggestion because Japanese trials were 
of lower quality and produced more positive results than their European and North America 
counterparts. However, Chang et al. (2005), in their analysis of inter-country differences in 
the outcomes of acute coronary syndrome, demonstrated that such differences could mainly 
be accounted for by patient level factors. Therefore, more in-depth investigation is needed to 
identify the main factors creating these apparent international differences in treatment 
effectiveness.  
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However, as also suggested in Chapter 7, these findings may reflect not just trial quality but 
rather the quality of reporting trials. Although studies into trial quality have been conducted 
for the past 30 years, it is disappointing to find that essential trial information, for example, 
methods of randomisation, is still not necessarily reported adequately. The Zhang et al. 
(2011) study found that over half of Asian trials failed to report what methods they had used 
to randomise patients, a finding that is consistent with those found in this panoramic meta-
analysis. Although studies suggest that quality of trial reporting is determined by trial quality, 
(Juni, Altman, & Egger, 2001; Liberati, Himel, & Chalmers, 1986; Schulz et al. 1995), it is 
not certain that for the trials included in this panoramic meta-analysis, this is the case. Further 
research is needed to ascertain the degree to which the quality of reporting trials reflects 
country or region specific norms, rather than trial quality itself.  
This thesis has also provided additional information by showing that trial quality is associated 
with exaggerated treatment effects when objective outcomes are assessed. Previous research 
had shown this only to be the case when subjective outcomes are considered (Wood, Egger, 
Gluud et al. 2008), finding no evidence of exaggerated treatment effects resulting from poor 
quality trials in the assessment of objective outcomes. However, the difference between the 
results of this thesis and the study by Wood et al. may be due to Wood et al. (2008) not 
accounting for bias due to attrition which might have confounded assessment of the effects of 
inadequate allocation concealment and lack of blinding in their study. Furthermore, while this 
thesis is based on data solely from cardiovascular trials, the work by Wood et al. relates to 
several conditions and this may account for the difference in the findings between these two 
studies with regards to objective outcomes.  
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8.3: Limitations and Strengths 
This section will now discuss the strengths and limitations of this study. 
 
8.3.1: Limitations 
While all efforts were taken to minimise them, there are still some limitations to this study. 
The literature search was conducted using a comprehensive search strategy in order to 
minimise the risk of missing relevant systematic reviews containing meta-analyses. However, 
this may not have located all published and unpublished systematic reviews and so, some 
relevant data may have been excluded from analysis.  
The search for relevant systematic reviews was only conducted in two databases: Medline 
and The Cochrane Library and again, may have resulted in relevant systematic reviews not 
being included in the analysis for this study. However, given the number of systematic 
reviews that were found to overlap between Medline and The Cochrane Library, and the fact 
that these databases are commonly viewed as the main listings for this type of study in this 
subject area, it is unlikely that searching other databases would have identified many 
additional relevant systematic reviews containing meta-analyses. Furthermore, it is argued 
that Medline provides an adequately representative sample of the best quality trials and 
systematic reviews (Vickers et al. 1998) and that, therefore, it is unlikely that the sample 
analysed in this dataset is unrepresentative of relevant systematic reviews.  
Another limitation of this study was that it only included systematic reviews published in 
English. This may create a language bias since systematic reviews not published in the 
English language would not have been identified, and some relevant trial data may therefore 
have been missed and excluded from the analysis. However, those searching and assessing 
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reviews for inclusion were not competent in other languages and no translator was available 
to assist the researchers. 
The inclusion of overlapping meta-analyses could also be considered a limitation of this 
study. Some of the systematic reviews included were answering the same clinical question 
and, therefore, contained several of the same trials. This meant that when meta-analyses were 
pooled, some trial results were duplicated, and resulted in exaggerated results as was evident 
in the pair-wise comparisons between Europe and North America for fatal endpoints and 
North America and Asia for non-fatal endpoints. However, as panoramic meta-analysis is 
based upon meta-analyses, the inclusion of duplicated trial results is inevitable and, therefore, 
should be accounted for in any analyses using this approach. Furthermore, the data set for this 
study would have been too small if overlapping meta-analyses had been excluded from the 
analysis, meaning that the detection of inter-continental differences in treatment effectiveness 
would not have been possible. 
This study did not attempt to extract patient level information from multinational trials that 
have arms in Europe, North America and Asia. Analysis involving this type of data could 
have increased statistical power, enabled a more flexible analysis of patient subgroups and 
outcomes (Clarke & Stewart, 2001) and may have allowed a more thorough investigation of 
inter-continental differences in treatment effectiveness. However, while researchers 
conducting multinational trials might be expected to monitor findings for country differences 
in treatment effect, these are rarely published. Consequently, obtaining patient level 
information is a difficult and time consuming task, which is not always possible. 
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No formal assessment of the quality of the systematic reviews containing meta-analyses was 
conducted as part of this study because it was initially envisaged that analysis would only 
pull data from the trials contained in meta-analyses (which were quality assessed see Chapter 
7) rather than use the meta-analytic data itself. However, as The Cochrane Collaboration has 
high quality requirements for systematic reviews, it is likely that any review and meta-
analysis linked to a Cochrane review and found on their database will be of high quality. 
Should further panoramic meta-analyses, using meta-analysis level data, be conducted, and to 
counter concerns that existing tools are still as yet ‘incomplete or inconsistent’ (Shea et al. 
2000), a comprehensive tool could be developed, bringing together elements of existing tools, 
to help address all components of quality. 
A limitation of this study was the use of the Jadad scale to assess trial quality. This scale 
places more emphasis on the quality of reporting than it does on the actual methodological 
quality of the trial. For instance, a trial reporting patient attrition rates will earn one point, 
irrespective of whether data was analysed using the intention to treat method. This, therefore, 
means that quality assessment of trials using this scale can only hint at the methodological 
quality of trials. Furthermore, a Jadad score of three, indicates a trial of high quality (Juni, 
Altman, & Egger, 2001). However, a trial can score three points even when it does not use 
random allocation or conceal allocation procedures from patients. Therefore, trial quality 
scores obtained using this scale may not adequately reflect the methodological quality of 
trials. In addition, this scale places considerable importance on blinding, even though 
blinding is not always feasible. Consequently, trials about, for example, surgical procedures, 
that are methodologically sound, may score low on quality because blinding is not possible.  
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However, while there is no “gold standard” scale to evaluate methodological quality of trials 
(Towheed, 2006) and none of the scales at the time of this study could be recommended 
without reservations (Higgins, 2010; Higgins & Green, 2005), the Jadad scale was the only 
one that had been constructed according to psychometric principles. As such, the Jadad scale, 
for this study, had to be the choice instrument for assessing trial quality. 
8.3.2: Strengths 
This study has a number of strengths. It presents the first empirical, direct, investigation into 
the existence of inter-continental differences in treatment effect between Europe, North 
America and Asia and is also the first study to investigate directly the association between 
these differences and trial quality.  
Using the novel panoramic meta-analytic approach, which has its foundations in the meta-
analytic approach; it has all of the strengths of this method. First, it followed a structured 
methodology involving meticulous review and analysis of all trials contained in the included 
meta-analyses. This overcame the biases that can be associated with basing conclusions on 
only a few trials and permitted the validity of the studies included to be determined. Second, 
this method permitted small trials, or those with non-significant effects, to be included in the 
analysis so that they contributed to the overall results of this study. In doing so, little data was 
wasted and the impact of bias that could have resulted from not including such trials (that 
could have distorted the results of this study) was reduced.  
The panoramic meta-analytic approach, however, enhances the strengths of meta-analysis in 
that it is more efficient for data collection. By identifying relevant studies through published 
meta-analyses and directly extracting data from them, large amounts of data can be collated 
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in a timely manner. In doing this, a vast amount of data can be included, which adds validity 
and increases generalisability of the findings. 
In addition, the panoramic meta-analytic approach builds on meta-analysis by comparing 
results across studies and across meta-analyses, thus providing a robust way of testing 
whether a particular variable can explain between-study heterogeneity. This was important 
since this study aimed to investigate ‘continent’ as a component of between-study 
heterogeneity over different types of interventions for different, but related, medical 
conditions. This is the first study to used meta-analytic techniques to investigate this issue.  
As part of the panoramic meta-analysis, this study conducted a detailed search to determine 
the countries and continents where each trial originated. This search involved the 
examination of the original trial reports and entailed contacting authors to obtain country and 
continent information. Without this, a thorough examination of inter-continental differences 
in treatment effectiveness could not have been conducted, as details such as these are rarely 
presented in systematic reviews themselves. This thorough examination about the countries in 
which trials were conducted, has not been done before.  
8.4: Future Research 
More work remains to be done in order to provide a comprehensive understanding of 
international differences in treatment effectiveness. This study focused solely on 
cardiovascular diseases. The differences found in treatment effectiveness for this group of 
conditions, however, highlight the need for comparative work on other conditions and groups 
of conditions to ascertain whether these differences are particular to CVDs or are more 
widely applicable. 
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Furthermore, this study only compared trials from Europe, North America and Asia, and, as 
such, comparative work needs to be conducted to determine whether other continents show 
similar differences. In particular, as this study did not include data from studies conducted in 
the Middle East (see Chapter 4), future research could look at whether differences exist 
between trials conducted in the Middle East and those conducted in the rest of Asia. 
Including studies from these additional regions would allow international differences to be 
observed on the world stage and the relative size of international differences in treatment 
effect to be explored. This would make those wanting to extrapolate overseas clinical data to 
help make decisions about approving interventions or for making guideline 
recommendations, more aware of which trial results they can place confidence in.  
The types of intervention likely to show inter-continental differences in effectiveness also 
require further examination. Although, this research has reported some novel findings about 
how different intervention types perform across the comparison continents, a more in-depth 
understanding is needed to allow clear decisions to be made about extrapolating data about 
particular intervention types between continents. For instance, research could be conducted 
into other types of intervention, such as management strategies. 
The original intention of this study was to compare treatment effectiveness between 
countries, as explained in Chapter 4. However, a lack of country-level data included in meta-
analyses meant that this was not possible. As the importance of country-level data on 
treatment effect has been shown in this research, namely by the fact that studies based in 
Japan show more positive results than those from Europe and North America, comparisons at 
the country-level is essential.  
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To be able to follow-up this research question, an additional research problem needs to be 
addressed that is both a research question and a research practice recommendation. Future 
research needs to identify methods by which country-level data can be collated and 
researchers need to provide more detail when reporting trials. For example, those conducting 
trials or systematic reviews need to be more explicit about where trials were carried out and 
those conducting multinational trials need to be prepared to release country-level breakdowns 
of their results. 
Further research is also needed around trial quality, particularly about the impact of trial 
quality on treatment effect estimates and about methods that allow quality of trials to be 
assessed directly so that those using the data can be sure this reflects trial quality rather than 
quality of reporting. While trial quality assessments may be stipulated in the protocols of 
some RCTs, a wider application of this approach is required and should be used as a matter of 
course. Future research could also utilise several different trial quality checklists and scales to 
explore the association between inter-continental differences in treatment effect and trial 
quality. In particular, the risk of bias tool developed by The Cochrane Collaboration in 2008
59
 
could be utilised. This tool was developed to distinguish between the actual research methods 
used in a study and those that the study reports. Therefore, it is a more robust tool and ideal 
for an investigation into trial quality differences and their impact on treatment effect.  
                                                 
59
 This tool was revised in 2010 after an evaluation project. In 2008 it had not been evaluated for use in 
systematic reviews and meta-analyses and so was not available for use in this study.  
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8.5: Empirical Recommendations 
The results of this study have provided some evidence that international differences in 
treatment effectiveness exist but that they may be explained, for fatal endpoints, by 
continental differences in the quality of trials. Below are the recommendations that can be 
made on the basis of these findings. 
Recommendation 1: Caution should be used when extrapolating clinical data between 
continents. It is recommended that countries should be cautious when using overseas clinical 
data as the basis for their local guideline recommendations or in approving new interventions 
locally. This thesis found clear differences between continents for both fatal and non-fatal 
endpoints. 
Recommendation 2: Trial quality should be taken into account when extrapolating 
clinical data. It is recommended that when extrapolating and interpreting clinical data for the 
purpose of approving a new intervention or as the basis of guideline recommendations, trial 
quality is taken into account. This is because low quality trials can introduce a bias into the 
purported effectiveness of interventions. 
Recommendation 3: Those conducting trials and systematic reviews should be more 
explicit about where trials are conducted and release country breakdowns of their 
results. From this study it is recommended that those who are conducting trials and 
systematic reviews should be explicit about where trials were conducted. It also recommends 
that those involved in multinational trials should release the country breakdowns of their 
results. In following these recommendations a more accurate measurement of differences in 
the trial results of individual countries could be carried out.  
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8.6: Methodological Recommendations 
Several recommendations can be made about the use of panoramic meta-analysis. 
Recommendation 1: Those using panoramic meta-analysis should take into account the 
quality not only of included trials but also of included meta-analyses. In doing this, 
researchers can ensure that any analysis has its foundations in the best available evidence. 
Furthermore, the impact of low quality trials and meta-analyses on their findings can be 
investigated. This could be done by developing a comprehensive tool specifically for 
panoramic meta-analysis based on the checklists and scales that already exist, for example, 
the QUORUM statement (Moher et al. 1999). 
Recommendation 2: The impact of including trial duplications from overlapping meta-
analyses should always be investigated. This is because it has the potential to impact on 
estimates of treatment effect. 
Recommendation 3: Where possible, individual patient data should be obtained. This 
would give the approach more statistical power and enable more flexible sub-group analyses 
to be conducted. 
8.7: Conclusion 
This study has provided some evidence that international differences in the effectiveness of 
interventions for treating and preventing cardiovascular diseases exist for both fatal and non-
fatal endpoints. For fatal endpoints, this study has highlighted that such differences may be 
explained by continental differences in trial quality. For non-fatal endpoints, on the other 
hand, such differences may be explained by their subjective nature. 
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Although this study naturally has its weaknesses, it is the first, to directly investigate the 
existence of inter-continental differences in treatment effectiveness. As such, this study’s 
findings, while echoing those of other studies that did not specifically aim to answer this 
question, provides the groundwork on which future research about inter-country, inter-region, 
and inter-continental differences in treatment effectiveness, trial quality and quality of trial 
reporting can be based. 
This research has used a new methodological approach – panoramic meta-analysis – an 
approach to meta-analysis that allows large amounts of data about many different, but related 
issues, to be collated and analysed. This thesis, therefore, constitutes a foundation on which 
to build future research using this unique methodology.    
 
Many lessons can be learnt from the findings presented here that can be applied to the 
development of guidelines and treatment approval processes. It is hoped that by providing a 
better understanding of inter-continental differences, improvements can be made in the way 
trial data is extrapolated between continents and in the quality of reporting of randomised 
controlled trials. Furthermore, it is hoped, on the basis of this study’s findings, improvements 
can be made to the evidence used as the foundation for guideline recommendations and that 
this will impact on the quality of support, services and interventions patients with CVD 
receive and the outcomes they are able to achieve. 
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Appendix 1. 
Trial Quality Questionnaire 
Trial Authors:                                                    Year:                                      Journal: 
 
 
 
  Jadad Questions Quality Scores 
1) Was the trial 
multi-centred?  
Y/N   
Randomisation:    
1) Is the study 
described as 
randomised?   
 
Y/N J  
2) Is the 
randomisation 
technique 
appropriate i.e. 
not using 
alternative 
patients? 
 
Y/N/Not Stated* J  
3) Was 
randomisation 
done by a third 
party i.e. it was 
not within the 
control of a given 
clinic? 
(Computer 
randomised trial 
centre, 
Telephone, Web 
Based)                                     
 
Y/N/ /Not stated*   
4) Was 
randomisation 
done by 
envelopes within 
the local setting? 
Y/N/Not stated*   
Blinding:    
1) Does the trial 
specify that 
blinding was 
used?                             
Y/N J  
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2) If not was a 
placebo used? 
3)  
Y/N/Not Stated*   
4) Was the 
patient 
blinded?            
 
Y/N/Not Stated*   
5) Was the 
investigator 
blinded?      
 
Y/N/Not Stated* / NA   
6) If the answer 
to 3) and 4) 
was “Yes” 
then was the 
blinding 
method 
described? 
 
Y/N J  
7) Was the main 
outcome 
considered 
objective (such 
as death) rather 
than subjective 
(such as pain)?  
 
Y/N   
Withdrawals and Drop-
outs: 
   
 1) Was the number of 
drop-outs between 
randomisation and the 
assessment of outcome 
given by group? 
 
Y/N J  
2) Did the trial follow a 
CONSORT-type detailed 
breakdown of both 
withdrawals and drop-outs 
following randomisation? 
 
Y/N 
 
  
Total Quality Score    
Comments: 
 
 
 
  
292 
 
 
 
 
 
 
 
 
 
 
* = Also means Unclear 
J = Indicates a question that is to be answered for the Jadad Scale. 
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Instructions: 
 
In order to provide the trials with a Jadad score the following items need to be scored: 
1) If the trial was described as randomised, then 1 point is awarded. 
2) If the study was described as blinded, then 1 point is awarded. 
3) If a description of withdrawals and drop-outs was given, then 1 point is awarded. 
4) If the method used to generate randomisation was described and it was 
appropriate, then 1 point is awarded. 
5) If the method of double blinding was described and it was appropriate, then 1 
point is awarded. 
 
The maximum score possible is 5 while the lowest score is 0. A score of 5 indicates that 
the quality of the trial is high.  
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Appendix 2. 
Meta-regression Output. 
 
Meta-regression 1 – Region 
Meta-regression                                                           Number of obs   =      33 
REML estimate of between-study variance                 tau2                    =   .1248 
% residual variation due to heterogeneity                   I-squared_res      =   8.57% 
Proportion of between-study variance explained       Adj R-squared    =  32.32% 
Joint test for all covariates                                          Model F(2,30)     =    3.29  
With Knapp-Hartung modification                             Prob> F              =  0.0512 
----------------------------------------------------------------------------- 
logTE |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
 _Iregion2_2 |  -.5773012   .3674232    -1.57   0.127     -1.32768     .173077 
 _Iregion2_3 |   .6694331   .4119743     1.62   0.115    -.1719307    1.510797 
          _cons |  -.3150137   .1835637    -1.72   0.096    -.6899007    .0598733 
----------------------------------------------------------------------------- 
 
      . test _Iregion2_2= _Iregion2_3 
 
( 1)  _Iregion2_2 - _Iregion2_3 = 0 
 
F(  1,    30) =    6.55       
Prob> F =    0.0158 
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Meta-regression 2 – Jadad Score after adjusting for Region 
Meta-regression                                                          Number of obs  =      33 
REML estimate of between-study variance               tau2          =   .1794 
% residual variation due to heterogeneity                  I-squared_res  =  11.58% 
Proportion of between-study variance explained       Adj R-squared  =   2.65% 
Joint test for all covariates                                          Model F(3,29)  =    2.27 
With Knapp-Hartung modification                       Prob> F       =  0.1012 
------------------------------------------------------------------------------ 
logTE |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       _Iregion2_2 |  -.2827954   .5170503    -0.55   0.589    -1.340282    .7746912 
 _      Iregion2_3 |   .8002819   .4594369     1.74   0.092    -.1393721    1.739936 
jadadscore |   .1316464    .157745     0.83   0.411    -.1909782    .4542711  
       _cons |  -.8547196   .6639058    -1.29   0.208    -2.212559    .5031202     
------------------------------------------------------------------------------  
 
Meta-regression 3 – Jadad Score  
Meta-regression                                                          Number of obs  =      33 
REML estimate of between-study variance               tau2                    =   .2446 
% residual variation due to heterogeneity                  I-squared_res=  22.98% 
Proportion of between-study variance explained       Adj R-squared    = -32.68% 
With Knapp-Hartung modification 
------------------------------------------------------------------------------ 
logTE |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
jadadscore |   .1812684   .1249541     1.45   0.157    -.0735772    .4361141   
       _cons |  -.9520952   .4422656    -2.15   0.039    -1.854102   -.0500886  
------------------------------------------------------------------------------ 
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